



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 129818

TO: Terra Gibbs
Location: rem/2d10
Art Unit: 1635
Thursday, August 12, 2004

2C18

Case Serial Number: 10/033742

From: Barb O'Bryen
Location: Biotech-Chem Library
Remsen 1A69
Phone: 571-272-2518

BOB

barbara.obryen@uspto.gov

Search Notes

Note:

EST database had no hits that matched your limitations. Consequently, there is no results set from the EST database in this packet.

THIS PAGE BLANK (USPTO)

O'Bryen, Barbara

From: Gibbs, Terra
Sent: Thursday, August 05, 2004 6:01 PM
To: O'Bryen, Barbara
Subject: Sequence search request...

Hi Barbara,

I have another request for a score over length search:

I need a length limited nucleotide sequence search nucleobases 361-425 of SEQ ID NO:3 in USSN 10/033,742, where the returns are rank ordered based on the score over length/ratio as we've discussed. I need the lengths limited to hits between 8 and 50 nucleotides, and I'll take as many hits as you can import into excel (64,000?), and alignments for anything above .75 on the above ratio. Hope this is clear, please call me if it's not. I also need the interference databases searched .

Terra Cotta Gibbs, Ph.D.
Art Unit 1635
Remsen Building 2D10
571-272-0758

THIS PAGE BLANK (USPTO)



STIC SEARCH RESULTS FEEDBACK FORM

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
Remsen Bldg. 01 D86
571-272-2507

Voluntary Results Feedback Form

➤ I am an examiner in Workgroup: Example: 1610

➤ Relevant prior art **found**, search results used as follows:

- ☐ 102 rejection
- ☐ 103 rejection
- ☐ Cited as being of interest.
- ☐ Helped examiner better understand the invention.
- ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
(journal articles, conference proceedings, new product announcements etc.)

➤ Relevant prior art **not found**:

- ☐ Results verified the lack of relevant prior art (helped determine patentability).
- ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC-Biotech-Chem Library Remsen Bldg.



THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 12, 2004, 15:34:29 ; Search time 0.001 Seconds

(without alignments)
164,450 Million cell updates/sec

Title: US-10-033-742-3

Perfect score: 65

Sequence: 1 ttcttggaatgcattgcac.....gtctgggttgaggtttcac 65

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 103 seqs, 1265 residues

Total number of hits satisfying chosen parameters: 206

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 103 summaries

Database : rncdb:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,

and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	19.8	30.5	23	1	US-09-071-353-12
2	19.8	30.5	23	1	US-09-426-326-12
3	14	21.5	18	1	US-08-525-654A-138
4	12.8	19.7	17	1	US-08-281-940-29
5	12.8	19.7	17	1	US-08-710-134-29
6	12.8	19.7	17	1	US-08-485-885-29
7	12.8	19.7	17	1	US-08-866-108A-2464
8	12.8	19.7	17	1	US-08-866-108A-2465
9	11.4	17.5	15	1	US-08-146-886-22
10	11.4	17.5	15	1	US-08-440-787A-139
11	11.4	17.5	15	1	US-08-109-613-32
12	11.4	17.5	15	1	US-08-730-635-5
13	11.4	17.5	15	1	US-08-730-635-5
14	10.8	16.6	14	1	US-08-242-664-25
15	10.8	16.6	14	1	US-08-484-138-25
16	10.8	16.6	14	1	US-09-580-923-29
17	10.8	16.6	14	1	US-09-580-923-30
18	10.8	16.6	14	1	PCT-US95-06379-25
19	10.4	16.0	12	1	US-08-004-800-9
20	10.4	16.0	12	1	US-08-004-800-10
21	10.4	16.0	12	1	US-08-004-800-11
22	10.4	16.0	12	1	US-08-004-800-12
23	10.4	16.0	12	1	US-08-115-497-14
24	10.4	16.0	12	1	US-08-115-497-15
25	10.4	16.0	12	1	US-08-413-813-9
26	10.4	16.0	12	1	US-08-413-813-9
27	10.4	16.0	12	1	US-08-413-813-10
28	10.4	16.0	12	1	US-08-413-813-28
29	10.4	16.0	12	1	US-08-413-813-29
30	10.4	16.0	12	1	US-08-413-813-31
31	10.4	16.0	12	1	US-08-466-670-14
32	10.4	16.0	12	1	US-08-466-670-15
33	10.4	16.0	12	1	US-08-466-670-17

34	10.4	16.0	12	1	US-08-467-346-9	Sequence 9, Appl
35	10.4	16.0	12	1	US-08-467-346-10	Sequence 10, Appl
36	10.4	16.0	12	1	US-08-467-346-28	Sequence 28, Appl
37	10.4	16.0	12	1	US-08-467-346-29	Sequence 29, Appl
38	10.4	16.0	12	1	US-08-467-346-31	Sequence 31, Appl
39	10.4	16.0	12	1	US-08-822-586-50	Sequence 50, Appl
40	10.4	16.0	12	1	PCT-US92-02480A-9	Sequence 9, Appl
41	10.4	16.0	12	1	PCT-US92-02480A-10	Sequence 10, Appl
42	10.4	16.0	12	1	PCT-US92-02480A-11	Sequence 11, Appl
43	10.4	16.0	12	1	PCT-US92-02480A-12	Sequence 12, Appl
44	10.4	16.0	13	1	US-08-284-746-14	Sequence 14, Appl
45	10.4	16.0	13	1	US-09-446-301A-45	Sequence 45, Appl
46	10.4	16.0	13	1	US-09-099-932-36	Sequence 36, Appl
47	10.4	16.0	13	1	US-09-862-844-6	Sequence 6, Appl
48	10.4	16.0	13	1	US-09-862-844-8	Sequence 8, Appl
49	10.4	16.0	13	1	US-08-152-955-3	Sequence 3, Appl
50	9.4	14.5	11	1	PCT-US93-05668-3	Sequence 3, Appl
51	9.4	14.5	12	1	US-08-115-497-12	Sequence 12, Appl
52	9.4	14.5	12	1	US-08-115-497-13	Sequence 13, Appl
53	9.4	14.5	12	1	US-08-031-147A-53	Sequence 53, Appl
54	9.4	14.5	12	1	US-08-413-813-38	Sequence 38, Appl
55	9.4	14.5	12	1	US-08-413-813-39	Sequence 39, Appl
56	9.4	14.5	12	1	US-08-466-670-12	Sequence 12, Appl
57	9.4	14.5	12	1	US-08-466-670-13	Sequence 13, Appl
58	9.4	14.5	12	1	US-08-494-301A-12	Sequence 12, Appl
59	9.4	14.5	12	1	US-08-467-346-38	Sequence 38, Appl
60	9.4	14.5	12	1	US-08-467-346-39	Sequence 39, Appl
61	9.4	14.5	12	1	US-08-403-888A-41	Sequence 41, Appl
62	9.4	14.5	12	1	US-08-403-888A-57	Sequence 57, Appl
63	9.4	14.5	12	1	US-08-819-867-35	Sequence 35, Appl
64	9.4	14.5	12	1	US-08-819-867-33	Sequence 33, Appl
65	9.4	14.5	12	1	US-08-819-867-35	Sequence 35, Appl
66	9.4	14.5	12	1	US-08-819-867-33	Sequence 33, Appl
67	9.4	14.5	12	1	US-08-819-867-35	Sequence 35, Appl
68	9.4	14.5	12	1	US-08-679-493A-64	Sequence 64, Appl
69	9.4	14.5	12	1	US-09-378-535-35	Sequence 35, Appl
70	9.4	14.5	12	1	US-09-378-535-33	Sequence 33, Appl
71	9.4	14.5	12	1	PCT-US94-02471-53	Sequence 53, Appl
72	9.4	14.5	12	1	US-08-462-115B-34	Sequence 34, Appl
73	9.4	14.5	12	1	US-08-472-802C-32	Sequence 32, Appl
74	9.4	14.5	12	1	US-09-057-351-32	Sequence 32, Appl
75	9.4	14.5	12	1	US-08-330-123A-10	Sequence 10, Appl
76	9.4	14.5	12	1	US-08-330-123A-10	Sequence 10, Appl
77	9.4	14.5	12	1	US-08-482-115B-10	Sequence 10, Appl
78	9.4	14.5	12	1	US-08-650-678A-10	Sequence 10, Appl
79	9.4	14.5	12	1	US-08-485-778-41	Sequence 41, Appl
80	9.4	14.5	12	1	US-08-472-802C-11	Sequence 11, Appl
81	9.4	14.5	12	1	US-08-388-353-513	Sequence 513, Appl
82	9.4	14.5	12	1	US-08-388-353-514	Sequence 514, Appl
83	9.4	14.5	12	1	US-08-388-353-547	Sequence 547, Appl
84	9.4	14.5	12	1	US-08-488-551B-548	Sequence 548, Appl
85	9.4	14.5	12	1	US-08-488-551B-831	Sequence 831, Appl
86	9.4	14.5	12	1	US-08-488-551B-832	Sequence 832, Appl
87	9.4	14.5	12	1	US-08-998-443-18	Sequence 18, Appl
88	9.4	14.5	12	1	US-09-060-523-10	Sequence 10, Appl
89	9.4	14.5	12	1	US-09-060-523-10	Sequence 10, Appl
90	9.4	14.5	12	1	US-09-057-351-10	Sequence 10, Appl
91	9.4	14.5	12	1	PCT-US96-09430-21	Sequence 21, Appl
92	9.4	14.5	12	1	US-08-117-91-19	Sequence 19, Appl
93	9.4	14.5	12	1	US-08-271-364A-19	Sequence 19, Appl
94	9.4	14.5	12	1	US-08-222-715B-19	Sequence 19, Appl
95	9.4	14.5	12	1	US-09-281-418-58	Sequence 58, Appl
96	9.4	14.5	12	1	PCT-US96-09430-17	Sequence 17, Appl
97	9.4	14.5	12	1	PCT-US96-09430-18	Sequence 18, Appl
98	9.4	14.5	12	1		
99	9.4	14.5	12	1		
100	9.4	14.5	12	1		
101	9.4	14.5	12	1		
102	9.4	14.5	12	1		
103	9.4	14.5	12	1		

ALIGNMENTS

RESULT 1
US-09-071-353-12/c
Sequence 12, Application US/09071353
Patent No. 6057426
GENERAL INFORMATION:
APPLICANT: Lesslauer, Werner
APPLICANT: Utans-Schneitz, Ulrike
TITLE OF INVENTION: NEW CHEROKINE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: N.J.
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,353
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 97107135.2
FILING DATE: 30-APR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Kreisler, Lewis J
REGISTRATION NUMBER: 38522
REFERENCE/DOCKET NUMBER: 13235
TELECOMMUNICATION INFORMATION:
TELEPHONE: (973) 235-4387
TELEFAX: (973) 235-2363
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-09-071-353-12

Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 1.1;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CTGGATGGAATTGGACATGACC 26
Db 23 CTGGATGGAATTGGACACAGCC 1

RESULT 2
US-09-426-326-12/c
Sequence 12, Application US/09426326
Patent No. 6537794
GENERAL INFORMATION:
APPLICANT: Lesslauer, Werner
APPLICANT: Utans-Schneitz, Ulrike
TITLE OF INVENTION: NEW CHEROKINE
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: N.J.
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/426,326
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/071,353
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Kreisler, Lewis J
REGISTRATION NUMBER: 38522
REFERENCE/DOCKET NUMBER: 13235
TELECOMMUNICATION INFORMATION:
TELEPHONE: (973) 235-4387
TELEFAX: (973) 235-2363
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 23 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "primer"
US-09-426-326-12

Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 1.1;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 4 CTGGATGGAATTGGACATGACC 26
Db 23 CTGGATGGAATTGGACACAGCC 1

RESULT 3
US-08-525-654A-138/c
Sequence 138, Application US/08525654A
Patent No. 5736356
GENERAL INFORMATION:
APPLICANT: SANO, KOICHIRO
APPLICANT: KIMAZAWA, YOSHIYUKI
APPLICANT: YASEUDA, HISASHI
APPLICANT: SEGUCHI, KATSUYA
APPLICANT: MOTOKI, MASAO
TITLE OF INVENTION: TRANSGUTAMINASE ORIGINATED FROM
NUMBER OF SEQUENCES: 150
CORRESPONDENCE ADDRESS:
ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
CITY: ARLINGTON
STATE: VA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/525,654A
FILING DATE: 28-SEP-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 6/8283
FILING DATE: 28-JAN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7/3876
FILING DATE: 13-JAN-1995

ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-760-0 PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-413-3000
TELEFAX: 703-413-2220
INFORMATION FOR SEQ ID NO: 138:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-525-654A-138

Query Match 21.5%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.3;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAAC 43
Db 16 GAACAGAAAGAAC 3

RESULT 4

US-08-281-940-29
Sequence 29, Application US/08281940
Patent No. 5589330
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: METHOD FOR MULTIPLE ALLELE-SPECIFIC
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: DARBY & DARBY P.C.
STREET: 805 THIRD AVENUE
CITY: NEW YORK
STATE: NEW YORK
COUNTRY: USA
ZIP: 10022
COMPUTER READABLE FORM:
MEDIUM TYPE: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/281,940
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: LUDWIG, S. PETER
REGISTRATION NUMBER: 25351
REFERENCE/DOCKET NUMBER: 0372/00966
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212/527-7700
TELEFAX: 212/753-6237
TELEX: 236687
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
ORIGINAL SOURCE:
ORGANISM: Homo sapien
IMMEDIATE SOURCE:
CLONE: Q4933M
US-08-281-940-29

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 26 CCAAGAACAGAAAGAA 41
Db 2 CTAAGAACAGAAATGAA 17

RESULT 5

US-08-710-134-29
Sequence 29, Application US/08710134
Patent No. 5834181
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genzyme Corporation
STREET: One Mountain Road
CITY: Framingham
STATE: Massachusetts
COUNTRY: USA
ZIP: 01701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/710,134
FILING DATE: 13-SEP-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Dugan, Deborah A.
REGISTRATION NUMBER: 37,315
REFERENCE/DOCKET NUMBER: IG5-8.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 508-872-8400
TELEFAX: 508-872-5415
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Oligonucleotides"
US-08-710-134-29

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGAACAGAAAGAA 41
Db 2 CTAAGAACAGAAATGAA 17

RESULT 6

US-08-485-885-29
Sequence 29, Application US/08485885
Patent No. 5849483
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genzyme Corporation
STREET: One Mountain Road
CITY: Framingham
STATE: Massachusetts
COUNTRY: USA

```

; ZIP: 01701
; COMPUTER READABLE FORM.
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,885
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Dugan, Deborah A.
; REGISTRATION NUMBER: 37,315
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 508-872-8400
; TELEFAX: 508-872-5415
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Oligonucleotides"
US-08-485-885-29

```

```

Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      26 CTAAGACAGAAAGAA 41
DB      2 CTAAGACAGATGAA 17

```

```

US-09-866-108A-2464
; Sequence 2464, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.

```

```

; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2464

```

```

Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      4 CTGGAATGAACTTGA 19
DB      2 CTGGAATGAACTTGA 17

```

```

RESULT 8
US-09-866-108A-2465
; Sequence 2465, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2465
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2465

```

```

Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 14;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      4 CTGGAATGAACTTGA 19
DB      1 CTGGAATGAACTTGA 16

```


RESULT 9
US-08-146-886-22
; Sequence 22, Application US/08146886
; Patent No. 563603
; GENERAL INFORMATION:
; APPLICANT: Dower, William J.
; APPLICANT: Barrett, Ronald W.
; APPLICANT: Gallop, Mark A.
; APPLICANT: Needels, Michael C.
; TITLE OF INVENTION: Method of Synthesizing Diverse
; TITLE OF INVENTION: Collections of Compounds
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Stewart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/146,886
; FILING DATE: 02-NOV-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/946,239
; FILING DATE: 16-SEP-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/762,522
; FILING DATE: 18-SEP-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5639603viel, Vernon A.
; REGISTRATION NUMBER: 32,483
; REFERENCE/DOCKET NUMBER: 11509-121/1007.2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (oligonucleotide)
US-08-146-886-22

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGATGGAATG 17
DB 2 TGGATGGAAGTG 14

RESULT 10
US-08-440-787A-139/C
; Sequence 139, Application US/08440787A
; Patent No. 5770434
; GENERAL INFORMATION:
; APPLICANT: Huee, William D.
; TITLE OF INVENTION: Soluble Peptides Having Constrained,
; TITLE OF INVENTION: Secondary Conformation in Solution and Method of Making
; TITLE OF INVENTION: Same.
; NUMBER OF SEQUENCES: 174
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego

STATE: California
COUNTRY: USA
ZIP: 92122
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/440,787A
FILING DATE: 15-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/978,893
FILING DATE: 10-NOV-1992
ATTORNEY/AGENT INFORMATION:
NAME: Campbell, Cathryn A.
REGISTRATION NUMBER: 31,815
REFERENCE/DOCKET NUMBER: P-IX 1586
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO: 139:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: misc.feature
LOCATION: 13..14
OTHER INFORMATION: /note= "N = X (used in Table VI),
OTHER INFORMATION: which represents an equal mixture of all four
OTHER INFORMATION: nucleotides."
US-08-440-787A-139

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2 TTCTGGAATGATTT 16
DB 15 TTNNTGGATGGAATTT 1

RESULT 11
US-09-109-613-22
; Sequence 22, Application US/09109613
; Patent No. 6165778
; GENERAL INFORMATION:
; APPLICANT: Dower, William J.
; APPLICANT: Barrett, Ronald W.
; APPLICANT: Gallop, Mark A.
; APPLICANT: Needels, Michael C.
; TITLE OF INVENTION: Method of Synthesizing Diverse
; TITLE OF INVENTION: Collections of Compounds
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Stewart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/109,613
; FILING DATE:
; CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/146,886
FILING DATE: 02-NOV-1993
APPLICATION NUMBER: US 07/946,239
FILING DATE: 16-SEP-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/762,522
FILING DATE: 18-SEP-1991
ATTORNEY/AGENT INFORMATION:
NAME: No. 6165778v1el, Vernon A.
REGISTRATION NUMBER: 32,483
REFERENCE/DOCKET NUMBER: 11509-121/1007.2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-326-2400
TELEFAX: 415-326-2422
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (oligonucleotide)
US-09-109-613-22

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 TCGAATGGAATG 17
Db 2 TCGAATGGAATG 14

RESULT 12
US-08-730-635-5/c
Sequence 5, Application US/08730635
Patent No. 6514693
GENERAL INFORMATION:
APPLICANT: Lansdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
TITLE OF INVENTION: a Repeat Sequence in a Nucleic Acid Molecule
Patent No. 6514693
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESS: HOMSON & HOMSON
STREET: 321 No. 65146931stowm Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
US-08-730-635-5

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 TCGAATGGAATG 17
Db 13 TCGAATGGAATG 1

RESULT 13
US-08-730-635-9
Sequence 9, Application US/08730635
Patent No. 6514693
GENERAL INFORMATION:
APPLICANT: Lansdorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
TITLE OF INVENTION: a Repeat Sequence in a Nucleic Acid Molecule
Patent No. 6514693
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESS: HOMSON & HOMSON
STREET: 321 No. 65146931stowm Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-730-635-9

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 23;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 TCGAATGGAATG 17
Db 3 TCGAATGGAATG 15

RESULT 14
US-08-242-664-25
Sequence 25, Application US/08242664
Patent No. 5571937
GENERAL INFORMATION:
APPLICANT: Watanabe, Kyoichi A.
APPLICANT: Ren, Wu-Yun
APPLICANT: Weil, Roger
TITLE OF INVENTION: Complementary DNA and Toxins

NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10112
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/242,664
FILING DATE: May 12, 1994
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-664-0525
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-242-664-25

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAAGAAATGAA 14

RESULT 15
US-08-484-138-25
Sequence 25, Application US/08484138
Patent No. 5652350
GENERAL INFORMATION:
APPLICANT: Watanabe, Kyoichi A.
APPLICANT: Ren, Wu-Yun
APPLICANT: Wei, Roger
TITLE OF INVENTION: Complementary DNA and Toxins
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,138
FILING DATE: June 7, 1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-z/JPW/MJG
TELECOMMUNICATION INFORMATION:

TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-484-138-25

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAAGAAATGAA 14

RESULT 16
US-09-580-923-29
Sequence 29, Application US/09580923
Patent No. 6319672
GENERAL INFORMATION:
APPLICANT: Crouzet, Joel
APPLICANT: Scherman, Daniel
APPLICANT: Wils, Pierre
APPLICANT: Cameron, Beatrice
APPLICANT: Blanche, Francis
TITLE OF INVENTION: IMMOBILIZED OLIGONUCLEOTIDE
FILE REFERENCE: 03804.0138-01
CURRENT APPLICATION NUMBER: US/09/580,923
CURRENT FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: 08/860,038
PRIOR FILING DATE: 1997-06-09
PRIOR APPLICATION NUMBER: PCT/FR95/01468
PRIOR FILING DATE: 1995-11-08
NUMBER OF SEQ ID NOS: 36
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 29
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
US-09-580-923-29

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAAGAAATGAA 14

RESULT 17
US-09-580-923-30/c
Sequence 30, Application US/09580923
Patent No. 6319672
GENERAL INFORMATION:
APPLICANT: Crouzet, Joel
APPLICANT: Scherman, Daniel
APPLICANT: Wils, Pierre
APPLICANT: Cameron, Beatrice
APPLICANT: Blanche, Francis
TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
FILE REFERENCE: 03804.0138-01
CURRENT APPLICATION NUMBER: US/09/580,923

;; CURRENT FILING DATE: 2000-05-26
;; PRIOR APPLICATION NUMBER: 08/860,038
;; PRIOR FILING DATE: 1997-06-09
;; PRIOR APPLICATION NUMBER: PCT/FR95/01468
;; PRIOR FILING DATE: 1995-11-08
;; NUMBER OF SEQ ID NOS: 36
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 30
;; LENGTH: 14
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence:
US-09-580-923-30

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGAACAGAAAGAA 41
Db 14 AAGAAAGAAATGAA 1

RESULT 18
PCT-US95-06379-25
Sequence 25, Application PC/TUS9506379
GENERAL INFORMATION:
APPLICANT: Matanabe, Kyoichi A.
APPLICANT: Ren, Wu-Yun
APPLICANT: Weil, Roger
TITLE OF INVENTION: Complementary DNA and Toxins
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44MB
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/06379
FILING DATE: May 13, 1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-278-0400
TELEFAX: 212-391-0526
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US95-06379-25

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 28;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGAACAGAAAGAA 41
Db 1 AAGAAAGAAATGAA 14

RESULT 19
US-08-004-800-9
Sequence 9, Application US/08004800
Patent No. 5426180
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/004,800
FILING DATE: 19930111
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 8085ZY
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-004-800-9

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 28 AAGAACAGAAAG 39
Db 1 AAGAAAGAAAG 12

RESULT 20
US-08-004-800-10/c
Sequence 10, Application US/08004800
Patent No. 5426180
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/004,800
FILING DATE: 19930111
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 8085ZY
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-004-800-10

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACGAAAG 39
|||||
Db 12 AAGAAAGAAAG 1

RESULT 21
US-08-004-800-11
Sequence 11, Application US/08004800
Patent No. 5426180
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
TITLE OF INVENTION: OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/004,800
FILING DATE: 19930111
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 8085ZY
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-004-800-11

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACGAAAG 39
|||||
Db 1 AAGAAAGAAAG 12

RESULT 22
US-08-004-800-12
Sequence 12, Application US/08004800
Patent No. 5426180
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
TITLE OF INVENTION: OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/004,800
FILING DATE: 19930111
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 8085ZY
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-004-800-12

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACGAAAG 39
|||||
Db 1 AAGAAAGAAAG 12

RESULT 23
US-08-115-497-14
Sequence 14, Application US/08115497
Patent No. 5514546
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City

```
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: Patent Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/115,497
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digigilo, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8771
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ US-08-115-497-14

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
DB      1 AAGATAGAAAG 12

RESULT 24
US-08-115-497-15
/ Sequence 15, Application US/08115497
/ Patent No. 5514546
/ GENERAL INFORMATION:
/ APPLICANT: KOOL, Eric T.
/ TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: Patent Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/115,497
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digigilo, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8771
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ INFORMATION FOR SEQ ID NO: 15:
/ SEQUENCE CHARACTERISTICS:
/
```

```
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ US-08-115-497-15

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
DB      1 AAGATAGAAAG 12

RESULT 25
US-08-115-497-17/C
/ Sequence 17, Application US/08115497
/ Patent No. 5514546
/ GENERAL INFORMATION:
/ APPLICANT: KOOL, Eric T.
/ TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: Patent Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/115,497
/ FILING DATE:
/ CLASSIFICATION: 514
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digigilo, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8771
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ INFORMATION FOR SEQ ID NO: 17:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ US-08-115-497-17

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      28 AAGAACAGAAAG 39
DB      12 AAGATAGAAAG 1

RESULT 26
US-08-413-813-9
/ Sequence 9, Application US/08413813
/ Patent No. 5683874
/ GENERAL INFORMATION:
/ APPLICANT: KOOL, Eric T.
/ TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
```

NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-9

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 28 AAGACGGAAG 39
DB 1 AAGAAAGAAAG 12

RESULT 27
US-08-413-813-10/c
Sequence 10, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366

TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-10

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 28 AAGACGGAAG 39
DB 12 AAGAAAGAAAG 1

RESULT 28
US-08-413-813-28
Sequence 28, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-28

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 30 GAACAGAAAGA 41
DB 1 GAAGAGAAAGA 12

RESULT 29
US-08-413-813-29
Sequence 29, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.

```

/ TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
/ NUMBER OF SEQUENCES: 44
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/413,813
/ FILING DATE:
/ CLASSIFICATION: 536
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8085ZYX
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ TELEX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 29:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
US-08-413-813-29

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
Db 1 AAAAAAGAAAGAA 12

RESULT 30
US-08-413-813-31/C
/ Sequence 31, Application US/08413813
/ Patent No. 5683874
/ GENERAL INFORMATION:
/ APPLICANT: Kool, Eric T.
/ TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
/ NUMBER OF SEQUENCES: 44
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/413,813
/ FILING DATE:
/ CLASSIFICATION: 536
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8085ZYX
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
```

```

/ TELEFAX: (516) 742-4366
/ TELEX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 31:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: circular
/
US-08-413-813-31

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
Db 12 AAAAAAGAAAGAA 1

RESULT 31
US-08-466-670-14
/ Sequence 14, Application US/08466670
/ Patent No. 5808036
/ GENERAL INFORMATION:
/ APPLICANT: Kool, Eric T.
/ TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
/ PARALLEL AND ANTIPARALLEL BINDING DOMAINS
/ NUMBER OF SEQUENCES: 21
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Scully, Scott, Murphy & Presser
/ STREET: 400 Garden City Plaza
/ CITY: Garden City
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 11530
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: IBM PC compatible
/ SOFTWARE: Patentin Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/466,670
/ FILING DATE:
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/115,497
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Digiglio, Frank S.
/ REGISTRATION NUMBER: 31,346
/ REFERENCE/DOCKET NUMBER: 8771
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (516) 742-4343
/ TELEFAX: (516) 742-4366
/ TELEX: 230 901 SANS UR
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 12 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/
US-08-466-670-14

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAAGAAAG 39
Db 1 AAGAATGAAG 12
```


RESULT 32
US-08-466-670-15
Sequence 15, Application US/08466670
Patent No. 5808036
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
TITLE OF INVENTION: PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-15

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACGGAAG 39
DB 1 AAGAAGGGAAG 12

RESULT 33
US-08-466-670-17/c
Sequence 17, Application US/08466670
Patent No. 5808036
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
TITLE OF INVENTION: PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-17

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACGGAAG 39
DB 12 AAGATGGAAG 1

RESULT 34
US-08-467-346-9
Sequence 9, Application US/08467346
Patent No. 5872105
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-346-9

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAAGAGAAG 39
DB 1 AAGAAAAGAAG 12

RESULT 35
US-08-467-346-10/c
Sequence 10, Application US/08467346
Patent No. 5872105

GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8085ZYX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-346-10

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAAGAGAAG 39
DB 12 AAGAAAAGAAG 1

RESULT 36
US-08-467-346-28
Sequence 28, Application US/08467346
Patent No. 5872105
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES

NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8085ZYX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-467-346-28

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAGAAG 41
DB 1 GAAGAAAAGAAG 12

RESULT 37
US-08-467-346-29
Sequence 29, Application US/08467346
Patent No. 5872105
GENERAL INFORMATION:
APPLICANT: KOOL, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/467,346
FILING DATE: 06-JUN-1995
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/413,813
FILING DATE: 30-MAR-1995
ATTORNEY/AGENT INFORMATION:

NAME: Digiglio, Frank S.
 REGISTRATION NUMBER: 31,346
 REFERENCE/DOCKET NUMBER: 80852YX
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (516) 742-4343
 TELEFAX: (516) 742-4366
 TELEX: 230 901 SANS UR
 INFORMATION FOR SEQ ID NO: 29:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 12 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-467-346-29

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 32;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
 ||| |||||
 Db 1 GAAAGAAAGAA 12

RESULT 38
 US-08-467-346-31/c
 Sequence 31, Application US/08467346
 Patent No. 5872105
 GENERAL INFORMATION:
 APPLICANT: Kool, Eric T.
 TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
 NUMBER OF SEQUENCES: 44
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Scully, Scott, Murphy & Presser
 STREET: 400 Garden City Plaza
 City: Garden City
 STATE: New York
 COUNTRY: USA
 ZIP: 11530
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/467,346
 FILING DATE: 06-JUN-1995
 CLASSIFICATION: 536
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/413,813
 FILING DATE: 30-MAR-1995
 ATTORNEY/AGENT INFORMATION:
 NAME: Digiglio, Frank S.
 REGISTRATION NUMBER: 31,346
 REFERENCE/DOCKET NUMBER: 80852YX
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (516) 742-4343
 TELEFAX: (516) 742-4366
 TELEX: 230 901 SANS UR
 INFORMATION FOR SEQ ID NO: 31:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 12 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: circular
 US-08-467-346-31

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 32;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
 ||| |||||

Db 12 GAAAGAAAGAA 1

RESULT 39
 US-08-822-586-50
 Sequence 50, Application US/08822586
 Patent No. 6015890
 GENERAL INFORMATION:
 APPLICANT: WILLIAM R. JACOBS, JR., JAMES M. MUSSER AND
 AMALIO TELENIT
 TITLE OF INVENTION: AN EMBCAB OPERON OF MYCOBACTERIA AND
 TITLE OF INVENTION: MUTANTS THEREOF
 NUMBER OF SEQUENCES: 57
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: AMSTER, ROTHSTEIN & EBENSTEIN
 STREET: 90 PARK AVENUE
 City: NEW YORK
 STATE: NEW YORK
 COUNTRY: U.S.A.
 ZIP: 10016
 COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5 INCH 1.44 MB STORAGE
 MEDIUM TYPE: DISKETTE
 COMPUTER: IBM PC COMPATIBLE
 OPERATING SYSTEM: MS-DOS
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/822,586
 FILING DATE: MARCH 20, 1997
 ATTORNEY/AGENT INFORMATION:
 NAME: ELIZABETH A. BOGOSIAN
 REGISTRATION NUMBER: 39,911
 REFERENCE/DOCKET NUMBER: 96700/437
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 697-5995
 TELEFAX: (212) 286-0854 or 286-0082
 TELEX: TWX 710-581-4766
 INFORMATION FOR SEQ ID NO: 50:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 12
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid
 HYPOTHETICAL: NO
 US-08-822-586-50

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 32;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 TGGACATAGCCC 27
 ||| |||||
 Db 1 TGGCATAGCCC 12

RESULT 40
 PCT-US92-02480A-9
 Sequence 9, Application PC/TUS9202480A
 GENERAL INFORMATION:
 APPLICANT: Kool, Eric T.
 TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
 NUMBER OF SEQUENCES: 15
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Scully, Scott, Murphy & Presser
 STREET: 400 Garden City Plaza
 City: Garden City
 STATE: New York
 COUNTRY: USA
 ZIP: 11530
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk

```
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/02480A
FILING DATE: 19920326
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US92-02480A-9
```

```
Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 28 AAGAACAGAAAG 39
Db 1 AAGAAAGAAAG 12
```

```
RESULT 41
PCT-US92-02480A-10/c
Sequence 10, Application PC/TUS9202480A
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/02480A
FILING DATE: 19920326
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US92-02480A-10
```

```
Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 28 AAGAACAGAAAG 39
Db 12 AAGAAAGAAAG 1
```

```
RESULT 42
PCT-US92-02480A-11
Sequence 11, Application PC/TUS9202480A
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/02480A
FILING DATE: 19920326
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US92-02480A-11
```

```
Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 28 AAGAACAGAAAG 39
Db 1 AAGAAAGAAAG 12
```

```
RESULT 43
PCT-US92-02480A-12
Sequence 12, Application PC/TUS9202480A
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
```

SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/02480A
FILING DATE: 19920326
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 80852
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US92-02480A-12

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 28 AAGAACGAAAG 39
Db 1 AAGAAUAGAAAG 12

RESULT 44
PCT-US92-02480A-13/c
Sequence 13, Application PC/TUS9202480A
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR
TITLE OF INVENTION: OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 15
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/02480A
FILING DATE: 19920326
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: McNulty, William E.
REGISTRATION NUMBER: 22,606
REFERENCE/DOCKET NUMBER: 80852
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US92-02480A-13

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 28 AAGAACGAAAG 39

Db 12 AAGATAGAAAG 1

RESULT 45
US-08-284-746-14/c
Sequence 14, Application US/08284746
Patent No. 5525468
GENERAL INFORMATION:
APPLICANT: James A. McSwigen
TITLE OF INVENTION: ASSAY FOR RIBOZYME TARGET SITE
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 611 West Sixth Street
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90017
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 Mb storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
SOFTWARE: WordPerfect (Version 5.1)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/284,746
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/883,849
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 197/070
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 13
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-284-746-14

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 10 TGAATTGACA 21
Db 13 TGAATCGACA 2

RESULT 46
US-09-446-301A-45/c
Sequence 45, Application US/09446301A
Patent No. 6506893
GENERAL INFORMATION:
APPLICANT: ELI SOLH, NEVINE
TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED
FILE REFERENCE: 03715-0059
CURRENT APPLICATION NUMBER: US/09/446,301A
CURRENT FILING DATE: 1999-12-20
NUMBER OF SEQ ID NOS: 51
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 45
LENGTH: 13

```
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-446-301A-45
```

```
Query Match          16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      7 GAATGGAATTGG 18
        |||||
Db      13 GAATGAGTTGG 2
```

```
RESULT 47
US-09-099-932-36/c
/ Sequence 36, Application US/09099932
/ Patent No. 6570001
/ GENERAL INFORMATION:
/ APPLICANT: El Solh, Nevine
/ APPLICANT: Allignet, Jeanine
/ TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE
/ TITLE OF INVENTION: TO STREPTOGAMIN A OR TO STREPTOGAMIN B AND RELATED
/ TITLE OF INVENTION: COMPOUNDS
/ FILE REFERENCE: 03495.0173-00000
/ CURRENT APPLICATION NUMBER: US/09/099,932
/ CURRENT FILING DATE: 1998-06-19
/ EARLIER APPLICATION NUMBER: 60/050,380
/ EARLIER FILING DATE: 1997-06-20
/ NUMBER OF SEQ ID NOS: 50
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 36
/ LENGTH: 13
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-099-932-36
```

```
Query Match          16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 32;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      7 GAATGGAATTGG 18
        |||||
Db      13 GAATGAGTTGG 2
```

```
RESULT 48
US-09-862-844-6/c
/ Sequence 6, Application US/09862844
/ Patent No. 6583986
/ GENERAL INFORMATION:
/ APPLICANT: Cai, Hong
/ APPLICANT: Keller, Richard
/ APPLICANT: Werner, James
/ APPLICANT: Goodwin, Peter
/ TITLE OF INVENTION: RAPID HAPLOTYPING BY SINGLE MOLECULE DETECTION
/ FILE REFERENCE: S-94,652
/ CURRENT APPLICATION NUMBER: US/09/862,844
/ CURRENT FILING DATE: 2001-05-21
/ NUMBER OF SEQ ID NOS: 21
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 6
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: PNA probe MLTCy5P
US-09-862-844-6
```

```
Query Match          15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      23 AGCCCAAGAA 32
        |||||
Db      11 AGCCCAAGAA 2
```

```
RESULT 49
US-09-862-844-8/c
/ Sequence 8, Application US/09862844
/ Patent No. 6583986
/ GENERAL INFORMATION:
/ APPLICANT: Cai, Hong
/ APPLICANT: Keller, Richard
/ APPLICANT: Werner, James
/ APPLICANT: Goodwin, Peter
/ TITLE OF INVENTION: RAPID HAPLOTYPING BY SINGLE MOLECULE DETECTION
/ FILE REFERENCE: S-94,652
/ CURRENT APPLICATION NUMBER: US/09/862,844
/ CURRENT FILING DATE: 2001-05-21
/ NUMBER OF SEQ ID NOS: 21
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 8
/ LENGTH: 12
/ TYPE: DNA
/ ORGANISM: LNA probe MLTCy5L
US-09-862-844-8
```

```
Query Match          15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 37;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      23 AGCCCAAGAA 32
        |||||
Db      11 AGCCCAAGAA 2
```

```
RESULT 50
US-08-152-955-3
/ Sequence 3, Application US/08152955
/ Patent No. 5474897
/ GENERAL INFORMATION:
/ APPLICANT: Weiss, Arthur
/ APPLICANT: Fraser, James
/ TITLE OF INVENTION: Screening Assay for the Identification
/ TITLE OF INVENTION: of Immunosuppressive Drugs
/ NUMBER OF SEQUENCES: 5
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Townsend and Townsend
/ STREET: One Market Plaza, Steuart Tower, Suite 2000
/ CITY: San Francisco
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94105
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/152,955
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/898,639
/ FILING DATE: 15-JUN-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Heslin, James M.
/ REGISTRATION NUMBER: 29,541
/ REFERENCE/DOCKET NUMBER: 2307U-356
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-326-2400
/ TELEFAX: 415-326-2422
/ INFORMATION FOR SEQ ID NO: 3:
/ SEQUENCE CHARACTERISTICS:
```

LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-152-955-3

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 44;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 54 TGGAGGTTTCA 64
|||||
Db 1 TGGAGGTTTCA 11

RESULT 51
PCT-US93-05668-3
Sequence 3, Application PC/TUS9305668

GENERAL INFORMATION:

APPLICANT: Welles, Arthur

APPLICANT: Frazer, James

TITLE OF INVENTION: Screening Assay for the Identification
of Immunosuppressive Drugs

NUMBER OF SEQUENCES: 5

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fisher & Amzel

STREET: 1320 Harbor Bay Parkway, Suite 225

CITY: Alameda

STATE: California

COUNTRY: USA

ZIP: 94501

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT/US93/05668

FILING DATE: 19930611

CLASSIFICATION:

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/898,639

FILING DATE: 15-JUN-1992

ATTORNEY/AGENT INFORMATION:

NAME: Fisher, Stanley P.

REGISTRATION NUMBER: 24,344

REFERENCE/DOCKET NUMBER: 91-143-1PCT

TELECOMMUNICATION INFORMATION:

TELEPHONE: 510-748-6868

TELEFAX: 510-748-6868

INFORMATION FOR SEQ ID NO: 3:

SEQUENCE CHARACTERISTICS:

LENGTH: 11 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

PCT-US93-05668-3

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 44;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 54 TGGAGGTTTCA 64
|||||
Db 1 TGGAGGTTTCA 11

RESULT 52
US-08-115-497-12
Sequence 12, Application US/08115497
Patent No. 551546

GENERAL INFORMATION:
APPLICANT: Koel, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESS:

ADDRESSEE: Scully, Scott, Murphy & Presser

STREET: 400 Garden City Plaza

CITY: Garden City

STATE: New York

COUNTRY: USA

ZIP: 11530

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/115,497

FILING DATE:

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Digilio, Frank S.

REGISTRATION NUMBER: 31,346

REFERENCE/DOCKET NUMBER: 8771

TELECOMMUNICATION INFORMATION:

TELEPHONE: (516) 742-4343

TELEFAX: (516) 742-4366

TELEX: 230 901 SANS UR

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 12 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-08-115-497-12

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAG 39
|||||
Db 1 AAGACAGAG 12

RESULT 53

US-08-115-497-13

Sequence 13, Application US/08115497

Patent No. 551546

GENERAL INFORMATION:

APPLICANT: Koel, Eric T.

TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS

NUMBER OF SEQUENCES: 21

CORRESPONDENCE ADDRESS:

ADDRESSEE: Scully, Scott, Murphy & Presser

STREET: 400 Garden City Plaza

CITY: Garden City

STATE: New York

COUNTRY: USA

ZIP: 11530

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/115,497

FILING DATE:

CLASSIFICATION: 514

ATTORNEY/AGENT INFORMATION:

NAME: Digilio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 13
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-115-497-13

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 28 AAGAACAGAAAG 39
Db 1 AAGAAAANAAG 12

RESULT 54
US-08-031-147A-53
Sequence 53, Application US/08031147A
Patent No. 5514577
GENERAL INFORMATION:
APPLICANT: Draper et al.
TITLE OF INVENTION: Oligonucleotide Therapies for
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Woodcock Washburn Kurtz
ADDRESS: Mackiewicz & No. 5514577is
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/031,147A
FILING DATE: March 12, 1993
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 485,297
FILING DATE: February 26, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 852,132
FILING DATE: April 28, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 954,185
FILING DATE: September 29, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISIS-0469
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

ANTI-SENSE: Yes
US-08-031-147A-53

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGG 12

RESULT 55
US-08-413-813-38
Sequence 38, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digilio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 38:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-38

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGAACAGAAAG 39
Db 1 AAGAAAANAAG 12

RESULT 56
US-08-413-813-39
Sequence 39, Application US/08413813
Patent No. 5683874
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City


```
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/413,813
FILING DATE:
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 80852YX
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 39:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-413-813-39

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGGAAG 39
      |||||
      1 AAGAAANNAAG 12

RESULT 57
US-08-466-670-12
Sequence 12, Application US/08466670
Patent No. 5808036
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
```

```
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-13

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGGAAG 39
      |||||
      1 AAGAAANNAAG 12

RESULT 58
US-08-466-670-13
Sequence 13, Application US/08466670
Patent No. 5808036
GENERAL INFORMATION:
APPLICANT: Kool, Eric T.
TITLE OF INVENTION: STEM-LOOP OLIGONUCLEOTIDES CONTAINING
PARALLEL AND ANTIPARALLEL BINDING DOMAINS
NUMBER OF SEQUENCES: 21
CORRESPONDENCE ADDRESSES:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: USA
ZIP: 11530
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/466,670
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/115,497
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Digiglio, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 8771
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-466-670-13

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGAACGGAAG 39
      |||||
      1 AAGAAANNAAG 12

RESULT 59
```

```
US-08-494-301A-12/C
; Sequence 12, Application US/08494301A
; Patent No. 5856461
; GENERAL INFORMATION:
; APPLICANT: Colote, Soudhir
; APPLICANT: Pitotzky, Eduardo
; TITLE OF INVENTION: Oligonucleotides to inhibit the
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lucas & Just
; STREET: 205 E. 42nd Street
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch,
; MEDIUM TYPE: 1.44 MB storage
; COMPUTER: IBM 486 Compatible
; OPERATING SYSTEM: MS-DOS 5.0
; SOFTWARE: WordPerfect 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/494,301A
; FILING DATE: 23-JUNE-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9413035.8
; FILING DATE: 29-JUNE-1994
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleotide
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: Yes
; US-08-494-301A-12

Query Match      14.5% Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      23 AGCCGAGAAC 33
Db      11 AGCCCAAAAC 1

RESULT 60
US-08-467-346-38
; Sequence 38, Application US/08467346
; Patent No. 5872105
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,346
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/413,813
; FILING DATE: 30-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 80852YX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-467-346-39

Query Match      14.5% Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
ISS.res

; FILING DATE: 30-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 80852YX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 38:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-467-346-38

Query Match      14.5% Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      28 AAGACAGAAAG 39
Db      1 AAGANAGAAAG 12

RESULT 61
US-08-467-346-39
; Sequence 39, Application US/08467346
; Patent No. 5872105
; GENERAL INFORMATION:
; APPLICANT: Kool, Eric T.
; TITLE OF INVENTION: SINGLE-STRANDED, CIRCULAR OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: USA
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,346
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/413,813
; FILING DATE: 30-MAR-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 80852YX
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 39:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-467-346-39

Query Match      14.5% Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 28 AGACAGAAAG 39
|||||
Db 1 AAGAAAMAAAG 12

RESULT 62
US-08-403-888A-41
Sequence 41, Application US/08403888A
Patent No. 5952490
GENERAL INFORMATION:
APPLICANT: Hanecak et al.
TITLE OF INVENTION: Oligonucleotides Having A Conserved G4 Core
TITLE OF INVENTION: Sequence
NUMBER OF SEQUENCES: 146
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5952490 is LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/403,888A
FILING DATE: 12-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/954,185
FILING DATE: 29-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legaard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-1229
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3439
TELEFAX: 215-568-3100
INFORMATION FOR SEQ ID NO: 41:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-403-888A-41

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGGG 12

RESULT 63
US-08-403-888A-57
Sequence 57, Application US/08403888A
Patent No. 5952490
GENERAL INFORMATION:
APPLICANT: Hanecak et al.
TITLE OF INVENTION: Oligonucleotides Having A Conserved G4 Core
TITLE OF INVENTION: Sequence
NUMBER OF SEQUENCES: 146
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5952490 is LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/403,888A
FILING DATE: 12-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/954,185
FILING DATE: 29-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legaard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-1229
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3439
TELEFAX: 215-568-3100
INFORMATION FOR SEQ ID NO: 57:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-403-888A-57

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGGG 12

RESULT 64
US-08-403-888A-113
Sequence 113, Application US/08403888A
Patent No. 5952490
GENERAL INFORMATION:
APPLICANT: Hanecak et al.
TITLE OF INVENTION: Oligonucleotides Having A Conserved G4 Core
TITLE OF INVENTION: Sequence
NUMBER OF SEQUENCES: 146
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5952490 is LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/403,888A
FILING DATE: 12-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/954,185
FILING DATE: 29-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legaard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-1229
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3439
TELEFAX: 215-568-3100
INFORMATION FOR SEQ ID NO: 113:
SEQUENCE CHARACTERISTICS:

LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-403-888A-113

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
DB 2 TGGGGTTGGAG 12

RESULT 65

US-08-819-867-5
Sequence 5, Application US/08819867
Patent No. 6007989

GENERAL INFORMATION:

APPLICANT: Michael D. West
APPLICANT: Calvin B. Harley
APPLICANT: Scott L. Weinrich
APPLICANT: Catherine M. Strahl
APPLICANT: Michael J. Weachern
APPLICANT: Jerry Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth H. Blackburn
APPLICANT: Nam Woo Kim
APPLICANT: Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
TITLE OF INVENTION: CONDITIONS RELATED TO
TITLE OF INVENTION: TELOMERE LENGTH AND/OR
TITLE OF INVENTION: TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/819,867
FILING DATE: March 14, 1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/153,051
FILING DATE: No. 6007989 September 12, 1993
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-819-867-5

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
DB 2 TGGGGTTGGAG 12

RESULT 66

US-08-819-867-33
Sequence 33, Application US/08819867
Patent No. 6007989

GENERAL INFORMATION:

APPLICANT: Michael D. West
APPLICANT: Calvin B. Harley
APPLICANT: Scott L. Weinrich
APPLICANT: Catherine M. Strahl
APPLICANT: Michael J. Weachern
APPLICANT: Jerry Shay
APPLICANT: Woodring E. Wright
APPLICANT: Elizabeth H. Blackburn
APPLICANT: Nam Woo Kim
APPLICANT: Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
TITLE OF INVENTION: CONDITIONS RELATED TO
TITLE OF INVENTION: TELOMERE LENGTH AND/OR
TITLE OF INVENTION: TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/819,867
FILING DATE: March 14, 1997
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/153,051
FILING DATE: No. 6007989 September 12, 1993
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-819-867-33

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGTTGAG 58
|||
Db 2 TGGGTTGAG 12

RESULT 67

US-08-819-867-35
; Sequence 35, Application US/08819867
; Patent No. 6007989
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; APPLICANT: Calvin B. Harley
; APPLICANT: Scott L. Weinrich
; APPLICANT: Catherine M. Strahl
; APPLICANT: Michael J. McEachern
; APPLICANT: Jerry Shay
; APPLICANT: Woodring E. Wright
; APPLICANT: Elizabeth H. Blackburn
; APPLICANT: Nam Woo Kim
; APPLICANT: Homayoun Vaziri
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
; TITLE OF INVENTION: CONDITIONS RELATED TO
; TITLE OF INVENTION: TELOMERE LENGTH AND/OR
; TITLE OF INVENTION: TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/819,867
; FILING DATE: March 14, 1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/153,051
; FILING DATE: No. 6007989 September 12, 1993
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Chambers, Daniel M.
; REGISTRATION NUMBER: 34,561
; REFERENCE/DOCKET NUMBER: 224/232
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-819-867-35

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGTTGAG 58
|||
Db 2 TGGGTTGAG 12

RESULT 68

US-08-679-493A-64/C
; Sequence 64, Application US/08679493A
; Patent No. 6303295
; GENERAL INFORMATION:
; APPLICANT: Taylor, Ethan W.
; TITLE OF INVENTION: SELENOPROTEINS, CODING SEQUENCES AND METHODS
; FILE REFERENCE: 55-95
; CURRENT APPLICATION NUMBER: US/08/679,493A
; CURRENT FILING DATE: 1996-07-12
; PRIOR APPLICATION NUMBER: 60/001203
; PRIOR FILING DATE: 1995-07-14
; PRIOR APPLICATION NUMBER: 60/003,112
; PRIOR FILING DATE: 1995-09-01
; NUMBER OF SEQ ID NOS: 216
; SOFTWARE: Patent Ver. 2.0
; SEQ ID NO 64
; LENGTH: 12
; TYPE: RNA
; ORGANISM: Human immunodeficiency virus type 1
; US-08-679-493A-64

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 3 TCTGGAATGGA 13
|||
Db 12 TCTGGAATGGA 2

RESULT 69

US-09-378-535-5
; Sequence 5, Application US/09378535
; Patent No. 6551774
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; Calvin B. Harley
; Scott L. Weinrich
; Catherine M. Strahl
; Michael J. McEachern
; Jerry Shay
; Woodring E. Wright
; Elizabeth H. Blackburn
; Nam Woo Kim
; Homayoun Vaziri
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
; CONDITIONS RELATED TO
; TELOMERE LENGTH AND/OR
; TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,535
; FILING DATE: 20-Aug-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/819,867
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:

NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-378-535-5

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||
Db 2 TGGGGTTGGAG 12

RESULT 70
US-09-378-535-33
Sequence 33, Application US/09378535
Patent No. 6551774
GENERAL INFORMATION:
APPLICANT: Michael D. West
Calvin B. Harley
Scott L. Weinrich
Catherine M. Strahl
Michael J. McEachern
Jerry Shay
Woodring E. Wright
Elizabeth H. Blackburn
Nam Woo Kim
Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
CONDITIONS RELATED TO
TELOMERE LENGTH AND/OR
TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/378,535
FILING DATE: 20-Aug-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/819,867
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-09-378-535-33

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||
Db 2 TGGGGTTGGAG 12

RESULT 71
US-09-378-535-35
Sequence 35, Application US/09378535
Patent No. 6551774
GENERAL INFORMATION:
APPLICANT: Michael D. West
Calvin B. Harley
Scott L. Weinrich
Catherine M. Strahl
Michael J. McEachern
Jerry Shay
Woodring E. Wright
Elizabeth H. Blackburn
Nam Woo Kim
Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
CONDITIONS RELATED TO
TELOMERE LENGTH AND/OR
TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/378,535
FILING DATE: 20-Aug-1999
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/819,867
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 35;
US-09-378-535-35

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGGG 12

RESULT 72
PCT-US94-02471-53
Sequence 53, Application PC/TUS9402471

GENERAL INFORMATION:
APPLICANT: Draper et al.
TITLE OF INVENTION: Oligonucleotide Therapies for
TITLE OF INVENTION: Modulating the Effects of Herpesviruses
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz
ADDRESSEE: Mackiewicz & Norris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2 PC-DOS
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/02471
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 485,297
FILING DATE: February 26, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 852,112
FILING DATE: April 28, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 954,185
FILING DATE: September 29, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISIS-0469
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 12
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
ANTI-SENSE: yes
PCT-US94-02471-53

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 45;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
|||||
Db 2 TGGGGTTGGGG 12

RESULT 73

US-08-482-115B-34/C
Sequence 34, Application US/08482115B
Patent No. 576679

GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Assays for the RNA Component of Human
TITLE OF INVENTION: Telomerase
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,115B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Stofella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000830US

TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA

US-08-482-115B-34

Query Match 13.8%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
|||||
Db 9 TGGGGTTGG 1

RESULT 74
US-08-472-802C-32/C
Sequence 32, Application US/08472802C
Patent No. 5958680

GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California

US-08-472-802C-32/C
Sequence 32, Application US/08472802C
Patent No. 5958680
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 44
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California

COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/472,802C
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000820
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0200
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-08-472-802C-32

Query Match 13.8%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
|||||
DB 9 TGGGGTTGG 1

RESULT 75
US-09-057-351-32/C
Sequence 32, Application US/09057351
Patent No. 6548298
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/057,351
FILING DATE: 08-APR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,802
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000821US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 32:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: RNA
US-09-057-351-32

Query Match 13.8%; Score 9; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
|||||
DB 9 TGGGGTTGG 1

RESULT 76
US-08-330-123A-10/C
Sequence 10, Application US/08330123A
Patent No. 5583018
GENERAL INFORMATION:
APPLICANT: VILLEPONTEAU, Bryant
APPLICANT: FENG, Junli
APPLICANT: FUNK, Walter
APPLICANT: ANDREWS, William H.
TITLE OF INVENTION: HUMAN TELOMERASE
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourlie and Crew
STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/330,123A
FILING DATE: 27-OCT-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000810
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA
US-08-330-123A-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGCTTG 56
Db 9 TGGGCTTG 1

RESULT 77
US-08-482-115B-10/C
Sequence 10, Application US/08482115B
Patent No. 5776679

GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Assays for the RNA Component of Human
TITLE OF INVENTION: Telomerase
NUMBER OF SEQUENCES: 40
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,115B
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000810US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-482-115B-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGCTTG 56
Db 9 TGGGCTTG 1

RESULT 78
US-08-660-678A-10/C

Sequence 10, Application US/08660678A
Patent No. 5837857

GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/660,678A
FILING DATE: 05-JUN-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000811US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-660-678A-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGCTTG 56
Db 9 TGGGCTTG 1

RESULT 79
US-08-485-778-41/C
Sequence 41, Application US/08485778
Patent No. 5876979
GENERAL INFORMATION:
APPLICANT: Andrews, William H.
APPLICANT: Avilion, Ariel Athena
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Greider, Carol
APPLICANT: Marhuenda, Maria Antonia Blasco
APPLICANT: Villeponteau, Bryant
TITLE OF INVENTION: RNA COMPONENT OF TELOMERASE
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Militia Drive

```

; CITY: Lexington
; STATE: MA
; COUNTRY: US
; ZIP: 02173
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,778
; FILING DATE: 07-JE-1995
; CLASSIFICATION: 435
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/387,524
; FILING DATE: 13-FEB-1995
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/330,123
; FILING DATE: 27-OCT-1994
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Granahan, Patricia
; REGISTRATION NUMBER: 32,227
; REFERENCE/DOCKET NUMBER: CSHL94-05A4
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-861-6240
; TELEFAX: 617-861-9540
; INFORMATION FOR SEQ ID NO: 41:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-485-778-41

Query Match      13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 TGGGGTTGG 56
      |||||
Db      9 TGGGGTTGG 1

RESULT 80
US-08-472-802C-11/C
; Sequence 11, Application US/08472802C
; Patent No. 5958680
; GENERAL INFORMATION:
; APPLICANT: Villeponteau, Bryant
; APPLICANT: Feng, Junli
; TITLE OF INVENTION: Mammalian Telomerase
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/472,802C
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 514
; PRIORITY APPLICATION DATA:

```

```

; APPLICATION NUMBER: US 08/272,102
; FILING DATE: 07-JUL-1994
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: US 08/330,123
; FILING DATE: 27-OCT-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 15389-000820
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: RNA
; US-08-472-802C-11

Query Match      13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 TGGGGTTGG 56
      |||||
Db      9 TGGGGTTGG 1

RESULT 81
US-08-388-353-513
; Sequence 513, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digilio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 513:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)

```

US-08-388-353-513

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 5 TGGAAATGGA 13
|||||||
Db 2 TGGAAATGGA 10

RESULT 82

US-08-388-353-514
; Sequence 514, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Digiglio, Frank S.
; REGISTRATION NUMBER: 31,346
; REFERENCE/DOCKET NUMBER: 9606
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; TELEX: 230 901 SANS UR
; INFORMATION FOR SEQ ID NO: 514:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-388-353-514

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 5 TGGAAATGGA 13
|||||||
Db 1 TGGAAATGGA 9

RESULT 83

US-08-388-353-547
; Sequence 547, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.

APPLICANT: Crowe, Suzanne
APPLICANT: Cooper, David
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 800
CORRESPONDENCE ADDRESS:
ADDRESSEE: Scully, Scott, Murphy & Presser
STREET: 400 Garden City Plaza
CITY: Garden City
STATE: New York
COUNTRY: United States
ZIP: 11530

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patentin Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/388,353

FILING DATE: 14-FEB-1995

CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:

NAME: Digiglio, Frank S.

REGISTRATION NUMBER: 31,346

REFERENCE/DOCKET NUMBER: 9606

TELECOMMUNICATION INFORMATION:

TELEPHONE: (516) 742-4343

TELEFAX: (516) 742-4366

TELEX: 230 901 SANS UR

INFORMATION FOR SEQ ID NO: 547:

SEQUENCE CHARACTERISTICS:

LENGTH: 10 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-08-388-353-547

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 54 TGGAGGTTT 62
|||||||
Db 2 TGGAGGTTT 10

RESULT 84

US-08-388-353-548
; Sequence 548, Application US/08388353
; Patent No. 6010895
; GENERAL INFORMATION:
; APPLICANT: Deacon, Nicholas J.
; APPLICANT: Learmont, Jennifer C.
; APPLICANT: McPhee, Dale A.
; APPLICANT: Crowe, Suzanne
; APPLICANT: Cooper, David
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 800
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Scully, Scott, Murphy & Presser
; STREET: 400 Garden City Plaza
; CITY: Garden City
; STATE: New York
; COUNTRY: United States
; ZIP: 11530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/388,353
; FILING DATE: 14-FEB-1995

CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: DIGIGLO, Frank S.
REGISTRATION NUMBER: 31,346
REFERENCE/DOCKET NUMBER: 9606
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
TELEX: 230 901 SANS UR
INFORMATION FOR SEQ ID NO: 548:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-388-353-548

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 TGGAGCTT 62
DB 1 TGGAGCTT 9

RESULT 85
US-08-520-550A-41/C
Sequence 41, Application US/08520550A
Patent No. 6013468
GENERAL INFORMATION:
APPLICANT: Andrews, William H.
APPLICANT: Avilion, Ariel A.
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Greider, Carol
APPLICANT: Marinenda, Maria A. B.
APPLICANT: Villeponteau, Bryant
TITLE OF INVENTION: RNA Component of Telomerase
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESS: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Millitia Drive
CITY: Lexington
STATE: MA
COUNTRY: US
ZIP: 02173
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/520, 550A
FILING DATE: 29-AUG-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/387,524
FILING DATE: 13-FEB-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: CSH94-05A3B
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540

INFORMATION FOR SEQ ID NO: 41:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-520-550A-41

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGCTGG 56
DB 9 TGGGCTGG 1

RESULT 86
US-08-488-551B-513
Sequence 513, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
APPLICANT: David Cooper
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESS:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488, 551B
FILING DATE: 07-JUN-1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3664 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLO
REFERENCE/DOCKET NUMBER: 9606Z
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 513:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-513

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGATGGA 13

Db 2 TGGATGCA 10

```

RESULT 87
US-08-488-551B-514
; Sequence 514, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PN0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PN3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 96062
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 514:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-514

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGATGCA 13
Db 1 TGGATGCA 9

RESULT 88
US-08-488-551B-547
; Sequence 547, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25

```

```

; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/488,551B
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PM3864 (AU)
; FILING DATE: 14-FEB-1994
; APPLICATION NUMBER: PM4002 (AU)
; FILING DATE: 21-FEB-1994
; APPLICATION NUMBER: PN0284 (AU)
; FILING DATE: 23-DEC-1994
; APPLICATION NUMBER: US 08/388,353
; FILING DATE: 14-FEB-1995
; APPLICATION NUMBER: PN3021/95
; FILING DATE: 17-MAY-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: FRANK S. DIGIGLIO
; REFERENCE/DOCKET NUMBER: 96062
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (516) 742-4343
; TELEFAX: (516) 742-4366
; INFORMATION FOR SEQ ID NO: 547:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 10 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-488-551B-547

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 TGGAGTTT 62
Db 2 TGGAGTTT 10

RESULT 89
US-08-488-551B-548
; Sequence 548, Application US/08488551B
; Patent No. 6015661
; GENERAL INFORMATION:
; APPLICANT: Nicholas J. Deacon
; APPLICANT: Dale A. McPhee
; APPLICANT: David Cooper
; TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
; NUMBER OF SEQUENCES: 841
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
; STREET: 400 GARDEN CITY PLAZA
; CITY: GARDEN CITY
; STATE: NEW YORK
; COUNTRY: U.S.A.
; ZIP: 11530-0299
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25

```

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 548:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-548

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 54 TGGAGGTTT 62
|||||||
Db 1 TGGAGGTTT 9

RESULT 90
US-08-488-551B-831
Sequence 831, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESSES:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95

FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 831:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-488-551B-831

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGATGGA 13
|||||||
Db 2 TGGATGGA 10

RESULT 91
US-08-488-551B-832
Sequence 832, Application US/08488551B
Patent No. 6015661
GENERAL INFORMATION:
APPLICANT: Nicholas J. Deacon
APPLICANT: Dale A. McPhee
TITLE OF INVENTION: NON-PATHOGENIC STRAINS OF HIV-1
NUMBER OF SEQUENCES: 841
CORRESPONDENCE ADDRESSES:
ADDRESSEE: SCULLY, SCOTT, MURPHY & PRESSER
STREET: 400 GARDEN CITY PLAZA
CITY: GARDEN CITY
STATE: NEW YORK
COUNTRY: U.S.A.
ZIP: 11530-0299
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/488,551B
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PM3864 (AU)
FILING DATE: 14-FEB-1994
APPLICATION NUMBER: PM4002 (AU)
FILING DATE: 21-FEB-1994
APPLICATION NUMBER: PM0284 (AU)
FILING DATE: 23-DEC-1994
APPLICATION NUMBER: US 08/388,353
FILING DATE: 14-FEB-1995
APPLICATION NUMBER: PM3021/95
FILING DATE: 17-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: FRANK S. DIGIGLIO
REFERENCE/DOCKET NUMBER: 96062
TELECOMMUNICATION INFORMATION:
TELEPHONE: (516) 742-4343
TELEFAX: (516) 742-4366
INFORMATION FOR SEQ ID NO: 832:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA
US-08-488-551B-832

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TGGATGCA 13
Db 1 TGGATGCA 9

RESULT 92

US-08-998-443-10/c
Sequence 10, Application US/08998443
Patent No. 6054575
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/998,443
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/660,678
FILING DATE: 05-JUN-1996
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000811US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-998-443-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGTTGG 56
Db 9 TGGGTTGG 1

RESULT 93

US-09-060-523-10/c
Sequence 10, Application US/09060523
Patent No. 6258535

GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/060,523
FILING DATE: 14-APR-1998
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/660,678
FILING DATE: 05-JUN-1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000813US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-060-523-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGTTGG 56
Db 9 TGGGTTGG 1

RESULT 94

US-09-580-517-10/c
Sequence 10, Application US/09580517
Patent No. 6320039
GENERAL INFORMATION:
APPLICANT: VILLEPONTEAU, Bryant
APPLICANT: FENG, Junli
APPLICANT: FUNK, Walter
APPLICANT: ANDREWS, William H.

TITLE OF INVENTION: HUMAN TELOMERASE
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Khourie and Crew

STREET: 379 Lytton Avenue
CITY: Palo Alto
STATE: California
COUNTRY: US
ZIP: 94301
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/580,517
FILING DATE: 25-May-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/330,123
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 15389-000810
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 326-2400
TELEFAX: (415) 326-2422
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 10:
US-09-580-517-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
|||||||
Db 9 TGGGGTTGG 1

RESULT 95
US-09-057-351-10/c
Sequence 10, Application US/09057351
Patent No. 6548298
GENERAL INFORMATION:
APPLICANT: Villeponteau, Bryant
APPLICANT: Feng, Junli
APPLICANT: Funk, Walter
APPLICANT: Andrews, William H.
TITLE OF INVENTION: Mammalian Telomerase
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/057,351
FILING DATE: 08-APR-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/272,102
FILING DATE: 07-JUL-1994

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/330,123
FILING DATE: 27-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/472,802
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Storella, John R.
REGISTRATION NUMBER: 32,944
REFERENCE/DOCKET NUMBER: 015389-000821US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 10 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-057-351-10

Query Match 13.8%; Score 9; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGG 56
|||||||
Db 9 TGGGGTTGG 1

RESULT 96
PCT-US96-09430-21/c
Sequence 21, Application PC/TUS9609430
GENERAL INFORMATION:
APPLICANT: Glazer, Peter M.
TITLE OF INVENTION: TREATMENT OF HEMOGLOBINOPATHIES
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: OncorPharm, Inc.
STREET: 200 Perry Parkway
CITY: Gaithersburg
STATE: Maryland
COUNTRY: US
ZIP: 20877
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/09430
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/473,845
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Katta, Glenn E.
REGISTRATION NUMBER: 30,649
REFERENCE/DOCKET NUMBER: PA-0040
TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-527-2058
TELEFAX: 301-208-6997
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 11 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO


```

APPLICANT: Perler, Francine
APPLICANT: Kucera, Rebecca
APPLICANT: Jack, William B.
TITLE OF INVENTION: RECOMBINANT THERMOSTABLE DNA
TITLE OF INVENTION: POLYMERASE FROM ARCHAEABACTERIA
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: GREGORY D. WILLIAMS, NEW ENGLAND BIOLABS,
ADDRESS: INC.
STREET: 32 TOZER ROAD
CITY: BEVERLY
STATE: MASSACHUSETTS
COUNTRY: US
ZIP: 01915
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/222,715B
FILING DATE: 04-APR-1994
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/167,238
FILING DATE: 15-DEC-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/686,340
FILING DATE: 17-APR-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/626,057
FILING DATE: 11-DEC-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/513,994
FILING DATE: 26-APR-1990
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Gregory D.
REGISTRATION NUMBER: 30901
REFERENCE/DOCKET NUMBER: NEB-054C3FC2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (508) 927-5054
TELEFAX: (508) 927-1705
TELEX:
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: unknown
TOPOLOGY: unknown
US-08-222-715B-19

Query Match 13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 AAGAACCTT 45
|||
Db 12 AAGAACCTT 4

RESULT 100
US-09-281-418-58
Sequence 58, Application US/09281418
Patent No. 6287769
GENERAL INFORMATION:
APPLICANT: Inoue, Takakazu
TITLE OF INVENTION: Method of Amplifying DNA Fragment, Apparatus for Amplifying DNA F
TITLE OF INVENTION: Agent, Method of Assaying Microorganisms, Method of Analyzing Mi
TITLE OF INVENTION: nisms and Method of Assaying Contaminant
FILE REFERENCE: 9982-7
CURRENT APPLICATION NUMBER: US/09/281,418
CURRENT FILING DATE: 1999-03-30
EARLIER APPLICATION NUMBER: JF/1998/87651

```

```

EARLIER FILING DATE: 1998-03-31
EARLIER APPLICATION NUMBER: JP/1999/69694
EARLIER FILING DATE: 1999-03-16
NUMBER OF SEQ ID NOS: 216
SEQ ID NO 58
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-09-281-418-58

Query Match          13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches          9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY          12 GAATTGGAC 20
DB          2 GAATTGGAC 10

RESULT 101
PCT-US96-09430-16/c
Sequence 16, Application PC/TUS9609430
GENERAL INFORMATION:
APPLICANT: Glazer, Peter M.
TITLE OF INVENTION: TREATMENT OF HEMOGLOBINOPATHIES
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: OncorPharm, Inc.
STREET: 200 Perry Parkway
CITY: Gaithersburg
STATE: Maryland
COUNTRY: US
ZIP: 20877
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/09430
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/473,845
FILING DATE: 07-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: Kaita, Glenn E.
REGISTRATION NUMBER: 30,649
REFERENCE/DOCKET NUMBER: PA-0040
TELECOMMUNICATION INFORMATION:
TELEPHONE: 301-527-2058
TELEFAX: 301-208-6997
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT-US96-09430-16

Query Match          13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches          9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY          36 AAAGAACCT 44
DB          12 AAAGAACCT 4

```

```
RESULT 102
PCT-US96-09430-17/c
; Sequence 17, Application PC/TUS9609430
; GENERAL INFORMATION:
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: TREATMENT OF HEMOGLOBINOPATHIES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oncorphan, Inc.
; STREET: 200 Perry Parkway
; CITY: Gaithersburg
; STATE: Maryland
; COUNTRY: US
; ZIP: 20877
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/09430
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/473,845
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Karta, Glenn E.
; REGISTRATION NUMBER: 30,649
; REFERENCE/DOCKET NUMBER: PA-0040
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-527-2058
; TELEFAX: 301-208-6997
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
;
PCT-US96-09430-17

Query Match          13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      36 AAAGAACT 44
      |||||
Db      12 AAAGAACT 4

RESULT 103
PCT-US96-09430-18/c
; Sequence 18, Application PC/TUS9609430
; GENERAL INFORMATION:
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: TREATMENT OF HEMOGLOBINOPATHIES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oncorphan, Inc.
; STREET: 200 Perry Parkway
; CITY: Gaithersburg
; STATE: Maryland
; COUNTRY: US
; ZIP: 20877
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
```

```

;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US96/09430
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/473,845
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Karta, Glenn E.
; REGISTRATION NUMBER: 30,649
; REFERENCE/DOCKET NUMBER: PA-0040
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 301-527-2058
; TELEFAX: 301-208-6997
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
;
PCT-US96-09430-18

Query Match          13.8%; Score 9; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 52;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      36 AAAGAACT 44
      |||||
Db      12 AAAGAACT 4
```

Search completed: August 12, 2004, 15:34:29
Job time : 0.001 secs

THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 12, 2004, 15:28:53 ; Search time 1 Seconds
(without alignments)
0.904 Million cell updates/sec

Title: US-10-033-742-3

Perfect score: 65

Sequence: 1 ttcttcggaatgcgaattgcac.....gtcggggcttgagagtttcac 65

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 534 seqs, 6954 residues

Total number of hits satisfying chosen parameters: 1068

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 534 summaries

Database : ngs:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	36.9	24	1	ADCO2407
2	20	30.8	20	1	AAD57273
3	20	30.8	20	1	AAD57274
4	20	30.8	20	1	AAD57275
5	20	30.8	20	1	AAD57275
6	19.8	30.5	23	1	AAV82678
7	15.8	24.3	21	1	AAF74520
8	14.4	22.2	18	1	AAI42340
9	14	21.5	18	1	AAO99361
10	13.4	20.6	16	1	ABX75231
11	13.4	20.6	16	1	ABX75231
12	13.4	20.6	16	1	ABX75231
13	13	20.0	17	1	ABK02829
14	13	20.0	17	1	ABK02829
15	13	20.0	17	1	ABK02829
16	13	20.0	17	1	ABK02829
17	13	20.0	17	1	ABK02829
18	12.8	19.7	17	1	AAFO6139
19	12.8	19.7	17	1	AAFO6139
20	12.8	19.7	17	1	ABK03743
21	12.8	19.7	17	1	ABK03743
22	12.8	19.7	17	1	ABK03743
23	12.4	19.1	15	1	AAZ97683
24	12.4	19.1	15	1	AAZ97683
25	12	18.5	12	1	AB167380
26	12	18.5	12	1	AB167380
27	12	18.5	12	1	AB167380
28	12	18.5	12	1	AB167380
29	12	18.5	12	1	AB167380
30	11.8	18.2	15	1	AAF51170
31	11.8	18.2	15	1	AAF51170
32	11.8	18.2	15	1	AAZ98678
33	11.8	18.2	15	1	AAZ98678

34	11.4	17.5	13	1	AAZ99594	Immunostimulatory
35	11.4	17.5	13	1	ABF69510	Oligonucleotide SE
36	11.4	17.5	13	1	ABH44501	Oligonucleotide SE
37	11.4	17.5	13	1	ABF69511	Oligonucleotide SE
38	11.4	17.5	13	1	ABF07727	Oligonucleotide SE
39	11.4	17.5	13	1	ABF07727	Oligonucleotide SE
40	11.4	17.5	13	1	ABF07727	Oligonucleotide SE
41	11.4	17.5	13	1	ABF07726	Oligonucleotide SE
42	11.4	17.5	13	1	ABH57826	Oligonucleotide SE
43	11.4	17.5	13	1	ABH44500	Oligonucleotide SE
44	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
45	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
46	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
47	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
48	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
49	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
50	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
51	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
52	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
53	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
54	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
55	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
56	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
57	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
58	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
59	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
60	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
61	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
62	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
63	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
64	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
65	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
66	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
67	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
68	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
69	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
70	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
71	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
72	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
73	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
74	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
75	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
76	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
77	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
78	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
79	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
80	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
81	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
82	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
83	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
84	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
85	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
86	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
87	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
88	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
89	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
90	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
91	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
92	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
93	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
94	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
95	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
96	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
97	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
98	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
99	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
100	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
101	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
102	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
103	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
104	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
105	11.4	17.5	13	1	ABH57827	Oligonucleotide SE
106	11.4	17.5	13	1	ABH57827	Oligonucleotide SE

C 107	10.4	16.0	12	1	AB124668	Oligonucleotide pr
C 108	10.4	16.0	12	1	AB157227	Oligonucleotide pr
C 109	10.4	16.0	12	1	ABH70112	Oligonucleotide pr
C 110	10.4	16.0	12	1	AB175408	Oligonucleotide pr
C 111	10.4	16.0	12	1	ABH76819	Oligonucleotide pr
C 112	10.4	16.0	12	1	ABH108168	Oligonucleotide pr
C 113	10.4	16.0	12	1	AB111964	Oligonucleotide pr
C 114	10.4	16.0	12	1	AB111865	Oligonucleotide pr
C 115	10.4	16.0	12	1	AB138926	Oligonucleotide pr
C 116	10.4	16.0	12	1	ABH73791	Oligonucleotide pr
C 117	10.4	16.0	12	1	AB177010	Oligonucleotide pr
C 118	10.4	16.0	12	1	AB123551	Oligonucleotide pr
C 119	10.4	16.0	12	1	AB142492	Oligonucleotide pr
C 120	10.4	16.0	12	1	AB175632	Oligonucleotide pr
C 121	10.4	16.0	12	1	AB126119	Oligonucleotide pr
C 122	10.4	16.0	12	1	AB117994	Oligonucleotide pr
C 123	10.4	16.0	12	1	AB107453	Oligonucleotide pr
C 124	10.4	16.0	12	1	AB162010	Oligonucleotide pr
C 125	10.4	16.0	12	1	AB100155	Oligonucleotide pr
C 126	10.4	16.0	12	1	ABC95493	Oligonucleotide pr
C 127	10.4	16.0	13	1	ABC72046	Oligonucleotide pr
C 128	10.4	16.0	13	1	ABC11945	Oligonucleotide pr
C 129	10.4	16.0	13	1	ABC87797	Oligonucleotide pr
C 130	10.4	16.0	13	1	ABC85082	Oligonucleotide pr
C 131	10.4	16.0	13	1	ABF60882	Oligonucleotide pr
C 132	10.4	16.0	13	1	ABF09494	Oligonucleotide pr
C 133	10.4	16.0	13	1	ABH08614	Oligonucleotide pr
C 134	10.4	16.0	13	1	AB18620	Oligonucleotide pr
C 135	10.4	16.0	13	1	ABC19997	Oligonucleotide pr
C 136	10.4	16.0	13	1	ABC95834	Oligonucleotide pr
C 137	10.4	16.0	13	1	ABC22672	Oligonucleotide pr
C 138	10.4	16.0	13	1	ABF53874	Oligonucleotide pr
C 139	10.4	16.0	13	1	ABC93477	Oligonucleotide pr
C 140	10.4	16.0	13	1	ABF19996	Oligonucleotide pr
C 141	10.4	16.0	13	1	ABF09495	Oligonucleotide pr
C 142	10.4	16.0	13	1	ABH45216	Oligonucleotide pr
C 143	10.4	16.0	13	1	ABR12720	Oligonucleotide pr
C 144	10.4	16.0	13	1	ABH18990	Oligonucleotide pr
C 145	10.4	16.0	13	1	ABH72258	Oligonucleotide pr
C 146	10.4	16.0	13	1	ABH64846	Oligonucleotide pr
C 147	10.4	16.0	13	1	ABH1688	Oligonucleotide pr
C 148	10.4	16.0	13	1	ABH18991	Oligonucleotide pr
C 149	10.4	16.0	13	1	ABC95492	Oligonucleotide pr
C 150	10.4	16.0	13	1	ABC97700	Oligonucleotide pr
C 151	10.4	16.0	13	1	ABF35272	Oligonucleotide pr
C 152	10.4	16.0	13	1	ABH56067	Oligonucleotide pr
C 153	10.4	16.0	13	1	ABC69962	Oligonucleotide pr
C 154	10.4	16.0	13	1	ABC00654	Oligonucleotide pr
C 155	10.4	16.0	13	1	ABF44599	Oligonucleotide pr
C 156	10.4	16.0	13	1	ABF72259	Oligonucleotide pr
C 157	10.4	16.0	13	1	ABC3476	Oligonucleotide pr
C 158	10.4	16.0	13	1	ABC00655	Oligonucleotide pr
C 159	10.4	16.0	13	1	ABF15052	Oligonucleotide pr
C 160	10.4	16.0	13	1	ABF15053	Oligonucleotide pr
C 161	10.4	16.0	13	1	ABF53875	Oligonucleotide pr
C 162	10.4	16.0	13	1	ABH08607	Oligonucleotide pr
C 163	10.4	16.0	13	1	ABH56066	Oligonucleotide pr
C 164	10.4	16.0	13	1	ABC55835	Oligonucleotide pr
C 165	10.4	16.0	13	1	ABC72047	Oligonucleotide pr
C 166	10.4	16.0	13	1	ABC75859	Oligonucleotide pr
C 167	10.4	16.0	13	1	ABC11944	Oligonucleotide pr
C 168	10.4	16.0	13	1	ABC87801	Oligonucleotide pr
C 169	10.4	16.0	13	1	ABF60883	Oligonucleotide pr
C 170	10.4	16.0	13	1	ABC99009	Oligonucleotide pr
C 171	10.4	16.0	13	1	ABC89701	Oligonucleotide pr
C 172	10.4	16.0	13	1	ABF67787	Oligonucleotide pr
C 173	10.4	16.0	13	1	ABF51528	Oligonucleotide pr
C 174	10.4	16.0	13	1	ABC69963	Oligonucleotide pr
C 175	10.4	16.0	13	1	ABC22673	Oligonucleotide pr
C 176	10.4	16.0	13	1	ABC99008	Oligonucleotide pr
C 177	10.4	16.0	13	1	ABC87800	Oligonucleotide pr
C 178	10.4	16.0	13	1	ABC89083	Oligonucleotide pr
C 179	10.4	16.0	13	1	ABF67786	Oligonucleotide pr
C 180	10.4	16.0	13	1	ABH08615	Oligonucleotide pr
C 181	10.4	16.0	13	1	ABH18621	Oligonucleotide pr
C 182	10.4	16.0	13	1	ABR12721	Oligonucleotide pr
C 183	10.4	16.0	13	1	ABH7796	Oligonucleotide pr
C 184	10.4	16.0	13	1	ABF35273	Oligonucleotide pr
C 185	10.4	16.0	13	1	ABF44598	Oligonucleotide pr
C 186	10.4	16.0	13	1	ABC75858	Oligonucleotide pr
C 187	10.4	16.0	13	1	ABC1689	Oligonucleotide pr
C 188	10.4	16.0	13	1	ABF51529	Oligonucleotide pr
C 189	10.4	16.0	13	1	ABH08606	Oligonucleotide pr
C 190	10.4	16.0	13	1	ABH45217	Oligonucleotide pr
C 191	10.4	16.0	13	1	ABH64847	Oligonucleotide pr
C 192	10	15.4	10	1	AAQ79357	Sequence of lympho
C 193	10	15.4	10	1	AAV50176	Yeast tag for addi
C 194	10	15.4	10	1	AAZ77894	Human dendritic ce
C 195	10	15.4	10	1	AAZ82445	Metastatic breast
C 196	10	15.4	10	1	AAZ56570	Human macrophage
C 197	10	15.4	10	1	AAH64133	Human ubiquitously
C 198	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 199	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 200	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 201	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 202	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 203	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 204	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 205	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 206	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 207	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 208	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 209	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 210	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 211	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 212	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 213	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 214	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 215	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 216	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 217	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 218	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 219	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 220	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 221	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 222	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 223	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 224	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 225	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 226	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 227	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 228	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 229	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 230	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 231	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 232	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 233	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 234	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 235	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 236	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 237	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 238	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 239	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 240	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 241	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 242	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 243	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 244	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 245	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 246	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 247	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 248	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 249	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 250	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 251	10	15.4	10	1	AAH64133	Yeast NORF gene SA
C 252	10	15.4	10	1	AAH64133	Yeast NORF gene SA

253	10	15.4	13	1	ABF78290	Oligonucleotide SE	C 326	10	15.4	13	1	ABF53077	Oligonucleotide SE
254	10	15.4	13	1	ABH09786	Oligonucleotide SE	C 327	10	15.4	13	1	ABC08543	Oligonucleotide SE
255	10	15.4	13	1	ABH14635	Oligonucleotide SE	C 328	10	15.4	13	1	ABF93014	Oligonucleotide SE
256	10	15.4	13	1	ABF35131	Oligonucleotide SE	C 329	10	15.4	13	1	ABH16776	Oligonucleotide SE
257	10	15.4	13	1	ABF68180	Oligonucleotide SE	C 330	10	15.4	13	1	ABC08542	Oligonucleotide SE
258	10	15.4	13	1	ABF72180	Oligonucleotide SE	C 331	10	15.4	13	1	ABC88550	Oligonucleotide SE
259	10	15.4	13	1	ABF78291	Oligonucleotide SE	C 332	10	15.4	13	1	ABF93538	Oligonucleotide SE
260	10	15.4	13	1	ABF78294	Oligonucleotide SE	C 333	10	15.4	13	1	ABF73194	Oligonucleotide SE
261	10	15.4	13	1	ABH12398	Oligonucleotide SE	C 334	10	15.4	13	1	ABH10858	Oligonucleotide SE
262	10	15.4	13	1	ABC18902	Oligonucleotide SE	C 335	10	15.4	13	1	ABF50991	Oligonucleotide SE
263	10	15.4	13	1	ABC18903	Oligonucleotide SE	C 336	10	15.4	13	1	ABC74004	Oligonucleotide SE
264	10	15.4	13	1	ABC63996	Oligonucleotide SE	C 337	10	15.4	13	1	ABF02806	Oligonucleotide SE
265	10	15.4	13	1	ABC53076	Oligonucleotide SE	C 338	10	15.4	13	1	ABF14905	Oligonucleotide SE
266	10	15.4	13	1	ABF14904	Oligonucleotide SE	C 339	10	15.4	13	1	ABC16840	Oligonucleotide SE
267	10	15.4	13	1	ABC16841	Oligonucleotide SE	C 340	10	15.4	13	1	ABH27161	Oligonucleotide SE
268	10	15.4	13	1	ABF29456	Oligonucleotide SE	C 341	10	15.4	13	1	ABH27162	Oligonucleotide SE
269	10	15.4	13	1	ABF78295	Oligonucleotide SE	C 342	10	15.4	13	1	ABF52056	Oligonucleotide SE
270	10	15.4	13	1	ABH28568	Oligonucleotide SE	C 343	10	15.4	13	1	ABE58187	Oligonucleotide SE
271	10	15.4	13	1	ABH09787	Oligonucleotide SE	C 344	9.8	15.1	13	1	AA019397	Partial PRSPTC-NFI
272	10	15.4	13	1	ABH41477	Oligonucleotide SE	C 345	9.8	15.1	13	1	ABF05600	Oligonucleotide SE
273	10	15.4	13	1	ABC38819	Oligonucleotide SE	C 346	9.8	15.1	13	1	ABC06574	Oligonucleotide SE
274	10	15.4	13	1	ABF35130	Oligonucleotide SE	C 347	9.8	15.1	13	1	ABC63815	Oligonucleotide SE
275	10	15.4	13	1	ABF68181	Oligonucleotide SE	C 348	9.8	15.1	13	1	ABF16688	Oligonucleotide SE
276	10	15.4	13	1	ABF72181	Oligonucleotide SE	C 349	9.8	15.1	13	1	ABF69512	Oligonucleotide SE
277	10	15.4	13	1	ABH28569	Oligonucleotide SE	C 350	9.8	15.1	13	1	ABF69513	Oligonucleotide SE
278	10	15.4	13	1	ABH66664	Oligonucleotide SE	C 351	9.8	15.1	13	1	ABH00238	Oligonucleotide SE
279	10	15.4	13	1	ABC08155	Oligonucleotide SE	C 352	9.8	15.1	13	1	ABF54295	Oligonucleotide SE
280	10	15.4	13	1	ABC08156	Oligonucleotide SE	C 353	9.8	15.1	13	1	ABF05602	Oligonucleotide SE
281	10	15.4	13	1	ABC88551	Oligonucleotide SE	C 354	9.8	15.1	13	1	ABC31788	Oligonucleotide SE
282	10	15.4	13	1	ABF14836	Oligonucleotide SE	C 355	9.8	15.1	13	1	ABC11500	Oligonucleotide SE
283	10	15.4	13	1	ABF39155	Oligonucleotide SE	C 356	9.8	15.1	13	1	ABC11501	Oligonucleotide SE
284	10	15.4	13	1	ABH36930	Oligonucleotide SE	C 357	9.8	15.1	13	1	ABC37879	Oligonucleotide SE
285	10	15.4	13	1	ABH59464	Oligonucleotide SE	C 358	9.8	15.1	13	1	ABH00234	Oligonucleotide SE
286	10	15.4	13	1	ABF21342	Oligonucleotide SE	C 359	9.8	15.1	13	1	ABF65172	Oligonucleotide SE
287	10	15.4	13	1	ABH27163	Oligonucleotide SE	C 360	9.8	15.1	13	1	ABH62562	Oligonucleotide SE
288	10	15.4	13	1	ABF52228	Oligonucleotide SE	C 361	9.8	15.1	13	1	ABC92815	Oligonucleotide SE
289	10	15.4	13	1	ABF60990	Oligonucleotide SE	C 362	9.8	15.1	13	1	ABC75155	Oligonucleotide SE
290	10	15.4	13	1	ABC68982	Oligonucleotide SE	C 363	9.8	15.1	13	1	ABC58518	Oligonucleotide SE
291	10	15.4	13	1	ABF02807	Oligonucleotide SE	C 364	9.8	15.1	13	1	ABC11401	Oligonucleotide SE
292	10	15.4	13	1	ABC66872	Oligonucleotide SE	C 365	9.8	15.1	13	1	ABF35262	Oligonucleotide SE
293	10	15.4	13	1	ABF18949	Oligonucleotide SE	C 366	9.8	15.1	13	1	ABF39902	Oligonucleotide SE
294	10	15.4	13	1	ABF24945	Oligonucleotide SE	C 367	9.8	15.1	13	1	ABH33027	Oligonucleotide SE
295	10	15.4	13	1	ABF73195	Oligonucleotide SE	C 368	9.8	15.1	13	1	ABH10963	Oligonucleotide SE
296	10	15.4	13	1	ABC69992	Oligonucleotide SE	C 369	9.8	15.1	13	1	ABH38624	Oligonucleotide SE
297	10	15.4	13	1	ABF18948	Oligonucleotide SE	C 370	9.8	15.1	13	1	ABH15566	Oligonucleotide SE
298	10	15.4	13	1	ABH16777	Oligonucleotide SE	C 371	9.8	15.1	13	1	ABH41660	Oligonucleotide SE
299	10	15.4	13	1	ABH42921	Oligonucleotide SE	C 372	9.8	15.1	13	1	ABH42926	Oligonucleotide SE
300	10	15.4	13	1	ABF14837	Oligonucleotide SE	C 373	9.8	15.1	13	1	ABH62128	Oligonucleotide SE
301	10	15.4	13	1	ABF21338	Oligonucleotide SE	C 374	9.8	15.1	13	1	ABC71135	Oligonucleotide SE
302	10	15.4	13	1	ABF21339	Oligonucleotide SE	C 375	9.8	15.1	13	1	ABC52081	Oligonucleotide SE
303	10	15.4	13	1	ABF35359	Oligonucleotide SE	C 376	9.8	15.1	13	1	ABF05603	Oligonucleotide SE
304	10	15.4	13	1	ABH36931	Oligonucleotide SE	C 377	9.8	15.1	13	1	ABC06244	Oligonucleotide SE
305	10	15.4	13	1	ABH42920	Oligonucleotide SE	C 378	9.8	15.1	13	1	ABF07731	Oligonucleotide SE
306	10	15.4	13	1	ABH66665	Oligonucleotide SE	C 379	9.8	15.1	13	1	ABC10826	Oligonucleotide SE
307	10	15.4	13	1	ABC08157	Oligonucleotide SE	C 380	9.8	15.1	13	1	ABC11400	Oligonucleotide SE
308	10	15.4	13	1	ABF21343	Oligonucleotide SE	C 381	9.8	15.1	13	1	ABF16686	Oligonucleotide SE
309	10	15.4	13	1	ABF24944	Oligonucleotide SE	C 382	9.8	15.1	13	1	ABF20476	Oligonucleotide SE
310	10	15.4	13	1	ABF52229	Oligonucleotide SE	C 383	9.8	15.1	13	1	ABF39903	Oligonucleotide SE
311	10	15.4	13	1	ABH10859	Oligonucleotide SE	C 384	9.8	15.1	13	1	ABF67880	Oligonucleotide SE
312	10	15.4	13	1	ABH12399	Oligonucleotide SE	C 385	9.8	15.1	13	1	ABF98316	Oligonucleotide SE
313	10	15.4	13	1	ABH41476	Oligonucleotide SE	C 386	9.8	15.1	13	1	ABF98317	Oligonucleotide SE
314	10	15.4	13	1	ABF14180	Oligonucleotide SE	C 387	9.8	15.1	13	1	ABH29613	Oligonucleotide SE
315	10	15.4	13	1	ABC66873	Oligonucleotide SE	C 388	9.8	15.1	13	1	ABH57829	Oligonucleotide SE
316	10	15.4	13	1	ABF39154	Oligonucleotide SE	C 389	9.8	15.1	13	1	ABH52563	Oligonucleotide SE
317	10	15.4	13	1	ABF93015	Oligonucleotide SE	C 390	9.8	15.1	13	1	ABC44907	Oligonucleotide SE
318	10	15.4	13	1	ABF52057	Oligonucleotide SE	C 391	9.8	15.1	13	1	ABC71134	Oligonucleotide SE
319	10	15.4	13	1	ABH14634	Oligonucleotide SE	C 392	9.8	15.1	13	1	ABC52080	Oligonucleotide SE
320	10	15.4	13	1	ABH59465	Oligonucleotide SE	C 393	9.8	15.1	13	1	ABF04649	Oligonucleotide SE
321	10	15.4	13	1	ABC68985	Oligonucleotide SE	C 394	9.8	15.1	13	1	ABF07729	Oligonucleotide SE
322	10	15.4	13	1	ABF29457	Oligonucleotide SE	C 395	9.8	15.1	13	1	ABC10827	Oligonucleotide SE
323	10	15.4	13	1	ABF96458	Oligonucleotide SE	C 396	9.8	15.1	13	1	ABC16849	Oligonucleotide SE
324	10	15.4	13	1	ABH27160	Oligonucleotide SE	C 397	9.8	15.1	13	1	ABF32796	Oligonucleotide SE
325	10	15.4	13	1	ABC74005	Oligonucleotide SE	C 398	9.8	15.1	13	1	ABF32797	Oligonucleotide SE

C 399	9.8	15.1	13	1	ABF47357	Oligonucleotide SE
C 400	9.8	15.1	13	1	ABF73592	Oligonucleotide SE
C 401	9.8	15.1	13	1	ABH35452	Oligonucleotide SE
C 402	9.8	15.1	13	1	ABF58451	Oligonucleotide SE
C 403	9.8	15.1	13	1	ABH34278	Oligonucleotide SE
C 404	9.8	15.1	13	1	ABF66466	Oligonucleotide SE
C 405	9.8	15.1	13	1	ABH16219	Oligonucleotide SE
C 406	9.8	15.1	13	1	ABH62129	Oligonucleotide SE
C 407	9.8	15.1	13	1	ABH31789	Oligonucleotide SE
C 408	9.8	15.1	13	1	ABF33180	Oligonucleotide SE
C 409	9.8	15.1	13	1	ABF67881	Oligonucleotide SE
C 410	9.8	15.1	13	1	ABH04581	Oligonucleotide SE
C 411	9.8	15.1	13	1	ABH05560	Oligonucleotide SE
C 412	9.8	15.1	13	1	ABF74671	Oligonucleotide SE
C 413	9.8	15.1	13	1	ABF04647	Oligonucleotide SE
C 414	9.8	15.1	13	1	ABF07330	Oligonucleotide SE
C 415	9.8	15.1	13	1	ABF34457	Oligonucleotide SE
C 416	9.8	15.1	13	1	ABF60968	Oligonucleotide SE
C 417	9.8	15.1	13	1	ABF20477	Oligonucleotide SE
C 418	9.8	15.1	13	1	ABF22178	Oligonucleotide SE
C 419	9.8	15.1	13	1	ABF32116	Oligonucleotide SE
C 420	9.8	15.1	13	1	ABF33905	Oligonucleotide SE
C 421	9.8	15.1	13	1	ABF73593	Oligonucleotide SE
C 422	9.8	15.1	13	1	ABH33543	Oligonucleotide SE
C 423	9.8	15.1	13	1	ABH10962	Oligonucleotide SE
C 424	9.8	15.1	13	1	ABF62973	Oligonucleotide SE
C 425	9.8	15.1	13	1	ABH15571	Oligonucleotide SE
C 426	9.8	15.1	13	1	ABH44502	Oligonucleotide SE
C 427	9.8	15.1	13	1	ABH62561	Oligonucleotide SE
C 428	9.8	15.1	13	1	ABF73212	Oligonucleotide SE
C 429	9.8	15.1	13	1	ABF01962	Oligonucleotide SE
C 430	9.8	15.1	13	1	ABF60969	Oligonucleotide SE
C 431	9.8	15.1	13	1	ABF61676	Oligonucleotide SE
C 432	9.8	15.1	13	1	ABF31799	Oligonucleotide SE
C 433	9.8	15.1	13	1	ABF32795	Oligonucleotide SE
C 434	9.8	15.1	13	1	ABH22410	Oligonucleotide SE
C 435	9.8	15.1	13	1	ABH05561	Oligonucleotide SE
C 436	9.8	15.1	13	1	ABH34279	Oligonucleotide SE
C 437	9.8	15.1	13	1	ABH16293	Oligonucleotide SE
C 438	9.8	15.1	13	1	ABH44503	Oligonucleotide SE
C 439	9.8	15.1	13	1	ABF73213	Oligonucleotide SE
C 440	9.8	15.1	13	1	ABF62973	Oligonucleotide SE
C 441	9.8	15.1	13	1	ABF04646	Oligonucleotide SE
C 442	9.8	15.1	13	1	ABF55719	Oligonucleotide SE
C 443	9.8	15.1	13	1	ABF09481	Oligonucleotide SE
C 444	9.8	15.1	13	1	ABF16848	Oligonucleotide SE
C 445	9.8	15.1	13	1	ABF17417	Oligonucleotide SE
C 446	9.8	15.1	13	1	ABF1397	Oligonucleotide SE
C 447	9.8	15.1	13	1	ABH21397	Oligonucleotide SE
C 448	9.8	15.1	13	1	ABF75985	Oligonucleotide SE
C 449	9.8	15.1	13	1	ABH38625	Oligonucleotide SE
C 450	9.8	15.1	13	1	ABH68819	Oligonucleotide SE
C 451	9.8	15.1	13	1	ABF44906	Oligonucleotide SE
C 452	9.8	15.1	13	1	ABF74670	Oligonucleotide SE
C 453	9.8	15.1	13	1	ABF04648	Oligonucleotide SE
C 454	9.8	15.1	13	1	ABF05436	Oligonucleotide SE
C 455	9.8	15.1	13	1	ABF05437	Oligonucleotide SE
C 456	9.8	15.1	13	1	ABF06575	Oligonucleotide SE
C 457	9.8	15.1	13	1	ABF058519	Oligonucleotide SE
C 458	9.8	15.1	13	1	ABF09480	Oligonucleotide SE
C 459	9.8	15.1	13	1	ABF16689	Oligonucleotide SE
C 460	9.8	15.1	13	1	ABF67882	Oligonucleotide SE
C 461	9.8	15.1	13	1	ABF98633	Oligonucleotide SE
C 462	9.8	15.1	13	1	ABF73728	Oligonucleotide SE
C 463	9.8	15.1	13	1	ABF92814	Oligonucleotide SE
C 464	9.8	15.1	13	1	ABF20850	Oligonucleotide SE
C 465	9.8	15.1	13	1	ABF73225	Oligonucleotide SE
C 466	9.8	15.1	13	1	ABF31798	Oligonucleotide SE
C 467	9.8	15.1	13	1	ABF32794	Oligonucleotide SE
C 468	9.8	15.1	13	1	ABF33181	Oligonucleotide SE
C 469	9.8	15.1	13	1	ABF75984	Oligonucleotide SE
C 470	9.8	15.1	13	1	ABF58450	Oligonucleotide SE
C 471	9.8	15.1	13	1	ABF90374	Oligonucleotide SE
C 472	9.8	15.1	13	1	ABF66699	Oligonucleotide SE
C 473	9.8	15.1	13	1	ABH57530	Oligonucleotide SE
C 474	9.8	15.1	13	1	ABF75154	Oligonucleotide SE
C 475	9.8	15.1	13	1	ABF05601	Oligonucleotide SE
C 476	9.8	15.1	13	1	ABF055718	Oligonucleotide SE
C 477	9.8	15.1	13	1	ABF17416	Oligonucleotide SE
C 478	9.8	15.1	13	1	ABF31794	Oligonucleotide SE
C 479	9.8	15.1	13	1	ABF31795	Oligonucleotide SE
C 480	9.8	15.1	13	1	ABF39904	Oligonucleotide SE
C 481	9.8	15.1	13	1	ABH00239	Oligonucleotide SE
C 482	9.8	15.1	13	1	ABF50558	Oligonucleotide SE
C 483	9.8	15.1	13	1	ABH12784	Oligonucleotide SE
C 484	9.8	15.1	13	1	ABF88569	Oligonucleotide SE
C 485	9.8	15.1	13	1	ABF65173	Oligonucleotide SE
C 486	9.8	15.1	13	1	ABH15570	Oligonucleotide SE
C 487	9.8	15.1	13	1	ABH16218	Oligonucleotide SE
C 488	9.8	15.1	13	1	ABH16292	Oligonucleotide SE
C 489	9.8	15.1	13	1	ABH42927	Oligonucleotide SE
C 490	9.8	15.1	13	1	ABH62560	Oligonucleotide SE
C 491	9.8	15.1	13	1	ABF62973	Oligonucleotide SE
C 492	9.8	15.1	13	1	ABF68818	Oligonucleotide SE
C 493	9.8	15.1	13	1	ABF34456	Oligonucleotide SE
C 494	9.8	15.1	13	1	ABH21396	Oligonucleotide SE
C 495	9.8	15.1	13	1	ABH22411	Oligonucleotide SE
C 496	9.8	15.1	13	1	ABF75610	Oligonucleotide SE
C 497	9.8	15.1	13	1	ABF75611	Oligonucleotide SE
C 498	9.8	15.1	13	1	ABH04580	Oligonucleotide SE
C 499	9.8	15.1	13	1	ABH12785	Oligonucleotide SE
C 500	9.8	15.1	13	1	ABF68985	Oligonucleotide SE
C 501	9.8	15.1	13	1	ABF54294	Oligonucleotide SE
C 502	9.8	15.1	13	1	ABF73224	Oligonucleotide SE
C 503	9.8	15.1	13	1	ABF73225	Oligonucleotide SE
C 504	9.8	15.1	13	1	ABF73729	Oligonucleotide SE
C 505	9.8	15.1	13	1	ABH00235	Oligonucleotide SE
C 506	9.8	15.1	13	1	ABF50559	Oligonucleotide SE
C 507	9.8	15.1	13	1	ABH29612	Oligonucleotide SE
C 508	9.8	15.1	13	1	ABF66467	Oligonucleotide SE
C 509	9.8	15.1	13	1	ABF68984	Oligonucleotide SE
C 510	9.8	15.1	13	1	ABF68984	Oligonucleotide SE
C 511	9.8	15.1	13	1	ABF06245	Oligonucleotide SE
C 512	9.8	15.1	13	1	ABF07728	Oligonucleotide SE
C 513	9.8	15.1	13	1	ABF61677	Oligonucleotide SE
C 514	9.8	15.1	13	1	ABF35263	Oligonucleotide SE
C 515	9.8	15.1	13	1	ABF47356	Oligonucleotide SE
C 516	9.8	15.1	13	1	ABH33026	Oligonucleotide SE
C 517	9.8	15.1	13	1	ABF8368	Oligonucleotide SE
C 518	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 519	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 520	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 521	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 522	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 523	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 524	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 525	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 526	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 527	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 528	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 529	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 530	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 531	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 532	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 533	9.8	15.1	13	1	ABF20851	Oligonucleotide SE
C 534	9.8	15.1	13	1	ABF20851	Oligonucleotide SE

ALIGNMENTS

RESULT 1
ADCC02407/c
ID ADCC02407 standard; DNA; 24 BP.
XX
AC ADCC02407;


```

XX 16-DEC-2003 (first entry)
DT Human macrophage inhibitory protein-3-alpha (MIP-3-alpha) PCR primer #4.
XX
XX osteoarthritis; macrophage inhibitory protein-3-alpha; MIP-3-alpha;
XX CCR6 receptor; PCR, primer; human; ss.
XX
XX Homo sapiens.
XX
XX WO2003069348-A2.
XX
XX 21-AUG-2003.
XX
XX 14-FEB-2003; 2003WO-EP001506.
XX
XX 15-FEB-2002; 2002US-0357588P.
XX
XX (NOVS ) NOVARTIS AG.
XX PA (NOVS ) NOVARTIS PHARMA GMBH.
XX
XX Kumar CS, Labow MA, Latario BJ;
XX
XX WPI; 2003-671684/63.
XX
XX Identifying compounds for diagnosing and treating osteoarthritis
PT utilizing reaction mixtures with chemokine macrophage inhibitory protein-
PT 3 alpha polypeptides and CCR6 receptors.
XX
XX Example 2; Page 62; 72pp; English.
XX
XX The invention comprises a method for identifying compounds that may be
XX used to treat osteoarthritis. The method involves contacting a reaction
XX mixture having a macrophage inhibitory protein-3-alpha (MIP-3-alpha) and
XX a CCR6 receptor with or without a test compound, detecting levels of
XX formation of the binding complex in the reaction mixture and comparing
XX the level of the binding complex formed in the presence and absence of
XX the test compound. A decrease indicates that the test compound may be
XX used to treat osteoarthritis. The method of the invention is useful for
XX identifying compounds that modulate MIP-3-alpha binding to its receptor,
XX and for treating, diagnosing and ameliorating osteoarthritis. The present
XX DNA sequence represents a PCR primer that was used to amplify the human
XX MIP-3-alpha gene.
XX
XX Sequence 24 BP; 1 A; 6 C; 5 G; 12 T; 0 U; 0 Other;
SQ
Query Match 36.9%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 17 GGACATAGCCCAAGAACAGAAAGA 40
DB 24 GGACATAGCCCAAGAACAGAAAGA 1

```

```

XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note="2'phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note="2'methoxyethyl nucleotides"
FT 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note="2'methoxyethyl nucleotides"
XX
XX WO2003057142-A2.
XX
XX 17-JUL-2003.
XX
XX 17-DEC-2002; 2002WO-US040426.
XX
XX 28-DEC-2001; 2001US-00033742.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Karras JG, Condon TP;
XX
XX WPI; 2003-598310/56.
XX
XX Novel oligonucleotide targeted to nucleic acids encoding macrophage
PT inflammatory protein-3-alpha and inhibiting expression of the protein,
PT useful for treating psoriasis.
XX
XX Claim 3; Page 104; 116pp; English.
XX
XX The invention relates to antisense compounds, compositions and methods
XX for modulating the expression of macrophage inflammatory protein-3-alpha
XX (MIP3A). MIP3A is also known as small inducible cytokine subfamily A (Cys
XX -Cys), member 20 (SCYA20), exodus 1, liver and activation-regulated
XX kinase (LARC), CC chemokine ligand 20 (CCL20). The invention is useful
XX for inhibiting the expression of MIP3A DNA in cells or tissues. It is
XX useful for treating an animal having a disease or condition associated
XX with MIP3A such as inflammatory disorder, psoriasis, irritable bowel
XX syndrome or Crohn's disease. The antisense compound is useful for
XX diagnosis, therapeutic, prophylaxis and as research reagents and kits.
XX It is also used in antisense therapy. The present sequence is an
XX antisense oligonucleotide targeted to human MIP3A DNA. This sequence is
XX used to illustrate the method of the invention
XX
XX Sequence 20 BP; 7 A; 6 C; 2 G; 5 T; 0 U; 0 Other;
SQ
Query Match 30.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TTTCGGAATGGAATTGAC 20
DB 20 TTTCGGAATGGAATTGAC 1

```

```
KM small inducible cytokine subfamily A; SCYA20; inflammatory disorder;
KW CCL20; psoriasis; irritable bowel syndrome; Crohn's disease; exodus 1;
XX human; phosphorothioate backbone; antisense; ss.
OS Homo sapiens.
XX Synthetic.
XX
FH Key
FT modified_base
FT 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base
FT 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base
FT 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003057142-A2.
XX
PD 17-JUL-2003.
XX
XX 17-DEC-2002; 2002WO-US040426.
XX
PR 28-DEC-2001; 2001US-00033742.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Karas JG, Condon TP;
XX
XX WPI; 2003-598310/56.
XX
DR Novel oligonucleotide targeted to nucleic acids encoding macrophage
PT inflammatory protein-3-alpha and inhibiting expression of the protein,
XX useful for treating psoriasis.
XX
XX Claim 3; Page 104; 116pp; English.
XX
XX The invention relates to antisense compounds, compositions and methods
XX for modulating the expression of macrophage inflammatory protein-3-alpha
XX (MIP3A). MIP3A is also known as small inducible cytokine subfamily A (Cys
XX -Cys), member 20 (SCYA20), exodus 1, liver and activation-regulated
XX kinase (LARC), CC chemokine ligand 20 (CCL20). The invention is useful
XX for inhibiting the expression of MIP3A DNA in cells or tissues. It is
XX useful for treating an animal having a disease or condition associated
XX with MIP3A such as inflammatory disorder, psoriasis, irritable bowel
XX syndrome or Crohn's disease. The antisense compound is utilised for
XX diagnostics, therapeutic, prophylaxis and as research reagents and kits.
XX It is also used in antisense therapy. The present sequence is an
XX antisense oligonucleotide targeted to human MIP3A DNA. This sequence is
XX used to illustrate the method of the invention
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 30.8%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 11 GGAATTGCATAGCCCAAG 30
DB ||||||||||||||||
20 GGAATTGCATAGCCCAAG 1
```

```
RESULT 4
AAD57276/C
XX AAD57276 standard; DNA; 20 BP.
AC
XX AAD57276;
```

```
DT 06-NOV-2003 (first entry)
XX
XX Human MIP3A DNA specific antisense oligo, ISIS 150690.
XX
XX Macrophage inflammatory protein-3-alpha; MIP3A; antisense therapy;
KW liver and activation-regulated kinase; LARC; CC chemokine ligand 20;
KW small inducible cytokine subfamily A; SCYA20; inflammatory disorder;
KW CCL20; psoriasis; irritable bowel syndrome; Crohn's disease; exodus 1;
XX human; phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
FH Key
FT modified_base
FT 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methylcytidines"
FT modified_base
FT 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base
FT 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003057142-A2.
XX
PD 17-JUL-2003.
XX
XX 17-DEC-2002; 2002WO-US040426.
XX
PR 28-DEC-2001; 2001US-00033742.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Karas JG, Condon TP;
XX
XX WPI; 2003-598310/56.
XX
DR Novel oligonucleotide targeted to nucleic acids encoding macrophage
PT inflammatory protein-3-alpha and inhibiting expression of the protein,
XX useful for treating psoriasis.
XX
XX Claim 3; Page 104; 116pp; English.
XX
XX The invention relates to antisense compounds, compositions and methods
XX for modulating the expression of macrophage inflammatory protein-3-alpha
XX (MIP3A). MIP3A is also known as small inducible cytokine subfamily A (Cys
XX -Cys), member 20 (SCYA20), exodus 1, liver and activation-regulated
XX kinase (LARC), CC chemokine ligand 20 (CCL20). The invention is useful
XX for inhibiting the expression of MIP3A DNA in cells or tissues. It is
XX useful for treating an animal having a disease or condition associated
XX with MIP3A such as inflammatory disorder, psoriasis, irritable bowel
XX syndrome or Crohn's disease. The antisense compound is utilised for
XX diagnostics, therapeutic, prophylaxis and as research reagents and kits.
XX It is also used in antisense therapy. The present sequence is an
XX antisense oligonucleotide targeted to human MIP3A DNA. This sequence is
XX used to illustrate the method of the invention
XX
SQ Sequence 20 BP; 6 A; 9 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 30.8%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 7.5;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 46 GCTGGGTTGAGGTTTCAC 65
DB ||||||||||||||||
20 GCTGGGTTGAGGTTTCAC 1
```

```

RESULT 5
ID AAD57275/c
XX AAD57275 standard; DNA; 20 BP.
AC AAD57275;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human MIP3A DNA specific antisense oligo, ISIS 150689.
XX
KW Macrophage inflammatory protein-3-alpha; MIP3A; antisense therapy;
KW liver and activation-regulated kinase; IARC; CC chemokine ligand 20;
KW small inducible cytokine subfamily A; SCYA20; inflammatory disorder;
KW CCR20; psoriasis; irritable bowel syndrome; Crohn's disease; exodus 1;
KW human; phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT methycytidines"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2-methoxyethyl nucleotides"
XX
XX WO2003057142-A2.
XX
XX 17-JUL-2003.
XX
XX 17-DEC-2002; 2002WO-US040426.
XX
XX 28-DEC-2001; 2001US-00033742.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Karres JG, Condon TP;
XX
XX WPI; 2003-598310/56.
XX
XX Novel oligonucleotide targeted to nucleic acids encoding macrophage
XX inflammatory protein-3-alpha and inhibiting expression of the protein,
XX useful for treating psoriasis.
XX
XX
XX Claim 3; Page 104; 116pp; English.
XX
XX The invention relates to antisense compounds, compositions and methods
XX for modulating the expression of macrophage inflammatory protein-3-alpha
XX (MIP3A). MIP3A is also known as small inducible cytokine subfamily A (Cys
XX -Cys), member 20 (SCYA20), exodus 1, liver and activation-regulated
XX kinase (IARC), CC chemokine ligand 20 (CCR20). The invention is useful
XX for inhibiting the expression of MIP3A DNA in cells or tissues. It is
XX useful for treating an animal having a disease or condition associated
XX with MIP3A such as inflammatory disorder, psoriasis, irritable bowel
XX syndrome or Crohn's disease. The antisense compound is utilised for
XX diagnostics, therapeutics, prophylaxis and as research reagents and kits.
XX It is also used in antisense therapy. The present sequence is an
XX antisense oligonucleotide targeted to human MIP3A DNA. This sequence is
XX used to illustrate the method of the invention
XX
XX Sequence 20 BP; 2 A; 4 C; 4 G; 10 T; 0 U; 0 Other;
XX
Query Match 30.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 27 CAGAAACAGAAAGACCTTG 46
Db 20 CAGAAACAGAAAGACCTTG 1

RESULT 6
ID AAV82678/c
XX AAV82678 standard; DNA; 23 BP.
XX
AC AAV82678;
XX
DT 16-FEB-1999 (first entry)
XX
DE Biotinylated probe used to detect ST38.2 cDNA.
XX
KW Rat; chemokine; ST38.2; chemotaxis; leucocyte-activating; inflammation;
KW immune response; brain injury; trauma; ischaemia;
KW autoimmune inflammation; multiple sclerosis; stroke;
KW rheumatoid arthritis; meningitis; encephalitis; probe; ss.
XX
OS Synthetic.
OS Rattus sp.
XX
PN WO9849309-A1.
XX
PD 05-NOV-1998.
XX
PF 23-APR-1998; 98WO-EP002405.
XX
PR 30-APR-1997; 97EP-00107135.
XX
PA (HOFF ) HOFFMANN LA ROCHE & CO AG F.
XX
XX Lesslauer W, Utansschneitz U;
XX
XX WPI; 1999-009430/01.
XX
XX
XX New chemokine ST38.2 with chemotactic and leucocyte-activating properties
XX - used to treat inflammation and immune responses and to identify
XX specific modulators.
XX
XX Example 5; Page 31; 64pp; English.
XX
XX The present biotinylated probe was used to detect a ST38.2 cDNA fragment
XX in a semiquantitative RT-PCR assay. In the course of the invention.
XX ST38.2 is a novel rat chemokine designated ST38.2. The protein has
XX chemotactic and leucocyte-activating properties. ST38.2 is involved in
XX inflammation and immune responses, particularly inflammatory response to
XX brain injury (trauma, ischaemia or autoimmune inflammation) but also in
XX multiple sclerosis, stroke, rheumatoid arthritis and infections
XX (particularly meningitis and encephalitis)
XX
XX Sequence 23 BP; 4 A; 8 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 9.4;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 4 CTGGATGGAATTGGACATAGCC 26
Db 23 CTGGATGGAATTGGACATAGCC 1

RESULT 7
ID AAF74520/c
XX AAF74520 standard; DNA; 21 BP.
XX
AC AAF74520;
XX
XX
XX 09-MAY-2001 (first entry)
XX
XX Clone 16467945 PRO16 forward PCR primer SEQ ID NO:117.
XX

```

```

XX Human; PRO; cyrostatic; immunomodulatory; reproduction;
KM gene therapy; cell proliferation; differentiation disorder; cancer;
KM immune associated disorder; gestational disease; pre-clampsia;
KM PCR primer; sequencing primer; ss.
XX
OS Homo sapiens.
XX
PN W0200110902-A2.
XX
PD 15-FEB-2001.
XX
PF 11-AUG-2000; 2000WO-US021857.
XX
PR 11-AUG-1999; 99US-0148433P.
XX
PR 10-AUG-2000; 2000US-00635949.
XX
PA (CUBA-) CUBAGEN CORP.
XX
PI Shimkets RA, Fernandes E;
XX
DR WPI; 2001-147509/15.
XX
PT Nucleic acids encoding secreted polypeptides, designated PROX
PT polypeptides, useful for treating a syndrome associated with a PROX-
PT associated disorder, e.g. cancer.
XX
PS Example 15; Page 148; 16pp; English.
XX
CC The present invention describes isolated nucleic acids encoding secreted
CC polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where
CC X is an integer from 1 to 17). PROX polypeptides have cyrostatic,
CC immunomodulatory and reproduction activities, and can be used in gene
CC therapy, and as PROX antagonists and PROX agonists. PROX polypeptides,
CC nucleic acids and antibodies are useful in the manufacture of a
CC medicament for treating a syndrome associated with a PROX-associated
CC disorder, e.g. a cell proliferation and/or differentiation disorder (e.g.
CC cancer or immune associated disorders) and a gestational disease (e.g.
CC pre-clampsia). They are also used for screening for a modulator of
CC activity or of latency or predisposition to a PROX-associated disorder.
CC AAF74432 to AAF74448 encode the specifically claimed human PROX
CC polypeptides PRO1 to PRO17 given in AAB70531 to AAB70547. The present
CC sequence represents a primer used in an example from the present
CC invention
XX
SQ Sequence 21 BP; 8 A; 9 C; 3 G; 1 T; 0 U; 0 Other;
XX
Query Match 24.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 41;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 42 CCTTGTGGGGTTGGAGCT 60
Db 21 CCTTGTGGGGTTGTAGCT 3

```

```

RESULT 8
AAL42340
ID AAL42340 standard; DNA; 18 BP.
XX
AC AAL42340;
XX
DT 28-JUN-2002 (first entry)
XX
DE Novel sand pear microsatellite DNA PCR primer 4.
XX
KM Sand pear; ss; PCR; primer; novel microsatellite DNA sequence;
KM Pyrus plant discrimination.
XX
OS Pyrus pyrifolia.
XX
PN JF2002034597-A.
XX

```

```

PD 05-FEB-2002.
XX
PF 21-JUL-2000; 2000JP-00220339.
XX
PR 21-JUL-2000; 2000JP-00220339.
XX
PA (DOKU-) DOKURITSU GYOSEI HOJIN NOGYO SEIBUTSU SH.
XX
DR WPI; 2002-298819/34.
XX
PT A new microsatellite DNA derived from a Pyrus plant and discrimination of
PT Pyrus plants by using it.
XX
PS Claim 6; Page 6; 22pp; Japanese.
XX
CC The invention comprises a novel microsatellite DNA sequence derived from
CC Pyrus plants. The invention also comprises a method for discriminating
CC Pyrus plants - utilising the novel Pyrus microsatellite DNA. The novel
CC microsatellite DNA sequence can be used in discriminating Pyrus plants.
CC The present DNA sequence represents a PCR primer specific for a novel
CC Pyrus pyrifolia (sand pear) microsatellite DNA sequence
XX
SQ Sequence 18 BP; 11 A; 4 C; 3 G; 0 T; 0 U; 0 Other;
XX
Query Match 22.2%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 60;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 28 AAGACAGAGAGAACCC 43
Db 2 AAGACAGACAGAACCC 17

```

```

RESULT 9
AAQ9361/C
ID AAQ9361 standard; DNA; 18 BP.
XX
AC AAQ9361;
XX
DT 07-MAR-1996 (first entry)
XX
DE Japanese oyster transglutaminase cDNA PCR primer.
XX
KM Japanese oyster; transglutaminase; gelling agent; PCR primer yoghurt;
KM jelly; cheese; fish-paste; calcium ion activation; ss.
XX
OS Synthetic.
XX
PN W09520662-A1.
XX
PD 03-AUG-1995.
XX
PF 30-JAN-1995; 95WO-JP000117.
XX
PR 28-JAN-1994; 94JP-00008283.
PR 13-JAN-1995; 95JP-00003876.
XX
PA (AJIN ) AJINOMOTO CO INC.
XX
PI Sano K, Kumazawa Y, Yasueda H, Seguro K, Motoki M;
XX
DR WPI; 1995-275447/36.
XX
PT Transglutaminase derived from the Japanese oyster - is activated by
PT calcium ions and is a gelling agent for foodstuffs.
XX
PS Example 9; Page 105; 127pp; Japanese.
XX
CC AAQ9360 and AAQ9361 are a primer pair for the PCR amplification of
CC Japanese oyster transglutaminase (TGA) cDNA. TGA (when activated by
CC calcium ions) is a gelling agent, useful in the prodn. of foodstuffs,
CC e.g. yoghurt, jelly, cheese and fishpaste
XX

```

Sequence 18 BP; 1 A; 3 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 21.5%; Score 14; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 70;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 30 GAACAGAAAGACC 43
16 GAACAGAAAGACC 3

Db

RESULT 10
ABX75231
ID ABX75231 standard; DNA; 16 BP.
XX
AC ABX75231;
XX
DT 25-MAR-2003 (first entry)
XX
DE Human 216 gene allele specific oligonucleotide probe #47.
XX
KW Human; mouse; ss; probe; gene 216; antiasthmatic; antiinflammatory;
KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism; SNP;
KW gene therapy; respiratory disease; asthma; obesity;
KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
KW adult respiratory distress syndrome; inflammatory bowel syndrome.
XX
OS Homo sapiens.
XX
PN WO200283077-A2.
XX
PD 24-OCT-2002.
XX
PF 15-APR-2002; 2002WO-US012063.
XX
PR 13-APR-2001; 2001US-00834597.
XX
PR 13-APR-2001; 2001WO-US012245.
XX
PA (SCHE) SCHERING CORP.
XX
PA (GENO-) GENOME THERAPEUTICS CORP.
XX
PI Keith T, Little RD, Van Eerdeewegh P, Dupuis J, Del Mastro RG;
PI Simon J, Allen K, Pandit S;
XX
DR WPI; 2003-092960/08.
XX
PT New isolated gene 216 nucleic acids, useful for diagnosing, preventing or
PT treating a disorder, such as asthma, bronchial hyper-responsiveness,
PT chronic obstructive pulmonary disease, obesity or inflammatory bowel
PT syndrome.
XX
XX Example 10; Page 166; 650pp; English.
XX
XX This invention relates to a novel isolated nucleic acid, gene 216,
XX identified from human chromosome 20p13-p12. The invention also discloses
XX regions of the 216 gene that contain single nucleotide polymorphisms
XX (SNP's) which may be used as markers for disease susceptibility or
XX severity. The nucleotides of the invention may have antiasthmatic,
XX antiinflammatory or anorectic activities and may be used in gene therapy.
XX The nucleic acids, antibodies or its fragments are useful for diagnosing,
XX preventing or treating a disorder, such as respiratory diseases (e.g.
XX asthma, bronchial hyper-responsiveness, chronic obstructive pulmonary
XX disease or adult respiratory distress syndrome), obesity, or inflammatory
XX bowel syndrome. The nucleic acids are also useful for identifying
XX increased susceptibility of a subject to the disorders mentioned. The
XX nucleic acids can also be used as primers and templates for the
XX recombinant production of disorder-associated peptides or polypeptides,
XX for chromosome and gene mapping, or for tissue distribution studies. The
XX present sequence represents a gene 216 specific oligonucleotide probe
XX used in the scope of the invention
XX
XX Sequence 16 BP; 1 A; 1 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 20.6%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 78;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 46 GCTGGGGTTGGAGT 60
2 GCTGGGGTTGGGGT 16

Db

RESULT 11
ABK02829/c
ID ABK02829 standard; RNA; 17 BP.
XX
AC ABK02829;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CD20 Hammerhead ribozyme #128.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNAAzyme; inozyme; G-cleaver; ambezyme; zinzyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX
XX
OS Homo sapiens.
XX
OS Synthetic.
XX
PN WO200159103-A2.
XX
PD 16-NOV-2001.
XX
PF 09-FEB-2001; 2001WO-US004273.
XX
PR 11-FEB-2000; 2000US-0181797P.
XX
PR 28-FEB-2000; 2000US-0185516P.
XX
PR 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX (BLAT/) BLATT L.
XX
XX (MCSW/) MCSWIGGEN J.
XX
XX (CHOW/) CHOWRIRA B M.
XX
PI Blatt L, Mcswiggen J, Chowrira BM;
XX
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX
PS Claim 30; Page 142; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO). The
XX nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNAAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a RN motif) or
XX an ambezyme (cleaving RNA with an NGW triplet), a zinzyme (cleaving RNA
XX with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
XX Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX the cell and treat a patient having a condition associated with the level
XX of CD20. The treatment may further comprise the use of one or more

therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting nucleic acid is used to cleave RNA of the NOGO gene in the presence of a divalent cation that is preferably Mg^{2+} . Furthermore, the nucleic acid may be contacted with a cell to reduce NOGO activity of the cell and treat a patient having a condition associated with the level of NOGO. The treatment may further comprise the use of one or more therapies. In particular, the NOGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present sequence is a hammerhead ribozyme of the invention

Query Match 20.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 83;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 24 GCCCAAGAACGAGAA 38
Db 15 GCCCAAGAACGAGAA 1

RESULT 12

ABK02828/C
ID ABK02828 standard; RNA; 17 BP.

AC ABK02828;

DT 12-MAR-2002 (first entry)

DE Human CD20 Hammerhead ribozyme #127.

Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic; cerebroprotective; neurotropic; neuroprotective; antiparkinsonian; muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme; DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia; B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia; human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia; inflammatory arthropathy; central nervous system injury; cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS; Parkinson's disease; ataxia; Huntington's disease; Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.

OS Homo sapiens.
OS Synthetic.

PN WO200159103-A2.

PD 16-AUG-2001.

PF 09-FEB-2001; 2001WO-US004273.

PR 11-FEB-2000; 2000US-0181797P.

PR 28-FEB-2000; 2000US-0185516P.

PR 06-MAR-2000; 2000US-0187128P.

PA (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGEN J.

PI (CHOW/) CHOWRIRA B M.

Blatt L, Mcswigen J, Chowrira BM;

WP1; 2001-607195/69.

Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense constructs, which down regulate expression of a CD20 gene or neurite growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and central nervous system injury.

Claim 30; Page 142; 200pp; English.

The invention relates to a nucleic acid molecule which down regulates expression of a CD20 gene and a nucleic acid molecule which down regulates expression of a neurite growth inhibitor gene (NOGO). The nucleic acids may be enzymatic nucleic acids (e.g., a ribozyme or a DNazyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or an amberzyme (cleaving RNA with an NGA triplet), a zinzyme (cleaving RNA with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA of CD20 in the presence of a divalent cation that is preferably Mg^{2+} . Furthermore, it may be contacted with a cell to reduce CD20 activity of the cell and treat a patient having a condition associated with the level of CD20. The treatment may further comprise the use of one or more therapies. In particular, the CD20 targeting nucleic acid may be used to treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic leukaemia, HIV (human immunodeficiency virus) associated NHL, lymphocytic lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting nucleic acid is used to cleave RNA of the NOGO gene in the presence of a divalent cation that is preferably Mg^{2+} . Furthermore, the nucleic acid may be contacted with a cell to reduce NOGO activity of the cell and treat a patient having a condition associated with the level of NOGO. The treatment may further comprise the use of one or more therapies. In particular, the NOGO-targeting nucleic acid may be used to treat central nervous system (CNS) injury and cerebrovascular accident (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS), chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS), Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob disease, muscular dystrophy, and/or other neurodegenerative disease states which respond to the modulation of NOGO expression. The present sequence is a hammerhead ribozyme of the invention

Sequence 17 BP; 2 A; 4 C; 4 G; 0 T; 7 U; 0 Other;

Query Match 20.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 83;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 24 GCCCAAGAACGAGAA 38
Db 16 GCCCAAGAACGAGAA 2

RESULT 13

ABK02830/C
ID ABK02830 standard; RNA; 17 BP.

AC ABK02830;

DT 12-MAR-2002 (first entry)

DE Human CD20 Hammerhead ribozyme #129.

Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic; cerebroprotective; neurotropic; neuroprotective; antiparkinsonian; muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme; DNazyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukaemia; B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia; human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma; MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia; inflammatory arthropathy; central nervous system injury; cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis; chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;

KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 OS Homo sapiens.
 OS Synthetic.
 XX MO200159103-A2.
 XX
 XX 16-AUG-2001.
 PD
 XX
 PF 09-FEB-2001; 2001MO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 DR WPI; 2001-607195/59.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 30; Page 142; 200pp; English.
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the
 CC presence of a divalent cation that is preferably Mg²⁺. Furthermore, the
 CC nucleic acid may be contacted with a cell to reduce NOCO activity of the
 CC cell and treat a patient having a condition associated with the level of
 CC NOCO. The treatment may further comprise the use of one or more
 CC therapies. In particular, the NOCO-targeting nucleic acid may be used to
 CC treat central nervous system (CNS) injury and cerebrovascular accident
 CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
 CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
 CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
 CC disease, muscular dystrophy, and/or other neurodegenerative disease
 CC states which respond to the modulation of NOCO expression. The present
 CC sequence is a hammerhead ribozyme of the invention
 XX
 SQ Sequence 17 BP; 1 A; 3 C; 4 G; 0 T; 9 U; 0 Other;
 Query Match 20 0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 97;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 24 GCCCAGACAGACA 36
 Db 13 GCCCAGACAGACA 1

RESULT 14
 ABK03198/C
 ID ABK03198 standard; RNA; 17 BP.
 XX
 XX ABK03198;
 AC
 XX
 DT 12-MAR-2002 (first entry)
 XX
 DE Human CD20 Inozyme #149.
 DE
 XX Human; ss; antisense therapy; cytosolic; antiinflammatory; haemostatic;
 KM cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
 KM muscular; CD20; neurite growth inhibitor gene; NOCO; hammerhead ribozyme;
 KM DNAzyme; inozyme; G-cleaver; amberzyme; zinzyme; lymphoma; leukemia;
 KM B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukemia;
 KM human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
 KM MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
 KM inflammatory arthropathy; central nervous system injury;
 KM cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
 KM chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
 KM Parkinson's disease; ataxia; Huntington's disease;
 KM Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN MO200159103-A2.
 XX
 PD 16-AUG-2001.
 XX
 PF 09-FEB-2001; 2001MO-US004273.
 XX
 PR 11-FEB-2000; 2000US-0181797P.
 PR 28-FEB-2000; 2000US-0185516P.
 PR 06-MAR-2000; 2000US-0187128P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 PA (BLAT/) BLATT L.
 PA (MCSW/) MCSWIGGEN J.
 PA (CHOW/) CHOWRIRA B M.
 XX
 PI Blatt L, Mcswiggen J, Chowrira BM;
 DR WPI; 2001-607195/59.
 XX
 PT Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
 PT constructs, which down regulate expression of a CD20 gene or neurite
 PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
 PT central nervous system injury.
 XX
 PS Claim 30; Page 148; 200pp; English.
 CC The invention relates to a nucleic acid molecule which down regulates
 CC expression of a CD20 gene and a nucleic acid molecule which down
 CC regulates expression of a neurite growth inhibitor gene (NOCO). The
 CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
 CC DNAzyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
 CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
 CC an amberzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA
 CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
 CC of CD20 in the presence of a divalent cation that is preferably Mg²⁺.
 CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
 CC the cell and treat a patient having a condition associated with the level
 CC of CD20. The treatment may further comprise the use of one or more
 CC therapies. In particular, the CD20 targeting nucleic acid may be used to
 CC treat lymphoma, leukemia, B-cell lymphoma, low-grade or follicular non-
 CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
 CC leukemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
 CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
 CC immune thrombocytopenia, and inflammatory arthropathy. The NOCO-
 CC targeting nucleic acid is used to cleave RNA of the NOCO gene in the

CC presence of a divalent cation that is preferably Mg^{2+} . Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is an Inozyme of the invention

XX SQ Sequence 17 BP; 1 A; 4 C; 4 G; 0 T; 8 U; 0 Other;

Query Match 20.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCCCAGAGACAGA 36
|||
Db 14 GCCCAGAGACAGA 2

RESULT 15
ABT39879
ID ABT39879 standard; DNA; 17 BP.
XX
AC ABT39879;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 5516.
XX
KM Cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; gene chip;
KM antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KM schizophrenia; protein chip; gene therapy; tumour suppression;
KM human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB004208.
XX
PR 17-SEP-2001; 2001FR-00011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases associated
PT with tumours and cell degeneration, also related polypeptides, antibodies
PT and transfected cells.
XX
PS Disclosure; Page 678; 720pp; French.
XX

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15 consecutive
CC nucleotides from the 17 mer sequence, a sequence with, after optimal
CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that
CC hybridizes to them under highly stringent conditions, or the complement
CC of any of them, or the corresponding RNA. The novel isolated nucleic
CC acids of the invention are useful as probes and primers for detecting,
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one
CC component of a gene chip, in vitro as (anti)sense reagents, and for
CC production of recombinant polypeptides. Any of the nucleic acids,
CC polypeptides, vectors containing the nucleic acids, cells containing the
CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention

XX SQ Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 20.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 97;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 TCGAATTGGACAT 22
|||
Db 5 TCGAATTGGACAT 17

RESULT 16
ADB40491
ID ADB40491 standard; DNA; 17 BP.
XX
AC ADB40491;
XX
DT 18-DEC-2003 (revised)
DT 04-DEC-2003 (first entry)
XX
DE Tumour suppression/reversion associated nucleotide #814.
XX
KM Cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;
KM primer; probe; tumour suppression; tumour reversion; apoptosis;
KM virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;
KM diagnosis.
XX
OS Homo sapiens.
XX
PN WO2003040369-A2.
XX
PD 15-MAY-2003.
XX
PF 17-SEP-2002; 2002WO-IB004219.
XX
PR 17-SEP-2001; 2001FR-00011981.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-441574/41.
XX
PT New nucleic acid encoding human prostate membrane-specific antigen,
PT useful e.g. for treatment of tumours and viral infection, also related
PT polypeptide and antibodies.
XX
PS Disclosure; Page 127; 771pp; French.
XX

CC The invention relates to the isolation of 637 nucleotide sequences,
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC sequence having at least 80% identity, after optimal alignment, with the
CC nucleotides, a sequence that hybridizes under stringent conditions with
CC the nucleotides, or the complement, or corresponding RNA, of the
CC nucleotides. The nucleotides are used as probes or primers for detecting,
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC sense and antisense sequences, of nucleotides involved in tumour
CC suppression or reversion, apoptosis and or viral resistance, to produce
CC recombinant polypeptides, and to prepare transgenic animals, as
CC experimental models. The nucleotides (also vectors containing them and
CC cells containing the vectors), the encoded polypeptides and antibodies
CC (Ab) against the polypeptide are useful for prevention and/or treatment

CC of viral infections or diseases characterized by development of tumours
 CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
 CC Analysis of the expression of the nucleotides can be used for diagnosis
 CC and/or prognosis of these diseases. The nucleotides and polypeptides can
 CC also be used to screen for their specific interactive molecules,
 CC potentially useful for treating diseases associated with abnormal
 CC expression of the nucleotides.

XX Sequence 17 BP; 5 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 97;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 TGGATTGACAT 22
 |||||
 DB 5 TGGATTGACAT 17

RESULT 17

AA60238
 ID AAT60238 standard; DNA; 17 BP.

XX AAT60238;

DT 19-OCT-1997 (first entry)

DE ASO Q493XM representing known cystic fibrosis mutation.

XX Multiplex allele-specific diagnostic assay; MASDA;

KM allele-specific oligonucleotide; ASO; polymorphism; genetic disease;

KM diagnosis; cystic fibrosis; ss.

XX Synthetic.

OS WO9710366-A2.

XX 20-MAR-1997.

PD 13-SEP-1996; 96WO-US014842.

XX 15-SEP-1995; 95US-0003788P.

PR (GEN2) GENZYME CORP.

XX Shuber AP;

DR WPI; 1997-202258/18.

PT Identifying genetic alterations or target sequences in nucleic acid
 PT samples - useful for detecting genetic alterations associated with a
 PT disease, e.g. cystic fibrosis and sickle cell anaemia.

XX Example 2; Page 40; 85pp; English.

XX Allele-specific oligonucleotides (ASOs) (AAT60210-41) representing known
 CC cystic fibrosis mutations, and corresponding ASOs (AAT60242-70)
 CC representing wild-type sequences, are examples of ASOs that can be used
 CC in a multiplex allele-specific diagnostic assay (MASDA) that has the
 CC capacity to analyse over 500 samples of a large number of mutations (over
 CC 100) in a single assay. Target DNA is immobilised to a solid support and
 CC interrogated in combinatorial fashion with a mixture of mutation-specific
 CC ASOs in solution. The ASOs(s) corresponding to the specific mutation(s)
 CC present in the sample is hybrid-selected from the pool, and the
 CC mutation(s) is identified. MASDA can be used to detect genetic
 CC alterations associated with genetic disorders, to identify genetic
 CC polymorphisms, to determine the molecular basis of genetic diseases, or
 CC for high-resolution identification of disease-causing microorganisms

XX Sequence 17 BP; 10 A; 2 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGACAGAAAGAA 41
 |||||
 DB 2 CTAAGAACAGAAAGAA 17

RESULT 18

AAF02139/C
 ID AAF02139 standard; DNA; 17 BP.

XX AAF02139;

DT 16-FEB-2001 (first entry)

DE Hammerhead ribozyme substrate #434.

XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;

KM interferon alpha; ss.

XX Homo sapiens.

XX WO200061729-A2.

PD 19-OCT-2000.

PF 11-APR-2000; 2000WO-US009721.

XX 12-APR-1999; 99US-0129390P.

XX (RIBO-) RIBOZYME PHARM INC.

PI Blatt L, Zwick M, Pavco P, Meswigen J;

DR WPI; 2000-647423/62.

PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor protein,
 PT interferon alpha and erythropoietin.

XX Claim 37; Page 65; 164pp; English.

XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
 CC factor gene, IRF-2 and/or the C/EBP Displacement protein (CDP).
 CC Inhibition of the repressors removes prevents inhibition (and
 CC consequently increases expression of) genes involved in the production of
 CC erythropoietin, granulocyte colony stimulating factor protein and
 CC interferon alpha

XX Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 1e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTCGGGTTGAGGTTT 62
 |||||
 DB 17 CTCGGGTTGAGGTTT 2

RESULT 19

AAF06172/C
 ID AAF06172 standard; DNA; 17 BP.

XX AAF06172;

DT 16-FEB-2001 (first entry)

DE Hammerhead ribozyme substrate #2969.

XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;

```

XX      interferon alpha; ss.
OS      Homo sapiens.
XX      WO200061729-A2.
XX      19-OCT-2000.
XX
XX      11-APR-2000; 2000MO-US009721.
XX
XX      12-APR-1999; 99US-0129390P.
XX
XX      (RIBO-) RIBOZYME PHARM INC.
XX
XX      Blatt L, Zwick M, Pavco P, Mcswigen J;
XX      WPI; 2000-647423/62.
XX
XX      Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX      useful for producing e.g. granulocyte colony stimulating factor protein,
XX      interferon alpha and erythropoietin.
XX
XX      Claim 42; Page 124; 164pp; English.
XX
XX      The present invention relates to enzymatic and antisense nucleic acid
XX      molecules that act as inhibitors of the expression of repressor genes
XX      encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription
XX      factor gene, IRF-2 and/or the C/EBP Displacement Protein (CDP).
XX      Inhibition of the repressors removes prevents inhibition (and
XX      consequently increases expression of) genes involved in the production of
XX      erythropoietin, granulocyte colony stimulating factor protein and
XX      interferon alpha
XX
XX      Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
XX
XX      Query Match      19.7%; Score 12.8; DB 1; Length 17;
XX      Best Local Similarity 87.5%; Pred. No. 1e+02;
XX      Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Oy      10 TGGAAATTGGAACATGAC 25
        |||||
        17 TGGAGTTGGACACAGC 2
XX
XX      RESULT 20
XX      ABR03743
XX      ID ABR03743 standard; RNA; 17 BP.
XX
XX      AC ABR03743;
XX
XX      12-MAR-2002 (first entry)
XX
XX      Human CD20 Ambergzyme #92.
XX
XX      Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX      cerebroprotective; neurotrophic; neuroprotective; antiparkinsonian;
XX      muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX      DNAzyme; inozyme; G-cleaver; ambergzyme; zinczyme; lymphoma; leukaemia;
XX      B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX      human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX      MCL; immunodeficiency virus; immune thrombocytopenia; stroke; dementia;
XX      inflammatory arthropathy; central nervous system injury;
XX      cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX      chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX      Parkinson's disease; ataxia; Huntington's disease;
XX      Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX      Homo sapiens.
XX      Synthetic.
XX      WO200159103-A2.
XX
XX      16-AUG-2001.

```

```

XX      09-FEB-2001; 2001MO-US004273.
XX
XX      11-FEB-2000; 2000US-0181797P.
XX
XX      28-FEB-2000; 2000US-0185516P.
XX
XX      06-MAR-2000; 2000US-0187128P.
XX
XX      (RIBO-) RIBOZYME PHARM INC.
XX      (BLAT/) BLATT L.
XX      (MCSW/) MCSWIGGEN J.
XX      (CHOW/) CHOWRIRA B M.
XX
XX      Blatt L, Mcswigen J, Chowrira BM;
XX      WPI; 2001-607195/69.
XX
XX      Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX      constructs, which down regulate expression of a CD20 gene or neurite
XX      growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX      central nervous system injury.
XX
XX      Claim 30; Page 168; 200pp; English.
XX
XX      The invention relates to a nucleic acid molecule which down regulates
XX      expression of a CD20 gene and a nucleic acid molecule which down
XX      regulates expression of a neurite growth inhibitor gene (NOGO). The
XX      nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX      DNAzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX      possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or
XX      an ambergzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
XX      with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA
XX      of CD20 in the presence of a divalent cation that is preferably Mg2+.
XX      Furthermore, it may be contacted with a cell to reduce CD20 activity of
XX      the cell and treat a patient having a condition associated with the level
XX      of CD20. The treatment may further comprise the use of one or more
XX      therapies. In particular, the CD20 targeting nucleic acid may be used to
XX      treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-
XX      Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
XX      leukaemia, HIV (human immunodeficiency virus) associated NHL, lymphocytic
XX      lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
XX      immune thrombocytopenia, and inflammatory arthropathy. The NOGO-
XX      targeting nucleic acid is used to cleave RNA of the NOGO gene in the
XX      presence of a divalent cation that is preferably Mg2+. Furthermore, the
XX      nucleic acid may be contacted with a cell to reduce NOGO activity of the
XX      cell and treat a patient having a condition associated with the level of
XX      NOGO. The treatment may further comprise the use of one or more
XX      therapies. In particular, the NOGO-targeting nucleic acid may be used to
XX      treat central nervous system (CNS) injury and cerebrovascular accident
XX      (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX      chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX      Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX      disease, muscular dystrophy, and/or other neurodegenerative disease
XX      states which respond to the modulation of NOGO expression. The present
XX      sequence is an ambergzyme molecule of the invention
XX
XX      Sequence 17 BP; 9 A; 2 C; 5 G; 0 T; 1 U; 0 Other;
XX
XX      Query Match      19.7%; Score 12.8; DB 1; Length 17;
XX      Best Local Similarity 87.5%; Pred. No. 1e+02;
XX      Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Oy      26 CCAAGAAACGAAGAA 41
        |||||
        2 CCAAGAAAGAGAGAA 17
XX
XX      RESULT 21
XX      ABR02473
XX      ID ABR02473 standard; DNA; 17 BP.
XX
XX      AC ABR02473;
XX
XX      29-MAY-2002 (first entry)

```

```
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2465.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX DR WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX PS Disclosure; SEQ ID NO 2465; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption/ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
XX CC The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence
XX SQ Sequence 17 BP; 3 A; 2 C; 6 G; 6 T; 0 U; 0 Other;
QY Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. NO. 1e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
DB 1 CTGGAATGCACTTGA 16
|||||
RESULT 22
ABN02472
ID ABN02472 standard; DNA; 17 BP.
XX AC ABN02472;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2464.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX KM muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US016981.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PR 30-JAN-2001; 2001WO-US000661.
XX PR 30-JAN-2001; 2001WO-US000662.
XX PR 30-JAN-2001; 2001WO-US000663.
XX PR 30-JAN-2001; 2001WO-US000664.
XX PR 30-JAN-2001; 2001WO-US000665.
XX PR 30-JAN-2001; 2001WO-US000666.
XX PR 30-JAN-2001; 2001WO-US000667.
XX PR 30-JAN-2001; 2001WO-US000668.
XX PR 30-JAN-2001; 2001WO-US000669.
XX PR 05-FEB-2001; 2001US-0266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX DR WPI; 2002-179446/23.
XX PT New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,
XX PT or as specific biomolecule capture probes for surface-enhanced laser
XX PT desorption ionization, comprises human myosin-like protein hGDMLP-1.
XX PS Disclosure; SEQ ID NO 2464; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-
XX CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1
XX CC nucleic acids can be used as probes to detect, characterise and quantify
XX CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to
XX CC provide initial substrates for the recombinant engineering of hGDMLP-1
XX CC protein variants having desired phenotypic improvements, and for
XX CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be
XX CC used as immunogens to raise antibodies that specifically recognise hGDMLP
XX CC -1 proteins, as standards in assays used to determine the concentration
XX CC and/or amount specifically of hGDMLP proteins, as specific biomolecule
XX CC capture probes for surface-enhanced laser desorption/ionisation, as
XX CC therapeutic supplement in patients having specific deficiency in hGDMLP-1
XX CC production, and in vaccines or for replacement therapy. The
XX CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a
XX CC disorder associated with the expression of hGDMLP-1, in particular heart
XX CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.
XX CC The present sequence represents an oligomer used in the screening of the
XX CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.
```

CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence
XX

SO Sequence 17 BP; 3 A; 2 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1e+02; Mismatches 2; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 4 CTGGAATGGAATTGGA 19
Db 2 CTGGAATGGAATTGGA 17

RESULT 23

AAZ97663
ID AAZ97663 standard; DNA; 15 BP.

AC AAZ97663;

DT 15-SEP-2003 (revised)

DT 26-APR-2000 (first entry)

DE HIV-1 protease gene probe SEQ ID NO:153.

KW Human immunodeficiency virus; HIV; protease; probe; detection;
KW drug selected mutation; hybridisation; genotyping; infection;
KW drug resistance; ss.

OS Human immunodeficiency virus 1.

PN WO967428-A2.

PD 29-DEC-1999.

PF 22-JUN-1999; 99WO-EP004317.

PR 24-JUN-1998; 98EP-00870143.

PA (INNO-) INNOGENETICS NV.

PI Stuyver L;

DR WPI; 2000-147219/13.

PT Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.

PS Claim 3; Page 35; 76pp; English.

XX The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC and AAZ97516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC assays. The probes are able to discriminate between wild type and mutated
CC drug resistance sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)

SO Sequence 15 BP; 2 A; 0 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 49 GGGTTGGAGGTTT 62
Db 1 GGAGTTGGAGGTTT 14

RESULT 24

AAZ97684
ID AAZ97684 standard; DNA; 15 BP.

AC AAZ97684;

DT 15-SEP-2003 (revised)

DT 26-APR-2000 (first entry)

DE HIV-1 protease gene probe SEQ ID NO:174.

KW Human immunodeficiency virus; HIV; protease; probe; detection;
KW drug selected mutation; hybridisation; genotyping; infection;
KW drug resistance; ss.

OS Human immunodeficiency virus 1.

PN WO967428-A2.

PD 29-DEC-1999.

PF 22-JUN-1999; 99WO-EP004317.

PR 24-JUN-1998; 98EP-00870143.

PA (INNO-) INNOGENETICS NV.

PI Stuyver L;

DR WPI; 2000-147219/13.

PT Detection of drug-selected mutations in the HIV protease gene used to
PT treat HIV infections.

PS Claim 3; Page 36; 76pp; English.

XX The present invention describes the detection of drug-selected mutations
CC in the HIV protease gene. The method of detection allows the simultaneous
CC characterisation of a range of codons involved in drug resistance using
CC sets of probes optimised to function together in a reverse-hybridisation
CC assay. AAZ97517 to AAZ97997 represent specifically claimed probes for use
CC in the assay, and AAZ97479 to AAZ97501 represent specifically claimed HIV
CC protease gene polymorphic nucleotide sequences. AAZ97502 to AAZ97515, and
CC AAZ98004 to AAZ98007, represent PCR primers for the HIV protease gene,
CC and AAZ97516 represents an HIV protease probe used in an example from the
CC present invention. The method, probes and primers can be used for the
CC detection of drug-selected mutations in the HIV protease gene. The method
CC allows the simultaneous characterisation of a range of codons involved in
CC assays. The probes are able to discriminate between wild type and mutated
CC drug resistance sequences. The method allows rapid and reliable detection of
CC drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
CC field)

SO Sequence 15 BP; 2 A; 0 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 49 GGGTTGGAGGTTT 62
Db 1 GGAGTTGGAGGTTT 14

RESULT 25

```

AB167380
ID AB167380 standard; DNA; 12 BP.
XX
AC AB167380;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 367353 for detecting SNP TSC0056294.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 367353; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 18.5%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 8 AATGAATTGA 19
DB 1 AATGAATTGA 12
XX
RESULT 26
ID AB148814/c
XX AB148814 standard; DNA; 12 BP.
XX
AC AB148814;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 348787 for detecting SNP TSC0045748.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 348787; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 18.5%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 99;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 50 GCGTTGAGAGTT 61
DB 12 GCGTTGAGAGTT 1
XX
RESULT 27
ID ABC19998
XX ABC1998 standard; DNA; 13 BP.
XX
AC ABC19998;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 20015 for detecting SNP TSC0004117.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

XX DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 20015; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;
XX
Query Match 18.5%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 48 TGGGGTTGGAGG 59
DB 2 TGGGGTTGGAGG 13
XX
RESULT 28
ABCI9999/c
ID ABCI9999 standard; DNA; 13 BP.
XX
AC ABCI9999;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 20016 for detecting SNP TSC0004117.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 20016; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 18.5%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 48 TGGGGTTGGAGG 59
DB 12 TGGGGTTGGAGG 1
XX
RESULT 29
AAL41830/c
ID AAL41830 standard; DNA; 15 BP.
XX
AC AAL41830;
XX
DT 25-APR-2002 (first entry)
XX
DE Human GCNT1 allele specific primer SEQ ID NO: 15.
XX
XX Human; glucosaminyl (N-acetyl) transferase 1, core 2; GCNT1; cancer;
XX gene therapy; haplotype; chromosome 9q13; SNP; primer; cytostatic;
XX single nucleotide polymorphism; ss.
XX
OS Homo sapiens.
XX
FN WO200204470-A2.
XX
PD 17-JAN-2002.
XX
PF 06-JUL-2001; 2001WO-US021451.
XX
PR 06-JUL-2000; 2000US-0216281P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Duda A, Finkel K, Koshy B;
XX
XX WPI; 2002-171696/22.
XX
XX
XX Genetic variants of glucosaminyl (N-acetyl) transferase 1, core 2 gene
XX useful in studying expression and function of the protein, and for
XX screening drugs to treat diseases e.g. cancer.
XX
XX
XX Claim 16; Page 13; 72pp; English.
XX
XX The present invention provides the gene, protein and cDNA sequences of
XX the human glucosaminyl (N-acetyl) transferase 1, core 1 (GCNT1). Also
XX identified are single nucleotide polymorphisms (SNPs) located within the
XX sequences. The sequences can be used in the treatment of GCNT1 related
XX diseases, including cancer. The present sequence is an allele specific
XX primer for the GCNT1 gene, which is located on chromosome 9q13
XX
SQ Sequence 15 BP; 3 A; 7 C; 2 G; 2 T; 0 U; 1 Other;
XX
Query Match 18.5%; Score 12; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 39 GAACCTTGCTGGGG 52
DB 15 GRAGCTTGCTGGGG 2

```

RESULT 30
AAF51170
ID AAF51170 standard; DNA; 15 BP.
XX
XX AAF51170;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #2130.
DE
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; vitricide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000MO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 74; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 3 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 18.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 35 GAAAGAACCTTGCTG 49
DB 1 GAAAGGCGCTTGCTG 15

```

```

XX
XX AAF51169;
XX
XX 30-MAR-2001 (first entry)
XX
XX IGF-1 oligonucleotide #2129.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; vitricide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
OS
XX WO200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000MO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisense nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 74; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 3 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 18.2%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 34 AGAAGAACCTTGCT 48
DB 1 AGAAGGCGCTTGCT 15

```

```

RESULT 31
AAF51169
ID AAF51169 standard; DNA; 15 BP.

```

```

RESULT 32
AAS98678/c
ID AAS98678 standard; DNA; 15 BP.
XX
XX AAS98678;
XX
XX 26-MAR-2002 (first entry)

```

XX Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #44.
 DE
 XX
 KW Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;
 KW cytostatic; gene therapy; malignant histiocytosis; isogene;
 KW myeloid malignancy; inflammatory disorder; transgenic animal; haplotype;
 KW genotype; human; allele specific oligonucleotide; ASO; probe; ss.
 OS
 XX Homo sapiens.
 XX
 PN WO200179225-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 12-APR-2001; 2001WO-US012044.
 XX
 PR 12-APR-2000; 2000US-0196411P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Chew A, Choi JY, Koshy B;
 XX
 DR WPI; 2002-075058/10.
 XX
 PT Novel polymorphic variants of colony stimulating factor 1 receptor useful
 PT in studying expression and function of the protein, useful for screening
 PT candidate drugs to treat diseases e.g. inflammatory disorders.
 XX
 PS Claim 15; Page 15; 164pp; English.
 XX
 CC The invention describes a novel isolated polynucleotide (I) comprising a
 CC sequence which is a polymorphic variant (PV) of a reference sequence for
 CC colony stimulating factor 1 receptor (CSF1R) gene, found on the
 CC polypeptide are useful for improving the discovery and development of
 CC drugs for treating diseases associated with CSF1R activity, e.g.,
 CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders
 CC and the haplotypes can be used to validate CSF1R as a candidate target
 CC for treating a specific condition or disease predicted to be associated
 CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also
 CC be used in developing diagnostic tests and therapeutic treatments. (I) is
 CC useful in studying the expression and function of CSF1R, and in
 CC expressing CSF1R protein for use in screening for candidate drugs to
 CC treat diseases related to CSF1R activity and in studying the effect of
 CC the variation on the biological activity of CSF1R as well as on the
 CC binding affinity of candidate drugs targeting CSF1R. Antibodies are
 CC useful in a variety of diagnostic and prognostic formats and therapeutic
 CC methods. A transgenic animal is useful in studying expression of the
 CC CSF1R isogenes in vivo, for in vivo screening and testing of drugs
 CC targeted against CSF1R protein, and for testing the efficacy of
 CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)
 CC are useful as probes and primers, and for assaying a polymorphism in the
 CC target region. Without requiring any a priori knowledge of the phenotypic
 CC effect of any particular CSF1R or haplotype the invention provides a
 CC method for identifying lead compounds that are more likely to show
 CC efficacy in clinical trials. This sequence is an allele specific
 CC oligonucleotide probe used for detecting CSF1R gene polymorphisms,
 CC described in the method of the invention
 XX
 SQ Sequence 15 BP; 1 A; 4 C; 4 G; 5 T; 0 U; 1 Other;

Query Match 18.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 17 GGACATGAGCCCAAGA 31
 |||||
 DB 15 GGGCATATGCCAAGA 1

RESULT 33
 AAL48106
 ID AAL48106 standard; DNA; 15 BP.
 XX

AC AAL48106;
 XX
 DT 27-SEP-2002 (first entry)
 XX
 DB Human neuropeptide Y allele specific primer SEQ ID NO: 30.
 XX
 KW Human; neuropeptide Y; NPY; isogene; SNP; atherosclerosis; obesity;
 KW psychological disorder; single nucleotide polymorphism; alcoholism;
 KW antiarteriosclerotic; anorectic; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200251857-A1.
 XX
 PD 04-JUL-2002.
 XX
 PF 21-DEC-2000; 2000WO-US034758.
 XX
 PR 21-DEC-2000; 2000WO-US034758.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Chew A, Denton RR, Lanz EM, Nandabalan K, Stephens JC;
 XX
 DR WPI; 2002-566671/60.
 XX
 PT New genetic variants of the human Neuropeptide Y (NPY) gene useful for
 PT treating disorders affected by abnormal expression or function of NPY
 PT isogene e.g., atherosclerosis or obesity.
 XX
 PS Claim 11; Page 17; 80pp; English.
 XX
 CC The present invention provides the human neuropeptide Y (NPY) gene and
 CC single nucleotide polymorphisms (SNPs) identified therein. The sequence
 CC can be used in the treatment of disorders associated with NPY, including
 CC atherosclerosis, obesity, psychological disorders and alcoholism. The
 CC present sequence is an allele specific primer used to isolate the human
 CC NPY coding sequence
 XX
 SQ Sequence 15 BP; 1 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 18.2%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.3e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTGGGCTTGGAGGTT 61
 |||||
 DB 1 CTGGGCGCGAGGTT 15

RESULT 34
 AAF99594
 ID AAF99594 standard; DNA; 13 BP.
 XX
 AC AAF99594;
 XX
 DT 12-JUN-2001 (first entry)
 XX
 DE Immunostimulatory nucleic acid #710.
 XX
 KW Vaccine; cytostatic; virucidal; bactericidal; fungicidal; anti-parasitic;
 KW immunostimulatory; tumour; viral infection; bacterial infection;
 KW fungal infection; parasitic infection; cancer; asthma;
 KW infectious disease; allergy; immune deficiency; phosphorohate; ss.
 XX
 OS Synthetic.
 XX
 PN WO200122972-A2.
 XX
 PD 05-APR-2001.
 XX
 PF 25-SEP-2000; 2000WO-US026383.
 XX


```
PR 25-SEP-1999; 99US-0156113P.
PR 27-SEP-1999; 99US-0156135P.
PR 23-AUG-2000; 2000US-0227436P.
XX
XX
PA (IOWA ) UNIV IOWA RES FOUND.
XX (COLE-) COLEY PHARM GMBH.
PI Krieg AM, Schetter C, Vollmer J;
XX WPI; 2001-273485/28.
DR
XX
PT Vaccinating against tumors, infectious diseases, allergies and asthma
XX using immunostimulatory Py-rich and TG nucleic acids.
XX
XX Claim 101; Page 54; 338pp; English.
XX
XX The present invention relates to a method for stimulating an immune
CC response. The method comprises administering an immunostimulatory nucleic
CC acid to a non-rodent subject in sufficient quantity to stimulate an
CC immune response. The present sequence is one such immunostimulatory
CC nucleic acid. The immunostimulatory nucleic acids can be pyrimidine rich
CC (py-rich) or thymidine (T) rich. The method is used to vaccinate subjects
CC against tumor antigens, viral antigens (e.g. herpesviridae, retroviridae
CC and/or orthomyxoviridae), bacterial antigens (e.g. toxoplasma,
CC haemophilus, campylobacter, clostridium, Escherichia coli and/or
CC staphylococcus), fungal antigens and/or parasitic antigens. The method is
CC also useful for preventing cancer, asthma, infectious disease, allergy or
CC immune deficiency. The present sequence can also be used to redirect a
CC Th2 to a Th1 immune response and to activate immune cells. Note: the
CC present sequence may have a phosphorothioate backbone
XX
SQ Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 17.5%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 49 GGGGTTGGAGGTT 61
Db 1 GGGGTTGGGAGTT 13
XX
RESULT 35
ABF69510
ID ABF69510 standard; DNA; 13 BP.
XX
XX ABF69510;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 169507 for detecting SNP TSC0042344.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
```

```
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 169507; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 17.5%; Score 11.4; DB 1; Length 13;
XX Best Local Similarity 92.3%; Pred. No. 1.4e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 49 GGGGTTGGAGGTT 61
Db 1 GGAGTTGGAGGTT 13
XX
RESULT 36
ABH44501/c
ID ABH44501 standard; DNA; 13 BP.
XX
XX ABH44501;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 244478 for detecting SNP TSC0059689.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 244478; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
```

CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 0 A; 3 C; 0 G; 10 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 28 AAGAACAGAAAGA 40
 |||||
 Db 13 AAGAAAGAAAGA 1

RESULT 37
 ABF69511/c
 ID ABF69511 standard; DNA; 13 BP.

AC ABF69511;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 169508 for detecting SNP TSC0042344.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIDENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 169508; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGGAGGTT 61
 |||||

Db 13 GGAGTTGGAGGTT 1

RESULT 38
 ABF07727/c
 ID ABF07727 standard; DNA; 13 BP.

AC ABF07727;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 107724 for detecting SNP TSC0026974.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIDENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 107724; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 1.4e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGGAGGTT 61
 |||||
 Db 13 GGGGTTGGAGGTT 1

RESULT 39

ID ABC73222

AC ABC73222;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 73239 for detecting SNP TSC0018875.

```

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 73239; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 46 GCTGGCGTTGGAG 58
Db 1 GGTGGCGTTGGAG 13
XX
RESULT 40
ABC73223/C
ID ABC73223 standard; DNA; 13 BP.
XX
AC ABC73223;
XX
DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 73240 for detecting SNP TSC0018875.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR 07-APR-2000; 2000DE-01019173.

```

```

XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 73240; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 46 GCTGGCGTTGGAG 58
Db 13 GGTGGCGTTGGAG 1
XX
RESULT 41
ABF07726
ID ABF07726 standard; DNA; 13 BP.
XX
AC ABF07726;
XX
DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 107723 for detecting SNP TSC0026974.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 107723; 29pp + Sequence Listing; German.
XX

```



```

ID ABH57827 standard; DNA; 13 BP.
XX
AC ABH57827;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 257804 for detecting SNP TSC0062709.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DB-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 257804; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, cardiovascular disorders, the
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGGTTT 62
DB 13 GGGTTGAGGTTT 1
XX
RESULT 45
ID ABS78312
ID ABS78312 standard; DNA; 13 BP.
XX
AC ABS78312;
XX
DT 13-DEC-2002 (first entry)
XX
DE Angiogenesis inhibitory oligonucleotide #796.
XX
KM Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;
KM tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;
KM diabetic retinopathy; retinopathy of prematurity; macular degeneration;
KM corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;
KM rubiosis; Oeler-Weber Syndrome; myocardial angiogenesis;

```

```

KM plaque neovascularisation; telangiectasia; haemophiliac joint;
KM angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;
KM scleroderma; hypertrophic scar.
XX
OS Synthetic.
XX
PN WO200253141-A2.
XX
PD 11-JUL-2002.
XX
PF 14-DEC-2001; 2001WO-US048458.
XX
PR 14-DEC-2000; 2000US-025534P.
XX
PA (COLE-) COLEY PHARM GROUP INC.
XX
PI Bratzler RJ;
XX
DR WPI; 2002-566930/60.
XX
PT Inhibiting angiogenesis in a subject, involves administering at least one
PT antiangiogenic nucleic acid molecule to the subject.
XX
PS Claim 2; Page 33; 276pp; English.
XX
CC The invention relates to inhibiting angiogenesis in a subject, comprising
CC administering at least one antiangiogenic nucleic acid molecule. Also
CC included is a kit comprising a first container housing the antiangiogenic
CC nucleic acids, and instructions for administering them to a subject
CC having a condition characterised by unwanted angiogenesis. The method is
CC useful for inhibiting angiogenesis associated with solid tumour growth,
CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
CC rubiosis, Oeler-Weber Syndrome, myocardial angiogenesis, plaque
CC neovascularisation, telangiectasia, haemophiliac joints, angiofibroma,
CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
CC acid of the invention
XX
SQ Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 49 GGGTTGAGGTTT 61
DB 1 GGGTTGAGGTTT 13
XX
RESULT 46
ID ABL39046
ID ABL39046 standard; DNA; 13 BP.
XX
AC ABL39046;
XX
DT 16-APR-2002 (first entry)
XX
DE Immunostimulatory nucleic acid SEQ ID NO: 450.
XX
KM Antibody-induced cell lysis; cancer; immunostimulatory; CD20;
KM angiogenesis; metastasis; cytostatic; phosphorothioate backbone; ss.
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..13
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN WO200197843-A2.

```

```

XX 27-DEC-2001.
PD
XX
XX 22-JUN-2001; 2001WO-US020154.
PF
XX 22-JUN-2000; 2000US-0213346P.
PR
XX (IOWA ) UNIV IOWA RES FOUND.
PA
XX
XX Weiner G, Hartmann G;
PI
XX
XX WPI; 2002-154611/20.
DR
XX
XX Treating or preventing cancer, such as basal cell carcinoma, comprises
PT administering immunostimulatory nucleic acids that induce expression of
PT cell surface antigens and antibodies to a subject having or at risk of
XX developing cancer.
XX
XX Disclosure; Page 209, 312pp; English.
XX
XX The present invention relates to methods for treating or preventing
CC cancer, involving administering to a subject having or at risk of
CC developing cancer immunostimulatory nucleic acids that induce expression
CC of cell surface antigens and antibodies. The methods are useful for
CC treating or preventing cancer such as basal cell carcinoma, bladder
CC cancer, bone cancer, brain and central nervous system (CNS) cancer,
CC breast cancer, cervical cancer, colon and rectum cancer, connective
CC tissue cancer, esophageal cancer, eye cancer, kidney cancer, larynx
CC cancer, leukemia, liver cancer, lung cancer, Hodgkin's lymphoma, non-
CC Hodgkin's lymphoma, melanoma, myeloma, oral cavity cancer, ovarian
CC cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin
CC cancer, stomach cancer, testicular cancer, and uterine cancer. The
CC present sequence is an immunostimulatory oligonucleotide described in the
XX exemplification of the invention
SQ
Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 49 GGGGTTGGAGGTT 61
Dd 1 GGGGTTGGGGGTT 13

```

```

XX
XX Krieger AM, Berg DJ;
PI
XX
XX WPI; 2003-521815/49.
DR
XX
XX Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
PT disease by administering an immunostimulatory nucleic acid.
XX
XX Disclosure; Page 29; 229pp; English.
XX
XX The invention describes a method of treating non-allergic inflammatory
CC disease comprising administering to a subject having or at risk of
CC developing a non-allergic inflammatory disease an immunostimulatory
CC nucleic acid for prevention or treatment of the disease. The method is
CC useful for treating non-allergic inflammatory diseases, such as
CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
XX This sequence represents an immunostimulatory nucleic acid
XX
SQ
Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 49 GGGGTTGGAGGTT 61
Dd 1 GGGGTTGGGGGTT 13

```

```

RESULT 47
ACH03134
ID ACH03134 standard; DNA; 13 BP.
XX
XX ACH03134;
AC
XX
XX 25-SEP-2003 (first entry)
DT
XX
XX Immunostimulatory nucleic acid #769.
DE
XX
XX Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
KW anticancer; gene therapy; vaccine; non-allergic inflammatory disease;
KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
XX
XX Synthetic.
OS
XX
XX US2003050268-A1.
PN
XX
XX 13-MAR-2003.
PD
XX
XX 29-MAR-2002; 2002US-00112653.
PF
XX
XX 29-MAR-2001; 2001US-0279642P.
PR
XX (KRIEGER) KRIEGER A M.
PA (BERG/) BERG D J.

```

```

RESULT 48
ADB37096
ID ADB37096 standard; DNA; 13 BP.
XX
XX ADB37096;
AC
XX
XX 04-DEC-2003 (first entry)
DT
XX
XX Immunostimulatory nucleic acid #710.
DE
XX
XX ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
KW hypo-responsive subject; immunostimulatory.
XX
XX Synthetic.
OS
XX
XX US2003087848-A1.
PN
XX
XX 08-MAY-2003.
PD
XX
XX 02-FEB-2001; 2001US-00776479.
PF
XX
XX 03-FEB-2000; 2000US-0179991P.
PR
XX
XX (BRATZLER) BRATZLER R L.
PA (PETERSEN) PETERSEN D M.
PA (FOUR/) FOURN Y.
XX
XX Bratzler RL, Petersen DM, Fourn Y;
PI
XX
XX WPI; 2003-657977/62.
DR
XX
XX Treating and/or preventing allergy or asthma using an immunostimulatory
PT nucleic acid alone or in combination with an asthma/allergy medicament.
XX
XX Disclosure; Page 16; 221pp; English.
XX
XX The invention relates to a method of treating or preventing allergy or
CC asthma which comprises administering to a subject a poly-G nucleic acid
CC in an aerosol formulation. The methods and compositions of the present
CC invention are useful for diagnosing and/or treating asthma and allergy
CC especially in a hypo-responsive subject. The present sequence represents
CC an immunostimulatory nucleic acid of the invention.

```

```

XX Sequence 13 BP; 0 A; 0 C; 9 G; 4 T; 0 U; 0 Other;
SQ
Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 1.4e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 49 GGGGTTGGAGGTT 61
Db 1 GGGGTTGGAGGTT 13

RESULT 49
AA297685
ID AA297685 standard; DNA; 14 BP.
AC AA297685;
XX
XX 15-SEP-2003 (revised)
DT 26-APR-2000 (first entry)
XX
XX HIV-1 protease gene probe SEQ ID NO:175.
DE
XX Human immunodeficiency virus; HIV; protease; probe; detection;
KM drug selected mutation; hybridisation; genotyping; infection;
KM drug resistance; 88.
XX
XX Human immunodeficiency virus 1.
OS
XX WO967428-A2.
XX
XX 29-DEC-1999.
XX
XX 22-JUN-1999; 99MO-EP004317.
XX
XX 24-JUN-1998; 98EP-00870143.
XX
XX (INNO-) INNOGENETICS NV.
XX
XX Stuyver L;
PI
XX WPI; 2000-147219/13.
XX
XX Detection of drug-selected mutations in the HIV protease gene used to
XX treat HIV infections.
XX
XX Claim 3; Page 36; 76pp; English.
XX
XX The present invention describes the detection of drug-selected mutations
XX in the HIV protease gene. The method of detection allows the simultaneous
XX characterisation of a range of codons involved in drug resistance using
XX sets of probes optimised to function together in a reverse-hybridisation
XX assay. AA297517 to AA297997 represent specifically claimed probes for use
XX in the assay, and AA297479 to AA297501 represent specifically claimed HIV
XX protease gene polymorphic nucleotide sequences. AA297502 to AA297515, and
XX AA298004 to AA298007 represent PCR primers for the HIV protease gene, the
XX and AA297516 represents an HIV protease probe used in an example from the
XX present invention. The method, probes and primers can be used for the
XX detection of drug-selected mutations in the HIV protease gene. The method
XX allows the simultaneous characterisation of a range of codons involved in
XX drug resistance. The method may also be used for HIV protease genotyping
XX assays. The probes are able to discriminate between wild type and mutated
XX protease sequences. The method allows rapid and reliable detection of
XX drug-selected mutation in HIV. (Updated on 15-SEP-2003 to standardise OS
XX field)
XX
XX Sequence 14 BP; 2 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
SQ
Query Match 17.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GGGTGGAGGTTT 62

```

```

Db 1 GAGTGGAGGTTT 13

RESULT 50
AAQ90131
ID AAQ90131 standard; DNA; 15 BP.
XX
XX AAQ90131;
XX
XX 09-JAN-1996 (first entry)
DT
XX
XX 69-mer oligonucleotide ST08 PCR primer SPI4.
DE
XX Opioid peptide dynorphin B; molecular synthesis; antigenic epitope; ST08;
KM monoclonal antibody D32.39; PCR primer SPI4; 88.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1 /*tag= a
FT /label= biotinylated
FT
XX
XX WO9512608-A1.
XX
XX 11-MAY-1995.
XX
XX 02-NOV-1994; 94MO-US012347.
XX
XX 02-NOV-1993; 93US-00146886.
XX
XX 02-NOV-1993; 93US-00149675.
XX
XX (AFFY-) AFFYMAX TECHNOLOGIES NV.
XX
XX Sugarman JH, Rava RP, Kedar H, Dower WJ, Barrett RW, Gallop MA,
XX Needle MC;
PI
XX WPI; 1995-185735/24.
XX
XX Apparatus and methods for synthesis of diverse molecules - for generating
XX PT and screening molecular libraries which contain tagged individual
XX PT molecules.
XX
XX Example 1; Page 129; 201pp; English.
XX
XX AAQ90130 and AAQ90131 are a pair of primers for the PCR amplification of
XX CC AAQ90129, the 69-mer oligonucleotide ST08. ST08 was synthesised in
XX CC parallel with the epitope AAR84884 reactive with the anti-dynorphin B
XX CC monoclonal antibody D32.39, on 10 micron diameter beads to demonstrate a
XX CC new molecular synthesis method
XX
XX Sequence 15 BP; 5 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGAATGGAATTG 17
Db 2 TGGAATGGAATTG 14

RESULT 51
AAT86416/c
ID AAT86416 standard; DNA; 15 BP.
XX
XX AAT86416;
XX
XX 28-JUN-1998 (first entry)
DT
XX Human satellite II and III centromere repeat peptide nucleic acid probe.
DE
XX

```


PT molecules such as tagged chemical libraries, has non-concentric shafts
XX which rotates reaction vessel holding brackets relatively.
PS Example 1; Col 100; 111pp; English.
XX
CC The present invention relate to non-concentric shafts mounted inside
CC housings are rotatably held by the brackets attached to reaction vessels.
CC A vortexing motor is attached to the top bracket and transmission
CC supplies rotational force to the shaft end connected to the bottom
CC bracket which causes rotation of the lower bracket relative to top
CC bracket thereby agitating contents of reaction vessels. The invention is
CC used for synthesizing very large collections of diverse molecules such as
CC tagged chemical libraries
XX
SQ Sequence 15 BP; 5 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGAAATGGAATTG 17
DB 2 TGGAAATGGAAGTG 14
XX
RESULT 54
ABN87928/C
ID ABN87928 standard; DNA; 15 BP.
XX
AC ABN87928;
XX
DT 12-AUG-2002 (first entry)
XX
DE Human GSR allele specific oligonucleotide primer SEQ ID NO:47.
XX
KM Human; glutathione reductase; GSR; enzyme; haemolytic anaemia; SNP;
KM gene therapy; anti anaemic; polymorphic; single nucleotide polymorphism;
KM primer; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_feature 14 /*tag= a
FT /note= "polymorphic base"
XX
PN WO200242320-A2.
XX
PD 30-MAY-2002.
XX
PF 13-NOV-2001; 2001WO-US046473.
XX
PR 10-NOV-2000; 2000US-0247202P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Bieglecki KM, Sanchis A, Sausker EA, Sun X;
XX
DR WPI; 2002-471719/50.
XX
PT New genetic variants of Glutathione reductase isogenes, useful for
PT improving efficiency and reliability in drug development for treating
PT hemolytic anemia.
XX
PS Claim 14; Page 14; 137pp; English.
XX
CC The present invention describes genetic variants of the human glutathione
CC reductase (GSR) gene (1). (1) has anti anaemic activity and can be used in
CC gene therapy. (1) can be used in screening for drugs targeting (1) that
CC are useful for treating haemolytic anaemia. Methods from the present
CC invention can be used: for improving the efficiency and reliability of
CC several steps in the discovery and development of drugs for treating
CC diseases associated with GSR activity; for haplotyping, which is also

CC used by the pharmaceutical research scientist to validate GSR as a
CC candidate target for treating a specific condition or disease predicted
CC to be associated with GSR activity, e.g. haemolytic anaemia, and in the
CC design of clinical trials for treating a specific condition of disease
CC associated with GSR activity; and for screening compounds targeting GSR.
CC (1) is useful in studying the expression and function of GSR, and in
CC expressing GSR protein for use in screening for candidate drugs to treat
CC diseases related to GSR activity. (1) is also useful in studying the
CC effect of the variation on the biological activity of GSR as well as on
CC the binding affinity of candidate drugs targeting GSR for the treatment
CC of haemolytic anaemia. The present sequence represents an allele specific
CC oligonucleotide (ASO) primer for the human GSR gene, which is given in
CC the exemplification of the present invention. N.B. The polymorphic base
CC (showing a single nucleotide polymorphism) in the ASO primer is shown
CC using an IUPAC ambiguity code (as given in the present invention)
XX
SQ Sequence 15 BP; 1 A; 4 C; 2 G; 7 T; 0 U; 1 Other;
XX
Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
QY 32 ACAGAAAGAACCTTG 46
DB 15 AAGAAAGAACCATG 1
XX
RESULT 55
AAS97335/C
ID AAS97335 standard; DNA; 15 BP.
XX
AC AAS97335;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human CRYBB1 gene ASO PCR primer #18.
XX
KM Human; crystallin beta B1; CRYBB1; chromosome 22q12.1; ophthalmological;
KM cataract; allele specific oligonucleotide; ASO; ss; haplotype;
KM genotyping; transgenic animal; PCR primer.
XX
OS Homo sapiens.
XX
PN WO200185998-A1.
XX
PD 15-NOV-2001.
XX
PF 07-MAY-2001; 2001WO-US014715.
XX
PR 05-MAY-2000; 2000US-0202253P.
XX
PA (GENA-) GENAISSANCE PHARM INC.
XX
PI Choi JY, Kazemi A, Kliehm SE, Koshy B, Rounds E;
XX
DR WPI; 2002-062253/08.
XX
PT Novel polymorphic variants of crystallin, beta B1 useful in studying
PT expression and function of the protein, useful for screening candidate
PT drugs to treat diseases e.g. cataract.
XX
PS Claim 15; Page 12; 94pp; English.
XX
CC The invention relates to an isolated polynucleotide comprising a sequence
CC which is a polymorphic variant of a reference sequence for crystallin,
CC beta B1 (CRYBB1, located on chromosome 22q12.1) gene or their fragment,
CC where the polymorphic variant comprises a CRYBB1 isogene defined by a
CC haplotype from haplotypes 1-16 as given in the specification. Also
CC included are a transgenic non-human animal transformed or transfected
CC with the polymorphic variant, a computer system for storing and analysing
CC polymorphism data for CRYBB1 gene, a genome anthology for the CRYBB1 gene
CC which comprises the defined CRYBB1 isogenes, methods of determining an
CC individuals haplotype or genotype as well as methods of determining the

CC association of a particular haplotype with a disease or trait and a
 CC composition comprising at least one genotyping oligonucleotide
 CC (especially allele-specific oligonucleotides (ASO)) for detecting a
 CC polymorphism in the CRYBB1. The isogenes or haplotypes are useful for
 CC improving the efficiency and reliability of several steps in the
 CC discovery and development of drugs for treating diseases associated with
 CC CRYBB1 activity, e.g. cataract, and can also be used by the
 CC pharmaceutical research scientist to validate CRYBB1 as a candidate
 CC target for, and in design of clinical trials of candidate drugs for,
 CC treating a specific condition drugs or disease predicted to be associated
 CC with CRYBB1 activity. The ASOs are useful as probes and primers, and for
 CC assaying a polymorphism in the target region. The present sequence is an
 CC ASO PCR primer for CRYBB1
 XX
 SQ Sequence 15 BP; 2 A; 8 C; 3 G; 1 T; 0 U; 1 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 92.3%; Pred. No. 1.5e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 46 GCTGGGGTTGGAG 58
 |||||
 DB 13 GCTGGGGCTGGAG 1

RESULT 56
 ABK54466
 ID ABK54466 standard; DNA; 15 BP.
 AC
 XX ABK54466;
 AC
 XX
 DT 05-JUN-2002 (first entry)
 XX
 DE ASO primer #16 to detect human BMPR2 gene polymorphisms.

XX Human; single nucleotide polymorphism; SNP; BMPR2; chromosome 2q33-q34;
 KW bone morphogenetic protein receptor type II; serine/threonine kinase;
 KW haplotyping; genotyping; gene; primary pulmonary hypertension; PPH;
 KW bone disorder; allele-specific oligonucleotide; ASO; primer; ss.
 XX Homo sapiens.
 OS
 XX
 PN WO200216398-A2.
 XX
 PD 28-FEB-2002.
 XX
 PF 27-AUG-2001; 2001WO-US026641.
 XX
 PR 25-AUG-2000; 2000US-0228272P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 PA (LANZ/) LANZ E M.
 PI Chew A, Kiem SE, Messer C, Sanchis A;
 XX
 DR WPI; 2002-280906/32.
 XX

PT Novel isolated polynucleotide which is a polymorphic variant of bone
 PT morphogenetic protein receptor, type II (serine/threonine kinase) (BMPR2)
 PT gene useful for expressing BMPR2 protein isoform used in drug screening.
 XX
 PS Claim 16; Page 15; 98pp; English.
 XX

CC The present invention relates to novel single nucleotide polymorphisms
 CC (SNPs) in the human bone morphogenetic protein receptor type II
 CC (serine/threonine kinase) (BMPR2) gene located on chromosome 2q33-q34,
 CC and methods for haplotyping and/or genotyping the BMPR2 gene. The methods
 CC of the invention make use of allele-specific oligonucleotides (ASOs) as
 CC probes and primers, and/or primer-extension oligonucleotides for
 CC detecting the BMPR2 gene polymorphisms. The polynucleotides and screened
 CC compounds are useful for the treatment of diseases associated with BMPR2
 CC activity, such as primary pulmonary hypertension (PPH) and bone
 CC disorders. ABK54451-ABK54466 represent ASO primers for detecting human

CC BMPR2 gene polymorphisms
 XX
 SQ Sequence 15 BP; 2 A; 1 C; 9 G; 2 T; 0 U; 1 Other;

Query Match 17.5%; Score 11.4; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 1.5e+02;
 Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 45 TGCTGGGGTTGGAG 59
 |||||
 DB 1 TGCAGGGGTGGAG 15

RESULT 57
 AB154483/C
 ID AB154483 standard; DNA; 12 BP.
 AC
 XX AB154483;
 AC
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 354456 for detecting SNP TSC0008950.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS
 XX Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPICGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 354456; 23pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABG000010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pat_sequences
 XX
 SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 16.9%; Score 11; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 1.5e+02;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 5 TCGAATGCAAT 15
 |||||
 DB 12 TCGAATGCAAT 2

```

RESULT 58
AB144216 standard; DNA; 12 BP.
XX ID AB144216;
XX AC AB144216;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 344189 for detecting SNP TSC0043433.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 344189; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 16.9%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTTT 62
XX |||||
XX 2 GTTGAGGTTT 12
XX
XX Db
XX
XX RESULT 59
XX AB18186/C
XX ID AB18186 standard; DNA; 12 BP.
XX
XX AC AB18186;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 318159 for detecting SNP TSC0028484.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

XX OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 318159; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 16.9%; Score 11; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 1.5e+02;
XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTTT 62
XX |||||
XX 12 GTTGAGGTTT 2
XX
XX Db
XX
XX RESULT 60
XX AB144217
XX ID AB144217 standard; DNA; 12 BP.
XX
XX AC AB144217;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide primer SEQ ID NO 344190 for detecting SNP TSC0043433.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX

```

```
PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 344190; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 1 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 16.9%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 52 GTTGAGGTTT 62
DB 2 GTTGAGGTTT 12
XX
RESULT 61
AB181139
ID AB181139 standard; DNA; 12 BP.
XX
AC AB181139;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 381112 for detecting SNP TSC0064177.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 381112; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
```

```
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.9%; Score 11; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 5 TGGATGGAAT 15
DB 1 TGGATGGAAT 11
XX
RESULT 62
AB106790
ID AB106790 standard; DNA; 12 BP.
XX
AC AB106790;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306763 for detecting SNP TSC0022165.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 306763; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 16.9%; Score 11; DB 1; Length 12;
```

Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 52 GTTGAGAGTTT 62
| | | | | | | | | |
Db 1 GTTGAGAGTTT 11

RESULT 63

AAK77962
ID AAK77962 standard; DNA; 13 BP.

AC AAX77962;

DT 16-AUG-1999 (first entry)

DE Human tenascin binding primer 38.

DE Tenascin; antipsooriasis; antivittiligo; anticancer; anti-inflammatory;

KM cardiovascular; treatment; disease; depigmentation; albinism; cancer;

KM psoriasis; vitiligo; metastasis; melanoma; inflammation; restenosis;

KM diagnosis; human; primer; ss.

XX Synthetic.

OS Homo sapiens.

XX Key

FT misc_difference 1..3

FT /*tag= a

FT /note= "Nucleotides joined by phosphodiester or

FT phosphorothioate linkages"

FT misc_difference 10..12 b

FT /*tag=

FT /note= "Nucleotides joined to others by phosphodiester or

FT phosphorothioate linkages"

FT DE19750702-A1.

XX 27-MAY-1999.

XX 15-NOV-1997; 97DE-01050702.

XX 15-NOV-1997; 97DE-01050702.

XX (HMRI) HOECHST MARION ROUSSEL DEUT GMBH.

XX Peyman A, Uhlmann E, Weiser C;

XX WPI; 1999-314075/27.

XX Antisense oligonucleotides that bind to sequences encoding human tenascin

XX for treating depigmentation, cancer, inflammation and cardiovascular

XX disease.

XX Claim 20; Page 16; 18pp; German.

XX This invention describes novel oligonucleotides with up to 17 optionally

XX modified nucleotides (nt), or their salts which are capable of binding to

XX a nucleic acid encoding an isoform of human tenascin, or a part of it.

XX The oligonucleotides of the invention have antipsooriasis, antivittiligo,

XX anticancer, anti-inflammatory and cardiovascular activity. The

XX oligonucleotides are used to treat or prevent diseases associated with

XX (over)expression of tenascin, particularly depigmentation (albinism,

XX psoriasis or vitiligo), cancer or metastases, particularly melanoma,

XX inflammation or cardiovascular disease (e.g. restenosis). A preferred

XX application is treatment of vitiligo. The oligonucleotides may also be

XX used for diagnosis of these diseases. AAX77925-X77981 represent the

XX primers used in the method of the invention

XX Sequence 13 BP; 7 A; 4 C; 2 G; 0 T; 0 U; 0 Other;

XX Query Match 16.9%; Score 11; DB 1; Length 13;

XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;

XX Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
| | | | | | | | | |
Db 3 ACAGAAAGAAC 13

RESULT 64

AAK77943
ID AAK77943 standard; DNA; 13 BP.

AC AAX77943;

DT 16-AUG-1999 (first entry)

DE Human tenascin binding primer 19.

DE Tenascin; antipsooriasis; antivittiligo; anticancer; anti-inflammatory;

KM cardiovascular; treatment; disease; depigmentation; albinism; cancer;

KM psoriasis; vitiligo; metastasis; melanoma; inflammation; restenosis;

KM diagnosis; human; primer; ss.

XX Synthetic.

OS Homo sapiens.

XX Key

FT DE19750702-A1.

FT 27-MAY-1999.

FT 15-NOV-1997; 97DE-01050702.

FT 15-NOV-1997; 97DE-01050702.

FT (HMRI) HOECHST MARION ROUSSEL DEUT GMBH.

FT Peyman A, Uhlmann E, Weiser C;

FT WPI; 1999-314075/27.

FT Antisense oligonucleotides that bind to sequences encoding human tenascin

FT for treating depigmentation, cancer, inflammation and cardiovascular

FT disease.

FT Claim 7; Page 15; 18pp; German.

FT This invention describes novel oligonucleotides with up to 17 optionally

FT modified nucleotides (nt), or their salts which are capable of binding to

FT a nucleic acid encoding an isoform of human tenascin, or a part of it.

FT The oligonucleotides of the invention have antipsooriasis, antivittiligo,

FT anticancer, anti-inflammatory and cardiovascular activity. The

FT oligonucleotides are used to treat or prevent diseases associated with

FT (over)expression of tenascin, particularly depigmentation (albinism,

FT psoriasis or vitiligo), cancer or metastases, particularly melanoma,

FT inflammation or cardiovascular disease (e.g. restenosis). A preferred

FT application is treatment of vitiligo. The oligonucleotides may also be

FT used for diagnosis of these diseases. AAX77925-X77981 represent the

FT primers used in the method of the invention

FT Sequence 13 BP; 7 A; 4 C; 2 G; 0 T; 0 U; 0 Other;

FT Query Match 16.9%; Score 11; DB 1; Length 13;

FT Best Local Similarity 100.0%; Pred. No. 1.6e+02;

FT Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

FT QY 32 ACAGAAAGAAC 42

FT | | | | | | | | | |

FT Db 3 ACAGAAAGAAC 13

FT RESULT 65

FT AAK77981

FT ID AAX77981 standard; DNA; 13 BP.

FT XX

```

AC AAX77981;
XX
XX 16-AUG-1999 (first entry)
XX
DE Human tenascin binding primer 57.
XX
XX Tenascin; antipsooriasis; antivittiligo; anticancer; anti-inflammatory;
XX cardiovascular; treatment; disease; depigmentation; albinism; cancer;
XX psoriasis; vitiligo; metastasis; melanoma; inflammation; restenosis;
XX diagnosis; human; primer; ss.
XX
OS Synthetic.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX misc_difference 1..2
XX /tag= a
XX /note= "nucleotides joined by phosphorothioate or
XX phosphorodiester bonds"
XX
XX misc_difference 3..9
XX /tag= b
XX /note= "nucleotides modified with 2'-O-Methyl, and/or 2'-
XX O-Propyl and/or 2'-Methoxyethoxy and or a peptide nucleic
XX acid backbone"
XX
XX misc_difference 10..12
XX /tag= c
XX /note= "nucleotides modified with 2'-O-Methyl, and/or 2'-
XX O-Propyl and/or 2'-Methoxyethoxy and or a peptide nucleic
XX acid backbone"
XX
XX DE19750702-A1.
XX
XX 27-MAY-1999.
XX
XX 15-NOV-1997; 97DE-01050702.
XX
XX 15-NOV-1997; 97DE-01050702.
XX
XX 15-NOV-1997; 97DE-01050702.
XX
XX (HMRI ) HOECHST MARION ROUSSEL DEUT GMBH.
XX
XX Peyman A, Uhlmann E, Weiser C;
XX
XX WPI; 1999-314075/27.
XX
XX Antisense oligonucleotides that bind to sequences encoding human tenascin
XX for treating depigmentation, cancer, inflammation and cardiovascular
XX disease.
XX
XX Claim 22; Page 17; 18pp; German.
XX
XX This invention describes novel oligonucleotides with up to 17 optionally
XX modified nucleotides (nu), or their salts which are capable of binding to
XX a nucleic acid encoding an isoform of human tenascin, or a part of it.
XX The oligonucleotides of the invention have antipsooriasis, antivittiligo,
XX anticancer, anti-inflammatory and cardiovascular activity. The
XX oligonucleotides are used to treat or prevent diseases associated with
XX (over)expression of tenascin, particularly depigmentation (albinism,
XX psoriasis or vitiligo), cancer or metastases, particularly melanoma,
XX inflammation or cardiovascular disease (e.g. restenosis). A preferred
XX application is treatment of vitiligo. The oligonucleotides may also be
XX used for diagnosis of these diseases. AAX77925-X77981 represent the
XX primers used in the method of the invention
XX
SQ Sequence 13 BP; 7 A; 4 C; 2 G; 0 T; 0 U; 0 Other;

```

```

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 32 ACAGAAAGAAC 42
DB 3 ACAGAAAGAAC 13

```

```

RESULT 66
ID ABC91347/C
XX ABC91347 standard; DNA; 13 BP.
XX
AC ABC91347;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 91364 for detecting SNP TSC0022885.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 91364; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 0 G; 0 T; 0 U; 1 Other;

```

```

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 48 TGGGGTTGGAGGT 60
DB 13 TGGGGTTGGGGY 1

```

```

RESULT 67
ID ABC57026
XX ABC57026 standard; DNA; 13 BP.
XX
AC ABC57026;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 57043 for detecting SNP TSC0015429.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX

```

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 57043; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB102073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 2 A; 0 C; 5 G; 5 T; 0 U; 1 Other;
SQ
Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 51 GGTGGAGGTTTC 63
Db 1 GGTGAAGGTTT 13
RESULT 68
ABF02652
ID ABF02652 standard; DNA; 13 BP.
XX
XX ABF02652;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 102649 for detecting SNP TSC0025640.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.

XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 102649; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB102073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 1 Other;
SQ
Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 48 TGGGTTGGAGGT 60
Db 1 TGGAGTTGAGGT 13
RESULT 69
ABH48359/c
ID ABH48359 standard; DNA; 13 BP.
XX
XX ABH48359;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248336 for detecting SNP TS00060682.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 248336; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 9 ATGGAATTGGA 19
DB 13 ATGGAATTGGA 3

RESULT 70

ABC91346
ID ABC91346 standard; DNA; 13 BP.

AC ABC91346;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 91363 for detecting SNP TSC0022885.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS
XX
XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PT Claim 1; SEQ ID NO 91363; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 0 A; 0 C; 9 G; 3 T; 0 U; 1 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGCTTGGAGCT 60
DB 1 TGGGCTTGGAGCT 13

RESULT 71

ABC57027/c
ID ABC57027 standard; DNA; 13 BP.

AC ABC57027;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 57044 for detecting SNP TSC0015429.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS
XX
XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

PT Claim 1; SEQ ID NO 57044; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 51 GGTGAGGCTTC 63
DB 13 GGTGAGGCTTC 1

RESULT 72

ABC01035/c
ID ABC01035 standard; DNA; 13 BP.


```

AC ABC01035;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 1026 for detecting SNP TSC0000335.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 1026; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
SQ
Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAG 58
DB 12 TGGGGTTGGAG 2
RESULT 73
ABH48358
ID ABH48358 standard; DNA; 13 BP.
XX
XX ABH48358;
AC
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 248335 for detecting SNP TSC0060682.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.

```

```

XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 248335; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;
SQ
Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 9 ATGGAATTGGA 19
DB 1 ATGGAATTGGA 11
RESULT 74
ABF02653/C
ID ABF02653 standard; DNA; 13 BP.
XX
XX ABF02653;
AC
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 102650 for detecting SNP TSC0025640.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 102650; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 1 Other;
XX
Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 1.6e+02;
Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAGT 60
DB 13 TGGAGTTGGAGGY 1
XX
RESULT 75
ID ABC01034 standard; DNA; 13 BP.
XX ABC01034;
XX ABC01034;
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 1025 for detecting SNP TSC0000336.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX
XX Homo sapiens.
XX
XX NO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Plegenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 1025; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX
Query Match 16.9%; Score 11; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAG 58
DB 2 TGGGGTTGGAG 12
XX
RESULT 76
ID AAX56933 standard; DNA; 14 BP.
XX AAX56933;
XX AAX56933;
XX 16-OCT-2003 (revised)
XX 15-JUL-1999 (first entry)
XX
DE HIV-1 proviral DNA fragment 16.
XX
XX DNA-targeting conjugate; anticancer drug; viral DNA-cleaving agent;
KW viral DNA-binding agent; solid support; primer; ss.
XX
OS Human immunodeficiency virus 1.
XX
XX WO9531434-A1.
XX
XX 23-NOV-1995.
XX
XX 12-MAY-1995; 95WO-US006379.
XX
XX 13-MAY-1994; 94US-00242664.
XX
XX (SLOK) SLOAN KETTERING INST CANCER RES.
XX (ZWI-) ZW BIOMEDICAL RES AG.
XX
XX Watanabe KA, Ren W, Weil R;
XX
XX WPI; 1996-010846/01.
XX
XX Derivatized solid supports and reagents for oligo:nucleotide synthesis -
XX and new oligo:nucleotide phosphoramidate conjugates.
XX
XX Disclosure; Page 46; 68pp; English.
XX
CC This invention describes novel derivatised solid supports of formula S'-L
CC -Z-CH2CH2-R, where: S' = a solid support; L = a bond or an (in)organic
CC linker; Z = SO2 or S-S; R = OH, an H-phosphate, alkaneophosphate,
CC phosphotriester, phosphite triester, phosphite diester, phosphorothioate,
CC phosphorodithioate, phosphoramidate or phosphoramidite group, OR1, SRI, or an
CC oligonucleotide of formula (N')gR2; g = 1-200; R1 = a protecting group;
CC R2 = an H-phosphate, alkaneophosphate, phosphotriester, phosphite
CC triester, phosphite diester, phosphorothioate, phosphotriester, phosphite
CC phosphoramidate or phosphoramidite group, OH, OR1, SRI or
CC OP(OCH2CH2CN)OCH2CH2CH2CH2OR1. Also mentioned are compounds of formula
CC R3CH2CH2CH2CH2R4, where: R3 = a protecting group; and R4 = OH or an H-
CC phosphate, alkaneophosphate, phosphotriester, phosphite triester,
CC or phosphoramidite group. Also claimed are new phosphoramidates, a
CC process for preparing an oligonucleotide 5'-phosphate, a process for
CC preparing a solid support useful for preparation of an oligonucleotide 3'-
CC phosphate, a process for preparing an oligonucleotide 3'-phosphate and a
CC process for preparing an oligonucleotide 3',5'-diphosphate. The
CC oligonucleotide 3'- and/or 5'-phosphates may be used to prepare DNA-

CC targeting conjugates, e.g. with anticancer drugs or viral (e.g. HIV) DNA-
CC cleaving or -binding agents. The process for preparing oligonucleotide
CC 3',5'-diphosphates is simple and suitable for use in automatic DNA
CC synthesizers. This sequence represents a fragment of the HIV-1 provirus
CC genome, used to describe the method of the invention. (Updated on 16-OCT-
CC 2003 to standardise OS field)

XX Sequence 14 BP; 10 A; 0 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAGAA 41
Db 1 AAGAAAAAAGAA 14

RESULT 77

AA259021
ID AA259021 standard; DNA; 14 BP.

XX AA259021;

DT 11-APR-2000 (first entry)

XX Triple helix forming target sequence from ori-gamma plasmids.

XX Antitumour; antiviral; antimicrobial; transfer vector; targeting system;
KM triplex; triple helix; antisense; ribozyme; gene therapy; blood factor;
KM hormone; tumour suppressor; antigenic peptide; vaccine; immunotherapy;
KM cancer; pCOR; ori; origin of replication; ss.

XX Unidentified.

OS

PN WO949067-A1.

PD 30-SEP-1999.

PF 19-MAR-1999; 99WO-FR000643.

PR 24-MAR-1998; 98FR-00003573.

XX 18-MAY-1998; 98US-0085848P.

PA (RHON) RHONE-POULENC RORER SA.

PI Ciolina C, Scherman D, Wils P;

DR WPI; 1999-572204/48.

XX

PT New nucleic acid transfer vector comprising double-stranded DNA linked to

PT oligonucleotide, used for gene therapy.

XX

PS Claim 13; Page 40; 72pp; French.

XX

CC The invention relates to a method of delivering a therapeutic double

CC stranded DNA to a target cell or tissue by administering the DNA in a

CC transfer vector. The vector comprises the double-stranded DNA molecule

CC and at least one oligonucleotide that is linked to a targeting system and

CC can form a triplex with a specific sequence within target cell or tissue.

CC This sequence represents an example of a target sequence able to form a

CC triple helix with the oligonucleotide. The sequence is found in the

CC gamma origin of replication of plasmids such as pCOR. The vector is used

CC to deliver therapeutic DNA (including antisense sequences or ribozymes)

CC for gene therapy, e.g. sequences that encode enzymes, blood factors,

CC hormones, tumour suppressors, also antigenic peptides for use as vaccines

CC or immunotherapeutic agents for control of microbial or viral infections,

CC or cancer

XX

XX Sequence 14 BP; 12 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

SQ

Query Match 16.6%; Score 10.8; DB 1; Length 14;

Best Local Similarity 85.7%; Pred. No. 1.8e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAGAA 41

Db 1 AAGAAAAAAGAA 14

RESULT 79

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAGAA 41
Db 1 AAGAAAAAAGAA 14

RESULT 78

AA21101
ID AA21101 standard; DNA; 14 BP.

XX AA21101;

DT 20-MAR-2002 (first entry)

XX Oligonucleotide corresponding to pXL3296 DNA sequence.

XX ss; DNA purification; triple helix; plasmid purification;

XX double purification.

OS Synthetic.

PN WO200192511-A2.

PD 06-DEC-2001.

PF 25-MAY-2001; 2001WO-US017122.

PR 26-MAY-2000; 2000US-00580923.

PA (AVENTIS PHARMA SA.

PI Crouzet J, Scherman D, Wils P, Blanche F, Cameron B;

DR WPI; 2002-097772/13.

XX

PT Purifying double-stranded (ds) DNA from a solution containing dsDNA and

PT other components, comprises passing the solution through a support

PT comprising a covalently coupled oligonucleotide able to form a triple

PT helix with the dsDNA.

XX

PS Claim 2; Page 23; 40pp; English.

XX

CC This invention comprises a method of purifying double-stranded DNA from a

CC solution containing the double-stranded DNA mixed with other components,

CC comprising passing the solution through a support comprising a covalently

CC coupled oligonucleotide capable of forming a triple helix with the double

CC -stranded DNA by hybridisation with a specific sequence present in the

CC double-stranded DNA. The method is useful for purifying double-stranded

CC DNA contained in a solution and mixed with other components. The new

CC method is a simple, rapid and effective method for DNA purification, and

CC makes it possible to obtain especially high purities with high yields.

CC The method enables DNA to be purified from complex mixtures comprising

CC other nucleic acids, proteins, endotoxins, nucleases and the like. The

CC supports may be readily recycled, and the DNAs obtained display improved

CC properties to pharmaceutical safety. Further, the method entails only one

CC step contrary to prior art. The present sequence represents an

CC oligonucleotide corresponding to a sequence contained within plasmid

CC pXL3296, that is capable of forming a triple helix for use in the DNA

CC double purification method of the invention

XX

XX Sequence 14 BP; 12 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

SQ

Query Match 16.6%; Score 10.8; DB 1; Length 14;

Best Local Similarity 85.7%; Pred. No. 1.8e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 28 AAGACAGAAAGAA 41

Db 1 AAGAAAAAAGAA 14

RESULT 79

AAS21102/c
 ID AAS21102 standard; DNA; 14 BP.
 AC AAS21102;
 XX
 DT 20-MAR-2002 (first entry)
 DE Oligonucleotide used to prepare a DNA triplex affinity gel.
 DE ss; DNA purification; triple helix; plasmid purification;
 KW homopyrimidine oligonucleotide.
 XX
 OS Synthetic.
 XX
 PN WO200192511-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US017122.
 XX
 PR 26-MAY-2000; 2000US-00580923.
 XX
 PA (AVERT) AVENTIS PHARMA SA.
 XX
 PI Crouzet J, Scherman D, Wils P, Blanche F, Cameron B;
 XX
 DR WPI; 2002-097772/13.
 XX
 PT Purifying double-stranded (ds) DNA from a solution containing dsDNA and
 PT other components, comprises passing the solution through a support
 PT comprising a covalently coupled oligonucleotide able to form a triple
 PT helix with the dsDNA.
 XX
 PS Claim 1; Page 23; 40pp; English.
 XX
 CC This invention comprises a method of purifying double-stranded DNA from a
 CC solution containing the double-stranded DNA mixed with other components,
 CC comprising passing the solution through a support comprising a covalently
 CC coupled oligonucleotide capable of forming a triple helix with the double
 CC double-stranded DNA by hybridisation with a specific sequence present in the
 CC DNA contained in a solution and mixed with other components. The new
 CC method is a simple, rapid and effective method for DNA purification, and
 CC makes it possible to obtain especially high purities with high yields.
 CC The method enables DNA to be purified from complex mixtures comprising
 CC other nucleic acids, proteins, endotoxins, nucleases and the like. The
 CC supports may be readily recycled, and the DNAs obtained display improved
 CC properties to pharmaceutical safety. Further, the method entails only one
 CC step contrary to prior art. The present sequence represents a homopyrimidine
 CC oligonucleotide used to purify the PCR plasmid using an oligonucleotide
 CC corresponding to a sequence present in the origin of replication (ori
 CC gamma) of the plasmid
 CC
 SO Sequence 14 BP; 0 A; 2 C; 0 G; 12 T; 0 U; 0 Other;
 XX
 Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 1.8e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 28 AAGAAACAGAAAGA 41
 DB 14 AAGAAAAAAGAA 1
 XX
 RESULT 80
 ABR38003/c
 ID ABR38003 standard; DNA; 13 BP.
 AC ABR38003;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 138000 for detecting SNP TSC0034524.
 XX

XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 138000; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -AB093989, ABR00010-ABF93989, ABR00010-ABH93989 and ABR00010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SO Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;
 XX
 Query Match 16.3%; Score 10.6; DB 1; Length 13;
 Best Local Similarity 90.9%; Pred. No. 1.8e+02;
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 OY 53 TTGAGGTTTC 63
 DB 11 TTGAGGTTT 1
 XX
 RESULT 81
 ABR38002
 ID ABR38002 standard; DNA; 13 BP.
 AC ABR38002;
 XX
 DT 21-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 137999 for detecting SNP TSC0034524.
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 DE peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 DE central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX

```

PR 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 137999; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;
SQ
XX
XX Query Match 16.3%; Score 10.6; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No. 1.8e+02;
XX Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
OY 53 TTGGAGGTTTC 63
XX |||||
XX 3 TTGGAGGTTT 13
DB
XX
XX RESULT 82
XX AAQ22815/c
XX ID AAQ22815 standard; DNA; 12 BP.
XX
XX AAQ22815;
AC
XX
XX 09-JUL-1992 (first entry)
DT
XX
XX Random oligonucleotide #35.
DE
XX
XX Diverse library; ss.
XX
XX Synthetic.
OS
XX
XX WO9203461-A.
PN
XX
XX 05-MAR-1992.
PD
XX
XX 20-AUG-1991; 91WO-US005939.
PF
XX
XX 24-AUG-1990; 90US-00573648.
PR
XX
XX (IXSY-) IXSYS INC.
PA
XX
XX Huse WD;
PI
XX
XX WPI; 1992-096824/12.
DR
XX
XX Synthesizing oligo-nucleotide(s) having random tuples - by sequentially
PT coupling monomers on separate supports, mixing, dividing and repeating
XX the steps.
XX
XX Claim 24; Page 20; 34pp; English.
PS
XX
XX The oligonucleotide was prep'd. using a new method for the synthesis of

```

```

CC oligos having random tuples, starting from individual monomers. The
CC method comprises: (1) sequentially coupling monomers on separate supports
CC to form at least 2 different tuples, the coupling being performed in
CC separate reaction vessels; (2) mixing the supports from the reaction
CC vessels; and (3) dividing the mixed supports into 2 or more separate reaction
CC vessels; and (4) repeating steps (1)-(3) one or more times in the
CC reaction vessel of (3), where the last step ends at step (2). The method
CC may also be used to prepare oligos having tuples which are diverse but
CC which are biased towards a predetermined sequence. See also AAQ22781-
CC Q22822
XX
XX Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 5 TGGATGGAATT 16
XX |||||
XX 12 TGGATGGAATT 1
DB
XX
XX RESULT 83
XX AAQ22813/c
XX ID AAQ22813 standard; DNA; 12 BP.
XX
XX AAQ22813;
AC
XX
XX 09-JUL-1992 (first entry)
DT
XX
XX Random oligonucleotide #33.
DE
XX
XX Diverse library; ss.
XX
XX Synthetic.
OS
XX
XX WO9203461-A.
PN
XX
XX 05-MAR-1992.
PD
XX
XX 20-AUG-1991; 91WO-US005939.
PF
XX
XX 24-AUG-1990; 90US-00573648.
PR
XX
XX (IXSY-) IXSYS INC.
PA
XX
XX Huse WD;
PI
XX
XX WPI; 1992-096824/12.
DR
XX
XX Synthesizing oligo-nucleotide(s) having random tuples - by sequentially
PT coupling monomers on separate supports, mixing, dividing and repeating
XX the steps.
XX
XX Claim 24; Page 19; 34pp; English.
PS
XX
XX The oligonucleotide was prep'd. using a new method for the synthesis of
XX oligos having random tuples, starting from individual monomers. The
XX method comprises: (1) sequentially coupling monomers on separate supports
XX to form at least 2 different tuples, the coupling being performed in
XX separate reaction vessels; (2) mixing the supports from the reaction
XX vessels; (3) dividing the mixed supports into 2 or more separate reaction
XX vessels; and (4) repeating steps (1)-(3) one or more times in the
XX reaction vessel of (3), where the last step ends at step (2). The method
XX may also be used to prepare oligos having tuples which are diverse but
XX which are biased towards a predetermined sequence. See also AAQ22781-
XX Q22822
XX
XX Sequence 12 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Qy 5 TGGATGGAATT 16
 ||| ||| ||| |||
 Db 12 TGGATGGAATT 1

RESULT 84
 AAQ91300
 ID AAQ91300 standard; DNA; 12 BP.
 XX
 AC AAQ91300;

DT 25-MAR-2003 (revised)
 DT 07-FEB-1996 (first entry)

DE Circular oligonucleotide end joining oligonucleotide.

KW Circular oligonucleotide; infection inhibitor; labelled probe;
 KW nuclease resistant; high selectivity; high affinity;
 KW gene expression inhibitor; end joining oligonucleotide; ss.

OS Synthetic.

PN US5426180-A.

PD 20-JUN-1995.

PF 11-JAN-1993; 93US-00004800.

PR 27-MAR-1991; 91US-00675843.

PR 26-MAR-1992; 92US-00859922.

PA (RESE) RESEARCH CORP TECHNOLOGIES INC.

PI Kool ET;

DR WPI; 1995-230952/30.

PT Prepn. of single-stranded circular oligo:nucleotide cpds. - using a
 PT linear pre-circle and an end-joining oligo:nucleotide to form distinct
 PT binding domains.

PS Example 1; Fig 3; 43pp; English.

CC AAQ91300 is a circular oligonucleotide end joining oligo, used in the
 CC prepn. of the circular oligos given in AAQ91296-98. Circular oligos can
 CC be used to inhibit viral infection and gene expression, or (when
 CC labelled) as probes for the detection of target sequences. Circular
 CC oligos are resistant to nucleases, and bind targets with higher
 CC selectivity and affinity than do linear oligos. (Updated on 25-MAR-2003
 CC to correct PF field.)

SQ Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 28 AAGAACGGAAG 39
 ||| ||| ||| |||
 Db 1 AAGAAAAGAAAG 12

RESULT 85
 AAT42866
 ID AAT42866 standard; DNA; 12 BP.
 XX
 AC AAT42866;

DT 10-JUN-1997 (first entry)

DE Single stranded circular oligonucleotide target sequence #2.

KW single stranded; circular; target sequence; parallel; detection;
 KW binding domain; anti-parallel; loop domain; complementarity; ss;
 KW synthesis; regulation; drug delivery; biosynthesis; tumour cell.

OS Synthetic.

PN WO9630384-A1.

PD 03-OCT-1996.

PF 21-MAR-1996; 96WO-US003757.

PR 30-MAR-1995; 95US-00413813.

PA (RESE) RESEARCH CORP TECHNOLOGIES INC.

PI Kool ET;

DR WPI; 1996-455262/45.

PT Single stranded circular oligo:nucleotide comprising parallel and or anti
 PT -parallel binding domain - used to regulate biosynthesis of DNA, RNA or
 PT protein in targetted mammalian tumour cell in vivo.

PS Example 2; Fig 2A; 195pp; English.

CC The sequences given in AAT42860-80 represent single stranded (ss)
 CC circular oligonucleotides or their target sequences. The ss circular
 CC oligonucleotides comprise a parallel binding (P) domain, and/or an anti-
 CC parallel binding (AP) domain, and at least 1 loop domain. The P and AP
 CC domains have sufficient complementarity to bind detectably to 1 strand of
 CC a defined nucleic acid target. The P domain is capable of binding in a
 CC parallel manner to the target. The AP domain is capable of binding in an
 CC anti-parallel manner to the target and the ends of the P and AP domains
 CC are separated by the loop domains. The ss circular oligonucleotides can
 CC be used to regulate the synthesis of DNA, RNA or protein (pref. by DNA
 CC replication, DNA reverse transcription, RNA splicing, RNA
 CC polyadenylation, RNA translocation or protein translocation) by binding a
 CC target sequence in the template. They can also be used to deliver a drug
 CC to a specific cell type by administering a drug covalently bound to them
 CC (i.e. to regulate the biosynthesis of DNA, RNA or protein in a targetted
 CC mammalian tumour cell in vivo, without substantially altering the
 CC biosynthesis of the DNA). They can also be used to detect a target
 CC nucleic acid by detecting an oligonucleotide-target complex. The circular
 CC oligonucleotide can bind both single and double stranded target nucleic
 CC acids, and has enhanced stability, compared to linear forms. This
 CC sequence is specifically the target region for the ss circular
 CC oligonucleotide given in AAT42863-64

SQ Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 28 AAGAACGGAAG 39
 ||| ||| ||| |||
 Db 1 AAGAAAAGAAAG 12

RESULT 86
 AAT42896
 ID AAT42896 standard; RNA; 12 BP.
 XX
 AC AAT42896;

DT 10-JUN-1997 (first entry)

DE Single stranded circular oligonucleotide RNA target region.

KW single stranded; circular; target sequence; parallel; detection;
 KW binding domain; anti-parallel; loop domain; complementarity; ss;
 KW synthesis; regulation; drug delivery; biosynthesis; tumour cell.

```

XX XX Synthetic.
OS XX WO630384-A1.
PN XX 03-OCT-1996.
PD XX 21-MAR-1996; 96WO-US003757.
XX XX 30-MAR-1995; 95US-00413813.
PR XX (RESE ) RESEARCH CORP TECHNOLOGIES INC.
PA XX
PI XX KOOL ET;
DR XX WPI; 1996-455262/45.
PT XX Single stranded circular oligo:nucleotide comprising parallel and or anti
PT -parallel binding domain - used to regulate biosynthesis of DNA, RNA or
PT protein in targeted mammalian tumour cell in vivo.
XX XX Example 9; Page 129; 195pp; English.
XX PS
XX CC The sequences given in AAT42894-96 represent target sequences bound by
XX CC the single stranded (ss) circular oligonucleotides of the invention.
XX CC These target regions have different backbones to determine if this is
XX CC important in the binding of the ss circular oligo's. The ss circular
XX CC oligonucleotides comprise a parallel binding (P) domain, and/or an anti-
XX CC parallel binding (AP) domain, and at least 1 loop domain. The P and AP
XX CC domains have sufficient complementarity to bind detectably to 1 strand of
XX CC a defined nucleic acid target. The P domain is capable of binding in a
XX CC parallel manner to the target. The AP domain is capable of binding in an
XX CC anti-parallel manner to the target and the ends of the P and AP domains
XX CC are separated by the loop domains. The ss circular oligonucleotides can
XX CC be used to regulate the synthesis of DNA, RNA or protein (pref. by DNA
XX CC replication, DNA reverse transcription, RNA splicing, RNA
XX CC polydenylation, RNA translocation or protein translocation) by binding a
XX CC target sequence in the template. They can also be used to deliver a drug
XX CC to a specific cell type by administering a drug covalently bound to them
XX CC (i.e. to regulate the biosynthesis of DNA, RNA or protein in a targeted
XX CC mammalian tumour cell in vivo, without substantially altering the
XX CC biosynthesis of the DNA). They can also be used to detect a target
XX CC nucleic acid by detecting an oligonucleotide- target complex. The
XX CC circular oligonucleotide can bind both single and double stranded target
XX CC nucleic acids, and has enhanced stability, compared to linear forms
XX CC
XX SQ Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 30 GAACAGAAAGAA 41
XX ||| |||||
XX 1 GAAGAAGAAAGAA 12.
XX Db
XX
XX RESULT 87
XX AAT42895
XX ID AAT42895 standard; DNA; 12 BP.
XX AC
XX XX AAT42895;
XX AC
XX XX 10-JUN-1997 (first entry)
XX DE Single stranded circular oligonucleotide DNA target region.
XX KW single stranded; circular; target sequence; parallel; detection;
XX KW binding domain; anti-parallel; loop domain; complementarity; ss;
XX KW synthesis; regulation; drug delivery; biosynthesis; tumour cell.
XX OS Synthetic.
XX XX

```

```

PN PN WO630384-A1.
XX XX 03-OCT-1996.
PD XX 21-MAR-1996; 96WO-US003757.
XX XX 30-MAR-1995; 95US-00413813.
PR XX (RESE ) RESEARCH CORP TECHNOLOGIES INC.
PA XX
PI XX KOOL ET;
DR XX WPI; 1996-455262/45.
PT XX Single stranded circular oligo:nucleotide comprising parallel and or anti
PT -parallel binding domain - used to regulate biosynthesis of DNA, RNA or
PT protein in targeted mammalian tumour cell in vivo.
XX XX Example 9; Page 129; 195pp; English.
XX PS
XX CC The sequences given in AAT42894-96 represent target sequences bound by
XX CC the single stranded (ss) circular oligonucleotides of the invention.
XX CC These target regions have different backbones to determine if this is
XX CC important in the binding of the ss circular oligo's. The ss circular
XX CC oligonucleotides comprise a parallel binding (P) domain, and/or an anti-
XX CC parallel binding (AP) domain, and at least 1 loop domain. The P and AP
XX CC domains have sufficient complementarity to bind detectably to 1 strand of
XX CC a defined nucleic acid target. The P domain is capable of binding in a
XX CC parallel manner to the target. The AP domain is capable of binding in an
XX CC anti-parallel manner to the target and the ends of the P and AP domains
XX CC are separated by the loop domains. The ss circular oligonucleotides can
XX CC be used to regulate the synthesis of DNA, RNA or protein (pref. by DNA
XX CC replication, DNA reverse transcription, RNA splicing, RNA
XX CC polydenylation, RNA translocation or protein translocation) by binding a
XX CC target sequence in the template. They can also be used to deliver a drug
XX CC to a specific cell type by administering a drug covalently bound to them
XX CC (i.e. to regulate the biosynthesis of DNA, RNA or protein in a targeted
XX CC mammalian tumour cell in vivo, without substantially altering the
XX CC biosynthesis of the DNA). They can also be used to detect a target
XX CC nucleic acid by detecting an oligonucleotide- target complex. The
XX CC circular oligonucleotide can bind both single and double stranded target
XX CC nucleic acids, and has enhanced stability, compared to linear forms
XX CC
XX SQ Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 30 GAACAGAAAGAA 41
XX ||| |||||
XX 1 GAAGAAGAAAGAA 12
XX Db
XX
XX RESULT 88
XX AAT42867/C
XX ID AAT42867 standard; DNA; 12 BP.
XX AC
XX XX AAT42867;
XX AC
XX XX 10-JUN-1997 (first entry)
XX DE Single stranded circular oligonucleotide target sequence #3.
XX KW single stranded; circular; target sequence; parallel; detection;
XX KW binding domain; anti-parallel; loop domain; complementarity; ss;
XX KW synthesis; regulation; drug delivery; biosynthesis; tumour cell.
XX OS Synthetic.
XX OS WO630384-A1.
XX PN
XX XX 03-OCT-1996.
XX PD

```

```

XX 21-MAR-1996; 96WO-US003757.
XX
XX 30-MAR-1995; 95US-00413813.
XX
XX (RESE ) RESEARCH CORP TECHNOLOGIES INC.
XX
XX Kool ET;
XX
XX WPI; 1996-455262/45.
XX
PT Single stranded circular oligonucleotide comprising parallel and or anti
PT -parallel binding domain - used to regulate biosynthesis of DNA, RNA or
PT protein in targeted mammalian tumour cell in vivo.
XX
PS Example 2; Fig 2B; 195pp; English.
XX
CC The sequences given in AAT42860-80 represent single stranded (ss)
CC circular oligonucleotides or their target sequences. The ss circular
CC oligonucleotides comprise a parallel binding (P) domain, and/or an anti-
CC parallel binding (AP) domain, and at least 1 loop domain. The P and AP
CC domains have sufficient complementarity to bind detectably to 1 strand of
CC a defined nucleic acid target. The P domain is capable of binding in a
CC parallel manner to the target. The AP domain is capable of binding in an
CC anti-parallel manner to the target and the ends of the P and AP domains
CC are separated by the loop domains. The ss circular oligonucleotides can
CC be used to regulate the synthesis of DNA, RNA or protein (pref. by DNA
CC replication, DNA reverse transcription, RNA splicing, RNA
CC polyadenylation, RNA translocation or protein translocation) by binding a
CC target sequence in the template. They can also be used to deliver a drug
CC to a specific cell type by administering a drug covalently bound to them
CC (i.e. to regulate the biosynthesis of DNA, RNA or protein in a targeted
CC mammalian tumour cell in vivo, without substantially altering the
CC biosynthesis of the DNA). They can also be used to detect a target
CC nucleic acid by detecting an oligonucleotide-target complex. The circular
CC oligonucleotide can bind both single and double stranded target nucleic
CC acids, and has enhanced stability, compared to linear forms
XX
SQ Sequence 12 BP; 0 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 28 AAGACGAGG 39
Db 12 AAGGAAAGAAAG 1
XX
RESULT 89
ID AB125498
ID AB125498 standard; DNA; 12 BP.
XX
AC AB125498;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 325471 for detecting SNP TSC0032556.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX

```

```

PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 325471; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 4 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 8 AATGGAATTGCA 19
Db 1 AATGGAATTGCA 12
XX
RESULT 90
ID AB107008/C
ID AB107008 standard; DNA; 12 BP.
XX
AC AB107008;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 306981 for detecting SNP TSC0022282.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 306981; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic

```



```
XX AC AB104542;
XX XX
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide primer SEQ ID NO 304515 for detecting SNP TSC0020975.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 304515; 29pp + Sequence listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 0 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 44 TTGCTGGGGTTG 55
XX ||| |||||
XX 1 TTGGTGGGGTTG 12
XX
XX RESULT 94
XX ID AB106919/C
XX ID AB106919 standard; DNA; 12 BP.
XX AC AB106919;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 306892 for detecting SNP TSC0022229.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
```

```
PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 306892; 29pp + Sequence listing; German.
XX XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 12 BP; 4 A; 3 C; 1 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 5 TGGAAATGGAAT 16
XX ||||| |||||
XX 12 TGGAAATGGAAT 1
XX
XX Db
XX
XX RESULT 95
XX ID AB107431
XX ID AB107431 standard; DNA; 12 BP.
XX AC AB107431;
XX XX
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 307404 for detecting SNP TSC0022484.
XX XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX XX
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 307404; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGGTT 61
Db 1 GGGTTGAGGAT 12
XX
RESULT 96
ABT61725
ID ABT61725 standard; DNA; 12 BP.
XX
AC ABT61725;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 361698 for detecting SNP TSC0052780.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 361698; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGGTTGAGGTT 62
Db 1 GGGTTGAGGTT 12
XX
RESULT 97
ABT22625
ID ABT22625 standard; DNA; 12 BP.
XX
AC ABT22625;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 322598 for detecting SNP TSC0030953.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 322598; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT92073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGAGTGGAGGT 60
 | | | | | | | | | |
 Db 1 GAGTTGGAGGT 12

RESULT 98

ID AB123553 standard; DNA; 12 BP.

AC AB123553;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 323526 for detecting SNP TSC0031438.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PE 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 323526; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 12 BP; 0 A; 2 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 52 GTTGGAGGTTTC 63
 | | | | | | | | | |
 Db 1 GTTGGCGGTTTC 12

RESULT 99

ID AB172830/c standard; DNA; 12 BP.

AC AB172830;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 372803 for detecting SNP TSC0059648.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PE 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 372803; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 12 BP; 6 A; 6 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GCTTGGAGGTTT 62
 | | | | | | | | | |
 Db 12 GCTTGGCGGTTT 1

RESULT 100

ID AB173289 standard; DNA; 12 BP.

AC AB173289;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 373262 for detecting SNP TSC0059932.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PE 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 373262; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 4 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 5 TCGAATCGAATT 16
Db 1 TCGAATCTAATT 12
RESULT 101
ABH94429
ID ABH94429 standard; DNA; 12 BP.
XX
XX ABH94429;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 294422 for detecting SNP TSC0016107.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIC-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.

PS Claim 1; SEQ ID NO 294422; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 50 GGGTTGAGGCTT 61
Db 1 GGGTGGAGGCTT 12
RESULT 102
ABI28154
ID ABI28154 standard; DNA; 12 BP.
XX
XX ABI28154;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 328127 for detecting SNP TSC0034118.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX (EPIC-) EPIGENOMICS AG.
XX PA
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX WPI; 2001-657177/75.
XX DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 328127; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at

```

CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 50 GGGTTGAGGTT 61
DB 1 GGGTTGAGGTT 12

RESULT 103
ABH80482
ID ABH80482 standard; DNA; 12 BP.
AC
XX
XX ABH80482;
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 280475 for detecting SNP TSC0008681.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 280475; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 9 G; 2 T; 0 U; 0 Other;

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 48 TGGGGTTGAGG 59
DB 1 TGGGGTTGAGG 12

```

```

RESULT 104
ABI06918/c
ID ABI06918 standard; DNA; 12 BP.
XX
XX ABI06918;
AC
XX
XX 22-FEB-2002 (first entry)
DT
DE Oligonucleotide primer SEQ ID NO 306891 for detecting SNP TSC0022229.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 306891; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 TGAATGGAATT 16
DB 12 TGAATGGAATT 1

RESULT 105
ABH84964
ID ABH84964 standard; DNA; 12 BP.
AC
XX ABH84964;
DT 22-FEB-2002 (first entry)
DE Oligonucleotide primer SEQ ID NO 284957 for detecting SNP TSC0012071.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

```

XX OS Homo sapiens.
XX XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD
XX XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX PR 07-APR-2000; 2000DE-01019173.
XX PS
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX CC
XX CC Claim 1; SEQ ID NO 284957, 29pp + Sequence Listing; German.
XX CC
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status; in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 8 AATGGAATTGGA 19
XX |||||
XX 1 AATGGAATTGTA 12
XX
Db
XX
XX RESULT 106
XX AB109323/C
XX ID AB109323 standard; DNA; 12 BP.
XX AC
XX XX ABI09323;
XX DT
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 309296 for detecting SNP TSC0023469.
XX XX
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX PN
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX PS
XX PA (EPIC-) EPIGENOMICS AG.
XX XX

```

```

PI Olek A, Piepenbrock C, Berlin K;
XX XX WPI; 2001-657177/75.
XX DR
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX CC
XX CC Claim 1; SEQ ID NO 309296, 29pp + Sequence Listing; German.
XX CC
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status; in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTTCGAGGTTT 62
XX |||||
XX 12 GGTTCGAGGTT 1
XX
Db
XX
XX RESULT 107
XX AB124668
XX ID AB124668 standard; DNA; 12 BP.
XX AC
XX XX AB124668;
XX DT
XX DT 22-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide primer SEQ ID NO 324641 for detecting SNP TSC0032154.
XX XX
XX XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX XX
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX PN
XX PD 18-OCT-2001.
XX XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX XX
XX PR 07-APR-2000; 2000DE-01019173.
XX PS
XX PA (EPIC-) EPIGENOMICS AG.
XX XX
XX XX Olek A, Piepenbrock C, Berlin K;
XX XX
XX XX WPI; 2001-657177/75.
XX DR
XX XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX CC
XX CC Claim 1; SEQ ID NO 324641; 29pp + Sequence Listing; German.
XX CC
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status; in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTT 61
Db 1 GGGTTGAGGTT 12

RESULT 108
AB157127/c
ID AB157127 standard; DNA; 12 BP.

XX AC AB157127;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 357100 for detecting SNP TSC0008265.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-1B000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PS (EPIC-) EPIDENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX PS Claim 1; SEQ ID NO 357100; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;

Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 6 GGAATGGAATTG 17
Db 12 GGAATGGAATTG 1

RESULT 109

ABH70112/c
ID ABH70112 standard; DNA; 12 BP.

XX AC ABH70112;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide primer SEQ ID NO 270089 for detecting SNP TSC0001994.

XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX OS Homo sapiens.

XX PN WO200177384-A2.

XX PD 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-1B000713.

XX PR 07-APR-2000; 2000DE-01019173.

XX PS (EPIC-) EPIDENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX PS Claim 1; SEQ ID NO 270089; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 12 BP; 3 A; 8 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTT 61
Db 12 GGGTTGAGGTT 1

RESULT 110

AB175408
ID AB175408 standard; DNA; 12 BP.

XX AC AB175408;

XX 22-FEB-2002 (first entry)
DT Oligonucleotide primer SEQ ID NO 375381 for detecting SNP TSC0061225.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 375381; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 48 TGGGGTTGAGG 59
DB 1 TGGGGTTGAGG 12
RESULT 111
ABH76819
ID ABH76819 standard; DNA; 12 BP.
XX
XX ABH76819;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 276812 for detecting SNP TSC0004295.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 276812; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 51 GGTGGAGGTTT 62
DB 1 GGTGGAGGTTT 12
RESULT 112
AB108168
ID AB108168 standard; DNA; 12 BP.
XX
XX AB108168;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 308141 for detecting SNP TSC0022886.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPiGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT

PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1, SEQ ID NO 308141; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 12 BP; 0 A; 0 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAGG 59
DB 1 TGGGGTTGGGGG 12
RESULT 113
AB11964/C
ID AB11964 standard; DNA; 12 BP.
AC AB11964;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 311937 for detecting SNP TSC0024770.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PT
XX
XX Claim 1; SEQ ID NO 311937; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 12 BP; 5 A; 7 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 51 GGTGGAGGTTT 62
DB 12 GGTGGGGGTTT 1
RESULT 114
AB113865/C
ID AB113865 standard; DNA; 12 BP.
AC AB113865;
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide primer SEQ ID NO 313838 for detecting SNP TSC0025998.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
DR
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PT
XX
XX Claim 1; SEQ ID NO 313838; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 48 TGGGGTTGGAGG 59
DB 1 TGGGGTTGGGGG 12

Db	12	TGGGTTTGAGC 1
RESULT 115		
AB138926		
ID	AB138926	standard; DNA; 12 BP.
XX		
AC	AB138926;	
XX		
DT	22-FEB-2002	(first entry)
DE	Oligonucleotide primer SEQ ID NO 338899	for detecting SNP TSC0005508.
XX		
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
OS	Homo sapiens.	
PN	WO200177384-A2.	
XX		
PD	18-OCT-2001.	
XX		
PF	06-APR-2001; 2001WO-IB000713.	
XX		
PR	07-APR-2000; 2000DE-01019173.	
XX		
PA	(EP1G-) EPIGENOMICS AG.	
XX		
PI	Olek A, Piepenbrock C, Berlin K;	
DR	WPI; 2001-657177/75.	
XX		
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
PT	methylation status.	
XX		
PS	Claim 1; SEQ ID NO 338899; 29pp + Sequence Listing; German.	
XX		
CC	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligomers are also used for detecting cell type differentiation. ABO00010	
CC	-ABG99989, ABO00010-ABF99989, ABO00010-ABH99989 and ABO00010-ABI82073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic format from WIPO at	
CC	ftp.wipo.int/pub/published_pat_sequences	
XX		
SO	Sequence 12 BP; 9 A; 0 C; 3 G; 0 T; 0 U; 0 Other;	
	Query Match	16.0%; Score 10.4; DB 1; Length 12;
	Best Local Similarity	91.7%; Pred. No. 1.8e+02;
	Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
OY	29 AGAACAAGAA 40	
	1 AGAAAAGAAAGA 12	
Db		
RESULT 116		
ABH73791/C		
ID	ABH73791	standard; DNA; 12 BP.
XX		
AC	ABH73791;	
XX		
DT	22-FEB-2002	(first entry)
DE	Oligonucleotide primer SEQ ID NO 273776	for detecting SNP TSC0003307.
XX		

KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
XX	
XX	18-OCT-2001.
PD	
XX	
XX	06-APR-2001; 2001WO-IB000713.
XX	
XX	07-APR-2000; 2000DE-01019173.
PR	
XX	
XX	(EPIG-) EPIDEMIOLOGICS AG.
PA	
XX	
XX	Olek A, Piepenbrock C, Berlin K;
PI	
XX	WPI; 2001-657177/75.
DR	
XX	
XX	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
PT	methylation status.
PS	
XX	Claim 1; SEQ ID NO 273776; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligonucleotides are also used for detecting cell type differentiation. The
CC	ABG00010, ABG00010-ABG99989, ABH00010-ABH99989 and ABH00010-ABH82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
XX	
SO	Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
	Query Match 16.0%; Score 10.4; DB 1; Length 12;
	Best Local Similarity 91.7%; Pred. No. 1.8e+02;
	Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0
QY	51 GGTGAGGTTT 62
	12 GGTGAGGTTT 1
DB	
	RESULT 117
	AB177010/c
ID	AB177010 standard; DNA; 12 BP.
XX	
AC	AB177010;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide primer SEQ ID NO 376983 for detecting SNP TSC0062083.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
XX	WO200177384-A2.
XX	
XX	18-OCT-2001.
PD	
XX	
XX	06-APR-2001; 2001WO-IB000713.
PF	
XX	07-APR-2000; 2000DE-01019173.
PR	

```

XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 376983; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 3 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGGTT 61
Db 12 GGGTAGGAGGTT 1
XX
RESULT 118
AB123551
ID AB123551 standard; DNA; 12 BP.
XX
AC AB123551;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 323524 for detecting SNP TSC0031438.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 323524; 29pp + Sequence Listing; German.
XX

```

```

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 0 A; 1 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 52 GTTGGAGGTTTC 63
Db 1 GTTGGGTGTTTC 12
XX
RESULT 119
AB142492/c
ID AB142492 standard; DNA; 12 BP.
XX
AC AB142492;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 342465 for detecting SNP TSC0042557.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 342465; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

```

SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 51 GGTGGAGGTTT 62
 | |||||
 DB 12 GATTGAGGTTT 1
 |||||
 RESULT 120
 AB175632/c
 ID AB175632 standard; DNA; 12 BP.
 AC AB175632;
 XX
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide primer SEQ ID NO 375605 for detecting SNP TSC0061350.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 375605; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/publicated_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 51 GGTGGAGGTTT 62
 | |||||
 DB 12 GATTGAGGTTT 1
 |||||
 RESULT 121
 AB126119/c
 ID AB126119 standard; DNA; 12 BP.
 AC AB126119;
 XX
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide primer SEQ ID NO 326092 for detecting SNP TSC0032896.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 326092; 29pp + Sequence Listing; German.
 PS
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/publicated_pct_sequences
 XX
 SQ Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 50 GGGTTGAGGTTT 61
 | |||||
 DB 12 GGTGGAGGTTT 1
 |||||
 RESULT 122
 AB117994/c
 ID AB117994 standard; DNA; 12 BP.
 AC AB117994;
 XX
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide primer SEQ ID NO 317967 for detecting SNP TSC0028358.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.

XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 317967; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 50 GGGTTGGAGGTT 61
XX 12 GGGTTGGAGGTTT 1
XX
XX RESULT 123
XX AB107453
XX ID AB107453 standard; DNA; 12 BP.
XX
XX AB107453;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 307426 for detecting SNP TSC0022492.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX

XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 307426; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH9989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 12;
XX Best Local Similarity 91.7%; Pred. No. 1.8e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 45 TGCTGGGGTTGG 56
XX 1 TGATGGGGTTGG 12
XX
XX RESULT 124
XX AB162010
XX ID AB162010 standard; DNA; 12 BP.
XX
XX AB162010;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 361983 for detecting SNP TSC0052976.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 361983; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SQ Sequence 12 BP; 5 A; 0 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGATGGAATT 16
 |||||
 Db 1 TGGAAAGGAATT 12

RESULT 125

ABI00155
 ID ABI00155 standard; DNA; 12 BP.

AC ABI00155;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide primer SEQ ID NO 300128 for detecting SNP TSC0018874.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 300128; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 12 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 12;
 Best Local Similarity 91.7%; Pred. No. 1.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGTTGAGGT 60
 |||||
 Db 1 GGGTTGAGGT 12

RESULT 126

ABC95493/c
 ID ABC95493 standard; DNA; 13 BP.

AC ABC95493;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 95510 for detecting SNP TSC023770.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PR (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 95510; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GGTGGAGGTTT 62
 |||||
 Db 13 GGTGGAGGTTT 2

RESULT 127

ABC72046
 ID ABC72046 standard; DNA; 13 BP.

AC ABC72046;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 72063 for detecting SNP TSC0018626.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 72063; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 9 G; 2 T; 0 U; 0 Other;
 XX
 QY Query Match 16.0%; Score 10.4; DB 1; Length 13;
 XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 XX Matches 11; Conservative 0; Mismatches 1;
 Db 49 GGGGTGGAGT 60
 1 GGGGTGGAGT 12
 RESULT 128
 ABC11945/C
 ID ABC11945 standard; DNA; 13 BP.
 XX
 AC ABC11945;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 11952 for detecting SNP TSC002866.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 11952; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;
 XX
 QY Query Match 16.0%; Score 10.4; DB 1; Length 13;
 XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 XX Matches 11; Conservative 0; Mismatches 1;
 Db 5 TGGATGGAAT 16
 12 TGGATGGAAT 1
 RESULT 129
 ABC87797/C
 ID ABC87797 standard; DNA; 13 BP.
 XX
 AC ABC87797;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 87814 for detecting SNP TSC0022071.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

XX Claim 1; SEQ ID NO 87814; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 51 GGTTCGAGGTTT 62
DB 12 GCGTGGAGGTTT 1
XX
XX RESULT 130
XX ABC89082
XX ID ABC89082 standard; DNA; 13 BP.
XX AC ABC89082;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 89099 for detecting SNP TSC0022367.
XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN MO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIDENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 89099; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 1 TTCTCGAATGC 12
DB 2 TTTTGGAAATGC 13
XX
XX RESULT 131
XX ABF60882
XX ID ABF60882 standard; DNA; 13 BP.
XX AC ABF60882;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 160879 for detecting SNP TSC0040514.
XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN MO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIDENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 160879; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 5 A; 0 C; 3 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY 5 TCGAATGGAATT 16
DB 1 TAGAATGGAATT 12

```
RESULT 132
ABF09494
ID ABF09494 standard; DNA; 13 BP.
XX
XX ABF09494;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 109491 for detecting SNP TSC0027394.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K,
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 109491; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ
XX
XX Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 51 GGTGGAGGTTT 62
Db 1 GGTGGAGGATT 12
RESULT 133
ABH08614
ID ABH08614 standard; DNA; 13 BP.
XX
XX ABH08614;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 208591 for detecting SNP TSC0050963.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW
```

```
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 208591; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ
XX
XX Sequence 13 BP; 4 A; 1 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGATGGAATT 16
Db 2 TGGATGGAATT 13
RESULT 134
ABC18620
ID ABC18620 standard; DNA; 13 BP.
XX
XX ABC18620;
AC
XX
XX 20-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 18627 for detecting SNP TSC0003928.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
```

XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 18627; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -AB093989, AB00010-AB093989, AB00010-AB093989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. NO. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 44 TTGCTGGGGCTTG 55
||| |||||
Db 2 TTGGTGGGGCTTG 13

RESULT 135
ABC19997/c
ID ABC19997 standard; DNA; 13 BP.
XX
AC ABC19997;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 20014 for detecting SNP TSC0004117.
XX
SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; seq;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 20014; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 10 C; 0 G; 1 T; 0 U; 0 Other;

Oy 48 TGGCGTTCGAGC 59
Db 12 TGGCGGTGCAGC 1

RESULT 136

ID ABC95834 standard; DNA; 13 BP.

AC ABC95834;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 95851 for detecting SNP TSC0023842.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX MO2001.77384-A2.
PN 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
PR (EPIG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 95851; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTTCTGGAATGG 12
DB 1 TTTTGGAAATGG 12

RESULT 137
ABC22672
ID ABC22672 standard; DNA; 13 BP.
AC ABC22672;
XX
XX 20-FEB-2002 (first entry)
XX
XX
XX Oligonucleotide SEQ ID NO 22669 for detecting SNP TSC0004469.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 22669; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
XX Sequence 13 BP; 9 A; 0 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 29 AGAAGCAAGA 40
DB 1 AGAAGCAAGA 12

RESULT 138
ABF53874
ID ABF53874 standard; DNA; 13 BP.
XX

AC ABF53874;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 153871 for detecting SNP TSC0038903.
XX
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 153871; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB102073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX
XX Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTGGAGGT 60
DB 1 GGGGTGGAGGT 12

RESULT 139
ABC93477/c
ID ABC93477 standard; DNA; 13 BP.
XX
XX ABC93477;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 93494 for detecting SNP TSC0023368.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX

```

PD 18-OCT-2001.
PP 06-APR-2001; 2001WO-IB000713.
PR 07-APR-2000; 2000DE-01019173.
PA (EPIG-) EPIGENOMICS AG.
PI Olek A, Piepenbrock C, Berlin K;
PP WI, 2001-657177/75.
PR
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PS designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 93494; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC09989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 5 C; 1 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. NO.2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 28 AAGAACAGAAAG 39
XX ||||| |||||
XX 12 AAGAACGAAAG 1
XX
XX RESULT 140
XX ABC19996
XX ID ABC19996 standard; DNA; 13 BP.
XX AC ABC19996;
XX
XX 20-FEB-2002 (first entry)
XX DT
XX
XX Oligonucleotide SEQ ID NO 20013 for detecting SNP TSC0004117.
XX DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX OS
XX
XX WO200177384-A2.
XX PN
XX
XX 18-OCT-2001.
XX PD
XX
XX 06-APR-2001; 2001WO-IB000713.
XX PF
XX
XX 07-APR-2000; 2000DE-01019173.
XX PR
XX
XX (EPIG-) EPIGENOMICS AG.
XX PA
XX
XX Olek A, Piepenbrock C, Berlin K;
XX PI
XX
XX WI; 2001-657177/75.
XX

```

```
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX.  
PS Claim 1; SEQ ID NO 20013; 29pp + Sequence Listing; German.  
CC This invention describes novel oligonucleotide primers or peptide nucleic  
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)  
CC and cytosine methylation status in chemically pretreated genomic DNA. The  
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a  
CC range of diseases including immune system, gastrointestinal, respiratory,  
CC central nervous system, cardiovascular and metabolic disorders. The  
CC oligomers are also used for detecting cell type differentiation. ABC00010  
CC -ABG9989, ABE00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073  
CC represent the oligomers described in the invention. NOTE: The sequence  
CC data for this patent did not form part of the printed specification, but  
CC was obtained in electronic format from WIPO at  
CC ftp.wipo.int/pub/published_pct_sequences  
SQ Sequence 13 BP; 1 A; 0 C; 10 G; 2 T; 0 U; 0 Other;  
  
Query Match 16.0%; Score 10.4; DB 1; Length 13;  
Best Local Similarity 91.7%; Pred. No. 2e+02;  
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0.  
  
QY 48 TGCGGTGGAGG 59  
||| |  
DB 2 TGGGGTGGAGG 13  
.. .  
  
RESULT 141  
ABF09495/C  
ID ABF09495 standard; DNA; 13 BP.  
AC ABBF09495;  
DT 21-FEB-2002 (first entry)  
DE Oligonucleotide SEQ ID NO 109492 for detecting SNP TSC0027394.  
XX  
XX  
KM SNP, single nucleotide polymorphism; human; diagnosis; PNA; Cancer; CNS;  
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; sex;  
KM central nervous system; gastrointestinal; respiratory; Immune; metabolic.  
OS Homo sapiens.  
XX  
PN MO200177384-A2.  
PD 18-OCT-2001.  
PF 06-APR-2001; 2001WO-IB000713.  
PP XX  
PR 07-APR-2000; 2000DF-01019173.  
PA (EPIG-) EPIGENOMICS AG.  
XX  
PI Olek A, Piepenbrock C, Berlin K;  
DR WPI; 2001-657177/75.  
XX  
PT Set of oligonucleotides, useful for diagnosis and cell typing, is  
PT designed to detect single-nucleotide polymorphisms and cytosine  
PT methylation status.  
XX  
XX  
PS Claim 1; SEQ ID NO 109492; 29pp + Sequence Listing; German.
```

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GGTGGAGGTTT 62
13 GGTGGAGGATT 2

RESULT 142

ABH45216
ID ABH45216 standard; DNA; 13 BP.

AC ABH45216;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 245193 for detecting SNP TSC0059877.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001MO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 245193; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAGG 59

Db 1 TGGGGTTGGAGG 12

RESULT 143

ABF12720
ID ABF12720 standard; DNA; 13 BP.

AC ABF12720;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 112717 for detecting SNP TSC0028167.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001MO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 112717; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

Sequence 13 BP; 10 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
1 GAAAGAAAGAA 12

RESULT 144

ABH18990
ID ABH18990 standard; DNA; 13 BP.

AC ABH18990;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 218967 for detecting SNP TSC0053258.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 218967; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 1 TTCTCGAATGG 12
|||
1 TTTTGGAAATGG 12
Db
RESULT 145
ID ABE72258
ABF72258 standard; DNA; 13 BP.
XX
AC ABE72258;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 172255 for detecting SNP TSC0042953.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX

PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 172255; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 49 GGGCTTGAGCT 60
|||
2 GGGCTTGAGCT 13
Db
RESULT 146
ID ABE64846
ABH64846 standard; DNA; 13 BP.
XX
XX ABE64846;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 264823 for detecting SNP TSC0064191.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 264823; 29pp + Sequence Listing; German.
XX

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGGAGGT 60
Db 1 GGGGTTGGAGAT 12

RESULT 147
ABC61688
ID ABC61688 standard; DNA; 13 BP.
XX ABC61688;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 61705 for detecting SNP TSC0016408.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 61705; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 44 TTGCTGGGTTG 55
Db 2 TTGATGGGTTG 13

RESULT 148
ABH18991/c
ID ABH18991 standard; DNA; 13 BP.
XX ABH18991;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 218968 for detecting SNP TSC0053258.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 218968; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC range of diseases including immune system, gastrointestinal, respiratory, CC central nervous system, cardiovascular and metabolic disorders. The CC oligomers are also used for detecting cell type differentiation. ABC00010 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073 CC represent the oligomers described in the invention. NOTE: The sequence CC data for this patent did not form part of the printed specification, but CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TTCTGGATGG 12
Db 13 TTTTGGATGG 2

RESULT 149


```

ABC95492
ID ABC95492 standard; DNA; 13 BP.
XX
AC ABC95492;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 95509 for detecting SNP TSC0023770.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 95509; 29pp + Sequence Listing; German.
XX
PS This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTTCGAGGTTT 62
XX |||||
XX 1 GGTTCGAGGTTT 12
XX
RESULT 150
ID ABC89700 standard; DNA; 13 BP.
XX
AC ABC89700;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 89717 for detecting SNP TSC0022492.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 89717; 29pp + Sequence Listing; German.
XX
PS This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTTCGAGGTTT 62
XX |||||
XX 1 GGTTCGAGGTTT 12
XX
RESULT 151
ID ABF35272 standard; DNA; 13 BP.
XX
AC ABF35272;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 135269 for detecting SNP TSC0033745.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

```

XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 135269; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTTT 61
DB 1 GAGTTGAGGTTT 12

RESULT 152
ABH56067/C
ID ABH56067 standard; DNA; 13 BP.
XX
XX ABH56067;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 256044 for detecting SNP TSC0062390.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 256044; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a

```

```

CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
XX
SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GGTGGAGGTTT 62
DB 12 GTTGGAGGTTT 1

RESULT 153
ABC69962
ID ABC69962 standard; DNA; 13 BP.
XX
XX ABC69962;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 69979 for detecting SNP TSC0018209.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 69979; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;

```

```

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2 TTCTGGAATGGA 13
   ||| |||||
   1 TTTCGGAATGGA 12
RESULT 154
ABC00654
ID ABC00654 standard; DNA; 13 BP.
AC ABC00654;
XX
XX 20-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 645 for detecting SNP TSC0000148.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 645; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 TTTCGGAATG 12
   ||| |||||
   2 TTTCGGAATG 13
Db
RESULT 155
ABF44599/c
ID ABF44599 standard; DNA; 13 BP.
XX
XX ABF44599;
AC
XX
XX

```

```

DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 144596 for detecting SNP TSC0036362.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 144596; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GGCTTGAGGTT 61
   ||| |||||
   13 GGCTTGAGGTT 2
Db
RESULT 156
ABF72259/c
ID ABF72259 standard; DNA; 13 BP.
XX
XX ABF72259;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 172256 for detecting SNP TSC0042953.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD

```

XX 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPiG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 172256; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 SQ Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 49 GGGGTTGGAGGT 60
 Db 12 GGGTTGGAGGT 1
 RESULT 157
 ABC93476
 ID ABC93476 standard; DNA; 13 BP.
 AC ABC93476;
 XX 21-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 93493 for detecting SNP TSC0023368.
 DE SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPiG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.
 XX Claim 1; SEQ ID NO 93493; 29pp + Sequence Listing; German.
 PS This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 SQ Sequence 13 BP; 7 A; 1 C; 5 G; 0 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 28 AAGAACGAAAG 39
 Db 2 AAGAACGAAAG 13
 RESULT 158
 ABC00655/C
 ID ABC00655 standard; DNA; 13 BP.
 AC ABC00655;
 XX 20-FEB-2002 (first entry)
 DT Oligonucleotide SEQ ID NO 646 for detecting SNP TSC0000148.
 DE SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS WO200177384-A2.
 PN 18-OCT-2001.
 PD 06-APR-2001; 2001WO-IB000713.
 PF 07-APR-2000; 2000DE-01019173.
 PR (EPiG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS Claim 1; SEQ ID NO 646; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC XX
 SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1 TTTCGGAATG 12
 Db 12 TTTCGGAATG 1
 RESULT 159
 ABF15052
 ID ABF15052 standard; DNA; 13 BP.
 XX
 AC ABF15052;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 115049 for detecting SNP TSC0028823.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN MO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 115049; 29pp + Sequence listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC XX
 SQ Sequence 13 BP; 0 A; 0 C; 10 G; 3 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 48 TGGGGTTGGAGG 59
 Db 1 TGGGGTTGGAGG 12

RESULT 160
 ABF15053/c
 ID ABF15053 standard; DNA; 13 BP.
 XX
 AC ABF15053;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 115050 for detecting SNP TSC0028823.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN MO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001MO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 115050; 29pp + Sequence listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC XX
 SQ Sequence 13 BP; 3 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 48 TGGGGTTGGAGG 59
 Db 13 TGGGGTTGGAGG 2
 RESULT 161
 ABF53875/c
 ID ABF53875 standard; DNA; 13 BP.
 XX
 AC ABF53875;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 153872 for detecting SNP TSC0038903.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 153872; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGT 60
XX |||||
XX 13 GGGGTGTAGT 2
XX
RESULT 162
ABH08607/c
ID ABH08607 standard; DNA; 13 BP.
XX
XX ABH08607;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 208584 for detecting SNP TSC0050963.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX

PA (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 208584; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 5 TGGATGGAATT 16
XX |||||
XX 12 TGAATTGAATT 1
XX
RESULT 163
ABH56066
ID ABH56066 standard; DNA; 13 BP.
XX
XX ABH56066;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 256043 for detecting SNP TSC0062390.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 256043; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 51 GGTTCGAGGTTT 62
Db 2 GTTTGAGGTTT 13

RESULT 164
ABC95835/c
ID ABC95835 standard; DNA; 13 BP.
XX
AC ABC95835;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 95852 for detecting SNP TSC0023842.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-1B000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 95852; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 TTTCTGGAATGG 12
Db 13 TTTTGGAAATGG 2

RESULT 165
ABC72047/c
ID ABC72047 standard; DNA; 13 BP.
XX
AC ABC72047;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 72064 for detecting SNP TSC0018626.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-1B000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 72064; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 9 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTCGAGGT 60
Db 13 GGGGTTCGAGGT 2

RESULT 166
ABC75859/c
ID ABC75859 standard; DNA; 13 BP.

```

XX AC ABC75859;
XX XX
DT 21-FEB-2002 (first entry)
XX DE
XX DE Oligonucleotide SEQ ID NO 75876 for detecting SNP TSC0019443.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 75876; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 50 GGGTTGAGGTT 61
XX |||||
XX 13 GGGTTGAGGTT 2
XX
XX RESULT 167
XX ABC11944
XX ID ABC11944 standard; DNA; 13 BP.
XX AC ABC11944;
XX XX
XX 20-FEB-2002 (first entry)
XX XX
XX Oligonucleotide SEQ ID NO 11951 for detecting SNP TSC0002866.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX XX

```

```

XX PN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 11951; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 5 TGGAAATGGAAT 16
XX |||||
XX 2 TGGAAATGGAAT 13
XX
XX Db
XX
XX RESULT 168
XX ABC87801/C
XX ID ABC87801 standard; DNA; 13 BP.
XX AC ABC87801;
XX XX
XX 21-FEB-2002 (first entry)
XX XX
XX Oligonucleotide SEQ ID NO 87818 for detecting SNP TSC0022071.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS
XX Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIC-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX XX

```


XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX Claim 1; SEQ ID NO 87818; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 7 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTTGAGGCTTT 62
DB 12 GGCTGAGGCTTT 1
XX
RESULT 169
ABF60883/C
ID ABF60883 standard; DNA; 13 BP.
XX
AC ABF60883;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 160880 for detecting SNP TSC0040514.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
OS
XX WO200177384-A2.
XX
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001MO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PA Olek A, Piepenbrock C, Berlin K;
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 160880; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 1 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 5 TGGAATGGAATT 16
DB 13 TGGAATGGAATT 2
XX
RESULT 170
ABC99009/C
ID ABC99009 standard; DNA; 13 BP.
XX
AC ABC99009;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 99026 for detecting SNP TSC0024596.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
OS
XX WO200177384-A2.
XX
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001MO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PA Olek A, Piepenbrock C, Berlin K;
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 99026; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 9 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

OY      46 GCTGGAGTTGA 57
DB      12 GCGGAGGTTGA 1
RESULT 171
ABC89701/C
AC      ABC89701 standard; DNA; 13 BP.
AC      ABC89701;
XX      21-FEB-2002 (first entry)
DE      Oligonucleotide SEQ ID NO 89718 for detecting SNP TSC0022492.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIG-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX      Claim 1; SEQ ID NO 89718; 29pp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other.
SQ
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY      51 GGTGGAGGTTT 62
DB      13 GGTGGAGGATT 2
RESULT 172
ABF67787/C
ID      ABF67787 standard; DNA; 13 BP.
XX      ABF67787;
XX      22-FEB-2002 (first entry)
DT
XX

```

```

DE      Oligonucleotide SEQ ID NO 167784 for detecting SNP TSC0010654.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIG-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX      Claim 1; SEQ ID NO 167784; 29pp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
SQ
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY      51 GGTGGAGGTTT 62
DB      12 GGTGGAGGTTT 1
RESULT 173
ABF51528
ID      ABF51528 standard; DNA; 13 BP.
XX      ABF51528;
XX      21-FEB-2002 (first entry)
DE      Oligonucleotide SEQ ID NO 151525 for detecting SNP TSC0038276.
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.

```

XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 151525; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 8 AATGGAATTGGA 19
XX |||||
XX 1 AATGGAATTGGA 12
XX
Db
XX
XX RESULT 174
XX ABC69963/c
XX ID ABC69963 standard; DNA; 13 BP.
XX
XX ABC69963;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 69980 for detecting SNP TSC0018209.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX

PS Claim 1; SEQ ID NO 69980; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2 TTCTGGAATGGA 13
XX |||||
XX 13 TTTTGAATGGA 2
XX
Db
XX
XX RESULT 175
XX ABC22673/c
XX ID ABC22673 standard; DNA; 13 BP.
XX
XX ABC22673;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 22690 for detecting SNP TSC0004469.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 22690; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at

```

CC      ftp.wipo.int/pub/published_pct_sequences
XX      SQ      Sequence 13 BP; 1 A; 3 C; 0 G; 9 T; 0 U; 0 Other;
XX
Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      29      AGAACGAGAGA 40
          ||||| |||||
          13      AGAAAAGAGA 2

RESULT 176
ABC99008
ID      ABC99008 standard; DNA; 13 BP.
XX
AC      ABC99008;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 99025 for detecting SNP TSC0024596.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      PA      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 99025; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 1 A; 1 C; 9 G; 2 T; 0 U; 0 Other;

Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      46      GGTGGGGTTGGA 57
          ||||| |||||
          2      GCGGGGGTTGGA 13

DB

```

```

RESULT 177
ABC87800
ID      ABC87800 standard; DNA; 13 BP.
XX
AC      ABC87800;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 87817 for detecting SNP TSC0022071.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      PA      (EPIG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
XX      Claim 1; SEQ ID NO 87817; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 1 A; 1 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY      51      GGTGGAGGTTT 62
          ||||| |||||
          2      GGTGGAGGTTT 13

DB

RESULT 178
ABC89083/c
ID      ABC89083 standard; DNA; 13 BP.
XX
AC      ABC89083;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 89100 for detecting SNP TSC0022367.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

XX Homo sapiens.
OS
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 89100; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 1 TTTCTGGAATGG 12
XX |||||
XX 12 TTTTGGAAATGC 1
XX
XX RESULT 179
XX ABF67786
XX ID ABF67786 standard; DNA; 13 BP.
XX
XX ABF67786;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 167783 for detecting SNP TSC0010654.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX
XX

```

```

PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 167783; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX 51 GGTTCGAGGTTT 62
XX |||||
XX 2 GGTTCGAGTTT 13
XX
XX RESULT 180
XX ABH08615/C
XX ID ABH08615 standard; DNA; 13 BP.
XX
XX ABH08615;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 208592 for detecting SNP TSC0050963.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 208592; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP, 5 A, 3 C, 1 G, 4 T, 0 U, 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 TGGATCGAATT 16
DB 12 TGGATCGAATT 1

RESULT 181
ABC18621/c
ID ABC18621 standard; DNA; 13 BP.
XX
AC ABC18621;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 18628 for detecting SNP TSC0003928.
XX
KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPICENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 18628; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP, 6 A, 7 C, 0 G, 0 T, 0 U, 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;

Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 44 TTGCTGGCGTTG 55
DB 12 TTGCTGGCGTTG 1

RESULT 182
ABF12721/c
ID ABF12721 standard; DNA; 13 BP.
XX
AC ABF12721;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 112718 for detecting SNP TSC0028167.
XX
KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPIC-) EPICENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 112718; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP, 0 A, 3 C, 0 G, 10 T, 0 U, 0 Other;

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 30 GAACAGAAAGAA 41
DB 13 GAACAGAAAGAA 2

RESULT 183
ABC87796
ID ABC87796 standard; DNA; 13 BP.
XX
AC ABC87796;

```

XX 18-OCT-2001.
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 87813 for detecting SNP TSC0022071.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 87813; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 51 GGTTCGAGGTTT 62
XX |||||||
XX 2 GCGTGGAGGTTT 13
XX
XX RESULT 184
XX ABF35273/C
XX ID ABF35273 standard; DNA; 13 BP.
XX
XX AC ABF35273;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 135270 for detecting SNP TSC0033745.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX OS
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX

```

```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 135270; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 50 GGTTCGAGGTT 61
XX |||||||
XX 13 GAGTTGAGGTT 2
XX
XX RESULT 185
XX ABF44598
XX ID ABF44598 standard; DNA; 13 BP.
XX
XX AC ABF44598;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 144595 for detecting SNP TSC0036362.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 144595; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GGGTTGAGGCTT 61
Db 1 GGGTTGAGGCTT 12
RESULT 186
ABC75858
ID ABC75858 standard; DNA; 13 BP.
XX
AC ABC75858;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 75875 for detecting SNP TSC0019443.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 75875; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GGGTTGAGGCTT 61
Db 1 GGGTTGAGGCTT 12
RESULT 187
ABC61689/C
ID ABC61689 standard; DNA; 13 BP.
XX
AC ABC61689;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 61706 for detecting SNP TSC0016408.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 61706; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 16.0%; Score 10.4; DB 1; Length 13;
XX Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
XX Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 44 TTGCTGGGCTTG 55
||| ||||| |||||

DB	12	TTGATGGGTTG 1
RESULT 188		
ABF51529/C		
ID	ABF51529	standard; DNA; 13 BP.
XX	ABF51529;	
AC		
XX		
XX	21-FEB-2002	(first entry)
DT		
DE	Oligonucleotide SEQ ID NO 151526	for detecting SNP TSC0038276.
XX		
XX	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
XX	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200177384-A2.	
XX		
PD	18-OCT-2001.	
XX		
PF	06-APR-2001; 2001WO-1B000713.	
XX		
PR	07-APR-2000; 2000DE-01019173.	
XX		
PA	(EPIC-) EPIGENOMICS AG.	
XX		
P1	Olek A, Piepenbrock C, Berlin K;	
XX		
DR	WPI; 2001-657177/75.	
XX		
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
PT	methylation status.	
XX		
PS		
XX		
XX	Claim 1; SEQ ID NO 151526; 29pp + Sequence Listing; German.	
CC		
CC	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligomers are also used for detecting cell type differentiation. ABC000010	
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic form from WIPO at	
CC	ftp.wipo.int/pub/published_pct_sequences	
XX		
XX		
SO	Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;	
Query Match	16.0%;	Score 10.4; DB 1; Length 13;
Best Local Similarity	91.7%;	Pred. No. 2e+02;
Matches 11; Conservative	0;	Mismatches 1; Indels 0; Gaps 0;
OY	8 AATGGAATTGGA 19	
DB	13 AATGGAATTGGA 2	
RESULT 189		
ABH08606		
ID	ABH08606	standard; DNA; 13 BP.
XX		
XX	ABH08606;	
AC		
XX		
XX	22-FEB-2002	(first entry)
DT		
DE	Oligonucleotide SEQ ID NO 208583	for detecting SNP TSC0050963.
XX		

KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.
XX	
PA	(EPIG-) EPIGENOMICS AG.
XX	
PI	Olek A, Piepenbrock C, Berlin K;
XX	
WP	WIPO; 2001-657177/75.
DR	
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cell cytosine methylation status.
XX	
PS	Claim 1; SEQ ID NO 208583; 29pp + Sequence Listing; German.
XX	
CC	This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The CC
CC	oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AEI00010-AEI82073
CC	represent the oligomers described in the invention. NCTR: The sequence data for this patent did not form part of the printed specification, but CC
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
	Query Match 16.0%; Score 10.4; DB 1; Length 13;
	Best Local Similarity 91.7%; Pred. No. 2e+02; 1; Indels 0; Gaps 0;
	Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Gy	5 TGGATGGAATT 16 2 TGGAAITGAATT 13
Db	
RESULT 190	
ABRH45217/c	
ID	ABRH45217 standard; DNA; 13 BP.
XX	
AC	ABRH45217;
XX	
DT	22-FEB-2002 (first entry)
XX	
DE	Oligonucleotide SEQ ID NO 245194 for detecting SNP TSC0059877.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX	
OS	Homo sapiens.
XX	
PN	WO200177384-A2.
PD	18-OCT-2001.
XX	
PF	06-APR-2001; 2001WO-IB000713.
XX	
PR	07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.
 PA
 XX Olek A, Piepenbrock C, Berlin K;
 PI
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 245194; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 48 TGGGTTGGAGG 59
 Db 13 TGGGTTGGAGG 2
 XX
 RESULT 191
 ABH64847/c
 ID ABH64847 standard; DNA; 13 BP.
 XX
 AC ABH64847;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 264824 for detecting SNP TSC0064191.
 XX
 KM SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1, SEQ ID NO 264824; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 8 C; 2 T; 0 U; 0 Other;
 XX
 Query Match 16.0%; Score 10.4; DB 1; Length 13;
 Best Local Similarity 91.7%; Pred. No. 2e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 49 GGGGTTGGAGGT 60
 Db 13 GGGGTTGGAGAT 2
 XX
 RESULT 192
 AAQ79357
 ID AAQ79357 standard; DNA; 10 BP.
 XX
 AC AAQ79357;
 XX
 DT 25-MAR-2003 (revised)
 DT 05-JUN-1995 (first entry)
 XX
 DE Sequence of lymphokine consensus sequence located at posn. 1871 in
 DE hepslH.
 XX
 KM Erythropoietin; erythropoiesis; red blood cell; regulatory element; ss.
 XX
 OS Synthetic.
 XX
 PN WO9423570-A1.
 XX
 PD 27-OCT-1994.
 XX
 PF 15-APR-1994; 94WO-US004141.
 XX
 PR 15-APR-1993; 93US-00046295.
 PR 23-JUN-1993; 93US-00082850.
 XX
 PA (UNIV) UNIV NEW YORK STATE.
 XX
 PI Lee-Huang S;
 XX
 DR WPI; 1994-341353/42.
 XX
 PT New regulatory regions of human erythropoietin gene - used for studying
 PT and treating diseases and for prodn. of transgenic animal models (Eng).
 XX
 PS Disclosure; Table I, p. 12; 81pp; English.
 XX
 CC AAQ79353 shows the nt. sequence of the entire 9.3 kb genomic clone
 CC hepslH. This nucleic acid sequence includes EPO coding sequence, a 5'
 CC flanking region contg. multiple regulatory elements and a 3' flanking
 CC region contg. multiple regulatory elements. AAQ79354 shows the extended
 CC 5' flanking region and includes all the 5' regulatory elements. This
 CC region, consisting of the first 3892 of AAQ79353, was not found in the
 CC 3.6 kb EPO genomic clone from fetal liver reported by others. The
 CC flanking region comprises 3892 bp and contains CAAT and TATA boxes and at
 CC lease 321 potential transcriptional regulatory elements. AAQ79356-079362
 CC show several of these elements and their positions. The nucleotide
 CC position of these elements is measured from the BamI site at the 5' end
 CC of AAQ79353. (Updated on 25-MAR-2003 to correct PN field.)
 CC

SQ Sequence 10 BP; 2 A; 2 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 56 GAGGTTTCAC 65
 1 GAGGTTTCAC 10
 DB 1 GAGGTTTCAC 10
 RESULT 193
 AAV50176/c
 ID AAV50176 standard; DNA; 10 BP.
 AC AAV50176;
 XX
 DT 21-OCT-1998 (first entry)
 XX
 DE Yeast tag for additional NORF chromosome 8 tag position 107992.
 XX
 KW Yeast; Saccharomyces cerevisiae; transcriptome; cell cycle; regulation;
 KM eukaryotic cell; antifungal; SAGE tag; gene expression;
 KW serial analysis of gene expression; probe; ss.
 XX
 OS Saccharomyces cerevisiae.
 OS Synthetic.
 XX
 PN WO9832847-A2.
 XX
 PD 30-JUL-1998.
 XX
 PF 22-JUN-1998; 98WO-US001216.
 XX
 PR 23-JAN-1997; 97US-0035917P.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
 XX
 PI Velculeacu VE, Vogelstein B, Kinzler KW;
 DR WPI; 1998-427943/36.
 XX
 PT Yeast transcriptome - useful for modulating eukaryotic cell, for
 screening antifungal agents, and for identifying genes in cell cycle
 progression.
 PT
 PS Claim 1; Page 24; 44pp; English.
 XX
 CC Yeast transcriptome is encoded by a DNA molecule comprising a yeast gene
 involved in cell cycle progression selected from the group of
 nonannotated ORF (NORF) genes. SAGE (serial analysis gene expression)
 tags for highly expressed genes and NORF genes are given in AAV50051 to
 AAV50345. The present invention describes: (1) a method of using yeast
 genes to modulate the cell cycle which comprises administering to a cell
 an isolated DNA molecule comprising a yeast gene which is involved in
 cell cycle progression selected from differentially expressed genes (SAGE
 tags given in AAV50051 to AAV50345); (2) a method for screening candidate
 antifungal drugs which comprises contacting a test substance with a yeast
 cell and monitoring expression of a yeast gene which is involved in cell
 cycle progression; (3) a method of identifying human genes which are
 involved in cell cycle progression which comprises hybridizing a probe
 comprising at least 10 contiguous nucleotides of a yeast gene which is
 differentially expressed between at least 2 phases selected from the log
 phase, the S phase and the G2/M phase; and (4) a probe for ascertaining
 the phase in the cell cycle, where the probe comprises at least 14
 contiguous nucleotides of a NORF gene (SAGE tags given in AAV50051 to
 AAV50345), or as an array of probes on a solid support
 CC
 XX
 SQ Sequence 10 BP; 1 A; 2 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 ATAGCCCAAG 30
 10 ATAGCCCAAG 1
 DB 10 ATAGCCCAAG 1
 RESULT 194
 AA277894/c
 ID AA277894 standard; DNA; 10 BP.
 AC AA277894;
 XX
 DT 10-APR-2000 (first entry)
 XX
 DE Human dendritic cell SAGE tag, SEQ ID NO:322.
 XX
 KW SAGE tag; serial analysis of gene expression; antigen-presenting cell;
 APC; monocyte-derived dendritic cell; differential gene expression;
 KM immunostimulatory cofactor; costimulatory factor; CTL;
 KW cytotoxic T-lymphocyte; tumour antigen; immunotherapy; anticancer; ss.
 XX
 OS Homo sapiens.
 OS
 XX
 PN WO965924-A2.
 XX
 PD 23-DEC-1999.
 XX
 PF 18-JUN-1999; 99WO-US013800.
 XX
 PR 19-JUN-1998; 98US-0089833P.
 PR 19-JUN-1998; 98US-0089844P.
 PR 19-JUN-1998; 98US-0089853P.
 PR 19-JUN-1998; 98US-0089878P.
 PR 19-JUN-1998; 98US-0089911P.
 PR 19-JUN-1998; 98US-0089922P.
 PR 19-JUN-1998; 98US-0089933P.
 PR 19-JUN-1998; 98US-0089944P.
 PR 19-JUN-1998; 98US-0089957P.
 PR 19-JUN-1998; 98US-0089999P.
 PR 19-JUN-1998; 98US-0090000P.
 PR 19-JUN-1998; 98US-0090035P.
 PR 19-JUN-1998; 98US-0090036P.
 PR 19-JUN-1998; 98US-0090040P.
 PR 19-JUN-1998; 98US-0090041P.
 PR 19-JUN-1998; 98US-0090042P.
 PR 19-JUN-1998; 98US-0090043P.
 PR 19-JUN-1998; 98US-0090044P.
 PR 19-JUN-1998; 98US-0090045P.
 PR 19-JUN-1998; 98US-0090047P.
 PR 19-JUN-1998; 98US-0090048P.
 PR 19-JUN-1998; 98US-0090072P.
 PR 19-JUN-1998; 98US-0090076P.
 PR 19-JUN-1998; 98US-0090077P.
 PR 19-JUN-1998; 98US-0090078P.
 PR 19-JUN-1998; 98US-0090079P.
 PR 19-JUN-1998; 98US-0090080P.
 PR 08-DEC-1998; 98US-0111715P.
 XX
 PA (GENZ) GENZYME CORP.
 PA (ROBE) ROBERTS B L.
 PA (SHAN/) SHANKARA S.
 XX
 PT Roberts BL, Shankara S;
 DR WPI; 2000-106077/09.
 XX
 PT Isolated polynucleotides differentially expressed in antigen-presenting
 cells, useful in gene vaccines against cancer.
 PS Claim 1; Page 73; 130pp; English.
 XX
 CC Sequences AA277573-279709 represent SAGE (serial analysis of gene

expression) tags used to identify mRNA transcripts encoding immunostimulatory cofactor proteins which are preferentially or differentially expressed in monocyte-derived dendritic cells compared with monocytes. Some of the transcripts correspond to known genes or ESTs (expressed sequence tags) which were previously unknown to be preferentially or differentially expressed in dendritic cells, while other transcripts correspond to novel genes. Antigen-presenting cell (APC)-associated costimulatory factors play an important role in the activation of the cytotoxic immune response, particularly against tumour cells. Tumour antigen presentation via the MHC (major histocompatibility complex) and subsequent recognition by T-cell receptors is alone insufficient to activate a robust cytotoxic immune response that can lyse the tumour cells; immunostimulatory cofactors also being required for efficient activation of cytotoxic T-lymphocytes (CTLs). Nucleic acid sequences identified using the SAGE tags have several potential uses. They may be used in vaccines to induce an immune response, particularly against a tumour antigen; to modulate the genotype of an APC; to screen for agents that modulate expression of differentially expressed genes in an APC; and as hybridisation probes/amplification primers for the diagnosis, prognosis and monitoring of diseases related to abnormal expression of these genes. Detection of the dendritic cell differentially expressed genes, or of their encoded proteins, can be used to identify cells as belonging to the monocyte lineage. Cells containing these genes can be used in active immunotherapy (or to stimulate production of a population of antigen-specific effector cells) and vectors containing them are used in gene therapy. Co-administration of tumour antigens and APC-associated costimulatory factors ensures adequate antigen presentation to endogenous APCs and upregulates the APCs for the presentation of co-stimulatory signals, migrates the APCs to the secretion of T cell growth factors and secretion of chemokines for recruitment of immune effector cells

Sequence 10 BP; 4 A; 5 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 44 TTGCTGGGGT 53
10 TTGCTGGGGT 1

RESULT 195
AA282445/C
ID AA282445 standard; DNA; 10 BP.

AC AA282445;

DT 07-APR-2000 (first entry)

DE Metastatic breast tumour cell upregulated transcript tag #1679.

KM Human; metastatic breast tumour tissue; breast cancer; tag; primer;
KW non-metastatic breast tumour tissue; gene therapy; anticancer;
KM anti-metastatic; vaccine; diagnosis; ss.

OS Homo sapiens.

PN WO965928-A2.

PD 23-DEC-1999.

PF 18-JUN-1999; 99WO-US013647.

PR 19-JUN-1998; 98US-0089853P.

PR 19-JUN-1998; 98US-0089997P.

PR 19-JUN-1998; 98US-0090039P.

PR 19-JUN-1998; 98US-0090040P.

PR 19-JUN-1998; 98US-0090041P.

PA (GENZ) GENZYME CORP.

PA (ROBE/) ROBERTS B L.

PA (SHAN/) SHANKARA S.

PI Roberts BL, Shankara S;

DR WPI; 2000-106079/09.

PT Isolated polynucleotides differentially expressed between metastatic and non-metastatic breast cancer cells, useful for diagnosis, prevention and treatment of cancer.

PS Claim 1; Page 103; 219pp; English.

AA280767 to AA283941 represent tags corresponding to distinct transcripts that are preferentially transcribed in the metastatic breast tumour tissue (i.e. are upregulated in metastatic breast tumour cells). AA283942 to AA286677 represent tags corresponding to distinct transcripts that are preferentially transcribed in the primary or non-metastatic breast tumour tissue (i.e. are downregulated in metastatic breast tumour cells). These transcripts can be used for diagnosis, prognosis, monitoring and treatment of breast cancer, particularly where metastatic. Diagnosis is by standard immunoassays or hybridisation/amplification reactions. Compounds that modulate expression of the transcripts are potentially useful for treatment of (metastatic) breast cancer, while promoters from the transcripts are used to direct expression, in selected cell types, of e.g. therapeutic genes (also ribozymes or antisense sequences), particularly an antigen-encoding sequence for use in gene or cell-based vaccines. Polypeptides encoded by the transcripts are also useful in vaccines. For diagnosing breast cancer and for raising specific antibodies (Ab). Ab are used to detect the polypeptides or as therapeutic agents. Host cells that produce the polypeptides can be used to expand and isolate populations of educated, antigen-specific immune effector cells, e.g. cytotoxic T lymphocytes, and these used for adoptive immunotherapy

Sequence 10 BP; 3 A; 3 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 56 GAGGTTTAC 65
10 GAGGTTTAC 1

RESULT 196
AAA56570
ID AAA56570 standard; DNA; 10 BP.

AC AAA56570;

DT 07-SEP-2000 (first entry)

DE Human macrophage gene Tag oligonucleotide sequence SEQ ID NO:464.

KM Human; monocyte; macrophage; GM-macrophage; tag;
KW granulocyte-macrophage colony-stimulating factor; characterisation;
KM GM-CSF; identification; diagnosis; gene specificity; oncogenesis;
KM disease onset mechanism; genetic disease; drug development; ss.

OS Homo sapiens.

PN WO200024892-A1.

PD 04-MAY-2000.

PF 28-OCT-1999; 99WO-JP005982.

PR 28-OCT-1998; 98JP-00307532.

PA (NISC-) JAPAN SCI & TECHNOLOGY CORP.

PA Hashimoto S, Matsushima K, Suzuki T;

```

XX DR WPI; 2000-350734/30.
XX
PT Genes most frequently expressed in human monocytes and GM-macrophages and
PT M-macrophages studied and with cDNAs characterized, for study of gene
PT specificity, disease onset mechanism, drug development and diagnosis.
XX
PS Claim 49; Page 132; 138pp; Japanese.
XX
CC The present invention describes 100 human genes, which are expressed most
CC frequently in human monocytes. The cDNA of each gene has a sequence fully
CC defined in the specification, and lacking the CARG sequence located
CC adjacent to polyA region. Also described are: (1) an antibody
CC specifically for the protein encoded by any of the genes; (2)
CC oligonucleotides obtained from the cDNA sequences; (3) 380 human genes
CC which are expressed most frequently in human macrophages, differentiated
CC from human monocytes by granulocyte-macrophage colony-stimulating factor,
CC the cDNA of each gene has a fully defined sequence, given in the
CC specification, lacking the base sequence CARG located most closely to the
CC poly A region; (4) an antibody specifically for the protein encoded by
CC any of the genes of (3); and (5) oligonucleotides obtained from the cDNA
CC sequences of (3). The genes and cDNAs, are used for the study of gene
CC specificity and disease onset mechanism e.g. oncogenesis, genetic
CC diseases, drug development and diagnosis. AAF6107 to AAF6586 represent
CC specifically claimed oligonucleotide tag sequences for human genes
CC expressed in monocytes and macrophages
XX
SQ Sequence 10 BP; 5 A; 3 C; 2 G; 0 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 26 CCAAGAACAG 35
    |||||
    1 CCAAGAACAG 10
Db
RESULT 197
AAH64133/C
ID AAH64133 standard; cDNA; 10 BP.
XX
AC AAH64133;
XX
DT 20-SEP-2001 (first entry)
XX
DE Human ubiquitously expressed transcriptome sequence SEQ ID NO: 973.
XX
KM Human: transcriptome; gene expression pattern; cancer; drug screening;
KM cancer diagnosis; cell specific gene expression; 88.
XX
OS Homo sapiens.
XX
PN WO200138577-A2.
XX
PD 31-MAY-2001.
XX
PF 21-NOV-2000; 2000MO-US031922.
XX
PR 24-NOV-1999; 99US-0048480.
XX
PA (UYJO ) UNIV JOHNS HOPKINS.
XX
PI Velculescu VE, Vogelstein B, Kinzler KW;
XX
DR WPI; 2001-367706/38.
XX
PT New isolated polynucleotides, useful for identifying specific cell type,
PT such as cancer cell, comprises transcriptomes expressed in particular
PT cell types.
XX
PS Claim 13; Page 61; 94pp; English.
XX

```

```

CC The present invention describes a method of identifying the type of cell
CC in a sample, involving determining which of the sequences AAH63161-
CC AAH64724 is expressed by the cell. The transcriptomes described in the
CC invention are cell-type specific, cancer specific or ubiquitously
CC expressed in humans. They can also be used to screen for drugs, reduce
CC cancer specific gene expression, standardise expression and restore the
CC function of a diseased cell or tissue. The present sequence is one of the
CC transcriptomes described in the exemplification of the invention
XX
SQ Sequence 10 BP; 3 A; 3 C; 2 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 56 GAGGTTTCAC 65
    |||||
    10 GAGGTTTCAC 1
Db
RESULT 198
AAF41485
ID AAF41485 standard; DNA; 10 BP.
XX
AC AAF41485;
XX
DT 23-MAR-2001 (first entry)
XX
DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:8224.
XX
XX Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
KM nor previously assigned open reading frame; nonannotated ORF; SAGE;
KM serial analysis of gene expression; antifungal; tag; identification;
KM linker; PCR primer; ds.
XX
XX Saccharomyces cerevisiae.
XX
PN WO200077214-A2.
XX
PD 21-DEC-2000.
XX
PF 14-JUN-2000; 2000MO-US016223.
XX
PR 16-JUN-1999; 99US-00335032.
XX
PA (UYJO ) UNIV JOHNS HOPKINS.
XX
PI Velculescu V, Vogelstein B, Kinzler K;
XX
DR WPI; 2001-061874/07.
XX
PT Yeast gene coding sequences comprising NORF genes with serial analysis of
PT gene expression (SAGE) tags, useful for studying, monitoring and
PT affecting phases of the cell cycle.
XX
XX Example; Page 293; 419pp; English.
XX
CC The present invention describes an isolated DNA molecule comprising a
CC coding sequence of a yeast gene selected from a group of 745 NORF (not
CC previously assigned open reading frame; or nonannotated ORF) genes
CC comprising a SAGE (serial analysis of gene expression) tag. Also
CC described are: (1) a method (M1) of using NORF genes to affect the cell
CC cycle comprising administering a NORF gene whose expression varies by at
CC least 10% between any two phases of the cell cycle selected from log
CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
CC antifungal drugs comprising: (a) contacting a test substance with a yeast
CC cell; and (b) monitoring expression of a NORF gene whose expression
CC varies as in M1, where a test substance which modifies the expression of
CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
CC identifying human genes which are involved in cell cycle progression
CC comprising contacting human DNA with a probe which comprises at least 10
CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
CC and (4) a method (M4) for identifying a candidate drug as a member of a

```

CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC method may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX

SQ Sequence 10 BP; 3 A; 1 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 4 CTGGAATGCA 13
 |||||
 1 CTGGAATGCA 10

Db

RESULT 199
 AAF36810/C
 ID AAF36810 standard; DNA; 10 BP.
 XX
 AC AAF36810;
 XX
 DT 23-MAR-2001 (first entry)
 XX

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:3549.

XX
 KM Yeast; Saccharomyces cerevisiae; characterisation: cell cycle; NORF;
 KM nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KM serial analysis of gene expression; antifungal; tag; identification;
 KM linker; PCR primer; ds.
 XX

OS Saccharomyces cerevisiae.
 XX
 PN WO200077214-A2.
 XX

PD 21-DEC-2000.
 XX

PF 14-JUN-2000; 2000WO-US016223.
 XX

PR 16-JUN-1999; 99US-00335032.
 XX

PA (UYJO) UNIV JOHNS HOPKINS.
 XX

PI Velculescu V, Vogelstein B, Kinzler K;
 XX
 DR WPI; 2001-061874/07.
 XX

PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX

PS Example; Page 126; 419pp; English.
 XX

CC The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression

CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF4064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention
 XX

SQ Sequence 10 BP; 2 A; 3 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 12 GAATTGACA 21
 |||||
 10 GAATTGACA 1

Db

RESULT 200
 AAF35563/C
 ID AAF35563 standard; DNA; 10 BP.
 XX
 AC AAF35563;
 XX
 DT 23-MAR-2001 (first entry)
 XX

DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:2302.

XX
 KM Yeast; Saccharomyces cerevisiae; characterisation: cell cycle; NORF;
 KM nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KM serial analysis of gene expression; antifungal; tag; identification;
 KM linker; PCR primer; ds.
 XX

OS Saccharomyces cerevisiae.
 XX
 PN WO200077214-A2.
 XX

PD 21-DEC-2000.
 XX

PF 14-JUN-2000; 2000WO-US016223.
 XX

PR 16-JUN-1999; 99US-00335032.
 XX

PA (UYJO) UNIV JOHNS HOPKINS.
 XX

PI Velculescu V, Vogelstein B, Kinzler K;
 XX
 DR WPI; 2001-061874/07.
 XX

PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX

PS Example; Page 82; 419pp; English.
 XX

CC The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log
 CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression

CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

SQ Sequence 10 BP; 1 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 ATAGCCCAAG 30
 |||||
 10 ATAGCCCAAG 1

Db 10 ATAGCCCAAG 1

RESULT 201
 AAF33393/c
 ID AAF33393 standard; DNA; 10 BP.
 AC AAF33393;
 XX 23-MAR-2001 (first entry)
 DT
 XX
 DE Yeast NORF gene SAGE tag oligonucleotide SEQ ID NO:132.
 KW Yeast; Saccharomyces cerevisiae; characterisation; cell cycle; NORF;
 KW nor previously assigned open reading frame; nonannotated ORF; SAGE;
 KW serial analysis of gene expression; antifungal; tag; identification;
 KW linker; PCR primer; ds.
 XX
 OS Saccharomyces cerevisiae.
 XX
 PN WO200077214-A2.
 XX
 PD 21-DEC-2000.
 XX
 PF 14-JUN-2000; 2000WO-US016223.
 XX
 PR 16-JUN-1999; 99US-00335032.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS.
 XX
 PI Velculescu V, Vogelstein B, Kinzler K;
 XX
 DR WPI; 2001-061874/07.
 XX
 PT Yeast gene coding sequences comprising NORF genes with serial analysis of
 PT gene expression (SAGE) tags, useful for studying, monitoring and
 PT affecting phases of the cell cycle.
 XX
 PS Claim 1; Page 24; 41pp; English.
 XX
 CC The present invention describes an isolated DNA molecule comprising a
 CC coding sequence of a yeast gene selected from a group of 745 NORF (not
 CC previously assigned open reading frame; or nonannotated ORF) genes
 CC comprising a SAGE (serial analysis of gene expression) tag. Also
 CC described are: (1) a method (M1) of using NORF genes to affect the cell
 CC cycle comprising administering a NORF gene whose expression varies by at
 CC least 10% between any two phases of the cell cycle selected from log

CC phase, S phase and G2/M; (2) a method (M2) for screening candidate
 CC antifungal drugs comprising: (a) contacting a test substance with a yeast
 CC cell; and (b) monitoring expression of a NORF gene whose expression
 CC varies as in M1, where a test substance which modifies the expression of
 CC the yeast gene is a candidate antifungal drug; (3) a method (M3) for
 CC identifying human genes which are involved in cell cycle progression
 CC comprising contacting human DNA with a probe which comprises at least 10
 CC contiguous nucleotides of a NORF gene whose expression varies as in M1;
 CC and (4) a method (M4) for identifying a candidate drug as a member of a
 CC class of drugs having a characteristic effect on gene expression in a
 CC yeast cell comprising contacting a yeast cell with a candidate drug and
 CC monitoring expression in the yeast cell of at least 1 NORF gene whose
 CC expression is affected by the class of drugs. The NORF genes may be used
 CC to study, monitor and affect phases of the cell cycle, the differentially
 CC expressed genes may be used as markers of phases of the cell cycle. The
 CC methods may be used to identify candidate drugs which affect the cell
 CC cycle and for identification of antifungal drugs. AAF33268 to AAF44064
 CC represent SAGE tags used in the exemplification of the present invention.
 CC AAF33262 to AAF33267 represent linkers and PCR primers used in the SAGE
 CC method, in the exemplification of the present invention

SQ Sequence 10 BP; 1 A; 2 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 21 ATAGCCCAAG 30
 |||||
 10 ATAGCCCAAG 1

Db 10 ATAGCCCAAG 1

RESULT 202
 AAD26008
 ID AAD26008 standard; DNA; 10 BP.
 AC AAD26008;
 XX 26-MAR-2002 (first entry)
 DT
 XX
 DE Primer #10 to detect human P14 gene polymorphisms.
 KW Human; protease inhibitor; P14; kallistatin; therapy; polymorphic site;
 KW P5; haplotyping; genotyping; acute pancreatitis; drug screening;
 KW antiinflammatory; chromosome 14q31-q32.1; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200179227-A2.
 XX
 PD 25-OCT-2001.
 XX
 PF 13-APR-2001; 2001WO-US012255.
 XX
 PR 13-APR-2000; 2000US-0196990P.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Choi JY, Koshy B, Sanchis A;
 XX
 DR WPI; 2002-075060/10.
 XX
 PT Genotyping protease inhibitor 4 gene of individual for determining
 PT haplotype of individual, involves determining identity of nucleotide pair
 PT at specific polymorphic sites for two copies of gene.
 XX
 PS Claim 18; Page 14; 79pp; English.
 XX
 CC The present invention relates to genotyping protease inhibitor (PI) 4
 CC (kallistatin) gene of an individual, involves determining for the two
 CC copies of the P14 gene present in the individual, the identity of the
 CC nucleotide pair at one or more polymorphic sites. P14 gene is located on
 CC chromosome 14q31-q32.1. Genotyping is useful for determining if an

CC individual has a haplotype or haplotype pairs defined in the
 CC specification. Haplotyping is useful for improving the efficacy and
 CC reliability of several steps in the discovery and development of drugs
 CC for treating diseases associated with P14 activity, e.g. acute
 CC pancreatitis, to validate P14 as a candidate agent for treating a
 CC specific condition or disease predicted to be associated with P14
 CC activity, and in the design of clinical trials of candidate drugs for
 CC creating a specific condition or disease predicted to be associated with
 CC P14 activity. The P14 gene is useful in studying the expression and
 CC function of P14, and in expressing P14 protein for use in screening for
 CC candidate drugs to treat diseases related to P14 activity. The present
 CC sequence is a primer to detect human P14 gene polymorphisms
 XX

Sequence 10 BP; 1 A; 0 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GGGTTGAGG 59
 |||||
 Db 1 GGGTTGAGG 10

RESULT 203
 ABV84279
 ID ABV84279 standard; cDNA; 10 BP.
 XX
 XX ABV84279;
 XX
 DT 12-DEC-2002 (first entry)
 XX
 DE Human ceruloplasmin SAGE tag #89.
 XX
 XX
 KW SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
 KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
 KW expression pattern; differential expression; ss.
 XX
 XX Homo sapiens.
 OS
 XX JP2002209591-A.
 PN
 XX 30-JUL-2002.
 PD
 XX 19-JAN-2001; 2001JP-00012328.
 PF
 XX 19-JAN-2001; 2001JP-00012328.
 PR
 XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
 PA
 XX WPI; 2002-631294/68.
 DR
 XX Human chronic hepatitis C tissue expression exaoperating gene group
 PT comprises 100 high-ranking genes.
 XX
 PS Claim 1; Page 12; 139pp; Japanese.
 XX
 CC The invention relates to SAGE (serial analysis of gene expression) tags
 CC representing groups of genes which are differentially expressed in human
 CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
 CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
 CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
 CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
 CC polyA region of cDNAs derived from a variety of genes. These tags serve
 CC to uniquely identify each transcript and can thus be used to analyse the
 CC pattern of gene expression in particular cell types. The invention also
 CC relates to proteins encoded by the genes expressed in chronic hepatitis C
 CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
 CC the expression of groups of genes that are overexpressed in chronic
 CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
 CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
 CC treatment of these diseases. Such genes, inhibitors of their expression
 CC or activity, and antibodies against the gene products may be used in the

CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
 CC ABV84191-ABV84290 are SAGE tags representing the 100 most highly
 CC expressed genes out of those genes which are overexpressed in chronic
 CC hepatitis C liver tissue compared with normal liver tissue
 XX

Sequence 10 BP; 3 A; 1 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 CTGGAATGGA 13
 |||||
 Db 1 CTGGAATGGA 10

RESULT 204
 ABV84417
 ID ABV84417 standard; cDNA; 10 BP.
 XX
 XX ABV84417;
 XX
 DT 12-DEC-2002 (first entry)
 XX
 DE Human ceruloplasmin (ferroxidase) SAGE tag #227.
 XX
 XX
 KW SAGE tag; serial analysis of gene expression; human; chronic hepatitis C;
 KW CH; liver tissue; hepatocellular carcinoma; cancer; tumour; HCC;
 KW expression pattern; differential expression; ss.
 XX
 XX Homo sapiens.
 OS
 XX JP2002209591-A.
 PN
 XX 30-JUL-2002.
 PD
 XX 19-JAN-2001; 2001JP-00012328.
 PF
 XX 19-JAN-2001; 2001JP-00012328.
 PR
 XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
 PA
 XX WPI; 2002-631294/68.
 DR
 XX Human chronic hepatitis C tissue expression exaoperating gene group
 PT comprises 100 high-ranking genes.
 XX
 PS Claim 19; Page 16; 139pp; Japanese.
 XX
 CC The invention relates to SAGE (serial analysis of gene expression) tags
 CC representing groups of genes which are differentially expressed in human
 CC chronic hepatitis C (CH) liver tissue or hepatitis C-induced
 CC hepatocellular carcinoma (HCC) compared with normal human liver tissue.
 CC The SAGE tags of this invention consist of a sequence of 10 nucleotides
 CC located downstream of the 5'-CATG-3' sequence motif lying nearest to the
 CC polyA region of cDNAs derived from a variety of genes. These tags serve
 CC to uniquely identify each transcript and can thus be used to analyse the
 CC pattern of gene expression in particular cell types. The invention also
 CC relates to proteins encoded by the genes expressed in chronic hepatitis C
 CC liver tissue or HCC, antibodies against these proteins, and inhibitors of
 CC the expression of groups of genes that are overexpressed in chronic
 CC hepatitis C liver tissue or HCC. Groups of genes differentially expressed
 CC in chronic hepatitis C tissue or HCC may be used for the diagnosis and
 CC treatment of these diseases. Such genes, inhibitors of their expression
 CC or activity, and antibodies against the gene products may be used in the
 CC development of drugs to treat chronic hepatitis C and/or HCC. Sequences
 CC ABV84391-ABV84490 are SAGE tags representing the 100 most highly
 CC expressed genes out of those genes which are overexpressed in
 CC hepatocellular carcinoma compared with normal liver tissue
 XX

Sequence 10 BP; 3 A; 1 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 10;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 CTGGAATGCA 13
DB 1 CTGGAATGCA 10

RESULT 205

ABQ87092/c
ID ABQ87092 standard; cDNA; 11 BP.

AC ABQ87092;

DT 10-SEP-2002 (first entry)

DE Human skin stress/ageing related EST SEQ ID NO 847.

KW Human; skin ageing; skin stress; EST; expressed sequence tag; ss.

OS Homo sapiens.

PN WO200253773-A2.

PD 11-JUL-2002.

PF 20-DEC-2001; 2001WO-EP015178.

PR 03-JAN-2001; 2001DE-01000121.

PA (HENK) HENKEL KGAA.

PI Petersohn D, Conradt M, Hofmann K;

DR WPI; 2002-528865/56.

PT Identifying genes involved in skin stress and aging, useful e.g. in

PT screening for cosmetic or therapeutic agents, based on differential gene

XX expression.

XX Claim 8; Page 72; 325pp; German.

CC The invention relates to identifying (M1) genes in vitro that, in humans

CC or animals, are important for skin ageing and/or skin stress by serial

CC analysis of gene expression between mixtures of transcribed and from

CC optionally translated, genetically encoded factors (A) obtained from

CC young and aged skin, to identify that genes that show strong differential

CC expression. (A) comprises protein or mRNAs or their fragments. (M1) is

CC useful for: identifying markers of skin ageing and/or stress; determining

CC skin ageing and/or stress; and identifying or determining the effects of

CC pharmaceutical or cosmetic agents for control of skin ageing. The present

CC sequence is one of a group of human skin ageing/stress related expressed

XX sequence tags (ABQ86246-ABQ87680) of the invention

XX Sequence 11 BP; 3 A; 2 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 AATTGGACAT 22

DB 10 AATTGGACAT 1

RESULT 206

ABV64736/c
ID ABV64736 standard; cDNA; 11 BP.

AC ABV64736;

DT 21-OCT-2002 (first entry)

DE Human skin EST 2522.

KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrheic;

KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;

KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

OS Homo sapiens.

PN WO200253774-A2.

PD 11-JUL-2002.

PF 20-DEC-2001; 2001WO-EP015179.

PR 03-JAN-2001; 2001DE-01000127.

PA (HENK) HENKEL KGAA.

PI Petersohn D, Conradt M, Hofmann K;

DR WPI; 2002-590638/63.

PT In vitro identification of skin-expressed genes, useful for determining

PT homeostasis and identifying cosmetic or pharmaceutical agents against

PT e.g. skin cancer.

XX Disclosure; Page 95; 1345pp; German.

XX The invention relates to in vitro identification (M1) of genes expressed

XX in the skin of humans or animals by subjecting a mixture of genetically

XX encoded factors from skin, to serial analysis of gene expression (SAGE)

XX so as to identify skin-expressed genes and quantify their expression.

XX (M1) is useful for identifying genes involved in skin homeostasis; to

XX determine skin homeostasis and to test agent (A) that maintains or

XX promotes skin homeostasis or that can be used for treating skin

XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;

XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;

XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the

XX skin. The present sequence is that of a human expressed sequence tag

XX (EST) of the invention

XX Sequence 11 BP; 3 A; 2 C; 1 G; 5 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 AATTGGACAT 22

DB 10 AATTGGACAT 1

RESULT 207

ABV71657/c
ID ABV71657 standard; cDNA; 11 BP.

AC ABV71657;

DT 21-OCT-2002 (first entry)

DE Human skin EST 9443.

KW Human; skin; dermatological; vulnery; antipsoriatic; antiseborrheic;

KW immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;

KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

OS Homo sapiens.

PN WO200253774-A2.

PD 11-JUL-2002.

PF 20-DEC-2001; 2001WO-EP015179.

XX 03-JAN-2001; 2001DE-01000127.
XX (HENK) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Claim 24; Page 304; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
SQ Sequence 11 BP; 3 A; 3 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX
XX Query Match 15.4%; Score 10; DB 1; Length 11;
XX Best Local Similarity 100.0%; Pred.No. 1.9e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 56 GAGGTTTCAC 65
XX |||||
XX 10 GAGGTTTCAC 1
XX
Db
XX
XX
XX RESULT 208
XX ABV64236/c
XX ID ABV64236 standard; cDNA; 11 BP.
XX
XX ABV64236;
XX
XX 21-OCT-2002 (first entry)
XX
XX Human skin EST 2022.
XX
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX
XX (HENK) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX

PS Disclosure; Page 81; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag
XX (EST) of the invention
XX
SQ Sequence 11 BP; 3 A; 3 C; 3 G; 2 T; 0 U; 0 Other;
XX
XX
XX Query Match 15.4%; Score 10; DB 1; Length 11;
XX Best Local Similarity 100.0%; Pred.No. 1.9e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 56 GAGGTTTCAC 65
XX |||||
XX 10 GAGGTTTCAC 1
XX
Db
XX
XX
XX RESULT 209
XX ABV70859/c
XX ID ABV70859 standard; cDNA; 11 BP.
XX
XX ABV70859;
XX
XX 21-OCT-2002 (first entry)
XX
XX Human skin EST 8645.
XX
XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
XX immunosuppressive; antiinflammatory; cytostatic; SAGE; neurodermatitis;
XX psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.
XX
XX Homo sapiens.
XX
XX WO200253774-A2.
XX
XX 11-JUL-2002.
XX
XX 20-DEC-2001; 2001WO-EP015179.
XX
XX 03-JAN-2001; 2001DE-01000127.
XX
XX (HENK) HENKEL KGAA.
XX
XX Petersohn D, Conradt M, Hofmann K;
XX WPI; 2002-590638/63.
XX
XX In vitro identification of skin-expressed genes, useful for determining
XX homeostasis and identifying cosmetic or pharmaceutical agents against
XX e.g. skin cancer.
XX
XX Claim 24; Page 277; 1345pp; German.
XX
XX The invention relates to in vitro identification (M1) of genes expressed
XX in the skin of humans or animals by subjecting a mixture of genetically
XX encoded factors from skin, to serial analysis of gene expression (SAGE)
XX so as to identify skin-expressed genes and quantify their expression.
XX (M1) is useful for identifying genes involved in skin homeostasis; to
XX determine skin homeostasis and to test agent (A) that maintains or
XX promotes skin homeostasis or that can be used for treating skin
XX disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX skin. The present sequence is that of a human expressed sequence tag

CC (EST) of the invention
XX Sequence 11 BP; 4 A; 3 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGCTTTCAC 65
DB 10 GAGCTTTCAC 1

RESULT 210
ABV63438/C
ID ABV63438 standard; cDNA; 11 BP.

AC ABV63438;

DT 21-OCT-2002 (first entry)

XX Human skin EST 1224.

XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KM immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

OS Homo sapiens.

PN WO200253774-A2.

PD 11-JUL-2002.

PF 20-DEC-2001; 2001MO-EP015179.

PR 03-JAN-2001; 2001DE-01000127.

PA (HENK) HENKEL KGAA.

PI Petersohn D, Conradt M, Hofmann K;

DR WPI; 2002-590638/63.

PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.

PS Disclosure; Page 58; 1345pp; German.

CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention

XX Sequence 11 BP; 4 A; 3 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGCTTTCAC 65
DB 10 GAGCTTTCAC 1

RESULT 211
ABV6020/C
ID ABV6020 standard; cDNA; 11 BP.

AC ABV6020;

DT 21-OCT-2002 (first entry)

XX Human skin EST 3806.

XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KM immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

OS Homo sapiens.

PN WO200253774-A2.

PD 11-JUL-2002.

PF 20-DEC-2001; 2001MO-EP015179.

PR 03-JAN-2001; 2001DE-01000127.

PA (HENK) HENKEL KGAA.

PI Petersohn D, Conradt M, Hofmann K;

DR WPI; 2002-590638/63.

PT In vitro identification of skin-expressed genes, useful for determining
PT homeostasis and identifying cosmetic or pharmaceutical agents against
PT e.g. skin cancer.

PS Disclosure; Page 130; 1345pp; German.

CC The invention relates to in vitro identification (M1) of genes expressed
CC in the skin of humans or animals by subjecting a mixture of genetically
CC encoded factors from skin, to serial analysis of gene expression (SAGE)
CC so as to identify skin-expressed genes and quantify their expression.
CC (M1) is useful for identifying genes involved in skin homeostasis; to
CC determine skin homeostasis and to test agent (A) that maintains or
CC promotes skin homeostasis or that can be used for treating skin
CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
CC skin. The present sequence is that of a human expressed sequence tag
CC (EST) of the invention

XX Sequence 11 BP; 4 A; 6 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 TTGCTGGGCT 53
DB 10 TTGCTGGGCT 1

RESULT 212
ABV65667
ID ABV65667 standard; cDNA; 11 BP.

AC ABV65667;

DT 21-OCT-2002 (first entry)

XX Human skin EST 3453.

XX Human; skin; dermatological; vulnery; antipsoriatic; antiseborrhoeic;
KM immunosuppressive; antinflammatory; cytostatic; SAGE; neurodermatitis;
KW psoriasis; dermatitis; skin cancer; EST; expressed sequence tag; ss.

```

XX OS Homo sapiens.
XX XX
XX PN WO200253774-A2.
XX PD
XX PF 11-JUL-2002.
XX PF 20-DEC-2001; 2001WO-EP015179.
XX PR 03-JAN-2001; 2001DE-01000127.
XX PA (HENK ) HENKEL KGAA.
XX PI Petersohn D, Conradt M, Hofmann K;
XX DR WPI; 2002-590638/63.
XX PT In vitro identification of skin-expressed genes, useful for determining
XX PT homeostasis and identifying cosmetic or pharmaceutical agents against
XX PT e.g. skin cancer.
XX PS
XX PS Disclosure; Page 121; 1345pp; German.
XX CC The invention relates to in vitro identification (M1) of genes expressed
XX CC in the skin of humans or animals by subjecting a mixture of genetically
XX CC encoded factors from skin, to serial analysis of gene expression (SAGE)
XX CC so as to identify skin-expressed genes and quantify their expression.
XX CC (M1) is useful for identifying genes involved in skin homeostasis; to
XX CC determine skin homeostasis and to test agent (A) that maintains or
XX CC promotes skin homeostasis or that can be used for treating skin
XX CC disorders, specifically neurodermatitis; sunburn; psoriasis; scleroderma;
XX CC ichthyosis; atopic dermatitis; acne; seborrhea; lupus erythematosus;
XX CC rosacea; melanoma; basal cell carcinoma; and carcinoma or sarcoma of the
XX CC skin. The present sequence is that of a human expressed sequence tag
XX CC (EST) of the invention
SQ Sequence 11 BP; 2 A; 3 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 40 AACCTGCTG 49
DB 2 AACCTGCTG 11

RESULT 213
ABK99462/c
ID ABK99462 standard; DNA; 11 BP.
XX AC
XX AC ABK99462;
XX DT 21-OCT-2002 (first entry)
XX DE Human CYP3A5 gene polymorphic reference DNA sequence #44.
XX DE
XX KM Human; CYP3A5; polymorphism; cancer; cardiovascular disease; diabetes;
XX KM AIDS; African American; forensic marker; pharmacological; cyclostatic;
XX KM antidiabetic; anti-HIV; gene therapy; ds.
XX OS
XX OS Homo sapiens.
XX PN WO200253775-A2.
XX PD
XX PD 11-JUL-2002.
XX PF 21-DEC-2001; 2001WO-EP015290.
XX PR 28-DEC-2000; 2000EP-00128627.
XX PR 28-DEC-2000; 2000US-0258684P.
XX PR 29-DEC-2000; 2000US-0258952P.
XX PR 16-JAN-2001; 2001EP-00100172.

```

```

PR 18-JAN-2001; 2001US-0262859P.
PR 16-AUG-2001; 2001EP-00118884.
PR 16-AUG-2001; 2001US-0312825P.
XX PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX PI Wojnowski L, Haberl M, Hueter E;
XX DR WPI; 2002-583628/62.
XX PT Novel CYP3A5 polynucleotide useful for diagnosis and treatment of cancer,
XX PT cardiovascular diseases, diabetes and AIDS, and for identifying
XX PT polymorphisms.
XX PS
XX PS Example 2; Page 51; 138pp; English.
XX CC The present invention relates to a new CYP3A5 polynucleotide encoding a
XX CC polypeptide, where the polynucleotide is capable of hybridizing to a
XX CC CYP3A5 gene. The invention is useful in an in vitro method for
XX CC identifying a polymorphism. The invention is also useful for useful for
XX CC diagnosing a disorder related to the presence of a molecular variant of a
XX CC CYP3A5 or susceptibility to such a disorder, where the disorder is
XX CC cancer, or diseases including cardiovascular diseases, diabetes and AIDS.
XX CC The invention can further be used for the preparation of a diagnostic
XX CC composition for diagnosing a disease in a subject having a genome
XX CC comprising a variant allele of the CYP3A5 gene, where the subject is an
XX CC African American. The molecules of the invention are as forensic markers
XX CC and in pharmacological studies. The present nucleic acid sequence
XX CC represents a human CYP3A5 gene polymorphism reference DNA sequence, as
XX CC described in the invention
SQ Sequence 11 BP; 3 A; 3 C; 1 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 AATGGAATTG 17
DB 10 AATGGAATTG 1

RESULT 214
AAV06858
ID AAV06858 standard; DNA; 12 BP.
XX AC
XX AC AAV06858;
XX DT 01-JUN-1998 (first entry)
XX DE One from an array of 58 cystic fibrosis oligonucleotides.
XX DE
XX KM H-ras; wild-type; immobilising; diagnosis; ethylene acrylic acid;
XX KM ethylene methacrylic acid; polypropylene; blotin; cystic fibrosis; array;
XX KM ss.
XX OS
XX OS Synthetic.
XX PN WO9746597-A1.
XX PD
XX PD 11-DEC-1997.
XX PF 22-MAY-1997; 97WO-US008880.
XX PR 05-JUN-1996; 96US-00658664.
XX PA (BECT ) BECKMAN INSTR INC.
XX PI Milton RC;
XX DR WPI; 1998-051910/05.
XX PT Polymeric reagents for immobilising biopolymers - are stable under

```

PT synthesis conditions.
 XX
 PS Example 7; Fig 19; 66pp; English.
 CC
 CC The present sequence represents one of an array of 58 cystic fibrosis
 CC oligonucleotides. The invention relates to a new reagent for immobilizing
 CC a biopolymer. It comprises a solid support fabricated from a polymeric
 CC material having at least one surface comprising pendant acyl fluoride
 CC functionalities. The reagent is stable under conditions for synthesizing
 CC and immobilising biopolymers and is stable under conditions used to
 CC analyse the biopolymers. The reagents can be formed into devices which
 CC are physically rugged and inexpensive which can be used in analytical and
 CC diagnostic procedures
 XX
 SQ Sequence 12 BP; 1 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 52 GTTGAGGTT 61
 Db 2 GTTGAGGTT 11
 RESULT 215
 AAC68048/c
 ID AAC68048 standard; DNA; 12 BP.
 AC AAC68048;
 XX
 XX 20-FEB-2001 (first entry)
 DT
 XX
 DE Oligonucleotide G11 used in a method for preparing biochips.
 XX
 KM Hydrogel biochip; biological activity screening; gene characterisation;
 KM gene function study; gene discovery;
 KM isocyanate-functional hydrogel prepolymer; ss.
 XX
 OS Unidentified.
 OS
 XX
 PN WO200065097-A1.
 XX
 PD 02-NOV-2000.
 XX
 PF 26-APR-2000; 2000WO-US011282.
 XX
 PR 26-APR-1999; 99US-00299831.
 XX
 PA (BIOC-) BIOCEPT INC.
 XX
 PI Hahn S, Fagnani R, Tainberg P;
 XX
 DR WPI; 2001-007095/01.
 XX
 PT Preparing hydrogel biochip with biomolecules immobilized on it, useful
 PT for gene discovery, comprises covalently binding hydrogel prepolymers and
 PT biomolecules, and initiating polymerization of the hydrogel prepolymer.
 XX
 PS Disclosure; Page 27; 58pp; English.
 XX
 CC The present invention relates to a method for preparing a hydrogel
 CC biochip, which has a biomolecule e.g. an oligonucleotide immobilised on
 CC it. The method comprises providing an organic solvent solution of
 CC isocyanate-functional hydrogel prepolymer (HP) and a solution of a
 CC biomolecule, covalently binding the biomolecule to HP, and initiating
 CC polymerisation of HP. The present sequence is an oligonucleotide which
 CC was used as a biomolecule in the present invention. This oligonucleotide
 CC is useful for making biochips which are useful for gene discovery, gene
 CC characterisation, functional gene studies, screening for biological
 CC activity and related studies
 XX

SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 53 TTGAGGTTT 62
 Db 12 TTGAGGTTT 3
 RESULT 216
 AB106792
 ID AB106792 standard; DNA; 12 BP.
 AC AB106792;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide primer SEQ ID NO 306765 for detecting SNP TSC0022165.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 306765; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. The
 CC -ABCG9989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH2073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pat_sequences
 XX
 SQ Sequence 12 BP; 1 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 52 GTTGAGGTT 61
 Db 1 GTTGAGGTT 10
 RESULT 217
 ABH04270/c

```
ID ABH84270 standard; DNA; 12 BP.
XX
AC ABH84270;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 284263 for detecting SNP TSC0011746.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 284263; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 53 TTGGAGGTTT 62
DB 10 TTGGAGGTTT 1
RESULT 218
AB142194/C
ID AB142194 standard; DNA; 12 BP.
XX
AC AB142194;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 342167 for detecting SNP TSC0042414.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
```

```
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 342167; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 5 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 52 GTTGAGGTTT 61
DB 10 GTTGAGGTTT 1
RESULT 219
AB146629
ID AB146629 standard; DNA; 12 BP.
XX
AC AB146629;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 346602 for detecting SNP TSC0044669.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
```

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 346602; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 12 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGGAGGTTT 62

|||||

Db 2 TTGGAGGTTT 11

RESULT 220

AB170669/c

XX ID AB170669 standard; DNA; 12 BP.

XX

AC AB170669;

XX

DT 22-FEB-2002 (first entry)

XX

DE Oligonucleotide primer SEQ ID NO 370642 for detecting SNP TSC0058289.

XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001WO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIC-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WPI; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 370642; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 12 BP; 3 A; 8 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 49 GGGGTTGGAG 58

|||||

Db 12 GGGGTTGGAG 3

RESULT 221

AB134548/c

XX ID AB134548 standard; DNA; 12 BP.

XX

AC AB134548;

XX

DT 22-FEB-2002 (first entry)

XX

DE Oligonucleotide primer SEQ ID NO 334521 for detecting SNP TSC0038211.

XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

PN WO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001WO-IB000713.

XX

PR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIC-) EPIGENOMICS AG.

XX

PI Olek A, Piepenbrock C, Berlin K;

XX

DR WPI; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX

PS Claim 1; SEQ ID NO 334521; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The

CC oligomers are also used for detecting cell type differentiation. ABC00010

CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073

CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

OY      53 TTGAGGTTT 62
      |||||
      11 TTGAGGTTT 2
Db
RESULT 222
AB169406/c
ID      AB169406 standard; DNA; 12 BP.
XX
AC      AB169406;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 369379 for detecting SNP TSC0000520.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 369379; 29bp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match      15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY      52 GTTGAGGTTT 61
      |||||
      12 GTTGAGGTTT 3
Db
RESULT 223
AB164587/c
ID      AB164587 standard; DNA; 12 BP.
XX
AC      AB164587;
XX
DT      22-FEB-2002 (first entry)
XX

```

```

XX      Oligonucleotide primer SEQ ID NO 364560 for detecting SNP TSC0054570.
DE
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 364560; 29bp + Sequence Listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 12 BP; 4 A; 3 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match      15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY      7 GAATGGAATT 16
      |||||
      12 GAATGGAATT 3
Db
RESULT 224
AB142193/c
ID      AB142193 standard; DNA; 12 BP.
XX
AC      AB142193;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide primer SEQ ID NO 342166 for detecting SNP TSC0042414.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX

```


PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 342166; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 52 GTTGAGGTT 61
 |||||
 10 GTTGAGGTT 1
 Db
 RESULT 225
 AB155467
 ID AB155467 standard; DNA; 12 BP.
 XX
 AC AB155467;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 355440 for detecting SNP TSC0049640.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

XX
 PS Claim 1; SEQ ID NO 355440; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 12 BP; 4 A; 0 C; 6 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 6 GGAATGGAAT 15
 |||||
 2 GGAATGGAAT 11
 Db
 RESULT 226
 AB107646
 ID AB107646 standard; DNA; 12 BP.
 XX
 AC AB107646;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide primer SEQ ID NO 307619 for detecting SNP TSC0022594.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 307619; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SO Sequence 12 BP; 1 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGGTTT 62
|||||
Db 1 TTGAGGTTT 10

RESULT 227
ABH84274/c
ID ABH84274 standard; DNA; 12 BP.
XX
AC ABH84274;
XX
DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 284267 for detecting SNP TSC0011747.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX
XX NO200177384-A2.

XX
XX 18-OCT-2001.

XX
XX 06-APR-2001; 2001WO-IB000713.

XX
XX 07-APR-2000; 2000DE-01019173.

XX
XX (EPIC-) EPIGENOMICS AG.

XX
XX Olek A, Piepenbrock C, Berlin K;

XX
XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
XX Claim 1; SEQ ID NO 284267; 29pp + Sequence listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SO Sequence 12 BP; 6 A; 5 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGGTTT 62
|||||
Db 11 TTGAGGTTT 2

RESULT 228
AB166699/c
ID AB166699 standard; DNA; 12 BP.
XX
AC AB166699;
XX

DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 366672 for detecting SNP TSC0055912.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX
XX NO200177384-A2.

XX
XX 18-OCT-2001.

XX
XX 06-APR-2001; 2001WO-IB000713.

XX
XX 07-APR-2000; 2000DE-01019173.

XX
XX (EPIC-) EPIGENOMICS AG.

XX
XX Olek A, Piepenbrock C, Berlin K;

XX
XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
XX Claim 1; SEQ ID NO 366672; 29pp + Sequence listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SO Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGGTTT 62
|||||
Db 12 TTGAGGTTT 3

RESULT 229
AB109673
ID AB109673 standard; DNA; 12 BP.
XX
AC AB109673;
XX

DT 22-FEB-2002 (first entry)
XX

DE Oligonucleotide primer SEQ ID NO 309646 for detecting SNP TSC0023602.

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

```

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 309646; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 52 GTTGAGGTT 61
Db 1 GTTGAGGTT 10
XX
RESULT 230
AB130165
ID AB130165 standard; DNA; 12 BP.
XX
AC AB130165;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 330138 for detecting SNP TSC0035356.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.

```

```

XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 330138; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 1 C; 7 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 50 GGGTTGAGG 59
Db 2 GGGTTGAGG 11
XX
RESULT 231
AB107667/c
ID AB107667 standard; DNA; 12 BP.
XX
AC AB107667;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 307640 for detecting SNP TSC0022603.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 307640; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

```

```
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGGAGGTTT 62
Db 11 TTGGAGGTTT 2

RESULT 232
AB12354/C
ID AB12354 standard; DNA; 12 BP.
XX
AC AB12354;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 352327 for detecting SNP TSC0047816.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 352327; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
```

```
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGGAGGTTT 62
Db 11 TTGGAGGTTT 2

RESULT 233
AB123654/C
ID AB123654 standard; DNA; 12 BP.
XX
AC AB123654;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide primer SEQ ID NO 365275 for detecting SNP TSC0055021.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS (EPig-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 365275; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GGGTTGGAGG 59
Db 12 GGGTTGGAGG 3

RESULT 234
AB123654
ID AB123654 standard; DNA; 12 BP.
XX
```


PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
XX Claim 1; SEQ ID NO 325644; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGGAGGTTT 62
DB 12 TTGGAGGTTT 3
RESULT 237
AB130164
ID AB130164 standard; DNA; 12 BP.
XX
XX AB130164;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 330137 for detecting SNP TSC0035356.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Plepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 330137; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 5 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 12 BP; 2 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GGCTTGAGG 59
DB 2 GGCTTGAGG 11
RESULT 238
AB146947/C
ID AB146947 standard; DNA; 12 BP.
XX
XX AB146947;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide primer SEQ ID NO 346920 for detecting SNP TSC0044834.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Plepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 346920; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 12 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGGAGGTTT 62

```

Db      10 TTGAGGTTT 1
|||||
RESULT 239
ID      ABH67422/c
XX      ABH67422 standard; DNA; 12 BP.
XX      ABH67422;
XX      22-FEB-2002 (first entry)
XX      Oligonucleotide primer SEQ ID NO 267399 for detecting SNP TSC0000164.
DE      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIC-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX      Claim 1; SEQ ID NO 267399; 29bp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 12 BP; 2 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
XX      Query Match      15.4%; Score 10; DB 1; Length 12;
XX      Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      5 TGGAATCGAA 14
      |||||||
      10 TGGAATCGAA 1
      Db
      RESULT 240
      ID      ABH91967
      XX      ABH91967 standard; DNA; 12 BP.
      XX      ABH91967;
      XX      22-FEB-2002 (first entry)
      XX      Oligonucleotide primer SEQ ID NO 291960 for detecting SNP TSC0015022.

```

```

XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIC-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
XX      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX      Claim 1; SEQ ID NO 291960; 29bp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
XX      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX      and cytosine methylation status in chemically pretreated genomic DNA. The
XX      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX      range of diseases including immune system, gastrointestinal, respiratory,
XX      central nervous system, cardiovascular and metabolic disorders. The
XX      oligomers are also used for detecting cell type differentiation. ABC00010
XX      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB102073
XX      represent the oligomers described in the invention. NOTE: The sequence
XX      data for this patent did not form part of the printed specification, but
XX      was obtained in electronic format from WIPO at
XX      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 12 BP; 3 A; 1 C; 4 G; 4 T; 0 U; 0 Other;
XX      Query Match      15.4%; Score 10; DB 1; Length 12;
XX      Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      54 TTGAGGTTTC 63
      |||||||
      3 TTGAGGTTTC 12
      Db
      RESULT 241
      ID      AAD25619/c
      XX      AAD25619 standard; DNA; 12 BP.
      XX      AAD25619;
      XX      26-MAR-2002 (first entry)
      XX      MLCy5L LNA probe used for haplotyping MLC-AE4/98(+) chimeric gene.
      XX      Haplotyping; single molecule detection; luminescent marker;
      XX      genetic marker; MLC-AE4/98(+); locked nucleic acid; LNA; probe; ss.
      XX      Unidentified.
      XX      OS
      XX      Key      Location/Qualifiers
      FT      modified_base 1 /*tag= a
      FT      /mod_base= OTHER
      FT      /note= "N,N'-biscarboxypentyl-5, 5'-
      FT      disulfonateindodicarbocyanine (Cy5) fluorophore labelled
      FT      thymine"

```

```

XX PN WO200190418-A1.
XX XX
XX PD 29-NOV-2001.
XX XX
XX PF 22-MAY-2001; 2001WO-US016394.
XX XX
XX PR 22-MAY-2000; 2000US-0206512P.
XX XX
XX PA (REGC ) UNIV CALIFORNIA.
XX XX
XX PI Cai H, Goodwin PM, Keller RA, Werner JH;
XX XX
XX DR WPI; 2002-083123/11.
XX XX
XX PT Rapid haplotyping of DNA or RNA segments, comprises labeling at least 2
XX PT target sites on a segment of DNA or RNA with separate distinguishable
XX PT fluorescent hybridization probes.
XX PS
XX PS Example 1; Page 22; 49pp; English.
XX XX
XX CC The invention relates to rapid haplotyping a DNA or RNA segment by single
XX CC molecule detection. The method involves labelling at least 2 target sites
XX CC on a DNA or RNA segment with separate distinguishable fluorescent marker
XX CC hybridisation probes, where the targets are selected genetic markers and
XX CC detecting the presence or absence of each fluorescent hybridisation probe
XX CC on each DNA segment to determine the haplotype of each DNA or RNA
XX CC segment. The method is useful for rapid haplotyping of DNA or RNA
XX CC for haplotyping ML-AF4/98(+) chimeric gene
XX XX
XX SQ Sequence 12 BP; 0 A; 3 C; 3 G; 6 T; 0 U; 0 Other;
XX XX
XX Query Match 15.4%; Score 10; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX QY 23 AGCCCAAGAA 32
XX DB 11 AGCCCAAGAA 2
XX XX
XX RESULT 242
XX AAD25617/C
XX ID AAD25617 standard; DNA; 12 BP.
XX XX
XX AC AAD25617;
XX XX
XX DT 26-MAR-2002 (first entry)
XX XX
XX DE ML-CySP PNA probe used for haplotyping ML-AF4/98(+) chimeric gene.
XX XX
XX KW Haplotyping; single molecule detection; luminescent marker;
XX KW genetic marker; ML-AF4/98(+); peptide nucleic acid; PNA; probe; ss.
XX XX
XX OS Unidentified.
XX XX
XX FH key Location/Qualifiers
XX FT 1
XX FT modified_base
XX FT /tag= a
XX FT /mod_base= OTHER
XX FT /note= "N,N'-biscarboxypentyl-5, 5'-
XX FT disulphonatocarbocyanine (Cy5) fluorophore labelled
XX FT thymine; This base is linked to the label via linker"
XX FT 12
XX FT misc_feature
XX FT /tag= b
XX FT /note= "This base is attached to a linker sequence"
XX XX
XX PN WO200190418-A1.
XX XX
XX PD 29-NOV-2001.
XX XX
XX PF 22-MAY-2001; 2001WO-US016394.
XX XX

```

```

XX PR 22-MAY-2000; 2000US-0206512P.
XX XX
XX XX (REGC ) UNIV CALIFORNIA.
XX XX
XX PI Cai H, Goodwin PM, Keller RA, Werner JH;
XX XX
XX DR WPI; 2002-083123/11.
XX XX
XX PT Rapid haplotyping of DNA or RNA segments, comprises labeling at least 2
XX PT target sites on a segment of DNA or RNA with separate distinguishable
XX PT fluorescent hybridization probes.
XX PS
XX PS Example 1; Page 22; 49pp; English.
XX XX
XX CC The invention relates to rapid haplotyping a DNA or RNA segment by single
XX CC molecule detection. The method involves labelling at least 2 target sites
XX CC on a DNA or RNA segment with separate distinguishable luminescent marker
XX CC hybridisation probes, where the targets are selected genetic markers and
XX CC detecting the presence or absence of each luminescent hybridisation probe
XX CC on each DNA segment to determine the haplotype of each DNA or RNA
XX CC segment. The method is useful for rapid haplotyping of DNA or RNA
XX CC for haplotyping ML-AF4/98(+) chimeric gene
XX XX
XX SQ Sequence 12 BP; 0 A; 3 C; 3 G; 6 T; 0 U; 0 Other;
XX XX
XX Query Match 15.4%; Score 10; DB 1; Length 12;
XX Best Local Similarity 100.0%; Pred. No. 2.1e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX QY 23 AGCCCAAGAA 32
XX DB 11 AGCCCAAGAA 2
XX XX
XX RESULT 243
XX ADE13956/C
XX ID ADE13956 standard; DNA; 12 BP.
XX XX
XX AC ADE13956;
XX XX
XX DT 29-JAN-2004 (first entry)
XX XX
XX DE Optineurin promoter motif, repeat element or regulatory region #65.
XX XX
XX KW Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
XX KW SNP; glaucoma; progressive ocular hypertensive disorder;
XX KW glaucoma related disorder; motif; repeat element; regulatory region.
XX XX
XX OS Homo sapiens.
XX XX
XX PN US2003190617-A1.
XX XX
XX PD 09-OCT-2003.
XX XX
XX PF 06-MAR-2002; 2002US-00091281.
XX XX
XX PR 06-MAR-2002; 2002US-00091281.
XX XX
XX PA (SIEE/) SI E.
XX PA (RAYM/) RAYMOND V.
XX PA (MORI/) MORISSETTE J.
XX XX
XX PI Raymond V, Morissette J, Si E;
XX XX
XX DR WPI; 2003-864168/80.
XX XX
XX PT New nucleic acid sequences of the optineurin gene are useful to detect
XX PT polymorphisms particularly single nucleotide polymorphisms in the
XX PT optineurin promoter to diagnose, prognosis and treat glaucoma and related
XX PT disorders.
XX XX

```


PS Claim 11; SEQ ID NO 67; 159bp; English.
 XX
 CC The invention relates to an isolated nucleic acid (N1) comprising at
 CC least 20 but not more than 1500 consecutive nucleotides of the optineurin
 CC promoter appearing as ADE13890. Also included are the optineurin promoter
 CC operably linked to a heterologous nucleic acid, a nucleic acid capable of
 CC detecting a single nucleotide polymorphism (SNP) in the optineurin
 CC promoter, a host cell comprising the promoter operably linked to a
 CC heterologous sequence, diagnosing or prognosing glaucoma in a sample
 CC obtained from a cell or bodily fluid (comprising detecting a polymorphism
 CC in a promoter region of the optineurin gene, associated with a glaucoma
 CC phenotype), detecting a SNP sequence variation in a sample containing
 CC DNA, detecting the presence of an optineurin promoter sequence variation
 CC in a sample containing DNA, determining the presence or increased
 CC susceptibility to glaucoma or to a progressive ocular hypertensive
 CC disorder resulting in loss of visual field in a patient (or the severity
 CC or progression of glaucoma in a patient, comprising providing
 CC amplification reaction primers that direct amplification of a selected
 CC nucleic acid region containing the variation within the optineurin
 CC promoter and amplifying the DNA) and detecting a polymorphism (comprising
 CC obtaining a sample containing human genomic DNA, providing a nucleic acid
 CC capable of detecting a SNP located within an optineurin promoter, and
 CC detecting the polymorphism). The invention is used to diagnose and
 CC prognose glaucoma and also to treat glaucoma related disorders. The
 CC present sequence is an optineurin promoter motif, repeat element or
 CC putative regulatory region.
 XX
 SQ Sequence 12 BP; 5 A; 2 C; 1 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 14 ATTGCACATA 23
 |||||
 10 ATTGCACATA 1
 DB
 RESULT 244
 AAV06855/c
 ID AAV06855 standard; DNA; 13 BP.
 XX
 AC AAV06855;
 XX
 DT 01-JUL-1998 (first entry)
 XX
 DE One from an array of 58 cystic fibrosis oligonucleotides.
 XX
 KW H-ras; wild-type; immobilising; diagnosis; ethylene acrylic acid;
 KW ethylene methacrylic acid; polypropylene; biotin; cystic fibrosis; array;
 KW 86.
 XX
 OS Synthetic.
 OS
 XX
 PN MO9746597-A1.
 XX
 PD 11-DEC-1997.
 XX
 PF 22-MAY-1997; 97MO-US008880.
 XX
 PR 05-JUN-1996; 96US-00658664.
 XX
 PA (BECT) BECKMAN INSTR INC.
 XX
 PI Milton RC;
 XX
 DR WPI; 1998-051910/05.
 XX
 PT Polymeric reagents for immobilising biopolymers - are stable under
 PT synthesis conditions.
 PS Example 7; Fig 19; 66bp; English.
 XX

CC The present sequence represents one of an array of 58 cystic fibrosis
 CC oligonucleotides. The invention relates to a new reagent for immobilising
 CC a biopolymer. It comprises a solid support fabricated from a polymeric
 CC material having at least one surface comprising pendant acyl fluoride
 CC functionalities. The reagent is stable under conditions for synthesising
 CC and immobilising biopolymers and is stable under conditions used to
 CC analyse the biopolymers. The reagents can be formed into devices which
 CC are physically rugged and inexpensive which can be used in analytical and
 CC diagnostic procedures
 XX
 SQ Sequence 13 BP; 1 A; 2 C; 4 G; 6 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 25 CCCAGAACCA 34
 |||||
 10 CCCAGAACCA 1
 DB
 RESULT 245
 ABC72460
 ID ABC72460 standard; DNA; 13 BP.
 XX
 AC ABC72460;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 72477 for detecting SNP TSC0018723.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; 86;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 OS
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-1B000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 72477; 29bp + Sequence listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and A3100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGGA 57
|||||
Db 4 TGGGGTTGGA 13

RESULT 246
ABC72461/c
ID ABC72461 standard; DNA; 13 BP.

AC ABC72461;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 72478 for detecting SNP TSC0018723.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PS Claim 1; SEQ ID NO 72478; 29pp + Sequence Listing; German.

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 72478; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGGA 57
|||||
Db 10 TGGGGTTGGA 1

RESULT 247
ABF96459/c
ID ABF96459 standard; DNA; 13 BP.
XX
AC ABF96459;

XX 22-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 196456 for detecting SNP TSC0008585.
XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

XX WO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001WO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

PS Claim 1; SEQ ID NO 196456; 29pp + Sequence Listing; German.

XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 196456; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGGA 57
|||||
Db 10 TGGGGTTGGA 1

RESULT 248
ABC98944
ID ABC98944 standard; DNA; 13 BP.

AC ABC98944;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 98961 for detecting SNP TSC0024580.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

OS Homo sapiens.

XX WO200177384-A2.

PN

```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 98961; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 50 GGGTTGAGG 59
XX |||||
XX 4 GGGTTGAGG 13
XX
XX RESULT 249
XX ABC98945/C
XX ID ABC98945 standard; DNA; 13 BP.
XX
XX AC ABC98945;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 98962 for detecting SNP TSC0024580.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001MO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX

```

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 98962; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 50 GGGTTGAGG 59
XX |||||
XX 10 GGGTTGAGG 1
XX
XX Db
XX
XX RESULT 250
XX ABC08152
XX ID ABC08152 standard; DNA; 13 BP.
XX
XX AC ABC08152;
XX
XX DT 20-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 8143 for detecting SNP TSC0002280.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001MO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 8143; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX

```

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGAGGTT 61
DB 3 GTTGAGGTT 12
RESULT 251
ABC38818
ID ABC38818 standard; DNA, 13 BP.
XX
AC ABC38818;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 38835 for detecting SNP TSC0011952.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 38835; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 9 A; 0 C; 2 G; 1 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 31 AACAGAAAGAC 42
|| |||||

DB 2 AAAAGAAAGAY 13
RESULT 252
ABF1481/c
ID ABF1481 standard; DNA, 13 BP.
XX
AC ABF1481;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 114178 for detecting SNP TSC0028568.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 114178; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGAGGTTT 62
DB 12 TTGAGGTTT 3
RESULT 253
ABF78290
ID ABF78290 standard; DNA, 13 BP.
XX
AC ABF78290;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 178287 for detecting SNP TSC0044161.
XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX OS
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIC-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 178287; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 52 GTTGAGGTTTC 63
 Db 2 GTTGAGTGTTC 13
 RESULT 254
 ABH09786
 ID ABH09786 standard; DNA; 13 BP.
 XX AC ABH09786;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 209763 for detecting SNP TSC0051216.
 XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PS Claim 1; SEQ ID NO 178287; 29pp + Sequence Listing; German.

XX (EPIC-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 209763; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 52 GTTGAGGTTT 61
 Db 4 GTTGAGGTTT 13
 RESULT 255
 ABH14635/C
 ID ABH14635 standard; DNA; 13 BP.
 XX AC ABH14635;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 214612 for detecting SNP TSC0052224.
 XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB000713.
 XX PR 07-APR-2000; 2000DE-01019173.
 XX PA (EPIC-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX PS Claim 1; SEQ ID NO 214612; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 GGGGTTGGAG 58
|||||||
Db 10 GGGGTTGAG 1

RESULT 256

ABF35131/c
ID ABF35131 standard; DNA; 13 BP.

AC ABF35131;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 135128 for detecting SNP TSC0033685.

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 135128; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGATTGGA 57
|||||||
Db 10 TGGGATTGGA 1

RESULT 257

ABF68180
ID ABF68180 standard; DNA; 13 BP.

AC ABF68180;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 168177 for detecting SNP TSC0042062.

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 168177; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 3 A; 0 C; 4 G; 5 T; 0 U; 1 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 TGGAAATTGGA 19
|||||||
Db 1 TGGAAATTGGA 10

RESULT 258

ABF72180

```

ID  ABF72180 standard; DNA; 13 BP.
XX
XX  ABF72180;
AC
XX  22-FEB-2002 (first entry)
DT
XX
XX  Oligonucleotide SEQ ID NO 172177 for detecting SNP TSC0042932.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS  Homo sapiens.
XX
XX  WO200177384-A2.
PN
XX  18-OCT-2001.
PD
XX
XX  06-APR-2001; 2001WO-IB000713.
PF
XX
XX  07-APR-2000; 2000DE-01019173.
PR
XX
XX  (EPIC-) EPIDENOMICS AG.
PA
XX  Olek A, Piepenbrock C, Berlin K;
PI
XX  WPI; 2001-657177/75.
DR
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
PS  Claim 1; SEQ ID NO 172177; 29bp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, metabolic disorders,
CC  central nervous system, cardiovascular and gastrointestinal, respiratory,
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;
XX
Query Match      15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY  51 GGTGAGGTTT 62
   |||||
   |||||
Db  2 GGTGGAAGTTT 13
XX
RESULT 259
ABF78291/c
ID  ABF78291 standard; DNA; 13 BP.
XX
XX  ABF78291;
AC
XX  22-FEB-2002 (first entry)
DT
XX
XX  Oligonucleotide SEQ ID NO 178288 for detecting SNP TSC0044161.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS

```

```

XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIDENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 178288; 29bp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
SQ  Sequence 13 BP; 7 A; 4 C; 0 G; 1 T; 0 U; 1 Other;
XX
Query Match      15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY  52 GGTGAGGTTTC 63
   |||||
   |||||
Db  12 GTTGAGTGTTTY 1
XX
RESULT 260
ABF78294
ID  ABF78294 standard; DNA; 13 BP.
XX
XX  ABF78294;
AC
XX  22-FEB-2002 (first entry)
DT
XX
XX  Oligonucleotide SEQ ID NO 178291 for detecting SNP TSC0044161.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
OS
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIC-) EPIDENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K;
XX

```

DR WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 178291; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 1 C; 4 G; 6 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 52 GTTGAGGTTTC 63
Db 2 GTTGACGTTT 13
RESULT 261
ABH12398
ID ABH12398 standard; DNA; 13 BP.
XX
XX ABH12398;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 212375 for detecting SNP TSC0051732.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
XX Claim 1; SEQ ID NO 212375; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 51 GGTGAGAGT 60
Db 1 GGTGAGAGT 10
RESULT 262
ABC18902
ID ABC18902 standard; DNA; 13 BP.
XX
XX ABC18902;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 18919 for detecting SNP TSC0003970.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
XX Claim 1; SEQ ID NO 18919; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 7 G; 2 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGGT 60
 DB 2 GAGGTTGGAGGY 13

RESULT 263
 ABC18903/C
 ID ABC18903 standard; DNA; 13 BP.
 XX
 AC ABC18903;
 XX
 DT 20-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 18920 for detecting SNP TSC0003970.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIC-) EPIGENOMICS AG.
 XX

PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 18920; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SO Sequence 13 BP; 2 A; 7 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGGT 60
 DB 12 GAGGTTGGAGGY 1

RESULT 264
 ABC69993/C
 ID ABC69993 standard; DNA; 13 BP.
 XX
 AC ABC69993;
 XX
 DT 21-FEB-2002 (first entry)
 XX

XX
 DE Oligonucleotide SEQ ID NO 70010 for detecting SNP TSC0018219.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIC-) EPIGENOMICS AG.
 XX

PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX

PS Claim 1; SEQ ID NO 70010; 29pp + Sequence Listing; German.
 XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SO Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGGAGGTTT 62
 DB 13 TTGGAGGTTT 4

RESULT 265
 ABC53076
 ID ABC53076 standard; DNA; 13 BP.
 XX
 AC ABC53076;
 XX
 DT 21-FEB-2002 (first entry)
 XX

DE Oligonucleotide SEQ ID NO 53093 for detecting SNP TSC0014670.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX

OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX

```
PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 53093; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 53 TTGAGAGTTT 62
XX |||||
XX 2 TTGAGAGTTT 11
XX
XX RESULT 266
XX ABF14904
XX ID ABF14904 standard; DNA; 13 BP.
XX
XX AC ABF14904;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 114901 for detecting SNP TSC0028776.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
```

```
XX
XX Claim 1; SEQ ID NO 114901; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 51 GGTTGAGAGT 60
XX |||||
XX 3 GGTTGAGAGT 12
XX
XX Db
XX
XX RESULT 267
XX ABC16841/C
XX ID ABC16841 standard; DNA; 13 BP.
XX
XX AC ABC16841;
XX
XX DT 20-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 16848 for detecting SNP TSC0003657.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 16848; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
```

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP, 8 A, 4 C, 0 G, 1 T, 0 U, 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGAGCTTT 62
|||||

Db 13 TTGAGAGCTTT 4

RESULT 268

ABF29456
ID ABF29456 standard; DNA; 13 BP.

AC ABF29456;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 129453 for detecting SNP TSC0032391.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX MO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001MO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is

PT designed to detect single-nucleotide polymorphisms and cytosine

PT methylation status.

XX Claim 1; SEQ ID NO 129453; 29bp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP, 2 A, 0 C, 8 G, 2 T, 0 U, 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;

Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 50 GGGTTGAGG 59
|||||

Db 2 GGGTTGAGG 11

RESULT 269
ABF78295/C
ID ABF78295 standard; DNA; 13 BP.

AC ABF78295;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 178292 for detecting SNP TSC0044161.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX MO200177384-A2.

PN 18-OCT-2001.

PD 06-APR-2001; 2001MO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PA Olek A, Piepenbrock C, Berlin K;

PI WPI; 2001-657177/75.

DR Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 178292; 29bp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP, 6 A, 4 C, 1 G, 1 T, 0 U, 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;

Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 52 GTTGAGAGCTTTC 63
|||||

Db 12 GTTGAGAGCTTTC 1

RESULT 270

ABH28568
ID ABH28568 standard; DNA; 13 BP.

AC ABH28568;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 228545 for detecting SNP TSC0009540.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 OS
 XX WO200177384-A2.
 FN
 XX 18-OCT-2001.
 PD
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 228545; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 4 T; 0 U; 1 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GGCTTGACAGTT 61
 DB 2 GGCTTGACAGTT 13
 XX
 RESULT 271
 ABH09787/C
 ID ABH09787 standard; DNA; 13 BP.
 XX
 AC ABH09787;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 209764 for detecting SNP TSC0051216.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX

XX Olek A, Piepenbrock C, Berlin K;
 PT WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 209764; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 52 GTTGACAGTT 61
 DB 10 GTTGACAGTT 1
 XX
 RESULT 272
 ABH1477/C
 ID ABH1477 standard; DNA; 13 BP.
 XX
 AC ABH1477;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 241454 for detecting SNP TSC0001145.
 XX
 SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPiG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 241454; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 6 C; 0 G; 3 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 10 TGGATTGGA 19
| | | | |
| | | | |
Db 13 TGGATTGGA 4
RESULT 273
ABC38819/c
ID ABC38819 standard; DNA; 13 BP.
XX
XX ABC38819;
AC
XX 20-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 38836 for detecting SNP TSC0011952.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 38836; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 2 C; 0 G; 9 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 31 AACGAAAGAAC 42
| | | | |
| | | | |
Db 12 AAAAGAAAGAA 1
RESULT 274
ABF35130
ID ABF35130 standard; DNA; 13 BP.
XX
XX ABF35130;
AC
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 135127 for detecting SNP TSC0033685.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 135127; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 TGGGTTTGA 57
| | | | |
| | | | |
Db 4 TGGGTTTGA 13
RESULT 275
ABF68181/c
ID ABF68181 standard; DNA; 13 BP.
XX

```
AC ABF68181;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 168178 for detecting SNP TSC0042062.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 168178; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 4 C; 0 G; 3 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 10 TGGAAATTGGA 19
Db 13 TGGAAATTGGA 4
XX
RESULT 276
ABF72181/C
ID ABF72181 standard; DNA; 13 BP.
XX
AC ABF72181;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 172178 for detecting SNP TSC0042932.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
```

```
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 172178; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GCTTGAGAGTTT 62
Db 12 GCTTGAGAGTTT 1
XX
RESULT 277
ABH28569/C
ID ABH28569 standard; DNA; 13 BP.
XX
AC ABH28569;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 228546 for detecting SNP TSC0009540.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 228546; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTCGAGGT 61
DB 12 GGGTTCGAGCTT 1
XX
RESULT 278
ABH66664
ID ABH66664 standard; DNA; 13 BP.
XX
AC ABH66664;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 266641 for detecting SNP TSC0064607.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 266641; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 6 C; 0 G; 2 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 50 GGGTTCGAGGT 61
DB 12 GGGTTCGAGCTT 1
XX
RESULT 278
ABH66664
ID ABH66664 standard; DNA; 13 BP.
XX
AC ABH66664;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 266641 for detecting SNP TSC0064607.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 8144; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 52 GTTGAGAGTT 61

CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 8 G; 2 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 49 GGGTTCGAGGT 60
DB 2 GAGTTGAGAGT 13
XX
RESULT 279
ABC08153/c
ID ABC08153 standard; DNA; 13 BP.
XX
AC ABC08153;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 8144 for detecting SNP TSC002280.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 8144; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 52 GTTGAGAGTT 61

```
Db          |||||
            11 GTTGAGGTT 2

RESULT 280
ABC08156
ID ABC08156 standard; DNA; 13 BP.
XX
AC ABC08156;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 8147 for detecting SNP TSC0002280.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 8147; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 1 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 52 GTTGAGGTT 61
Db 3 GTTGAGGTT 12

RESULT 281
ABC88551/C
ID ABC88551 standard; DNA; 13 BP.
XX
AC ABC88551;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 88568 for detecting SNP TSC0022253.
```

```
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 88568; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 7 GATGGAATT 16
Db 13 GATGGAATT 4

RESULT 282
ABF14836
ID ABF14836 standard; DNA; 13 BP.
XX
AC ABF14836;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 114833 for detecting SNP TSC0028759.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
```


PR 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 PI WPI; 2001-657177/75.
 DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 114833; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 GGTGGAGGT 60
 |||||
 |||||
 DB 2 GGTGGAGGT 11
 RESULT 283
 ABF39155/C
 ID ABF39155 standard; DNA; 13 BP.
 XX
 AC ABF39155;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 139152 for detecting SNP TSC0034855.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 139152; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 51 GGTGGAGGTTT 62
 |||||
 |||||
 DB 12 GGTGGAGGTTT 1
 RESULT 284
 ABH36930
 ID ABH36930 standard; DNA; 13 BP.
 XX
 AC ABH36930;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 236907 for detecting SNP TSC0000091.
 XX
 DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX (EPIC-) EPIGENOMICS AG.
 PA
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 XX WPI; 2001-657177/75.
 DR WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 236907; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

```
XX SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 52 GTTGAGGTT 61
DB 4 GTTGAGGTT 13

RESULT 285
ABH59464
ID ABH59464 standard; DNA; 13 BP.
XX AC ABH59464;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 259441 for detecting SNP TSC0063013.
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PA (EPIC-) EPIGENOMICS AG.
XX PI WPI; 2001-657177/75.
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 259441; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 5 TTGAATGGAATT 16
DB 2 TTGAATGGAATT 13

RESULT 286
```

```
ABF21342
ID ABF21342 standard; DNA; 13 BP.
XX AC ABF21342;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 121339 for detecting SNP TSC0030310.
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PA (EPIC-) EPIGENOMICS AG.
XX PI WPI; 2001-657177/75.
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 121339; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 1 A; 1 C; 6 G; 4 T; 0 U; 1 Other;
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 52 GTTGAGGTTTC 63
DB 2 GTTGAGGTTTC 13

RESULT 287
ABH27163/C
ID ABH27163 standard; DNA; 13 BP.
XX AC ABH27163;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 227140 for detecting SNP TSC0055396.
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
```

```

OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX PD
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 227140; 29pp + Sequence listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 6 A; 5 C; 1 G; 0 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTTTC 63
XX ||||| |||||
XX 2 GTTGAGGTTTY 1
XX
XX Db 12 GTTGAGGTTTY 1
XX
XX RESULT 288
XX ABE52228
XX ID ABE52228 standard; DNA; 13 BP.
XX
XX AC ABE52228;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 152225 for detecting SNP TSC0038463.
XX
XX SNF, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX

```

```

XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 152225; 29pp + Sequence listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 3 A; 0 C; 5 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTTTC 63
XX ||||| |||||
XX 2 GTTGAGGTTTY 13
XX
XX Db 2 GTTGAGGTTTY 13
XX
XX RESULT 289
XX ABE60990
XX ID ABE60990 standard; DNA; 13 BP.
XX
XX AC ABE60990;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 160987 for detecting SNP TSC0040537.
XX
XX SNF, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 160987; 29pp + Sequence listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a

```

```
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 53 TTGAGGTTT 62
   |||||
   1 TTGAGGTTT 10
DB
RESULT 290
ABC68982
ID ABC68982 standard; DNA; 13 BP.
XX
AC ABC68982;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 68999 for detecting SNP TSC0017967.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO20017384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS Claim 1; SEQ ID NO 68999; 29pp + Sequence Listing; German.
XX
PT This invention describes novel oligonucleotide primers or peptide nucleic
PT acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
PT and cytosine methylation status in chemically pretreated genomic DNA. The
PT oligonucleotides are used for diagnosis and/or prognosis of cancer and a
PT range of diseases including immune system, gastrointestinal, respiratory,
PT central nervous system, cardiovascular and metabolic disorders. The
PT oligomers are also used for detecting cell type differentiation. ABC00010
PT -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
PT represent the oligomers described in the invention. NOTE: The sequence
PT data for this patent did not form part of the printed specification, but
PT was obtained in electronic format from WIPO at
PT ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 10 TGGATTGGA 19
   |||||
   3 TGGATTGGA 12
DB
RESULT 291
ABF02807/C
ID ABF02807 standard; DNA; 13 BP.
XX
AC ABF02807;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 102804 for detecting SNP TSC0025690.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO20017384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS Claim 1; SEQ ID NO 102804; 29pp + Sequence Listing; German.
XX
PT This invention describes novel oligonucleotide primers or peptide nucleic
PT acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
PT and cytosine methylation status in chemically pretreated genomic DNA. The
PT oligonucleotides are used for diagnosis and/or prognosis of cancer and a
PT range of diseases including immune system, gastrointestinal, respiratory,
PT central nervous system, cardiovascular and metabolic disorders. The
PT oligomers are also used for detecting cell type differentiation. ABC00010
PT -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
PT represent the oligomers described in the invention. NOTE: The sequence
PT data for this patent did not form part of the printed specification, but
PT was obtained in electronic format from WIPO at
PT ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 53 TTGAGGTTT 62
   |||||
   12 TTGAGGTTT 3
DB
RESULT 292
ABC6872
ID ABC6872 standard; DNA; 13 BP.
XX
AC ABC6872;
XX
```

```

DT 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 66889 for detecting SNP TSC0017525.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIDENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 66889; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 51 GGTGGAGCT 60
DB 2 GGTGGAGCT 11
XX
XX RESULT 293
XX ABF18949/C
XX ID ABF18949 standard; DNA; 13 BP.
XX
XX ABF18949;
XX
XX 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 118946 for detecting SNP TSC0029695.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD

```

```

XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIDENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 118946; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGGAGCTT 62
DB 11 TTGGAGCTT 2
XX
XX RESULT 294
XX ABF24945/C
XX ID ABF24945 standard; DNA; 13 BP.
XX
XX ABF24945;
XX
XX 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 124942 for detecting SNP TSC0031231.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIDENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

```

PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 124942; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 49 GGGGTTTGGAG 58
 |||||
 10 GGGGTTTGGAG 1

Db
 RESULT 295
 ABF73195/C
 ID ABF73195 standard; DNA; 13 BP.
 AC
 XX ABF73195;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 173192 for detecting SNP TSC0043135.
 XX
 SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS
 XX Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DB-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 173192; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence

CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 TTGGGTTTGA 57
 |||||
 11 TTGGGTTTGA 2

Db
 RESULT 296
 ABC69992
 ID ABC69992 standard; DNA; 13 BP.
 XX
 AC ABC69992;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 70009 for detecting SNP TSC0018219.
 XX
 SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS
 XX Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DB-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 70009; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 53 TTGGAGGTTT 62
 |||||
 1 TTGGAGGTTT 10

Db

```

RESULT 297
ABH18948
ID ABH18948 standard; DNA; 13 BP.
XX
AC ABH18948;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 118945 for detecting SNP TSC0029695.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 118945; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGAGCTTT 62
   |||||
   |||||
Db 3 TTGAGCTTT 12
XX
RESULT 298
ABH16777/C
ID ABH16777 standard; DNA; 13 BP.
XX
AC ABH16777;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 216754 for detecting SNP TSC0052685.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

```

```

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 216754; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 10 TGGATTGGA 19
   |||||
   |||||
Db 10 TGGATTGGA 1
XX
RESULT 299
ABH42921/C
ID ABH42921 standard; DNA; 13 BP.
XX
AC ABH42921;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 242898 for detecting SNP TSC0000705.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

```

```

PA      (EPiG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
PI
XX      WPI; 2001-657177/75.
DR
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 242898; 29pp + Sequence listing; German.
PS
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
SQ
XX
XX      Query Match      15.4%; Score 10; DB 1; Length 13;
XX      Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY      52 GTTTGAGGTT 61
XX      |||||
XX      13 GTTGGAGGTT 4
DB
XX
XX      RESULT 300
XX      ABF14837/C
XX      ID ABF14837 standard; DNA; 13 BP.
XX
XX      ABF14837;
XX
XX      21-FEB-2002 (first entry)
XX
XX      Oligonucleotide SEQ ID NO 114834 for detecting SNP TSC0028759.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPiG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
PI
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 114834; 29pp + Sequence listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic

```

```

CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 4 A; 7 C; 0 G; 1 T; 0 U; 1 Other;
SQ
XX
XX      Query Match      15.4%; Score 10; DB 1; Length 13;
XX      Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX      Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY      51 GCTTGAGGTT 60
XX      |||||
XX      12 GCTTGAGGTT 3
DB
XX
XX      RESULT 301
XX      ABF21338
XX      ID ABF21338 standard; DNA; 13 BP.
XX
XX      ABF21338;
XX
XX      21-FEB-2002 (first entry)
XX
XX      Oligonucleotide SEQ ID NO 121335 for detecting SNP TSC0030310.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPiG-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
PI
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 121335; 29pp + Sequence listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
XX      Sequence 13 BP; 1 A; 0 C; 6 G; 5 T; 0 U; 1 Other;
SQ

```



```

Query Match          15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY      52 GTTGAGGTTTC 63
        |||||       |
DB      12 GTTGAAGCTGT 13

RESULT 302
ABF21339/C
ID   ABF21339 standard; DNA; 13 BP.
AC   ABF21339;
DT   21-FEB-2002 (first entry)
DE   Oligonucleotide SEQ ID NO 121336 for detecting SNP TSC0030310.
KW   SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM   peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
CN   central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS   Homo sapiens.
XX
XX      WO200177384-A2.
PN      18-OCT-2001.
PD
PF      06-APR-2001; 2001WO-IB000713.
PR      07-APR-2000; 2000DE-01019173.
PI      (EPIG-) EPIGENOMICS AG.
PA
PI      Olek A, Piepenbrock C, Berlin K;
XX      WPI, 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 121336; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, cardiovascular, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pat_sequences
CX
CX      Sequence 13 BP; 5 A; 6 C; 0 G; 1 T; 0 U; 1 Other;

Query Match          15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY      52 GTTGAGGTTTC 63
        |||||       |
DB      12 GTTGAAGCTGT 13

RESULT 303
ABF93539/C
ID   ABF93539 standard; DNA; 13 BP.

```

XX	ABP93539;	
AC	22-FEB-2002	(first entry)
XX		
DT		
XX		
DE	Oligonucleotide SEQ ID NO 193536 for detecting SNP TSC0047609.	
XX		
KM	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KM	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
OS	Homo sapiens.	
XX		
XX	WO200177384-A2.	
XX	18-OCT-2001.	
PD		
XX		
PF	06-APR-2001; 2001WO-IB000713.	
XX		
PR	07-APR-2000; 2000DE-01019173.	
XX		
PA	(EPIG-) EPIGENOMICS AG.	
PI	Olek A, Piepenbrock C, Berlin K,	
XX	WPI, 2001-657177/75.	
DR		
XX		
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is	
PT	designed to detect single-nucleotide polymorphisms and cytosine	
PT	methylation status.	
XX		
PS	Claim 1; SEQ ID NO 193536; 29pp + Sequence Listing; German.	
XX		
XX	This invention describes novel oligonucleotide primers or peptide nucleic	
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)	
CC	and cytosine methylation status in chemically pretreated genomic DNA. The	
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a	
CC	range of diseases including immune system, gastrointestinal, respiratory,	
CC	central nervous system, cardiovascular and metabolic disorders. The	
CC	oligomers are also used for detecting cell type differentiation. ABC00010	
CC	-ABG9989, ABP00010-ABP99989, ABH00010-ABH99989 and AH00010-AH182073	
CC	represent the oligomers described in the invention. NOTE: The sequence	
CC	data for this patent did not form part of the printed specification, but	
CC	was obtained in electronic format from WIPO at	
CC	ftp.wipo.int/pub/published_pct_sequences	
XX		
XX		
SEQ	Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;	
	Query Match	15.4%; Score 10; DB 1; Length 13;
	Best Local Similarity	100.0%; Pred. No. 2.3e+02;
	Matches	10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	10 TCGAATTGGA 19	
	11 TCGAATTGGA 2	
DB		
	RESULT 304	
	ABH36931/c	
ID	ABH36931 standard; DNA; 13 BP.	
XX		
AC	ABH36931;	
XX		
DT	22-FEB-2002 (first entry)	
XX		
DE	Oligonucleotide SEQ ID NO 236508 for detecting SNP TSC00000091.	
XX		
XX	SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;	
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;	
KW	central nervous system; gastrointestinal; respiratory; immune; metabolic.	
OS	Homo sapiens.	
XX		

```
PN WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 236908; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTT 61
XX |||||
XX 10 GTTGAGGTT 1
XX
XX RESULT 305
XX ABH42920
XX ID ABH42920 standard; DNA; 13 BP.
XX
XX AC ABH42920;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 242897 for detecting SNP TSC0000705.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
```

```
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 242897; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 52 GTTGAGGTT 61
XX |||||
XX 1 GTTGAGGTT 10
XX
XX Db
XX
XX RESULT 306
XX ABH6665/C
XX ID ABH6665 standard; DNA; 13 BP.
XX
XX AC ABH6665;
XX
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 266642 for detecting SNP TSC0064607.
XX
XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPiG-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 266642; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
```

CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 2 A; 8 C; 0 G; 2 T; 0 U; 1 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 49 GGGGTGAGGT 60
 12 GAGGTTGAGGT 1

RESULT 307
 ABC08157/c
 ID ABC08157 standard; DNA; 13 BP.
 AC ABC08157;
 XX
 XX
 DT 20-FEB-2002 (first entry)
 XX
 XX
 DE Oligonucleotide SEQ ID NO 8148 for detecting SNP TSC0002280.
 XX
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 8148; 29pp + Sequence Listing; German.
 XX
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 4 A; 6 C; 1 G; 2 T; 0 U; 0 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 52 GTTGAGGTT 61
 11 GTTGAGGTT 2

RESULT 308
 ABF21343/c
 ID ABF21343 standard; DNA; 13 BP.
 AC ABF21343;
 XX
 XX
 DT 21-FEB-2002 (first entry)
 XX
 XX
 DE Oligonucleotide SEQ ID NO 121340 for detecting SNP TSC0030310.
 XX
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX
 PS Claim 1; SEQ ID NO 121340; 29pp + Sequence Listing; German.
 XX
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 4 A; 6 C; 1 G; 1 T; 0 U; 1 Other;

QY Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 52 GTTGAGGTTTC 63
 12 GTTGAGGTTCT 1

RESULT 309
 ABF24944
 ID ABF24944 standard; DNA; 13 BP.
 AC ABF24944;
 XX
 XX
 DT 21-FEB-2002 (first entry)
 XX

```

DE Oligonucleotide SEQ ID NO 124941 for detecting SNP TSC0031231.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
XX Claim 1; SEQ ID NO 124941; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX
XX QY 49 GGGGTTGGAG 58
XX |||||
XX 4 GGGGTTGGAG 13
XX
XX
XX RESULT 310
XX ABF52229/c
XX ID ABF52229 standard; DNA; 13 BP.
XX
XX AC ABF52229;
XX
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 152226 for detecting SNP TSC0038463.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX

```

```

XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
XX Claim 1; SEQ ID NO 152226; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 1 Other;
XX
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 83.3%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX
XX QY 52 GTTGAGGTTTC 63
XX |||||
XX 12 GTTGAGGTTTY 1
XX
XX
XX RESULT 311
XX ABH10859/c
XX ID ABH10859 standard; DNA; 13 BP.
XX
XX AC ABH10859;
XX
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 210836 for detecting SNP TSC0051461.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX

```

PS Claim 1; SEQ ID NO 210836; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 6 A; 4 C; 0 G; 2 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 53 TTGGAGCTTT 62
 |||||
 12 TTGGAGCTTT 3
 Db
 RESULT 312
 ABH12399/C
 ID ABH12399 standard; DNA; 13 BP.
 XX
 AC ABH12399;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 212376 for detecting SNP TSC0051732.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 212376; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 GCTTGGAGCT 60
 |||||
 13 GCTTGGAGCT 4
 Db
 RESULT 313
 ABH41476
 ID ABH41476 standard; DNA; 13 BP.
 XX
 AC ABH41476;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 241453 for detecting SNP TSC3001145.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 241453; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB:00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 0 C; 6 G; 3 T; 0 U; 1 Other;
 Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 10 TCGAATTGGA 19
 |||||
 1 TCGAATTGGA 10
 Db

```
RESULT 314
ABF14180
ID ABF14180 standard; DNA; 13 BP.
XX
XX
AC ABF14180;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 114177 for detecting SNP TSC0028568.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPiG-) EPIGENOMICS AG.
XX
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
DR WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1: SEQ ID NO 114177; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP0010-ABF9989, ABH0010-ABH9989 and AB10010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 1 A; 0 C; 4 G; 7 T; 0 U; 1 Other;
XX
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGGAGGTTT 62
XX |||||||
XX 2 TTGGAGGTTT 11
XX
XX
RESULT 315
ABC66873/c
ID ABC66873 standard; DNA; 13 BP.
XX
XX
AC ABC66873;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 66890 for detecting SNP TSC0017525.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
```

```
XX
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPiG-) EPIGENOMICS AG.
XX
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX
DR WPI; 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1: SEQ ID NO 66890; 29pp + Sequence Listing; German.
XX
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP0010-ABF9989, ABH0010-ABH9989 and AB10010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 51 GGTTGAGAGT 60
XX |||||||
XX 12 GGTTGAGAGT 3
XX
XX
RESULT 316
ABF39154
ID ABF39154 standard; DNA; 13 BP.
XX
XX
AC ABF39154;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 139151 for detecting SNP TSC0034855.
XX
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200177384-A2.
XX
XX
PD 18-OCT-2001.
XX
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX
PA (EPiG-) EPIGENOMICS AG.
XX
```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 139151; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
QY 51 GGTGGAGGTTT 62
||| ||| |||
Db 2 GGTGGGGGTTT 13
XX
RESULT 317
ID ABF93015/c
XX ABF93015 standard; DNA; 13 BP.
XX
XX ABF93015;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 193012 for detecting SNP TSC0047481.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX W0200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 193012; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGGAGGTTT 62
||| ||| |||
Db 13 TTGGAGGTTT 4
XX
RESULT 318
ID ABF52057/c
XX ABF52057 standard; DNA; 13 BP.
XX
XX ABF52057;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 152054 for detecting SNP TSC0038422.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX W0200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 152054; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;

Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGGAGGTTT 62
DB 12 TTGGAGGTTT 3

RESULT 319

ABH14634
ID ABH14634 standard; DNA; 13 BP.

AC ABH14634;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 214611 for detecting SNP TSC0052224.

KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 214611; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABR00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 49 GGGGTTGGAG 58
DB 4 GGGGTTGGAG 13

RESULT 320

ABH59465/C
ID ABH59465 standard; DNA; 13 BP.

XX ABH59465;
AC ABH59465;

XX 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 259442 for detecting SNP TSC0063013.

KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 259442; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABR00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 4 A; 5 C; 0 G; 3 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 5 TGAATGGAATT 16
DB 12 TGAATGGAATT 1

RESULT 321

ABC68983/C
ID ABC68983 standard; DNA; 13 BP.

AC ABC68983;

DT 21-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 69000 for detecting SNP TSC0017967.

KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.

PN WO200177384-A2.


```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 69000; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 10 TGGATTGCA 19
DB 11 TGGATTGCA 2
XX
RESULT 322
ABF29457/C
ID ABF29457 standard; DNA; 13 BP.
XX
XX ABF29457;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 129454 for detecting SNP TSC0032391.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX

```

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 129454; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 8 C; 0 G; 2 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 2.3e+02;
XX Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 50 GGGTTGGAGG 59
DB 12 GGGTTGGAGG 3
XX
RESULT 323
ABP96458
ID ABP96458 standard; DNA; 13 BP.
XX
XX ABP96458;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 196455 for detecting SNP TSC0008585.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001MO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 196455; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX

```

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 TGGGGTTGGA 57
|||||
Db 4 TGGGGTTGGA 13

RESULT 324

ABH27160
ID ABH27160 standard; DNA; 13 BP.

AC ABH27160;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 227137 for detecting SNP TSC005396.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPiG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1, SEQ ID NO 227137; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 0 A; 0 C; 5 G; 7 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 52 GTTGAGGTTTC 63
|||||

Db 2 GTTGAGGTTTY 13

RESULT 325

ABC74005/C
ID ABC74005 standard; DNA; 13 BP.

XX ABC74005;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 74022 for detecting SNP TSC0019042.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPiG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1, SEQ ID NO 74022; 29pp + Sequence listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQ Sequence 13 BP; 1 A; 10 C; 0 G; 1 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 83.3%; Pred. No. 2.3e+02;
Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGAGGT 60
|||||
Db 12 GGGGTTGAGGY 1

RESULT 326

ABC53077/C
ID ABC53077 standard; DNA; 13 BP.

XX ABC53077;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 53094 for detecting SNP TSC0014670.

```

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 53094; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGGAGCTTT 62
DB 12 TTGGAGCTTT 3
XX
RESULT 327
ABC08543/C
ID ABC08543 standard; DNA; 13 BP.
XX
AC ABC08543;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 8534 for detecting SNP TSC0002341.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PS Claim 1; SEQ ID NO 53094; 29pp + Sequence Listing; German.

```

```

XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 8534; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 50 GGGTTGGAGG 59
DB 11 GGGTTGGAGG 2
XX
RESULT 328
ABF93014
ID ABF93014 standard; DNA; 13 BP.
XX
AC ABF93014;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 193011 for detecting SNP TSC0047481.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 193011; 29pp + Sequence Listing; German.

```

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGAGGCTT 62
|||||
Db 1 TTGAGGCTT 10

RESULT 329

ABH16776
ID ABH16776 standard; DNA; 13 BP.

XX ABH16776;

DT 22-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 216753 for detecting SNP TSC0052685.

DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 216753; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 10 TCGAATTGGA 19
|||||
Db 4 TCGAATTGGA 13

RESULT 330

ABC08542
ID ABC08542 standard; DNA; 13 BP.

XX ABC08542;

DT 20-FEB-2002 (first entry)

XX Oligonucleotide SEQ ID NO 8533 for detecting SNP TSC0002341.

DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 8533; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GGGTTGAGG 59
|||||
Db 3 GGGTTGAGG 12

RESULT 331

ABC88550

```

ID ABC88550 standard; DNA; 13 BP.
XX
AC ABC88550;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 88567 for detecting SNP TSC0022253.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 88567; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, cardiovascular disorders, the
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 7 GAATGAATT 16
|||||
Db 1 GAATGAATT 10
XX
RESULT 332
ABF93538
ID ABF93538 standard; DNA; 13 BP.
XX
AC ABF93538;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 193535 for detecting SNP TSC0047609.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX

```

```

XX
XX WO200177384-A2.
XX
PN 18-OCT-2001.
XX
PD 06-APR-2001; 2001WO-IB000713.
XX
PF 07-APR-2000; 2000DE-01019173.
XX
PR (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
PI WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 193535; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred.No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 10 TCGAATTGCA 19
|||||
Db 3 TCGAATTGCA 12
XX
RESULT 333
ABF73194
ID ABF73194 standard; DNA; 13 BP.
XX
AC ABF73194;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 173191 for detecting SNP TSC0043135.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 173191; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 48 TTGGGTTTGA 57
Db 3 TTGGGTTTGA 12
XX
RESULT 334
ABH10858
ID ABH10858 standard; DNA; 13 BP.
XX
AC ABH10858;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 210835 for detecting SNP TSC0051461.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 210835; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,

CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 6 T; 0 U; 1 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 53 TTGAGGTTT 62
Db 2 TTGAGGTTT 11
XX
RESULT 335
ABF60991/c
ID ABF60991 standard; DNA; 13 BP.
XX
AC ABF60991;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 160988 for detecting SNP TSC0040537.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 160988; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGGTTT 62
 DB 13 TTGAGGTTT 4

RESULT 336
 ABC74004 standard; DNA; 13 BP.
 ABC74004;
 21-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 74021 for detecting SNP TSC0019042.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.

WO200177384-A2.

18-OCT-2001.

06-APR-2001; 2001WO-IB000713.

07-APR-2000; 2000DE-01019173.

(EPIG-) EPIGENOMICS AG.

Olek A, Piepenbrock C, Berlin K;
 WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is designed to detect single-nucleotide polymorphisms and cytosine methylation status.

Claim 1; SEQ ID NO 74021; 29bp + Sequence Listing; German.

This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The oligonucleotides are used for diagnosis and/or prognosis of cancer and a range of diseases including immune system, gastrointestinal, respiratory, central nervous system, cardiovascular and metabolic disorders. The oligomers are also used for detecting cell type differentiation. ABC00010 -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989 represent the oligomers described in the invention. NOTE: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format from WIPO at ftp.wipo.int/pub/published_pct_sequences

Sequence 13 BP; 1 A; 0 C; 10 G; 1 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

OY 49 GGGGTTGAGGT 60
 DB 2 GGGGTTGAGGY 13

RESULT 337
 ABF02806 standard; DNA; 13 BP.
 ABF02806;
 21-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 102803 for detecting SNP TSC0025690.
 XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.
 XX Claim 1; SEQ ID NO 102803; 29bp + Sequence Listing; German.
 XX This invention describes novel oligonucleotide primers or peptide nucleic
 XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 XX and cytosine methylation status in chemically pretreated genomic DNA. The
 XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 XX range of diseases including immune system, gastrointestinal, respiratory,
 XX central nervous system, cardiovascular and metabolic disorders. The
 XX oligomers are also used for detecting cell type differentiation. ABC00010
 XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT99989
 XX represent the oligomers described in the invention. NOTE: The sequence
 XX data for this patent did not form part of the printed specification, but
 XX was obtained in electronic format from WIPO at
 XX ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 53 TTGAGGTTT 62
 DB 2 TTGAGGTTT 11

RESULT 338
 ABF14905/c
 ID ABF14905 standard; DNA; 13 BP.
 ABF14905;
 21-FEB-2002 (first entry)

Oligonucleotide SEQ ID NO 114902 for detecting SNP TS00028776.

SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; central nervous system; gastrointestinal; respiratory; immune; metabolic.

Homo sapiens.

WO200177384-A2.

18-OCT-2001.

PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 114902; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 51 GGTGGAGGT 60
DB 11 GGTGGAGGT 2
XX
RESULT 339
ABCI6840
ID ABCI6840 standard; DNA; 13 BP.
XX
AC ABCI6840;
XX
DN 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 16847 for detecting SNP TSC0003657.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 16847; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
XX
Query Match 15.4%; Score 10; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 53 TTGAGGTTT 62
DB 1 TTGAGGTTT 10
XX
RESULT 340
ABH27161/C
ID ABH27161 standard; DNA; 13 BP.
XX
AC ABH27161;
XX
DN 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 227138 for detecting SNP TSC0055396.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-1B000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 227138; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

SO Sequence 13 BP; 7 A; 5 C; 0 G; 0 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 52 GTTGAGGTTTC 63
 |||||
 DB 12 GTTGAGGTTT 1

RESULT 341

ABH27162
 ID ABH27162 standard; DNA; 13 BP.

AC ABH27162;

XX 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 227139 for detecting SNP TSC0055396.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 227139; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 0 A; 1 C; 5 G; 6 T; 0 U; 1 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 83.3%; Pred. No. 2.3e+02;
 Matches 10; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 52 GTTGAGGTTTC 63
 |||||
 DB 2 GTTGAGGTTT 13

RESULT 342
 ABF52056
 ID ABF52056 standard; DNA; 13 BP.

AC ABF52056;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 152053 for detecting SNP TSC0038422.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 152053; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI02073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 15.4%; Score 10; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 53 TTGAGGTTT 62
 |||||
 DB 2 TTGAGGTTT 11

RESULT 343

ABZ58187
 ID ABZ58187 standard; DNA; 13 BP.

AC ABZ58187;

XX 22-APR-2003 (first entry)

DE Thrombin binding aptamer.

XX Thrombin; blood clotting; thrombosis; thrombolytic; anticoagulant;
 KM cerebroprotective; cardiac; antiinflammatory; gene therapy; aptamer; ss.

```
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT misc_difference 7
XX PT /*tag= a
XX /note= "N represents a sequence of 2-5 nucleotides"
XX PN WO2003002592-A1.
XX PD 09-JAN-2003.
XX PF 28-JUN-2002; 2002WO-AU000853.
XX PR 29-JUN-2001; 2001AU-00006041.
XX PA (UNIX ) UNISEARCH LTD.
XX PI King GC;
XX PS WPI; 2003-210238/20.
XX DR
XX PT New aptamer for treating and/or preventing thrombosis, stroke, myocardial
XX PT infarction, respiratory failure, inflammation, cancer or neural disease,
XX PT comprises a circular oligonucleotide defining one to four target binding
XX PT regions.
XX PS Disclosure; Page 3; 55pp; English.
XX CC The present sequence is an example of a known thrombin binding aptamer
XX CC used as an antithrombotic agent. The invention relates to novel cyclic
XX CC thrombin inhibitor aptamers (see AB258178-85) that include thrombin
XX CC binding quadruplex regions (see AB258177). These aptamers are generally
XX CC better inhibitors of thrombin in serum than their linear counterparts,
XX CC show improved stability in serum and are more stable to nuclease. They
XX CC are used in claimed methods of treating thrombosis, of preventing or
XX CC reducing coagulation of blood or blood-derived products, and of capturing
XX CC leucocytes from a physiological fluid. They can also be used to prevent
XX CC thrombosis, to prevent and/or treat stroke, myocardial infarction,
XX CC respiratory failure, inflammatory disorders, cancer or its metastasis and
XX CC neural disease, and in conjunction with tissue and/or organ transplants
XX CC and/or xenotransplants, particularly in relation to vascular grafts
XX CC
XX SQ Sequence 13 BP; 0 A; 0 C; 8 G; 4 T; 0 U; 1 Other;
XX
XX Query Match 15.4%; Score 10; DB 1; Length 13;
XX Best Local Similarity 90.9%; Pred. No.2.3e+02;
XX Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 51 GGTGGAGGTT 61
XX |||||
XX 1 GGTGGAGGTT 11
XX
XX DB
XX
XX RESULT 344
XX AAD19397
XX ID AAD19397 standard; DNA; 13 BP.
XX
XX AC AAD19397;
XX
XX DT 18-DEC-2001 (first entry)
XX
XX DE Partial pRSETC-NFIL6 vector #2 to construct mutated C/EBPbeta-1 vector.
XX
XX CC CCAAT/enhancer binding protein; C/EBPbeta; transcription factor;
XX CC interleukin; IL; p20; inflammation; adult respiratory distress syndrome;
XX CC allergic rhinitis; arthritis; bronchitis; bronchopulmonary dysplasia;
XX CC cystic fibrosis; extensive allergic alveolitis; anti-inflammatory;
XX CC idiopathic pulmonary fibrosis; interstitial lung disease; anti-allergic;
XX CC inflammatory bowel disease; respiratory viral infection; anti-arthritis;
XX CC anti-asthma; intestinal; antiviral; ds.
XX
XX OS Unidentified.
```

```
XX PN WO200160320-A2.
XX PD 23-AUG-2001.
XX PF 20-FEB-2001; 2001WO-US005578.
XX PR 18-FEB-2000; 2000US-0183584P.
XX PA (UYVA-) UNIV VANDERBILT.
XX PI Brigham XL, Stecenko AA, Sealy L;
XX PS WPI; 2001-581897/65.
XX DR
XX PT Treating inflammation, particularly of the lung, by increasing activity
XX PT of p20, the beta3-isoform of CCAAT/enhancer binding protein.
XX PS Example 6; Fig 11D; 20pp; English.
XX CC The present sequence is a partial pRSETC-NFIL6 vector which is used for
XX CC constructing epitope tagged CCAAT/Enhancer Binding Protein (C/EBP) beta-1
XX CC retroviral vector with a mutation in the C/EBPbeta-2 translation
XX CC initiation site. The C/EBPbeta is a transcription factor which is
XX CC identified as being critical for maximal interleukin (IL)-6 and IL-8
XX CC expression. The isoforms of C/EBPbeta are C/EBPbeta-1, C/EBPbeta-2 and
XX CC C/EBPbeta-3 (referred as p20). The p20 isoform of C/EBPbeta is useful for
XX CC treating inflammation, adult respiratory distress syndrome, allergic
XX CC rhinitis, arthritis, bronchitis, bronchopulmonary dysplasia, cystic
XX CC fibrosis, extensive allergic alveolitis, idiopathic pulmonary fibrosis,
XX CC inflammatory bowel disease, interstitial lung disease and respiratory
XX CC viral infection
XX
XX SQ Sequence 13 BP; 4 A; 2 C; 5 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No.2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 9 ATGCAATTGACA 21
XX |||||
XX 1 ATGCAATTGACCA 13
XX
XX DB
XX
XX RESULT 345
XX ABR05600
XX ID ABR05600 standard; DNA; 13 BP.
XX
XX AC ABR05600;
XX
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 105597 for detecting SNP TSC0026469.
XX
XX CC SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX CC peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX CC central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX PS WPI; 2001-657177/75.
XX DR
```

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 105597; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGAGGTT 61
DB 1 GGAGTTGAGGTT 13
XX
RESULT 346
ABC06574
ID ABC06574 standard; DNA; 13 BP.
XX
AC ABC06574;
XX
DT 20-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 6565 for detecting SNP TSC0002008.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 6565; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 11 A; 0 C; 2 G; 0 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 29 AGAAGGAGAGAA 41
DB 1 AAAAGGAGAGAA 13
XX
RESULT 347
ABC63815
ID ABC63815 standard; DNA; 13 BP.
XX
AC ABC63815;
XX
DT 21-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 63832 for detecting SNP TSC0016855.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPig-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 63832; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 10 A; 3 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY      26 CCAAGACGAGAA 38
      ||| ||| |||
DB      1 CCAAAAACAAAA 13

RESULT 348
ABF16688
ID      ABF16688 standard; DNA; 13 BP.
XX
AC      ABF16688;
XX
DT      21-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 116685 for detecting SNP TSC0029195.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 116685; 29bp + Sequence Listing; German.
XX
SQ      This invention describes novel oligonucleotide primers or peptide nucleic
SQ      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 0 A; 1 C; 6 G; 6 T; 0 U; 0 Other;
XX
Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      44 TTGCTGGGTTGG 56
      ||| ||| |||
DB      1 TTGTTGGGTTGG 13

RESULT 349
ABF69512
ID      ABF69512 standard; DNA; 13 BP.
XX
AC      ABF69512;
XX
DT      22-FEB-2002 (first entry)
XX

```

```

DE      Oligonucleotide SEQ ID NO 169509 for detecting SNP TSC0042344.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 169509; 29bp + Sequence Listing; German.
XX
SQ      This invention describes novel oligonucleotide primers or peptide nucleic
SQ      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;
XX
Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY      49 GGGGTTGGAGGTT 61
      ||| ||| |||
DB      1 GGAGTTAGAGGTT 13

RESULT 350
ABF69513/C
ID      ABF69513 standard; DNA; 13 BP.
XX
AC      ABF69513;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 169510 for detecting SNP TSC0042344.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX

```

```

XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX Claim 1; SEQ ID NO 169510; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGTT 61
XX |||||
XX 13 GGAGTTAGAGGTT 1
XX
Db
XX
XX RESULT 351
XX ABH00238
XX ID ABH00238 standard; DNA; 13 BP.
XX
XX ABH00238;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 200215 for detecting SNP TSC0049265.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.

```

```

PS Claim 1; SEQ ID NO 200215; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 1 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 50 GGGTTCGAGGTTT 62
XX |||||
XX 1 GGGTTCGAGGTTT 13
XX
Db
XX
XX RESULT 352
XX ABC54295/c
XX ID ABC54295 standard; DNA; 13 BP.
XX
XX ABC54295;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SBQ ID NO 54312 for detecting SNP TSC0014910.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 54312; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at

```

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 49 GGGGTTGAGGTT 61
 DB 13 GAGGTCGAGGTT 1

RESULT 353
 ABF05602

ID ABF05602 standard; DNA; 13 BP.

AC ABF05602;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 105599 for detecting SNP TSC0026469.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 105599; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 1 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 49 GGGGTTGAGGTT 61
 DB 1 GGAGTCGAGGTT 13

RESULT 354

ABC31788

ID ABC31788 standard; DNA; 13 BP.

AC ABC31788;

DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 31805 for detecting SNP TSC0009913.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 31805; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 45 TGCTGGGCTTGA 57
 DB 1 TGTTGGGTTGA 13

RESULT 355

ABC11500

ID ABC11500 standard; DNA; 13 BP.

AC ABC11500;

DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 11499 for detecting SNP TSC0002800.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 11499; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ
SQ Sequence 13 BP; 0 A; 1 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 44 TTGCTGGGGTTGG 56
XX 1 TGCGGGGGTTGG 13
Db
RESULT 356
ABC1501/c
ID ABC1501 standard; DNA; 13 BP.
XX
XX ABC1501;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 11500 for detecting SNP TSC0002800.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX

PI Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 11500; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 44 TTGCTGGGGTTGG 56
XX 13 TGCGGGGGTTGG 1
Db
RESULT 357
ABC37879/c
ID ABC37879 standard; DNA; 13 BP.
XX
XX ABC37879;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 37896 for detecting SNP TSC0011764.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 37896; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The


```

XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 262539 for detecting SNP TSC0007733.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 262539; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB102073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 33 CAGAAAGACCTT 45
XX |||||
XX 13 CATTAACACCTT 1
XX
XX RESULT 361
XX ABC92815/C
XX ID ABC92815 standard; DNA; 13 BP.
XX
XX ABC92815;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 92832 for detecting SNP TSC0023215.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX
XX

```

```

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 92832; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AB100010-AB102073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 50 GGGTTGAGGCTT 62
XX |||||
XX 13 GGGTAGAGGCTT 1
XX
XX RESULT 362
XX ABC75155
XX ID ABC75155 standard; DNA; 13 BP.
XX
XX ABC75155;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 75172 for detecting SNP TSC0019290.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX
XX
XX

```

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 75172; 29pp + Sequence Listing; German.

PS

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

QY

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 21 ATAGCCCAAGAAC 33
1 ATTAACCAATAC 13

RESULT 363

ABC58518
ID ABC58518 standard; DNA; 13 BP.

XX

AC ABC58518;

XX

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 58535 for detecting SNP TSC0015706.

XX

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX

OS Homo sapiens.

XX

XX MO200177384-A2.

XX

PD 18-OCT-2001.

XX

PF 06-APR-2001; 2001WO-IB000713.

XX

FR 07-APR-2000; 2000DE-01019173.

XX

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX

XX WPI; 2001-657177/75.

XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX

PS Claim 1; SEQ ID NO 58535; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX

Query Match	Best Local Similarity	Score	DB 1	Length
Matches 11; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;
1 TTTCTGGAGATGA	13	11	11	11
1 TTTTGGAGTGA	13	11	11	11
Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;				
Query Match	Best Local Similarity	Score	DB 1	Length
Matches 11; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;
1 TTTCTGGAGATGA	13	11	11	11
1 TTTTGGAGTGA	13	11	11	11
Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;				
Query Match	Best Local Similarity	Score	DB 1	Length
Matches 11; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0;
1 TTTCTGGAGATGA	13	11	11	11
1 TTTTGGAGTGA	13	11	11	11
Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;				

```

Db      13 GCGTAGGAGCTGT 1
RESULT 365
ID      ABF35262
XX      ABF35262 standard; DNA; 13 BP.
XX      ABF35262;
AC      ABF35262;
XX      21-FEB-2002 (first entry)
XX      Oligonucleotide SEQ ID NO 135259 for detecting SNP TSC0033738.
DE      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIC-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX      Claim 1; SEQ ID NO 135259; 29pp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY      52 GTTGAGGTTTCA 64
      |||||
      1 GTTAGGAGTTTTA 13
Db
RESULT 366
ID      ABF39902
XX      ABF39902 standard; DNA; 13 BP.
XX      ABF39902;
AC      ABF39902;
XX      21-FEB-2002 (first entry)
XX      Oligonucleotide SEQ ID NO 139899 for detecting SNP TSC0035033.
XX

```

```

KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX      (EPIC-) EPIGENOMICS AG.
XX      Olek A, Piepenbrock C, Berlin K;
XX      WPI; 2001-657177/75.
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX      Claim 1; SEQ ID NO 139899; 29pp + Sequence Listing; German.
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX      Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;
SQ
Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY      48 TTGGGTTGAGCT 60
      |||||
      1 TTGGGTTGAGCT 13
Db
RESULT 367
ID      ABH33027/C
XX      ABH33027 standard; DNA; 13 BP.
XX      ABH33027;
AC      ABH33027;
XX      22-FEB-2002 (first entry)
XX      Oligonucleotide SEQ ID NO 233004 for detecting SNP TSC0056853.
DE      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX      Homo sapiens.
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      07-APR-2000; 2000DE-01019173.
XX

```

XX (EPIC-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 233004; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 46 GCTGGGGTTTGAG 58
 Db 13 GTTGGGGTTTGAG 1
 RESULT 368
 ABH10963/c
 ID ABH10963 standard; DNA; 13 BP.
 XX
 AC ABH10963;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 210940 for detecting SNP TSC0051481.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 210940; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 46 GCTGGGGTTTGAG 58
 Db 13 GTTGGGGTTTGAG 1
 RESULT 369
 ABH38624
 ID ABH38624 standard; DNA; 13 BP.
 XX
 AC ABH38624;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 238601 for detecting SNP TSC0001527.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 238601; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

```

SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 5 TGGATGGAATTG 17
DB 1 TGGAGGGAATTG 13

RESULT 370
ABH15566
ID ABH15566 standard; DNA; 13 BP.
XX
XX ABH15566;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 215543 for detecting SNP TSC0052427.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WPI; 2001-657177/75.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX claim 1; SEQ ID NO 215543; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 6 GGAATGGAATTG 18
DB 1 GGAATGCTTTGG 13

RESULT 371
ABH41660/c
```

```

ID ABH41660 standard; DNA; 13 BP.
XX
XX ABH41660;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 241637 for detecting SNP TSC0058921.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WPI; 2001-657177/75.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX claim 1; SEQ ID NO 241637; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and AEI00010-AEI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 32 ACAGAGAAGACCT 44
DB 13 ACATATAATACCT 1

RESULT 372
ABH42926
ID ABH42926 standard; DNA; 13 BP.
XX
XX ABH42926;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 242903 for detecting SNP TSC0000706.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
```

```

XX  WO200177384-A2.
PN  18-OCT-2001.
XX  06-APR-2001; 2001WO-IB000713.
PD  07-APR-2000; 2000DE-01019173.
XX  (EPIC-) EPIGENOMICS AG.
XX  Olek A, Piepenbrock C, Berlin K;
PI  WPI; 2001-657177/75.
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX  Claim 1; SEQ ID NO 242903; 29pp + Sequence Listing; German.
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences

SQ  Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  49 GGGGTTGGAGGTT 61
Db 1 GGGGATGGAGCTT 13

RESULT 373
ID ABH62128/c
AC ABH62128 standard; DNA; 13 BP.
XX ABH62128;
AC 22-FEB-2002 (first entry)
DT 22-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 262105 for detecting SNP TSC0063595.
DE Oligonucleotide SEQ ID NO 262105 for detecting SNP TSC0063595.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI
XX

```

```

DR  WPI; 2001-657177/75.
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX  Claim 1; SEQ ID NO 262105; 29pp + Sequence Listing; German.
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences

SQ  Sequence 13 BP; 0 A; 0 C; 5 G; 8 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  26 CCAGACACGAAA 38
Db 13 CCAGACACGAAA 1

RESULT 374
ID ABC71135
AC ABC71135 standard; DNA; 13 BP.
XX ABC71135;
AC 21-FEB-2002 (first entry)
DT 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 71152 for detecting SNP TSC0018445.
DE Oligonucleotide SEQ ID NO 71152 for detecting SNP TSC0018445.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPIC-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX Claim 1; SEQ ID NO 71152; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,

```

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF05603, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SO Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 36 AAGAACTTGCT 48
 |||||
 DB 1 AAAAACCTTACT 13

RESULT 375

ABC52081
 ID ABC52081 standard; DNA; 13 BP.

AC ABC52081;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 52098 for detecting SNP TSC0014495.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIDENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 52098; 29pp + Sequence Listing; German.

XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SO Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 20 CATAGCCCAAGAA 32
 |||||
 DB 1 CATAGCCCAATGA 13

RESULT 376

ABF05603/c
 ID ABF05603 standard; DNA; 13 BP.

AC ABF05603;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 105600 for detecting SNP TSC0026469.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

OS

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIC-) EPIDENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 105600; 29pp + Sequence Listing; German.

XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABH00010-ABH82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SO Sequence 13 BP; 4 A; 6 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 49 GGGGTTGAGGTT 61
 |||||
 DB 13 GGAGTTCGAGGTT 1

RESULT 377

ABC06244/c
 ID ABC06244 standard; DNA; 13 BP.

AC ABC06244;

DT 20-FEB-2002 (first entry)

```

XX  Oligonucleotide SEQ ID NO 6235 for detecting SNP TSC0001951.
DE
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIG-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K,
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 6235; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 13 BP; 0 A; 0 C; 4 G; 9 T; 0 U; 0 Other:
SQ
XX
XX  Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX  Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX  Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 25 CCCAGAACAGAA 37
Db 13 CCCAAAAACAAA 1
XX
XX  RESULT 378
XX  ABF07731/c
XX  ID ABF07731 standard; DNA; 13 BP.
XX
XX  ABF07731;
XX
XX  21-FEB-2002 (first entry)
XX
XX  Oligonucleotide SEQ ID NO 107728 for detecting SNP TSC0026974.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX
XX

```

```

PF 06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIG-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K,
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX
XX  Claim 1; SEQ ID NO 107728; 29pp + Sequence Listing; German.
XX
XX  This invention describes novel oligonucleotide primers or peptide nucleic
CC  acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC  and cytosine methylation status in chemically pretreated genomic DNA. The
CC  oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC  range of diseases including immune system, gastrointestinal, respiratory,
CC  central nervous system, cardiovascular and metabolic disorders. The
CC  oligomers are also used for detecting cell type differentiation. ABC00010
CC  -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC  represent the oligomers described in the invention. NOTE: The sequence
CC  data for this patent did not form part of the printed specification, but
CC  was obtained in electronic format from WIPO at
CC  ftp.wipo.int/pub/published_pct_sequences
XX
XX  Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX  Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX  Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 49 GGGGTTGAGGTT 61
Db 13 GGGTTGAGGTT 1
XX
XX  RESULT 379
XX  ABC10826
XX  ID ABC10826 standard; DNA; 13 BP.
XX
XX  ABC10826;
XX
XX  20-FEB-2002 (first entry)
XX
XX  Oligonucleotide SEQ ID NO 10817 for detecting SNP TSC0002699.
XX
XX  SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW  peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW  central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX  Homo sapiens.
XX
XX  WO200177384-A2.
XX
XX  18-OCT-2001.
XX
XX  06-APR-2001; 2001WO-IB000713.
XX
XX  07-APR-2000; 2000DE-01019173.
XX
XX  (EPIG-) EPIGENOMICS AG.
XX
XX  Olek A, Piepenbrock C, Berlin K,
XX
XX  WPI; 2001-657177/75.
XX
XX  Set of oligonucleotides, useful for diagnosis and cell typing, is
PT  designed to detect single-nucleotide polymorphisms and cytosine
PT  methylation status.
XX

```


XX Claim 1; SEQ ID NO 10817; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) and cytosine methylation status in chemically pretreated genomic DNA. The CC
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC
CC range of diseases including immune system, gastrointestinal, respiratory, CC
CC central nervous system, cardiovascular and metabolic disorders. The CC
CC oligomers are also used for detecting cell type differentiation. ABC00010 CC
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC
CC represent the oligomers described in the invention. NOTE: The sequence CC
CC data for this patent did not form part of the printed specification, but CC
CC was obtained in electronic format from WIPO at CC
CC ftp.wipo.int/pub/published_pct_sequences CC
XX
SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 44 TTGCTGGGGTTGG 56
DB 1 TTGCTGGGGTTGG 13
RESULT 380
ABC11400
ID ABC11400 standard; DNA; 13 BP.
XX
XX ABC11400;
AC
XX
DT 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 11399 for detecting SNP TSC0002788.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; CC
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; CC
XX central nervous system; gastrointestinal; respiratory; immune; metabolic. CC
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is CC
XX designed to detect single-nucleotide polymorphisms and cytosine CC
XX methylation status.
XX
XX
PS Claim 1; SEQ ID NO 11399; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic CC
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) CC
XX and cytosine methylation status in chemically pretreated genomic DNA. The CC
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC
XX range of diseases including immune system, gastrointestinal, respiratory, CC
XX central nervous system, cardiovascular and metabolic disorders. The CC
XX oligomers are also used for detecting cell type differentiation. ABC00010 CC
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC
XX represent the oligomers described in the invention. NOTE: The sequence CC
XX data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 50 GGGTTGGAGGTTT 62
DB 1 GGGTTGGAGGTTT 13
RESULT 381
ABF16686
ID ABF16686 standard; DNA; 13 BP.
XX
XX ABF16686;
AC
XX
DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 116683 for detecting SNP TSC0029195.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS; CC
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss; CC
XX central nervous system; gastrointestinal; respiratory; immune; metabolic. CC
XX Homo sapiens.
XX
XX MO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is CC
XX designed to detect single-nucleotide polymorphisms and cytosine CC
XX methylation status.
XX
XX
PS Claim 1; SEQ ID NO 116683; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic CC
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP) CC
XX and cytosine methylation status in chemically pretreated genomic DNA. The CC
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a CC
XX range of diseases including immune system, gastrointestinal, respiratory, CC
XX central nervous system, cardiovascular and metabolic disorders. The CC
XX oligomers are also used for detecting cell type differentiation. ABC00010 CC
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073 CC
XX represent the oligomers described in the invention. NOTE: The sequence CC
XX data for this patent did not form part of the printed specification, but CC
XX was obtained in electronic format from WIPO at CC
XX ftp.wipo.int/pub/published_pct_sequences CC
XX
SQ Sequence 13 BP; 0 A; 0 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 44 TTGCTGGGGTTGG 56
DB 1 TTGCTGGGGTTGG 13

RESULT 382
ABF20476
ID ABF20476 standard; DNA; 13 BP.
XX
XX
AC ABF20476;
XX
XX
DT 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 120473 for detecting SNP TSC0030069.
XX
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS
XX Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PS (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 120473; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 7 GAATGGAATTGGA 19
XX ||||| |||||
XX 1 GAATGTAATGGA 13
XX
XX Db
XX
XX RESULT 383
XX ABF39903/c
XX ID ABF39903 standard; DNA; 13 BP.
XX
XX AC ABF39903;
XX
XX OS
XX DT 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 139900 for detecting SNP TSC00305033.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX

KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PS (EPIC-) EPIGENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
PS Claim 1; SEQ ID NO 139900; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 48 TGGCGTTGAGCT 60
XX ||||| |||||
XX 13 TTGGCTTGTAGCT 1
XX
XX Db
XX
XX RESULT 384
XX ABF67880
XX ID ABF67880 standard; DNA; 13 BP.
XX
XX AC ABF67880;
XX
XX OS
XX DT 22-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 167877 for detecting SNP TSC0006909.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX
XX PN WO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PS (EPIC-) EPIGENOMICS AG.
XX

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 167877; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 0 A; 0 C; 7 G; 6 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 44 TTGCTGGGGTTGG 56
 Db 1 TTGCTGGGGTTGG 13
 RESULT 385
 ABF98316
 ID ABF98316 standard; DNA; 13 BP.
 AC ABF98316;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 198313 for detecting SNP TSC0048804.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 198313; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 0 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 5 TGGATGGAATTG 17
 Db 1 TGGATGGAATTG 13
 RESULT 386
 ABF98317/C
 ID ABF98317 standard; DNA; 13 BP.
 AC ABF98317;
 XX
 DT 22-FEB-2002 (first entry)
 DE Oligonucleotide SEQ ID NO 198314 for detecting SNP TSC0048804.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001WO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 XX
 XX (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1; SEQ ID NO 198314; 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 TGAATGGAATTG 17
Db 13 TGAATGGAATTG 1
RESULT 387
ABH29613/c
ID ABH29613 standard; DNA; 13 BP.
AC ABH29613;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 229590 for detecting SNP TSC0055987.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 229590; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 4 A; 5 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 TGAATGGAATTG 17
Db 13 TGAATGGAATTG 1
RESULT 388
ABH57829/c
ID ABH57829 standard; DNA; 13 BP.
XX

AC ABH57829;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 257806 for detecting SNP TSC0062709.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 257806; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 50 GGATTGAGGTTT 62
Db 13 GGATTGAGGTTT 1
RESULT 389
ABH62563
ID ABH62563 standard; DNA; 13 BP.
XX
XX ABH62563;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 262540 for detecting SNP TSC0007733.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX

```

XX 18-OCT-2001.
PD 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR WPI; 2001-657177/75.
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 262540; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 33 CAGAAAGAACCTT 45
   |||||
Db 1 CATMAACAACCTT 13

RESULT 390
ABC44907/c
ID ABC44907 standard; DNA; 13 BP.
XX
AC ABC44907;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 44924 for detecting SNP TSC0013136.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR WPI; 2001-657177/75.

```

```

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 44924; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 2 C; 0 G; 11 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 AGAACGAAAGAA 41
   |||||
Db 13 AGAAAGAAAGAA 1

RESULT 391
ABC71134/c
ID ABC71134 standard; DNA; 13 BP.
XX
AC ABC71134;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 71151 for detecting SNP TSC0018445.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
DR WPI; 2001-657177/75.
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX Claim 1; SEQ ID NO 71151; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010

```

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 36 AAGAACCTTCT 48
DB 13 AAAAACTTACT 1

RESULT 392

ABC52080/C ID ABC52080 standard; DNA; 13 BP.

XX ABC52080;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 52097 for detecting SNP TSC0014495.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-1B000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 52097; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 20 CATAGCCCAAGAA 32

DB 13 CATAGCCCAATAA 1

RESULT 393

ABF04649/C ID ABF04649 standard; DNA; 13 BP.

XX ABF04649;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 104646 for detecting SNP TSC0026161.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-1B000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 104646; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 6 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 50 GCGTTGAGGTTT 62
DB 13 GCGTTGAGGTTT 1

RESULT 394

ABF07729/C ID ABF07729 standard; DNA; 13 BP.

XX ABF07729;

XX 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 107726 for detecting SNP TSC0026974.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 107726; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 QY Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 Db 49 GGGGTTGGAGGTT 61
 |||||
 13 GGGTTTGAAGTT 1
 XXXX
 RESULT 395
 ABC10827/c
 ID ABC10827 standard; DNA; 13 BP.
 XX
 AC ABC10827;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 10818 for detecting SNP TSC0002699.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX

PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 10818; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 QY Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 Db 44 TTGCTGGGGTTGG 56
 |||||
 13 TTGTAGGGGTTGG 1
 XXXX
 RESULT 396
 ABC16849/c
 ID ABC16849 standard; DNA; 13 BP.
 XX
 AC ABC16849;
 XX
 DT 20-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 16856 for detecting SNP TSC0003661.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 DE 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 16856; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 0 A; 2 C; 0 G; 11 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 28 AAGAACAGAAAGA 40
|||
Db 13 AAAAAAGAAAGA 1

RESULT 397
ABF32796/C
ID ABF32796 standard; DNA; 13 BP.

AC ABF32796;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 132793 for detecting SNP TSC0033116.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 132793; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 2 A; 0 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 33 CAGAAAGAACTT 45
|||
Db 13 CAAAAAAACTT 1

RESULT 398
ABF32797
ID ABF32797 standard; DNA; 13 BP.

AC ABF32797;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 132794 for detecting SNP TSC0033116.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 132794; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 13 BP; 8 A; 3 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 33 CAGAAAGAACTT 45
|||
Db 1 CAAAAAAACTT 13

RESULT 399


```

ABF47357/c
ID ABF47357 standard; DNA; 13 BP.
XX
AC ABF47357;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 147354 for detecting SNP TSC0037222.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 147354; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 7 A; 5 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 52 GTTGAGGTTTCA 64
Db 13 GTTGAGGTTTCA 1
XX
RESULT 400
ABF73692
ID ABF73692 standard; DNA; 13 BP.
XX
AC ABF73692;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 173689 for detecting SNP TSC0043258.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 173689; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 8 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 6 GGAATGGAATTGC 18
Db 1 GGAATGGAATTGC 13
XX
RESULT 401
ABH33542
ID ABH33542 standard; DNA; 13 BP.
XX
AC ABH33542;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 233519 for detecting SNP TSC0010037.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIDENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

```
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 23519; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
XX
XX      Query Match      15.1%; Score 9.8; DB 1; Length 13;
XX      Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX      Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY      10 TCGAATTGCACAT 22
XX      |||||
XX      1 TGTAAATTCGAAT 13
XX
XX      RESULT 402
XX      ID ABF58451/C
XX      ABF58451 standard; DNA; 13 BP.
XX
XX      ABF58451;
XX
XX      21-FEB-2002 (first entry)
XX
XX      Oligonucleotide SEQ ID NO 158448 for detecting SNP TSC0039892.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 158448; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
```

```
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match      15.1%; Score 9.8; DB 1; Length 13;
XX      Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX      Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY      50 GGGTTGAGGTTT 62
XX      |||||
XX      13 GGGTTGAAAGTTT 1
XX
XX      RESULT 403
XX      ID ABH34278
XX      ABH34278 standard; DNA; 13 BP.
XX
XX      ABH34278;
XX
XX      22-FEB-2002 (first entry)
XX
XX      Oligonucleotide SEQ ID NO 234255 for detecting SNP TSC0057164.
XX
XX      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX      Homo sapiens.
XX
XX      WO200177384-A2.
XX
XX      18-OCT-2001.
XX
XX      06-APR-2001; 2001WO-IB000713.
XX
XX      07-APR-2000; 2000DE-01019173.
XX
XX      (EPIC-) EPIGENOMICS AG.
XX
XX      Olek A, Piepenbrock C, Berlin K;
XX
XX      WPI; 2001-657177/75.
XX
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
PT      methylation status.
XX
XX      Claim 1; SEQ ID NO 234255; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 U; 0 Other;
XX
XX      Query Match      15.1%; Score 9.8; DB 1; Length 13;
XX      Best Local Similarity 84.6%; Pred. No. 2.4e+02;
```

```

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 49 GCGGTTGAGGTT 61
   |||||
Db 1 GAGGTTGGGGTT 13

RESULT 404
ABF6466
ID ABF6466 standard; DNA; 13 BP.
XX
AC ABF6466;
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 186463 for detecting SNP TSC0045930.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 186463; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 0 C; 5 G; 0 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 28 AAGAACGAAAGA 40
   |||||
Db 1 AAGAAAGAGAAGA 13

RESULT 405
ABH16219/C
ID ABH16219 standard; DNA; 13 BP.
XX
AC ABH16219;
XX

```

```

DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 216196 for detecting SNP TSC0052577.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 216196; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 29 AAGAACGAAAGA 41
   |||||
Db 13 AAAATGAAAGAA 1

RESULT 406
ABH62129
ID ABH62129 standard; DNA; 13 BP.
XX
AC ABH62129;
XX
DT 22-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 262106 for detecting SNP TSC0063595.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX

```

```
XX 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 262106; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 8 A; 5 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 26 CCAAGAACAGAAA 38
DB 1 CCAACACACACAAA 13
XX
XX RESULT 407
XX ABC31789/c
XX ID ABC31789 standard; DNA; 13 BP.
XX AC ABC31789;
XX 20-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 31806 for detecting SNP TSC0009913.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
```

```
PT methylation status.
XX Claim 1; SEQ ID NO 31806; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 13 BP; 6 A; 6 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 45 TGCTGGCGTTTGA 57
DB 13 TGTTGGGTTTGA 1
XX
XX RESULT 408
XX ABF33180
XX ID ABF33180 standard; DNA; 13 BP.
XX AC ABF33180;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 133177 for detecting SNP TSC0033237.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB000713.
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 133177; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
```

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 8 G; 5 T; 0 U; 0 Other;
QY
Db 48 TGGGGTTGAGGT 60
1 TGGGTTGGGGGT 13
RESULT 409
ABF67881/c
ID ABF67881 standard; DNA; 13 BP.
XX
XX ABF67881;
AC
XX 22-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 167878 for detecting SNP TSC0006309.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-1B000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 167878; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 6 A; 7 C; 0 G; 0 T; 0 U; 0 Other;
QY
Db 44 TTGCTGGGCTTG 56
13 TTGCTGGGCTTG 1

RESULT 410
ABH04581/c
ID ABH04581 standard; DNA; 13 BP.
XX
XX ABH04581;
AC
XX 22-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 204558 for detecting SNP TSC0050176.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
PD
XX 06-APR-2001; 2001WO-1B000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 204558; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
QY
Db 2 TTCTGAATGAA 14
13 TTTTGAATGTA 1
RESULT 411
ABH05560
ID ABH05560 standard; DNA; 13 BP.
XX
XX ABH05560;
AC
XX 22-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 205537 for detecting SNP TSC0050381.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 205537; 29pp + Sequence listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 34 AGAAGAAGACCTTG 46
 |||||
 1 AGAAGAAGATTTG 13
 DB
 RESULT 412
 ABC74671/C
 ID ABC74671 standard; DNA; 13 BP.
 XX
 AC ABC74671;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 74688 for detecting SNP TSC0019191.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 74688; 29pp + Sequence listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 50 GGGTGGAGGTTT 62
 |||||
 13 GGTGTGAGGTTT 1
 DB
 RESULT 413
 ABF04647/C
 ID ABF04647 standard; DNA; 13 BP.
 XX
 AC ABF04647;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 104644 for detecting SNP TSC0026161.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 FN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 104644; 29pp + Sequence listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
CC
SQ Sequence 13 BP; 7 A; 6 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGGTTGAGAGTTT 62
||||| |||||
Db 13 GGGTTTGTGGTTT 1

RESULT 414
ABF07730
ID ABF07730 standard; DNA; 13 BP.
AC ABF07730;
XX
XX 21-FEB-2002 (first entry)
XX
XX
DE Oligonucleotide SEQ ID NO 107727 for detecting SNP TSC0026974.
XX
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; 95;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX MO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-1B000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI, 2001-657177/75.
DR
XX
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 107727; 29pp + Sequence Listing; German.
XX
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;

```

Query Match          15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      .      49 GGGGTTGGAGGTT 61
      ||| ||| ||| |||
      1 GGGTTTCGAGGTT 13

Db

RESULT 415
ABC34457/C
ID      ABC34457 standard; DNA; 13 BP.
XX
AC      ABC34457;
XX
DT      20-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 34474 for detecting SNP TSC0010991.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
XX      WO200177384-A2.
XX      18-OCT-2001.
XX      06-APR-2001; 2001WO-IB000713.
XX      PF
XX      07-APR-2000; 2000DE-01019173.
XX      PR
XX      (EPiG-) EPIGENOMICS AG.
PA      Olek A. Plepenbrock C, Berlin K;
PI      WPI: 2001-657177/75.
DR
XX      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cell cytosine
PT      methylation status.
XX
PS      Claim 1; SEQ ID NO 34474; 29pp + Sequence Listing; German.
XX
XX      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABJ00010-ABJ82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pat_sequences
CC
SQ      Sequence 13 BP; 0 A; 3 C; 0 G; 10 T; 0 U; 0 Other;

Query Match          15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      29 AGAACGAGAAAGAA 41
      ||| ||| ||| |||
      13 AAAAGAGAAAGAA 1

Db

RESULT 416
ABC60968
ID      ABC60968 standard; DNA; 13 BP.

```

```

XX AC ABC60968;
XX XX
DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 60985 for detecting SNP TSC0016246.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 60985; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGGTT 61
XX ||| ||| ||| |||
XX 1 GGAGGTGGAGGTT 13

RESULT 417
ID ABF20477 standard; DNA; 13 BP.
XX AC ABF20477;
XX XX
XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 120474 for detecting SNP TSC0030069.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX

```

```

EN WO200177384-A2.
XX XX
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 120474; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 13 BP; 3 A; 4 C; 0 G; 6 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 7 GAATGGAATTGGA 19
XX ||| ||| ||| |||
XX 13 GAATGTAATTGGA 1

RESULT 418
ID ABF22178 standard; DNA; 13 BP.
XX AC ABF22178;
XX XX
XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 122175 for detecting SNP TSC0030537.
XX XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX XX
XX WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-1B000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPiG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.

```


XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
PS Claim 1; SEQ ID NO 122175; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF39989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 5 TGGATGCAATTC 17
1 TTTGATTGCAATTC 13
XX
DB 1 TTTGATTGCAATTC 13
XX
RESULT 419
ABF32116
ID ABF32116 standard; DNA; 13 BP.
XX
AC ABF32116;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 132113 for detecting SNP TSC0032971.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 132113; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF39989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF39989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 5 TGGATGCAATTC 17
1 TTTGATTGCAATTC 13
XX
DB 1 TTTGATTGCAATTC 13
XX
RESULT 420
ABF39905/C
ID ABF39905 standard; DNA; 13 BP.
XX
AC ABF39905;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 139902 for detecting SNP TSC0035033.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 139902; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF39989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 6 C; 1 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

OY      48 TGGGTTGGAGT 60
      |||||
      13 TCGGTTGAGT 1

RESULT 421
ABF73693/C
ID      ABF73693 standard; DNA; 13 BP.
XX
AC      ABF73693;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 173690 for detecting SNP TSC0043258.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
PS      Claim 1; SEQ ID NO 173690; 29bp + Sequence listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 2 A; 8 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY      6 GGAAATGGAATTGG 18
      |||||
      13 GGAAAGGAGTTGG 1
DB
XX
RESULT 422
ABH33543/C
ID      ABH33543 standard; DNA; 13 BP.
XX
AC      ABH33543;
XX
DT      22-FEB-2002 (first entry)
XX

```

```

DE      Oligonucleotide SEQ ID NO 233520 for detecting SNP TSC0010037.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX
PR      07-APR-2000; 2000DE-01019173.
XX
PA      (EPIC-) EPIGENOMICS AG.
XX
PI      Olek A, Piepenbrock C, Berlin K;
XX
DR      WPI; 2001-657177/75.
XX
PT      Set of oligonucleotides, useful for diagnosis and cell typing, is
PT      designed to detect single-nucleotide polymorphisms and cytosine
XX      methylation status.
XX
PS      Claim 1; SEQ ID NO 233520; 29bp + Sequence listing; German.
XX
CC      This invention describes novel oligonucleotide primers or peptide nucleic
CC      acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC      and cytosine methylation status in chemically pretreated genomic DNA. The
CC      oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC      range of diseases including immune system, gastrointestinal, respiratory,
CC      central nervous system, cardiovascular and metabolic disorders. The
CC      oligomers are also used for detecting cell type differentiation. ABC00010
CC      -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC      represent the oligomers described in the invention. NOTE: The sequence
CC      data for this patent did not form part of the printed specification, but
CC      was obtained in electronic format from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 13 BP; 5 A; 3 C; 0 G; 5 T; 0 U; 0 Other;
XX
Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY      10 TGAATTGGACAT 22
      |||||
      13 TGAATTGGAAT 1
DB
XX
RESULT 423
ABH10962
ID      ABH10962 standard; DNA; 13 BP.
XX
AC      ABH10962;
XX
DT      22-FEB-2002 (first entry)
XX
DE      Oligonucleotide SEQ ID NO 210939 for detecting SNP TSC0051481.
XX
KW      SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW      peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW      central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS      Homo sapiens.
XX
PN      WO200177384-A2.
XX
PD      18-OCT-2001.
XX
PF      06-APR-2001; 2001WO-IB000713.
XX

```

```
XX 07-APR-2000; 2000DE-01019173.
PR (EPIC-) EPIGENOMICS AG.
PA Olek A, Piepenbrock C, Berlin K;
PI MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 210939; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 46 GCTGGGGTTGGAG 58
DB 1 GTTGGGGTTTGAG 13
XX
XX RESULT 424
XX ABF62973/c
XX ID ABF62973 standard; DNA; 13 BP.
XX
XX ABF62973;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 162970 for detecting SNP TSC0040972.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
```

```
PS Claim 1; SEQ ID NO 162970; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 4 C; 0 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 5 TGGAAATGGAATTG 17
DB 13 TGAATGGAATTG 1
XX
XX RESULT 425
XX ABH15571/c
XX ID ABH15571 standard; DNA; 13 BP.
XX
XX ABH15571;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 215548 for detecting SNP TSC0052427.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 215548; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
```

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 3 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 6 GGAATGGAATTGG 18
 DB 13 GGAATGCGCTTGG 1

RESULT 426

ABH44502
 ID ABH44502 standard; DNA; 13 BP.

AC ABH44502;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 244479 for detecting SNP TSC0053689.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO20017384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

CC Claim 1; SEQ ID NO 244479; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 9 A; 0 C; 4 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 28 AAGAACAGAAACA 40
 DB 1 AAGAAAGAAAGA 13

RESULT 427

ABH62561
 ID ABH62561 standard; DNA; 13 BP.

AC ABH62561;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 262538 for detecting SNP TSC000733.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX WO20017384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIG-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

CC Claim 1; SEQ ID NO 262538; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 33 CAGAAAGACCTT 45
 DB 1 CATTAATTAACCTT 13

RESULT 428

ABC73212
 ID ABC73212 standard; DNA; 13 BP.

AC ABC73212;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 73229 for detecting SNP TSC0018874.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX OS Homo sapiens.
XX XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIC-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI, 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 73229; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 49 GGGGTGAGGTT 61
Db 1 GGATTGTAGTT 13
RESULT 429
ABC01962
ID ABC01962 standard; DNA; 13 BP.
XX
XX ABC01962;
XX AC 20-FEB-2002 (first entry)
XX DT 20-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide SEQ ID NO 1953 for detecting SNP TSC0000769.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIC-) EPIGENOMICS AG.
XX PA
XX XX

```

```

PI Olek A, Piepenbrock C, Berlin K;
XX WPI, 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX PS Claim 1; SEQ ID NO 1953; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 50 GGGGTGAGGTT 62
Db 1 GGATTGTAGTT 13
RESULT 430
ABC60969/c
ID ABC60969 standard; DNA; 13 BP.
XX
XX ABC60969;
XX AC 21-FEB-2002 (first entry)
XX DT 21-FEB-2002 (first entry)
XX XX
XX DE Oligonucleotide SEQ ID NO 60986 for detecting SNP TSC0016246.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX OS Homo sapiens.
XX XX
XX XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD 06-APR-2001; 2001WO-IB000713.
XX PF 07-APR-2000; 2000DE-01019173.
XX PR (EPIC-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI WPI, 2001-657177/75.
XX DR Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PT
XX PS Claim 1; SEQ ID NO 60986; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC XX

SEQ Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 49 GGGGTGGAGGTT 61
Db 13 GGAGGTGGAGGTT 1

RESULT 431

ABC61676
ID ABC61676 standard; DNA; 13 BP.

XX
AC ABC61676;

XX
DT 21-FEB-2002 (first entry)

XX
DE Oligonucleotide SEQ ID NO 61693 for detecting SNP TSC0016406.

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.

XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.

XX
PF 06-APR-2001; 2001WO-IB000713.

XX
PR 07-APR-2000; 2000DE-01019173.

XX
PS (EPIC-) EPIDENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;

XX
DR WPI; 2001-657177/75.

XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 61693; 29bp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC XX

SEQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 50 GGGTGGAGGTT 62
Db 1 GGGTGGAGGTT 13

RESULT 432

ABF31799/c
ID ABF31799 standard; DNA; 13 BP.

XX
AC ABF31799;

XX
DT 21-FEB-2002 (first entry)

XX
DE Oligonucleotide SEQ ID NO 131796 for detecting SNP TSC0032899.

XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX
OS Homo sapiens.

XX
PN WO200177384-A2.

XX
PD 18-OCT-2001.

XX
PF 06-APR-2001; 2001WO-IB000713.

XX
PR 07-APR-2000; 2000DE-01019173.

XX
PS (EPIC-) EPIDENOMICS AG.

XX
PI Olek A, Piepenbrock C, Berlin K;

XX
DR WPI; 2001-657177/75.

XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX
PS Claim 1; SEQ ID NO 131796; 29bp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC XX

SEQ Sequence 13 BP; 1 A; 3 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 29 AGAATGAGAA 41
Db 13 AGAATGAGAA 1

RESULT 433

ABF32795
ID ABF32795 standard; DNA; 13 BP.

XX
AC ABF32795;

XX 21-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 132792 for detecting SNP TSC0033116.
XX
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 132792; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 33 CAGAAAGAACCTT 45
DB 1 CAATAACAACCTT 13
RESULT 434
ABH22410
ID ABH22410 standard; DNA; 13 BP.
XX
XX ABH22410;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 222387 for detecting SNP TSC0054107.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX

PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 222387; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 0 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 7 GAATGAAATTGCA 19
DB 1 GAATGAAATTGAA 13
RESULT 435
ABH05561/C
ID ABH05561 standard; DNA; 13 BP.
XX
XX ABH05561;
AC
XX
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 205538 for detecting SNP TSC0050381.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT

PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 205538; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 34 AGAAGACCTTG 46
13 AGAAGAAATTTTG 1
XX
Db 13 AGAAGAAATTTTG 1
XX
RESULT 436
ABH34279/c
ID ABH34279 standard; DNA; 13 BP.
XX
AC ABH34279;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 234256 for detecting SNP TSC0057164.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 234256; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGGTTGGAGGTT 61
13 GAGGTTGGGGGTT 1
XX
Db 13 GAGGTTGGGGGTT 1
XX
RESULT 437
ABH16293/c
ID ABH16293 standard; DNA; 13 BP.
XX
AC ABH16293;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 216270 for detecting SNP TSC0052602.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 216270; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 7 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 49 GGGGTTGGAGGTT 61
XX 13 GGGGTTGGAGGTT 61


```
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 99232; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 5 A; 7 C; 0 G; 1 T; 0 U; 0 Other;
SO
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 49 GGGCTTGAGGTT 61
XX |||||
XX 13 GGGATTGGTGGTT 1
XX
XX RESULT 441
XX ID ABF04646 standard; DNA; 13 BP.
XX AC ABF04646;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 104643 for detecting SNP TSC0026161.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 104643; 29pp + Sequence Listing; German.
XX
```

```
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 0 C; 6 G; 7 T; 0 U; 0 Other;
SO
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 50 GGGCTTGAGGTT 62
XX |||||
XX 1 GGGTTTGGTGGTT 13
XX
XX RESULT 442
XX ID ABC55719 standard; DNA; 13 BP.
XX AC ABC55719;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 55736 for detecting SNP TSC0015187.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 55736; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABP99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
```

SQL Sequence 13 BP; 8 A; 4 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 22 TAGCCCAAGACA 34
1 TAAACCAAAACA 13

RESULT 443
ABF09481/c
ID ABF09481 standard; DNA; 13 BP.

AC ABF09481;
DT 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 109478 for detecting SNP TSC0027391.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

XX Claim 1; SEQ ID NO 109478; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 48 TGGGTTGAGGT 60
13 TGAAGTTGAGGT 1

RESULT 444
ABCI6848

ID ABCI6848 standard; DNA; 13 BP.

AC ABCI6848;
XX 20-FEB-2002 (first entry)
DT 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 16855 for detecting SNP TSC0003661.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 16855; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 11 A; 0 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACGAAGA 40
1 AAAAAAAGAAACA 13

RESULT 445
ABFI7417
ID ABFI7417 standard; DNA; 13 BP.

AC ABFI7417;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 117414 for detecting SNP TSC0029372.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.

XX WO200177384-A2.
 PN 18-OCT-2001.
 XX
 PD 06-APR-2001; 2001WO-IB000713.
 XX
 PF 07-APR-2000; 2000DE-01019173.
 XX
 PR (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 117414; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 21 ATAGCCCAAGAAC 33
 Db 1 ATATCCCAAAAC 13
 XX
 RESULT 446
 ABF32117/C
 ID ABF32117 standard; DNA; 13 BP.
 XX
 AC ABF32117;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 132114 for detecting SNP TSC0032971.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PI (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI
 XX

DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 132114; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 5 TGGAAATGGAATTG 17
 Db 13 TTGAATGGAATTG 1
 XX
 RESULT 447
 ABH21397/C
 ID ABH21397 standard; DNA; 13 BP.
 XX
 AC ABH21397;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 221374 for detecting SNP TSC0053878.
 XX
 KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PI (EPIG-) EPIGENOMICS AG.
 PA Olek A, Piepenbrock C, Berlin K;
 PI
 XX
 DR WPI; 2001-657177/75.
 XX
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PS
 PS Claim 1; SEQ ID NO 221374; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC9989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 6 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GGAAATGGAATTG 18
 DB 13 GGAAAGGGAATTG 1

RESULT 448
 ABF75985/C
 ID ABF75985 standard; DNA; 13 BP.
 AC ABF75985;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 175982 for detecting SNP TSC0005690.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001MO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PS (EPIC-) EPIGENOMICS AG.
 PA (EPIC-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 175982; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 7 A; 6 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GCGTTGAGGTTT 62
 DB 13 GGTTCGTGGTTT 1

RESULT 449
 ABH38625/C
 ID ABH38625 standard; DNA; 13 BP.
 AC ABH38625;
 XX
 XX 22-FEB-2002 (first entry)
 DT
 XX
 DE Oligonucleotide SEQ ID NO 238602 for detecting SNP TSC0001527.
 XX
 XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 PF 06-APR-2001; 2001MO-IB000713.
 PR 07-APR-2000; 2000DE-01019173.
 PS (EPIC-) EPIGENOMICS AG.
 PA (EPIC-) EPIGENOMICS AG.
 PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 DR
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 PT
 XX
 PS Claim 1; SEQ ID NO 238602; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 CC
 SQ Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5 TGGAAATGGAATTG 17
 DB 13 TGGAGGGAATTG 1

RESULT 450
 ABC68819/C
 ID ABC68819 standard; DNA; 13 BP.
 AC ABC68819;
 XX
 XX 21-FEB-2002 (first entry)
 DT

XX Oligonucleotide SEQ ID NO 68836 for detecting SNP TSC0017929.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 68836; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 48 TGGGCTTGGAGGT 60
DB 13 TGGGCGGTGGGGGT 1
XX
RESULT 451
ABC44906
XX ABC44906 standard; DNA; 13 BP.
XX
XX ABC44906;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 44923 for detecting SNP TSC0013136.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX

PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 44923; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 11 A; 0 C; 2 G; 0 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 29 AGAACGAGAGAA 41
DB 1 AGAAGAGAGAGAA 13
XX
RESULT 452
ABC74670
XX ABC74670 standard; DNA; 13 BP.
XX
XX ABC74670;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 74687 for detecting SNP TSC0019191.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX

XX PS Claim 1; SEQ ID NO 74687; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 50 GGGTTGAGGTTT 62
XX |||||
XX 1 GGTGTGAGGTTT 13
XX
XX RESULT 453
XX ABF04648
XX ID ABF04648 standard; DNA; 13 BP.
XX
XX AC ABF04648;
XX
XX XX 21-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 104645 for detecting SNP TSC0026161.
XX
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN MO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIDENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 104645; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 0 A; 1 C; 6 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 50 GGGTTGAGGTTT 62
XX |||||
XX 1 GGGTTGAGGTTT 13
XX
XX RESULT 454
XX ABC05436
XX ID ABC05436 standard; DNA; 13 BP.
XX
XX AC ABC05436;
XX
XX XX 20-FEB-2002 (first entry)
XX
XX DE Oligonucleotide SEQ ID NO 5427 for detecting SNP TSC0001821.
XX
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX PN MO200177384-A2.
XX
XX PD 18-OCT-2001.
XX
XX PF 06-APR-2001; 2001WO-IB000713.
XX
XX PR 07-APR-2000; 2000DE-01019173.
XX
XX PA (EPIC-) EPIDENOMICS AG.
XX
XX PI Olek A, Piepenbrock C, Berlin K;
XX
XX DR WPI; 2001-657177/75.
XX
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX PS Claim 1; SEQ ID NO 5427; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 3 A; 0 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 49 GGGTTGAGGTTT 61
XX |||||
XX 1 GAGTTGAGGAT 13

```

RESULT 455
ABC05437/C
ID ABC05437 standard; DNA; 13 BP.
XX
AC ABC05437;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 5428 for detecting SNP TSC0001821.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 5428; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 49 GGGGTTGAGGTT 61
| | | | | | | | | |
Db 13 GAGGTTGAGGAT 1

```

```

XX
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 6566; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 2 C; 0 G; 11 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 29 AGACAGAAAGAA 41
| | | | | | | | | |
Db 13 AAAAAGAAAGAA 1

```


XX Olek A, Piepenbrock C, Berlin K;
 XX MPI, 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1, SEQ ID NO 58536, 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 1 TTTCTGGAATGGA 13
 Db 13 TTTTGGAGTGA 1
 RESULT 458
 ABF09480
 ID ABF09480 standard; DNA; 13 BP.
 AC ABF09480;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 109477 for detecting SNP TSC0027391.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX MPI, 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1, SEQ ID NO 109477, 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 48 TGGGCTTGGAGCT 60
 Db 1 TGAGCTTGAAGT 13
 RESULT 459
 ABF16689/c
 ID ABF16689 standard; DNA; 13 BP.
 AC ABF16689;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 116686 for detecting SNP TSC029195.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX MPI, 2001-657177/75.
 DR Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1, SEQ ID NO 116686, 29pp + Sequence Listing; German.
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 6 A; 6 C; 1 G; 0 T; 0 U; 0 Other;


```
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIC-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 173725; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 5 A; 0 C; 3 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2 TTCTGGAATGGA 14
XX 1 TTATGTAATGGA 13
DB
XX
XX RESULT 463
XX ABC92814
XX ID ABC92814 standard; DNA; 13 BP.
XX
XX ABC92814;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 92831 for detecting SNP TSC0023215.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX
```

```
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 92831; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX
XX Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 50 GCGTGGAGGTTT 62
XX 1 GGGTAGGAGGTT 13
DB
XX
XX RESULT 464
XX ABC20850
XX ID ABC20850 standard; DNA; 13 BP.
XX
XX ABC20850;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 20867 for detecting SNP TSC0004238.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status..
XX
XX Claim 1; SEQ ID NO 20867; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
```

CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQL Sequence 13 BP; 2 A; 0 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 48 TGCGGTTGAGGT 60
| | | | | | | | | | | | | | | | | |
Db 1 TAGGTTGATGT 13

RESULT 465
ABCT3225/C
ID ABC73225 standard; DNA; 13 BP.
XX
AC ABC73225;
XX

DT 21-FEB-2002 (first entry)
XX

DE Oligonucleotide SEQ ID NO 73242 for detecting SNP TSC0018875.
XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
XX

PN WO200177384-A2.
XX

PD 18-OCT-2001.
XX

PF 06-APR-2001; 2001WO-IB000713.
XX

PR 07-APR-2000; 2000DE-01019173.
XX

PA (EPig-) EPIGENOMICS AG.
XX

PI Olek A, Piepenbrock C, Berlin K;
XX

DR WPI; 2001-657177/5.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX

PS Claim 1; SEQ ID NO 73242; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQL Sequence 13 BP; 4 A; 8 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 46 GCTGGGTTTGAG 58

Db | | | | | | | | | | | | | | | | | |
13 GCTGGGTTTGAG 1

RESULT 466
ABF31798
ID ABF31798 standard; DNA; 13 BP.
XX
AC ABF31798;
XX

DT 21-FEB-2002 (first entry)
XX

DE Oligonucleotide SEQ ID NO 131795 for detecting SNP TSC0032899.
XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.
XX

PN WO200177384-A2.
XX

PD 18-OCT-2001.
XX

PF 06-APR-2001; 2001WO-IB000713.
XX

PR 07-APR-2000; 2000DE-01019173.
XX

PA (EPig-) EPIGENOMICS AG.
XX

PI Olek A, Piepenbrock C, Berlin K;
XX

DR WPI; 2001-657177/5.
XX

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single-nucleotide polymorphisms and cytosine
methylation status.
XX

PS Claim 1; SEQ ID NO 131795; 29pp + Sequence Listing; German.
XX

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SQL Sequence 13 BP; 8 A; 1 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 29 AGAACAGAAAGAA 41
| | | | | | | | | | | | | | | | | |
Db 1 AGAATCGAAGAA 13

RESULT 467
ABF32794/C
ID ABF32794 standard; DNA; 13 BP.
XX
AC ABF32794;
XX

DT 21-FEB-2002 (first entry)
XX

DE Oligonucleotide SEQ ID NO 132791 for detecting SNP TSC0033116.
XX

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 132791; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 33 CAGAAAGAACCTT 45
XX |||||
Db 13 CAAAAACAACTT 1
XX
RESULT 468
ABF33181/c
ID ABF33181 standard; DNA; 13 BP.
XX
AC ABF33181;
XX
XX 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 133178 for detecting SNP TSC003237.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX

PR 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 133178; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 8 C; 0 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 48 TGGGCTTGGAGGT 60
XX |||||
Db 13 TTGGCTTGGGCGGT 1
XX
RESULT 469
ABF75984
ID ABF75984 standard; DNA; 13 BP.
XX
AC ABF75984;
XX
XX 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 175981 for detecting SNP TSC0005690.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 175981; 29pp + Sequence Listing; German.
XX


```

ABF66699/c
ID ABF66699 standard; DNA; 13 BP.
XX
AC ABF66699;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 166696 for detecting SNP TSC0041746.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
PI Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 166696; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 1 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 29 AGAACGAGAGAA 41
DB 13 AGAATGAGAAAA 1
XX
RESULT 473
ABH57530
ID ABH57530 standard; DNA; 13 BP.
XX
AC ABH57530;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 257507 for detecting SNP TSC0005086.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX

```

```

OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 257507; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 0 C; 3 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 11 GGAATTGACATA 23
DB 1 GGAATTGATATA 13
XX
RESULT 474
ABC75154/c
ID ABC75154 standard; DNA; 13 BP.
XX
AC ABC75154;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 75171 for detecting SNP TSC0019290.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
PI Homo sapiens.
OS
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX

```

XX WPI, 2001-657177/75.
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 75171; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABR00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the invention. NOTE: The sequence
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 21 ATAGCCCAAGAAC 33
Db 13 ATAACCAATAAC 1

RESULT 475
ABF05601/c
ID ABR05601 standard; DNA, 13 BP.
XX
XX ABR05601;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 105598 for detecting SNP TSC0026469.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; cancer; CNS;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN 18-OCT-2001.
XX
XX PD 06-APR-2001; 2001WO-IB000713.
PF 07-APR-2000; 2000DE-01019173.
PR (EPIG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI WPI; 2001-657177/75.
DR
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX
PS Claim 1; SEQ ID NO 105598; 29bp + Sequence Listing; German.

CC	range of diseases including immune system, gastrointestinal, respiratory
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010-ABH9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
XX	
Query Match	15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity	84.6%; Pred. No. 2.4e+02;
Matches	11; Conservative 0; Mismatches 2; Indels 0; Gaps 0
OY	49 GGAGTTGGAGTTC 61 Db 13 GGAGTTTGAGGTT 1
RESULT 476	
ID	ABC5718 standard; DNA; 13 BP.
XX	
AC	ABC5718;
XX	
DT	21-FEB-2002 (first entry)
DE	Oligonucleotide SEQ ID NO 55735 for detecting SNP TSC0015187.
XX	
KW	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS	Homo sapiens.
PD	WO200177384-A2.
FN	18-OCT-2001.
PE	06-APR-2001; 2001MO-IBO00713.
PR	07-APR-2000; 2000DB-01019173.
PA	(EPIG-) EPIGENOMICS AG.
Pf	Olek A, Piepenbrock C, Berlin K;
XX	
WP	WIPI; 2001-657177/5.
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is
PT	designed to detect single-nucleotide polymorphisms and cytosine
XX	methylation status.
XS	
Claim 1; SEQ ID NO 55735; 29pp + Sequence Listing; German.	
CC	This invention describes novel oligonucleotide primers or peptide nucleic
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC	and cytosine methylation status in chemically pretreated genomic DNA. The
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC	range of diseases including immune system, gastrointestinal, respiratory,
CC	central nervous system, cardiovascular and metabolic disorders. The
CC	oligomers are also used for detecting cell type differentiation. ABC00010-
CC	-ABH9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
CC	represent the oligomers described in the invention. NOTE: The sequence
CC	data for this patent did not form part of the printed specification, but
CC	was obtained in electronic format from WIPO at
CC	ftp.wipo.int/pub/published_pct_sequences
SQ	Sequence 13 BP; 1 A; 0 C; 4 G; 8 T; 0 U; 0 Other;
XX	
Query Match	15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity	84.6%; Pred. No. 2.4e+02;


```

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 22 TAGCCCAAGACA 34
   |||||
Db 13 TAACCCAAAAACA 1

RESULT 477
ABF17416/C
ID ABF17416 standard; DNA; 13 BP.
XX
AC ABF17416;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 117413 for detecting SNP TSC0029372.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 117413; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other:
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 21 ATAGCCCAAGAC 33
   |||||
Db 13 ATATCCCAAAACA 1

RESULT 478
ABF31794
ID ABF31794 standard; DNA; 13 BP.
XX
AC ABF31794;
XX

```

```

DT 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 131791 for detecting SNP TSC0032899.
XX
DE SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 131791; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 8 A; 0 C; 3 G; 2 T; 0 U; 0 Other:
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 29 AGAACGAAAGAA 41
   |||||
Db 1 AGAATGAAAGAA 13

RESULT 479
ABF31795/C
ID ABF31795 standard; DNA; 13 BP.
XX
AC ABF31795;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 131792 for detecting SNP TSC0032899.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
PD 18-OCT-2001.
XX

```

```

XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPiG-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX WPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX Claim 1; SEQ ID NO 131792; 29pp + Sequence Listing; German.
CC
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 2 A; 3 C; 0 G; 8 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 29 AGAACAGAAAGAA 41
DB 13 AGAATTGAAAGAA 1

RESULT 480
ABF39904
ID ABF39904 standard; DNA; 13 BP.
XX
AC ABF39904;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 139901 for detecting SNP TSC0035033.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine

```

```

PT methylation status.
XX
PS Claim 1; SEQ ID NO 139901; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 1 A; 1 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 48 TGGCGTTGGAGGT 60
DB 1 TGGCGTTGGAGGT 13

RESULT 481
ABH00239/C
ID ABH00239 standard; DNA; 13 BP.
XX
AC ABH00239;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 200216 for detecting SNP TSC0049265.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPiG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PS
XX Claim 1; SEQ ID NO 200216; 29pp + Sequence Listing; German.
CC
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence

```

CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 5 A; 7 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 50 GGGTTGAGGCTT 62
DB 13 GGGTTGAGGCTT 1
RESULT 482
ABF50558
ID ABF50558 standard; DNA; 13 BP.
XX
AC ABF50558;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 150555 for detecting SNP TSC0037990.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 150555; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1 TTTTCTGAATGGA 13
DB 1 TTTTCTGAATGGA 13

RESULT 483
ABH12784/c
ID ABH12784 standard; DNA; 13 BP.
XX
AC ABH12784;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 212761 for detecting SNP TSC0051837.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 212761; 29pp + Sequence listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB12073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 20 CATAGCCCAAGAA 32
DB 13 CATATCCCAAAA 1
RESULT 484
ABF88569/c
ID ABF88569 standard; DNA; 13 BP.
XX
AC ABF88569;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 188566 for detecting SNP TSC0010549.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;

KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX WO200177384-A2.
 XX 18-OCT-2001.
 XX PD 06-APR-2001; 2001WO-IB000713.
 XX PF 07-APR-2000; 2000DE-01019173.
 XX PR (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX DR WPI; 2001-657177/75.
 XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 188566; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 2 C; 0 G; 10 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 28 AGAGACAGAAAGA 40
 ||| |||||
 13 AATTAAGAAAGA 1
 DB
 RESULT 485
 ABF65173/C
 ID ABF65173 standard; DNA; 13 BP.
 XX
 AC ABF65173;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 165170 for detecting SNP TSC0041424.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX

PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 165170; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 49 GGGGTTGAGGTT 61
 ||||| |||||
 13 GAGGTTGAGGTT 1
 DB
 RESULT 486
 ABH15570
 ID ABH15570 standard; DNA; 13 BP.
 XX
 AC ABH15570;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 215547 for detecting SNP TSC0052427.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 215547; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic

CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 2 A; 1 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 6 GGAATGCAATTGG 18
Dn 1 GGAATGGCGTTGG 13
Dn
RESULT 487
ABH16218
ID ABH16218 standard; DNA; 13 BP.
AC
XX ABH16218;
AC
XX 22-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 216195 for detecting SNP TSC0052577.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; seq;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPIG-) EPIGENOMICS AG.
PA
XX
XX Olek A, Plepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
XX
XX Claim 1; SEQ ID NO 216195; 29pp + Sequence Listing; German.
PS
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC000010
CC -ABG99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

Query Match	15.1%	Score 9.8	DB 1	Length 13
Best Local Similarity	84.6%	Pred. No. 2.4e+02		
Matches 11	Conservative 0	Mismatches 2	Indels 0	Gaps 0
Qy	29 AGACAGAAAGAA 41 			
Db	1 AAAATGAAAGAA 13			
RESULT 488				
ID	ABH16292			
	ABH16292 standard; DNA; 13 BP.			
AC	ABH16292;			
AD	22-FEB-2002 (first entry)			
DE	Oligonucleotide SEQ ID NO 216269 for detecting SNP TSCC052602.			
KM	SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;			
KW	peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;			
XX	central nervous system; gastrointestinal; respiratory; immune; metabolic.			
OS	Homo sapiens.			
XX				
PN	WO200177384-A2.			
PD	18-OCT-2001.			
PF	06-APR-2001; 2001WO-IB000713.			
PR	07-APR-2000; 2000DE-01019173.			
XX				
PA	(EPIC-) EPIGENOMICS AG.			
PI	Olek A, Piepenbrock C, Berlin K;			
DR	WPI, 2001-657177/75.			
XX				
PT	Set of oligonucleotides, useful for diagnosis and cell typing, is			
PT	designed to detect single-nucleotide polymorphisms and cytosine			
PT	methylation status.			
XX				
PS	Claim 1; SEQ ID NO 216269; 29pp + Sequence Listing; German.			
XX				
CC	This invention describes novel oligonucleotide primers or peptide nucleic			
CC	acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)			
CC	and cytosine methylation status in chemically pretreated genomic DNA. The			
CC	oligonucleotides are used for diagnosis and/or prognosis of cancer and a			
CC	range of diseases including immune system, gastrointestinal, respiratory,			
CC	central nervous system, cardiovascular and metabolic disorders. The			
CC	oligomers are also used for detecting cell type differentiation. ABC00010			
CC	-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB:00010-AB182073			
CC	represent the oligomers described in the invention. NOTE: The sequence			
CC	data for this patent did not form part of the printed specification, but			
CC	was obtained in electronic format from WIPO at			
CC	ftp.wipo.int/pub/published_pct_sequences			
XX				
XX				
SO	Sequence 13 BP; 0 A; 0 C; 7 G; 6 T; 0 U; 0 Other;			
Qy	Query Match 15.1%; Score 9.8; DB 1; Length 13;			
Db	Best Local Similarity 84.6%; Pred. No. 2.4e+02;			
	Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
Qy	49 GGGGTTGGAGGTT 61 			
Db	1 GGGTTTGGTGGTT 13			
RESULT 489				
ID	ABH42927/c			
	ABH42927 standard; DNA; 13 BP.			

```

XX AC ABH42927;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 242904 for detecting SNP TSC0000706.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PS (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 242904; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 49 GGGGTTGAGGCTT 61
XX |||||
XX 13 GGGGATGGAGCTT 1
XX
XX RESULT 490
XX ABH62560/c
XX ID ABH62560 standard; DNA; 13 BP.
XX AC ABH62560;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 262537 for detecting SNP TSC0007733.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX

```

```

PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PS (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 262537; 29pp + Sequence Listing; German.
XX
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC9989, ABF00010-ABF9989, ABH00010-ABH9989 and ABI00010-ABI82073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 13 BP; 4 A; 0 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 33 CAGAAAGAACCTT 45
XX |||||
XX 13 CATAAATTAACCTT 1
XX
XX RESULT 491
XX ABC68818
XX ID ABC68818 standard; DNA; 13 BP.
XX AC ABC68818;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 68835 for detecting SNP TSC0017929.
XX
XX KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PS (EPIG-) EPIGENOMICS AG.
XX PA Olek A, Piepenbrock C, Berlin K;
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX

```

```
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1, SEQ ID NO 68835, 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 0 A; 0 C; 10 G; 3 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      48 TGGGGTTGAGGT 60
Db      1 TGGGGGTGGGGT 13

RESULT 492
ABC34456
ID ABC34456 standard; DNA; 13 BP.
XX
XX ABC34456;
XX
XX 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 34473 for detecting SNP TSC0010991.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1, SEQ ID NO 34473; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI2073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 0 C; 10 G; 3 T; 0 U; 0 Other;
```

```
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABP0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI2073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 10 A; 0 C; 3 G; 0 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      29 AGACGAAAGAA 41
Db      1 AAAAGGAAAGAA 13

RESULT 493
ABH21396
ID ABH21396 standard; DNA; 13 BP.
XX
XX ABH21396;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 221373 for detecting SNP TSC0053878.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1, SEQ ID NO 221373; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABG9989, ABP0010-ABF9989, ABH0010-ABH9989 and ABI00010-ABI2073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 6 G; 3 T; 0 U; 0 Other;
```

OY 6 GGATGGAATTGG 18
 DB 1 GGAAGGGAATTGG 13

RESULT 494

ABH22411/C
 ID ABH22411 standard; DNA; 13 BP.

AC ABH22411;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 222388 for detecting SNP TSC0054107.

KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 222388; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 4 A; 4 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 7 GAATGGAATTGGA 19
 DB 13 GAATGGAATTGGA 1

RESULT 495

ABF75610
 ID ABF75610 standard; DNA; 13 BP.

AC ABF75610;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 175607 for detecting SNP TSC0043628.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.

XX 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 XX designed to detect single-nucleotide polymorphisms and cytosine
 XX methylation status.

PS Claim 1; SEQ ID NO 175607; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 TTTCTGGAATGGA 13
 DB 1 TGTGTGGAATGGA 13

RESULT 496

ABF75611/C
 ID ABF75611 standard; DNA; 13 BP.

AC ABF75611;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 175608 for detecting SNP TSC0043628.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

XX MO200177384-A2.

XX 18-OCT-2001.

XX 06-APR-2001; 2001WO-IB000713.


```
XX 07-APR-2000; 2000DE-01019173.
XX (EPiG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 175608; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 6 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1 TTCTGGATGGA 13
XX | | | | |
XX | | | | |
XX 13 TGTGTGATGGA 1
XX
XX RESULT 497
XX ABH04580
XX ID ABH04580 standard; DNA; 13 BP.
XX
XX ABH04580;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 204557 for detecting SNP TSC0050176.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
```

```
PS Claim 1; SEQ ID NO 204557; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 3 A; 0 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 2 TTCTGGATGGA 14
XX | | | | |
XX | | | | |
XX 1 TTCTGGATGGA 13
XX
XX Db 1 TTCTGGATGGA 13
XX
XX RESULT 498
XX ABH12785
XX ID ABH12785 standard; DNA; 13 BP.
XX
XX ABH12785;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 212762 for detecting SNP TSC0051837.
XX
XX SNP: single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX MPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 212762; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
```

CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 4 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 20 CATAGCCCAAGAA 32
 DB 1 CATATCCCAAAA 13

RESULT 499
 ABC68985/c
 ID ABC68985 standard; DNA; 13 BP.

XX ABC68985;

AC 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 69002 for detecting SNP TSC0017967.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 69002; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 3 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 46 GCTGGCGTTTGAG 58
 DB 13 GGTGAGTTTGAG 1

RESULT 500

ABC73224
 ID ABC73224 standard; DNA; 13 BP.

XX ABC73224;

AC 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 73241 for detecting SNP TSC0018875.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PS (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 73241; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 46 GCTGGCGTTTGAG 58
 DB 1 GGTGAGTTTGAG 13

RESULT 501

ABC54294
 ID ABC54294 standard; DNA; 13 BP.

XX ABC54294;

AC 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 54311 for detecting SNP TSC0014910.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

```

XX OS Homo sapiens.
XX XX WO200177384-A2.
XX PN 18-OCT-2001.
XX PD
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 54311; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 49 GGGGTTGGAGGTT 61
XX 1 GAGGCTGAGGTT 13
XX Db
XX
XX RESULT 502
XX ABF67883/c
XX ID ABF67883 standard; DNA; 13 BP.
XX AC ABF67883;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 167880 for detecting SNP TSC0006909.
XX XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX XX

```

```

PI PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 167880; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 13 BP; 5 A; 7 C; 1 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX Qy 44 TTGCTGGGCTTGG 56
XX 13 TTGCTGGGCTTGG 1
XX Db
XX
XX RESULT 503
XX ABF73729/c
XX ID ABF73729 standard; DNA; 13 BP.
XX AC ABF73729;
XX DT 22-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 173726 for detecting SNP TSC0043265.
XX XX
XX SNF; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB000713.
XX PR 07-APR-2000; 2000DE-01019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX PS Claim 1; SEQ ID NO 173726; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The

```

CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SEQ Sequence 13 BP; 5 A; 3 C; 0 G; 5 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;

Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 TTCTGGAATGGA 14
DB 13 TTTTGTAAATAGA 1

RESULT 504

ID ABH00235/C
XX ABH00235 standard; DNA; 13 BP.

AC ABH00235;

DT 22-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 200212 for detecting SNP TSC0049265.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 200212; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SEQ Sequence 13 BP; 6 A; 7 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;

Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGGTTGAGGTTT 62
DB 13 GGGTTTGGGTTT 1

RESULT 505

ID ABF50559/C
XX ABF50559 standard; DNA; 13 BP.

AC ABF50559;

DT 21-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 150556 for detecting SNP TSC0037990.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.

OS Homo sapiens.

PN WO200177384-A2.

PD 18-OCT-2001.

PF 06-APR-2001; 2001WO-IB000713.

PR 07-APR-2000; 2000DE-01019173.

PA (EPIG-) EPIGENOMICS AG.

PI Olek A, Piepenbrock C, Berlin K;

DR WPI; 2001-657177/75.

PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.

PS Claim 1; SEQ ID NO 150556; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX

SEQ Sequence 13 BP; 6 A; 3 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 TTCTGGAATGGA 13
DB 13 TTTTGTAAATAGA 1

RESULT 506

ID ABH29612
XX ABH29612 standard; DNA; 13 BP.

AC ABH29612;

```
XX 22-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 229589 for detecting SNP TSC0055987.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX MPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 229589; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 0 C; 5 G; 4 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 5 TCGAATGCAATTG 17
DB 1 TCGAATGCAATTG 13
XX
XX RESULT 507
XX ABF86467/C
XX ID ABF86467 standard; DNA; 13 BP.
XX
XX ABF86467;
XX
XX 22-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 186464 for detecting SNP TSC0045930.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX
```

```
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX MPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 186464; 29pp + Sequence listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABF99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 5 C; 0 G; 8 T; 0 U; 0 Other;
SQ
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 28 AAGAACGAAAGA 40
DB 13 AAGAACGAAAGA 1
XX
XX RESULT 508
XX ABF62972
XX ID ABF62972 standard; DNA; 13 BP.
XX
XX ABF62972;
XX
XX 22-FEB-2002 (first entry)
DT Oligonucleotide SEQ ID NO 162969 for detecting SNP TSC0040972.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX 07-APR-2000; 2000DE-01019173.
PR
XX (EPIC-) EPIGENOMICS AG.
PA
XX Olek A, Piepenbrock C, Berlin K;
PI
XX MPI; 2001-657177/75.
DR
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT
```

PT designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
PS Claim 1; SEQ ID NO 162969; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABG9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 4 A; 0 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 5 TGGATGGAATTG 17
1 TGAATGGAATTG 13
Db
RESULT 509
ABC68984
ID ABC68984 standard; DNA; 13 BP.
AC ABC68984;
XX
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 69001 for detecting SNP TSC0017967.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
PS Claim 1; SEQ ID NO 69001; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073

CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
SQ Sequence 13 BP; 2 A; 0 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 46 GCTGGGCTTGAG 58
1 GGTGGAGTTGAG 13
Db
RESULT 510
ABC99662
ID ABC99662 standard; DNA; 13 BP.
AC ABC99662;
XX
XX 21-FEB-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 99679 for detecting SNP TSC0024759.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
XX WO200177384-A2.
PN
XX
XX 18-OCT-2001.
PD
XX
XX 06-APR-2001; 2001WO-IB000713.
PF
XX
XX 07-APR-2000; 2000DE-01019173.
PR
XX
XX (EPig-) EPIGENOMICS AG.
PA
XX
XX Olek A, Piepenbrock C, Berlin K;
PI
XX
XX WPI; 2001-657177/75.
DR
XX
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
PT
PS Claim 1; SEQ ID NO 99679; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC9989, ABF0010-ABF9989, ABH0010-ABH9989 and ABI0010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 6 GGAATGGAATTG 18
1 TGAATGGAATTG 13

Db 1 GGTATGGAGTTGG 13

RESULT 511
ABC06245
ID ABC06245 standard; DNA; 13 BP.
XX
AC ABC06245;
XX
DT 20-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 6236 for detecting SNP TSC0001951.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 6236; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 9 A; 4 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 25 CCCAAGACAGAA 37
||| ||| ||| |||
1 CCCAAAAACAAA 13

Db

RESULT 512
ABF07728
ID ABF07728 standard; DNA; 13 BP.
XX
AC ABF07728;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 107725 for detecting SNP TSC0026974.
XX

KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 107725; 29pp + Sequence Listing; German.

CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences

CC Sequence 13 BP; 1 A; 0 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 49 GGGTTTGAAGTT 61
||| ||| ||| |||
1 GGGTTTGAAGTT 13

Db

RESULT 513
ABC61677/c
ID ABC61677 standard; DNA; 13 BP.
XX
AC ABC61677;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 61694 for detecting SNP TSC0016406.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX

```
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 61694; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 50 GGGTTGAGGTTT 62
XX ||| |||||
XX 13 GGGGTAGAGGTTT 1
XX
XX RESULT 514
XX ID ABR35263 standard; DNA; 13 BP.
XX
XX ABR35263;
XX
XX 21-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 135260 for detecting SNP TSC0033738.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPiG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1, SEQ ID NO 135260; 29pp + Sequence Listing; German.
```

```
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
CC Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 U; 0 Other;
CC
CC Query Match 15.1%; Score 9.8; DB 1; Length 13;
CC Best Local Similarity 84.6%; Pred. No. 2.4e+02;
CC Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
CC
CC 52 GTTGAAGTTTCA 64
CC ||| |||||
CC 13 GTAGAGGTTTCA 1
CC
CC RESULT 515
CC ID ABR47356 standard; DNA; 13 BP.
CC
CC ABR47356;
CC
CC 21-FEB-2002 (first entry)
CC
CC Oligonucleotide SEQ ID NO 147353 for detecting SNP TSC0037222.
CC
CC SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
CC peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
CC central nervous system; gastrointestinal; respiratory; immune; metabolic.
CC Homo sapiens.
CC
CC WO200177384-A2.
CC
CC 18-OCT-2001.
CC
CC 06-APR-2001; 2001WO-IB000713.
CC
CC 07-APR-2000; 2000DE-01019173.
CC
CC (EPiG-) EPIGENOMICS AG.
CC
CC Olek A, Piepenbrock C, Berlin K;
CC WPI; 2001-657177/75.
CC
CC Set of oligonucleotides, useful for diagnosis and cell typing, is
CC designed to detect single-nucleotide polymorphisms and cytosine
CC methylation status.
CC
CC Claim 1; SEQ ID NO 147353; 29pp + Sequence Listing; German.
CC
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
CC
```


SO Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 52 GTTGAGGTTTCA 64
||| ||| ||| |||
1 GTTGAGGTTTCA 13

DB

RESULT 516
ABH33026
ID ABH33026 standard; DNA; 13 BP.
AC ABH33026;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 233003 for detecting SNP TSC0056853.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX W0200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 233003; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 46 GCTGGGTTGAG 58
||| ||| ||| |||
1 GTTGAGGTTGAG 13

DB

RESULT 517
ABF88568

ID ABF88568 standard; DNA; 13 BP.
XX
XX ABF88568;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 188565 for detecting SNP TSC0010549.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX W0200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX Claim 1; SEQ ID NO 188565; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences

SO Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 40
||| ||| ||| |||
1 AATTAAGAAAG 13

DB

RESULT 518
ABC20851/C
ID ABC20851 standard; DNA; 13 BP.
XX
XX ABC20851;
XX
XX 20-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 20868 for detecting SNP TSC0004238.
XX
XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.

XX WO200177384-A2.
 XX 18-OCT-2001.
 XX 06-APR-2001; 2001WO-IB000713.
 XX 07-APR-2000; 2000DE-01019173.
 XX (EPIG-) EPIGENOMICS AG.
 XX Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 20868; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 48 TGGGTTGGAGGT 60
 DB 13 TACGTTGGAGGT 1
 XX
 RESULT 519
 ABC99214
 ID ABC99214 standard; DNA; 13 BP.
 XX
 AC ABC99214;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 99231 for detecting SNP TSC0024650.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX

DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 99231; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 1 A; 0 C; 7 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 49 GCGATTGGAGTT 61
 DB 1 GCGATTGGAGTT 13
 XX
 RESULT 520
 ABC99663/C
 ID ABC99663 standard; DNA; 13 BP.
 XX
 AC ABC99663;
 XX
 DT 21-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 99680 for detecting SNP TSC0024759.
 XX
 KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIG-) EPIGENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 PS Claim 1; SEQ ID NO 99680; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC

CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX
 SO Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GGAATGGAATTCG 18
 |||||
 DB 13 GGATGGAATTCG 1

RESULT 521

ABC01963/c
 ID ABC01963 standard; DNA; 13 BP.

AC ABC01963;

XX 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 1954 for detecting SNP TSC000769.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001MO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 1954; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 6 A; 5 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGGTGGAGGTTT 62
 |||||
 DB 13 GGATTTGAGGTTT 1

RESULT 522

ABC37878
 ID ABC37878 standard; DNA; 13 BP.

AC ABC37878;

XX 20-FEB-2002 (first entry)

DE Oligonucleotide SEQ ID NO 37895 for detecting SNP TSC0011764.

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KM central nervous system; gastrointestinal; respiratory; immune; metabolic.

XX Homo sapiens.

XX WO200177384-A2.

XX 18-OCT-2001.

PD 06-APR-2001; 2001MO-IB000713.

PF 07-APR-2000; 2000DE-01019173.

XX (EPIC-) EPIGENOMICS AG.

XX Olek A, Piepenbrock C, Berlin K;

XX WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.

PS Claim 1; SEQ ID NO 37895; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABG9989, ABF00010-ABF9989, ABH00010-ABH9989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences

XX Sequence 13 BP; 1 A; 0 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 50 GGGTGGAGGTTT 62
 |||||
 DB 1 GGTTTGGAGGTTT 13

RESULT 523

ABC63814/c
 ID ABC63814 standard; DNA; 13 BP.

AC ABC63814;

XX 21-FEB-2002 (first entry)

```
XX Oligonucleotide SEQ ID NO 63831 for detecting SNP TSC0016855.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 63831; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 0 A; 0 C; 3 G; 10 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 26 CCAGACAGAGAAA 38
Db 13 CCAAAAACAAAA 1
RESULT 524
ABF16687/C
ID ABF16687 standard; DNA; 13 BP.
XX
XX ABF16687;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 116684 for detecting SNP TSC0029195.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX
```

```
PF 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
XX Claim 1; SEQ ID NO 116684; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 7 A; 6 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 44 TTGCTGGGCTTGG 56
Db 13 TTGTTGGGTTGG 1
RESULT 525
ABF22179/C
ID ABF22179 standard; DNA; 13 BP.
XX
XX ABF22179;
AC
XX
XX 21-FEB-2002 (first entry)
DT
XX
XX Oligonucleotide SEQ ID NO 122176 for detecting SNP TSC0030537.
DE
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
```

XX Claim 1; SEQ ID NO 122176; 29bp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 5 TGGATGGAATTG 17
Db 13 TTGATTGGAATTG 1
XX
RESULT 526
ABF72760
ID ABF72760 standard; DNA; 13 BP.
XX
AC ABF72760;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 172757 for detecting SNP TSC0009140.
XX
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
PS Claim 1; SEQ ID NO 172757; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but

CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 2 A; 0 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 6 GGAATGGAATTG 18
Db 1 GGAATGGGTTTG 13
XX
RESULT 527
ABF72761/C
ID ABF72761 standard; DNA; 13 BP.
XX
AC ABF72761;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 172758 for detecting SNP TSC0009140.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIC-) EPIDENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single-nucleotide polymorphisms and cytosine
XX methylation status.
XX
XX
PS Claim 1; SEQ ID NO 172758; 29bp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation. ABC00010
XX -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and ABI00010-ABI82073
XX represent the oligomers described in the invention. NOTE: The sequence
XX data for this patent did not form part of the printed specification, but
XX was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
XX
Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 6 GGAATGGAATTG 18
Db 13 GGAATGGGTTTG 1

```

RESULT 528
ABF98632
ID ABF98632 standard; DNA; 13 BP.
XX
XX
AC ABF98632;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 198629 for detecting SNP TSC0008196.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 198629; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 29 AGAACAGAAAGAA 41
XX |||||
XX 1 ATAAAGAAAGAA 13
XX
RESULT 529
ABF90375/C
ID ABF90375 standard; DNA; 13 BP.
XX
XX
AC ABF90375;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 190372 for detecting SNP TSC0046824.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM

```

```

XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single-nucleotide polymorphisms and cytosine
XX PT methylation status.
XX
XX Claim 1; SEQ ID NO 190372; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation. ABC00010
XX CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
XX CC represent the oligomers described in the invention. NOTE: The sequence
XX CC data for this patent did not form part of the printed specification, but
XX CC was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 13 BP; 6 A; 4 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 15.1%; Score 9.8; DB 1; Length 13;
XX Best Local Similarity 84.6%; Pred. No. 2.4e+02;
XX Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
OY 5 TCGAATGGAATTG 17
XX |||||
XX 13 TCGAATGGAATTG 1
XX
RESULT 530
ABH15567/C
ID ABH15567 standard; DNA; 13 BP.
XX
XX
AC ABH15567;
XX
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 215544 for detecting SNP TSC0052427.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB000713.
XX
XX 07-APR-2000; 2000DE-01019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX

```

XX Olek A, Piepenbrock C, Berlin K;
 XX WPI, 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1, SEQ ID NO 215544; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 4 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 6 GGAATGGAATTGG 18
 Db 13 GGAATGCTTTGG 1
 XX
 RESULT 531
 ABH41661
 ID ABH41661 standard; DNA; 13 BP.
 XX
 AC ABH41661;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 241638 for detecting SNP TSC0058921.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1, SEQ ID NO 241638; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)

CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 7 A; 3 C; 0 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 2.4e+02;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 32 ACAGAAAGAACTT 44
 Db 1 ACATAAATTAACCT 13
 XX
 RESULT 532
 ABF66698
 ID ABF66698 standard; DNA; 13 BP.
 XX
 AC ABF66698;
 XX
 DT 22-FEB-2002 (first entry)
 XX
 DE Oligonucleotide SEQ ID NO 166695 for detecting SNP TSC0041746.
 XX
 KW SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX
 OS Homo sapiens.
 XX
 PN WO200177384-A2.
 XX
 PD 18-OCT-2001.
 XX
 PF 06-APR-2001; 2001WO-IB000713.
 XX
 PR 07-APR-2000; 2000DE-01019173.
 XX
 PA (EPIC-) EPIDENOMICS AG.
 XX
 PI Olek A, Piepenbrock C, Berlin K;
 XX
 DR WPI; 2001-657177/75.
 XX
 PT Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single-nucleotide polymorphisms and cytosine
 PT methylation status.
 XX
 XX Claim 1, SEQ ID NO 166695; 29pp + Sequence Listing; German.
 XX
 CC This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation. ABC00010
 CC -ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and AB100010-AB182073
 CC represent the oligomers described in the invention. NOTE: The sequence
 CC data for this patent did not form part of the printed specification, but
 CC was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 13 BP; 10 A; 0 C; 2 G; 1 T; 0 U; 0 Other;

```

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      29 AGAACAGAGAGAA 41
      |||||
      1 AGAATGAGAAAAA 13

RESULT 533
ABH57531/c
ID ABH57531 standard; DNA; 13 BP.
XX
AC ABH57531;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 257508 for detecting SNP TSC005086.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 257508; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 4 A; 3 C; 0 G; 6 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      11 GGAATGACATTA 23
      |||||
      13 GGAATTGAAATTA 1

RESULT 534
ABH57828
ID ABH57828 standard; DNA; 13 BP.
XX

```

```

AC ABH57828;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 257805 for detecting SNP TSC0062709.
XX
KM SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KM peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KM central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB000713.
XX
PR 07-APR-2000; 2000DE-01019173.
XX
PA (EPIC-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.
XX
PT Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single-nucleotide polymorphisms and cytosine
PT methylation status.
XX
PS Claim 1; SEQ ID NO 257805; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation. ABC00010
CC -ABC99989, ABP00010-ABF99989, ABH00010-ABH99989 and ABT00010-ABT82073
CC represent the oligomers described in the invention. NOTE: The sequence
CC data for this patent did not form part of the printed specification, but
CC was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 U; 0 Other;

Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 2.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      50 GGGTTGAGGATT 62
      |||||
      1 GGGTTGAGGATT 13

```

Search completed: August 12, 2004, 15:28:58
Job time : 5 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 12, 2004, 15:32:42 ; Search time 1 Seconds
(without alignments)
0.227 Million cell updates/sec

Title: US-10-033-742-3

Perfect score: 65
Sequence: 1 ttcttgatgcatgacgac.....gctgggttgaggttccac 65

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 0.5

Searched: 134 seqs, 1745 residues

Total number of hits satisfying chosen parameters: 268

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 134 summaries

Database: rgcdh:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19.8	30.5	23	1	ACCESSION:AR3656
C 2	19.8	30.5	23	1	ACCESSION:AR300570
C 3	19.8	30.5	23	1	ACCESSION:BD106469
C 4	15.8	24.3	21	1	ACCESSION:AX084313
C 5	14.4	22.2	18	1	ACCESSION:BD107600
C 6	14.4	21.5	18	1	ACCESSION:AR000413
C 7	13.8	21.2	17	1	ACCESSION:BD183671
C 8	13.4	20.6	17	1	ACCESSION:AX217386
C 9	13.4	20.6	17	1	ACCESSION:AX217387
C 10	13.4	20.6	17	1	ACCESSION:AX217388
C 11	13.4	20.0	17	1	ACCESSION:AX217756
C 12	13.4	20.0	17	1	ACCESSION:AX217756
C 13	13.4	20.0	17	1	ACCESSION:AX733882
C 14	12.8	19.7	17	1	ACCESSION:AR053059
C 15	12.8	19.7	17	1	ACCESSION:AR053059
C 16	12.8	19.7	17	1	ACCESSION:AR065020
C 17	12.8	19.7	17	1	ACCESSION:BD254337
C 18	12.8	19.7	17	1	ACCESSION:BD258370
C 19	12.8	19.7	17	1	ACCESSION:BD258370
C 20	12.4	19.1	15	1	ACCESSION:BD233057
C 21	12.4	19.1	15	1	ACCESSION:BD233078
C 22	12.4	19.1	15	1	ACCESSION:AX007611
C 23	12.4	19.1	15	1	ACCESSION:AX007611
C 24	11.4	17.5	13	1	ACCESSION:AX104604
C 25	11.4	17.5	13	1	ACCESSION:AX547657
C 26	11.4	17.5	13	1	ACCESSION:AX547657
C 27	11.4	17.5	14	1	ACCESSION:BD233079
C 28	11.4	17.5	14	1	ACCESSION:AX007633
C 29	11.4	17.5	15	1	ACCESSION:AX5950
C 30	11.4	17.5	15	1	ACCESSION:AR278927
C 31	11.4	17.5	15	1	ACCESSION:AR278931
C 32	11.4	17.5	15	1	ACCESSION:AX587070
C 33	11.4	16.9	13	1	ACCESSION:BD086489

34	11	16.9	13	1	BD086508	ACCESSION:BD086508
35	11	16.9	13	1	BD086527	ACCESSION:BD086527
36	10.8	16.6	14	1	AR178312	ACCESSION:AR178312
37	10.8	16.6	14	1	AR178313	ACCESSION:AR178313
38	10.8	16.6	14	1	I28572	ACCESSION:I28572
39	10.8	16.6	14	1	I58734	ACCESSION:I58734
40	10.8	16.6	14	1	AX016242	ACCESSION:AX016242
41	10.8	16.6	14	1	AX287231	ACCESSION:AX287231
42	10.8	16.6	14	1	AX323394	ACCESSION:AX323394
43	10.8	16.6	14	1	AX323395	ACCESSION:AX323395
44	10.8	16.6	14	1	BD135020	ACCESSION:BD135020
45	10.4	16.0	12	1	A14857	ACCESSION:A14857
46	10.4	16.0	12	1	AR036346	ACCESSION:AR036346
47	10.4	16.0	12	1	AR036347	ACCESSION:AR036347
48	10.4	16.0	12	1	AR036365	ACCESSION:AR036365
49	10.4	16.0	12	1	AR036366	ACCESSION:AR036366
50	10.4	16.0	12	1	AR036368	ACCESSION:AR036368
51	10.4	16.0	12	1	I12563	ACCESSION:I12563
52	10.4	16.0	12	1	I12564	ACCESSION:I12564
53	10.4	16.0	12	1	I12565	ACCESSION:I12565
54	10.4	16.0	12	1	I20199	ACCESSION:I20199
55	10.4	16.0	12	1	I20200	ACCESSION:I20200
56	10.4	16.0	12	1	I20202	ACCESSION:I20202
57	10.4	16.0	12	1	I72094	ACCESSION:I72094
58	10.4	16.0	12	1	I72095	ACCESSION:I72095
59	10.4	16.0	12	1	I72113	ACCESSION:I72113
60	10.4	16.0	12	1	I72114	ACCESSION:I72114
61	10.4	16.0	12	1	I72116	ACCESSION:I72116
62	10.4	16.0	12	1	BD080369	ACCESSION:BD080369
63	10.4	16.0	13	1	I21837	ACCESSION:I21837
64	10.4	16.0	13	1	AR275240	ACCESSION:AR275240
65	10.4	16.0	13	1	AR339891	ACCESSION:AR339891
66	10.4	16.0	13	1	AX711144	ACCESSION:AX711144
67	10.4	16.0	10	1	BD238904	ACCESSION:BD238904
68	10.4	16.0	10	1	AX153058	ACCESSION:AX153058
69	10.4	16.0	10	1	BD065196	ACCESSION:BD065196
70	10.4	16.0	10	1	BD166544	ACCESSION:BD166544
71	10.4	16.0	10	1	BD166682	ACCESSION:BD166682
72	10.4	16.0	11	1	AX471270	ACCESSION:AX471270
73	10.4	16.0	11	1	AX471279	ACCESSION:AX471279
74	10.4	16.0	11	1	AX624183	ACCESSION:AX624183
75	10.4	16.0	11	1	AX624981	ACCESSION:AX624981
76	10.4	16.0	11	1	AX625481	ACCESSION:AX625481
77	10.4	16.0	11	1	AX626412	ACCESSION:AX626412
78	10.4	16.0	11	1	AX626765	ACCESSION:AX626765
79	10.4	16.0	11	1	AX631604	ACCESSION:AX631604
80	10.4	16.0	11	1	AX632402	ACCESSION:AX632402
81	10.4	16.0	12	1	I05995	ACCESSION:I05995
82	10.4	16.0	12	1	I08795	ACCESSION:I08795
83	10.4	16.0	12	1	AR349259	ACCESSION:AR349259
84	10.4	16.0	12	1	AR349261	ACCESSION:AR349261
85	9.8	15.1	13	1	A01985	ACCESSION:A01985
86	9.8	15.1	13	1	A06431	ACCESSION:A06431
87	9.8	15.1	13	1	BD062265	ACCESSION:BD062265
88	9.4	14.5	11	1	I16094	ACCESSION:I16094
89	9.4	14.5	11	1	AX393078	ACCESSION:AX393078
90	9.4	14.5	11	1	AX470597	ACCESSION:AX470597
91	9.4	14.5	11	1	AX470878	ACCESSION:AX470878
92	9.4	14.5	11	1	AX471365	ACCESSION:AX471365
93	9.4	14.5	11	1	AX623489	ACCESSION:AX623489
94	9.4	14.5	11	1	AX624179	ACCESSION:AX624179
95	9.4	14.5	11	1	AX624329	ACCESSION:AX624329
96	9.4	14.5	11	1	AX624484	ACCESSION:AX624484
97	9.4	14.5	11	1	AX625720	ACCESSION:AX625720
98	9.4	14.5	11	1	AX625789	ACCESSION:AX625789
99	9.4	14.5	11	1	AX626474	ACCESSION:AX626474
100	9.4	14.5	11	1	AX627570	ACCESSION:AX627570
101	9.4	14.5	11	1	AX628639	ACCESSION:AX628639
102	9.4	14.5	11	1	AX628640	ACCESSION:AX628640
103	9.4	14.5	11	1	AX628771	ACCESSION:AX628771
104	9.4	14.5	11	1	AX629905	ACCESSION:AX629905
105	9.4	14.5	11	1	AX630278	ACCESSION:AX630278
106	9.4	14.5	11	1	AX630910	ACCESSION:AX630910

C 107 9.4 14.5 11 1 AX631600
C 108 9.4 14.5 11 1 AX631750
109 9.4 14.5 11 1 AX631905
110 9.4 14.5 12 1 A03728
111 9.4 14.5 12 1 A03729
112 9.4 14.5 12 1 A03738
113 9.4 14.5 12 1 A03921
114 9.4 14.5 12 1 A31783
C 115 9.4 14.5 12 1 A47652
C 116 9.4 14.5 12 1 AR027870
117 9.4 14.5 12 1 AR036375
118 9.4 14.5 12 1 AR036376
119 9.4 14.5 12 1 AR074233
120 9.4 14.5 12 1 AR074249
121 9.4 14.5 12 1 AR074305
C 122 9.4 14.5 12 1 AR172240
123 9.4 14.5 12 1 AR172240
124 9.4 14.5 12 1 AR172240
125 9.4 14.5 12 1 AR172240
126 9.4 14.5 12 1 AR172240
127 9.4 14.5 12 1 AR172240
128 9.4 14.5 12 1 AR172240
129 9.4 14.5 12 1 AR172240
130 9.4 14.5 12 1 AR172240
131 9.4 14.5 12 1 AR172240
132 9.4 14.5 12 1 AR172240
133 9.4 14.5 12 1 AR172240
C 134 9.4 14.5 12 1 AR172240

ALIGNMENTS

RESULT 1
LOCUS A83656 23 bp DNA linear PAT 21-JAN-2000
DEFINITION Sequence 12 from Patent WO9849309.
ACCESSION A83656
VERSION A83656.1 GI:6732906
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 23)
AUTHORS Utans-Schneitz U. and Lesslauer W.
TITLE RAT ST38.2 CHEMOKINE
JOURNAL Patent: WO 9849309-A 12 05-NOV-1998;
HOFERMAN LA ROCHE (CH)
FEATURES
source Location/Qualifiers
1..23
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 1.6;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 CTGGATGGAATTGACATAGCC 26
Db 23 CTGGATGGAATTGACACAGCC 1

RESULT 2
LOCUS AR300570/c 23 bp DNA linear PAT 12-JUN-2003
DEFINITION Sequence 12 from patent US 6537794.
ACCESSION AR300570
VERSION AR300570.1 GI:31688075
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1
TITLE Unclassified.

REFERENCE 1 (bases 1 to 23)
AUTHORS Lesslauer W. and Utans-Schneitz U.
TITLE Chemokine
JOURNAL Patent: US 6537794-A 12 25-MAR-2003;
FEATURES
source Location/Qualifiers
1..23
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 1.6;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 CTGGATGGAATTGACATAGCC 26
Db 23 CTGGATGGAATTGACACAGCC 1

RESULT 3
LOCUS BD106469/c 23 bp DNA linear PAT 18-SEP-2002
DEFINITION Rat ST38.2 chemokine.
ACCESSION BD106469
VERSION BD106469.1 GI:23201287
KEYWORDS JP 2002500509-A/10.
SOURCE Chlamydia sp.
ORGANISM Chlamydia sp.
REFERENCE 1 (bases 1 to 23)
AUTHORS Lesslauer W. and Schneitz U.
TITLE RAT ST38.2 chemokine
JOURNAL Patent: JP 2002500509-A 10 08-JAN-2002;
F HOFERMAN LA ROCHE AG
PN JP 2002500509-A/10
PD 08-JAN-2002
PF 23-APR-1998 JP 1998546575
PR 30-APR-1997 EP 97107135.2
PI WEBER LESSLAUER UTARIKE UTANS SCHNEITZ
PC C12N15/19,C07K14/52,C12N5/08,C12N5/10,C12Q1/68,C07K19/00, PC
C07K16/24,
PC A61K38/19,G01N33/50,G01N33/53
CC Strandedness: Single;
CC Topology: Linear;
CC /desc = 'primer';
FH Key Location/Qualifiers.
1..23
/organism="Chlamydia sp."
/mol_type="genomic DNA"
/db_xref="taxon:35827"

Query Match 30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 1.6;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 CTGGATGGAATTGACATAGCC 26
Db 23 CTGGATGGAATTGACACAGCC 1

RESULT 4
LOCUS AX084313/c 21 bp DNA linear PAT 26-FEB-2001
DEFINITION Sequence 107 from Patent WO0110902.
ACCESSION AX084313
VERSION AX084313.1 GI:13185815
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Shimkete R.A. and Fernandes B.
TITLE Nucleic acids and secreted polypeptides encoded thereby

JOURNAL Patent: WO 0110902-A 107 15-FEB-2001;

FEATURES Curagen Corporation (US)

source

Location/Qualifiers

1. .21

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="PCR PRIMER"

Query Match 24.3%; Score 15.8; DB 1; Length 21;

Best Local Similarity 89.5%; Pred. No. 7.8;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

42 CCTTGGGGGGTGGAGGT 60

Db 21 CCTTCTGGGGTGTAGGT 3

RESULT 5

BD107600

LOCUS BD107600 18 bp DNA linear PAT 18-SEP-2002

DEFINITION Novel microsatellite DNA derived from pear plants and method for

discriminating pear plants using the same.

ACCESSION BD107600.1 GI:23202418

VERSION JP 2002034597-A/9.

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM artificial sequences.

REFERENCE 1 (bases 1 to 18)

Yamamoto,T., Sawamura,Y., Imai,T., Matsuda,N., Saito,T., Shoda,M.,

Kotobuki,K., Hayaishi,K., Ba,Y., Kozono,M. and Kimura,T.

Novel microsatellite DNA derived from pear plants and method for

discriminating pear plants using the same

Patent: JP 2002034597-A 9 05-FEB-2002;

FRUIT TREE RES STATION

COMMENT OS Artificial Sequence

PN JP 2002034597-A/9

PD 05-FEB-2002 JP 20020220339

PF 21-JUL-2000 JP 2000220339

PI TOSHIBA YAMAMOTO, YUTAKA SAWAMURA, TSUYOSHI IMAI, NAGAO MATSUDA,

PI TOSHIHIRO SAITO, MORIYUKI SHODA, KAZUO KOTOBUKI, KENKI HAYASHI,

PI YOSHIYUKI BAN,

PI MASANORI KOZONO, TETSUYA KIMURA

PC C12Q1/68, A01H/00, C12N15/09, C12N15/00

CC Description of Artificial Sequence: Primer

FM Key Location/Qualifiers

FT source 1. .18

Location/Qualifiers

1. .18

/organism="Artificial Sequence".

Location/Qualifiers

1. .18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 22.2%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 12;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY

28 AAGACGAGAAAGACC 43

Db 2 AAGACGAGAAAGACC 17

RESULT 6

AR000413/c

LOCUS AR000413

DEFINITION Sequence 138 from patent US 5736356.

ACCESSION AR000413

VERSION AR000413.1 GI:3962944

KEYWORDS

SOURCE Unknown.

ORGANISM Unknown.

Unclassified.

1 (bases 1 to 18)

REFERENCE

Sano,K., Kumazawa,Y., Yasueda,H., Seguro,K. and Moroki,M.

Transglutaminase originating from *Craesostrea gigas*

Patent: US 5736356-A 138 07-APR-1998;

Location/Qualifiers

1. .18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 21.5%; Score 14; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 14;

Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

30 GAACAGAAAGACC 43

Db 16 GAACAGAAAGACC 3

RESULT 7

BD183671/c

LOCUS BD183671 17 bp DNA linear PAT 17-JUN-2003

DEFINITION Method for classifying genotype of hepatitis B viruses, and primers

and probes for the same.

ACCESSION BD183671.1 GI:31875871

VERSION JP 2002355098-A/8.

KEYWORDS unidentified

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 17)

Taninaka,A., Osaka,T., Mizoue,M., Kato,H., Orito,E. and Ueda,R.

Method for classifying genotype of hepatitis B viruses, and primers

and probes for the same

Patent: JP 2002355098-A 8 10-DEC-2002;

GENOME SCIENCE LABORATORIES CO LTD

OS Hepatitis virus (hepatitis B virus)

PN JP 2002355098-A/8

PD 10-DEC-2002 JP 2001246141

PF 14-AUG-2001 JP 2001246141

PI AKIKO TANINAKA, TAKUYA OSAKA, MASASHI MIZOUE, HIDEAKI KATO, ETSURO

PI ORITO, UEDA

PC C12Q1/68, C12N15/09, C12N15/09, G01N33/50, G01N33/53, PC

G01N33/56,

PC G01N33/569/(C12Q1/68, C12R1:93), (C12Q1/70, C12R1:93), C12N15/00,

PC C12N15/00

CC Probe employing the naturally occurred sequence of Hepatitis B

virus)

FM Key Location/Qualifiers

FT source 1. .17

Location/Qualifiers

1. .17

/organism="Hepatitis virus (hepatitis B

virus)"

Location/Qualifiers

1. .17

/organism="unidentified"

/mol_type="genomic DNA"

/db_xref="taxon:32644"

Query Match 21.2%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 14;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

39 GAACCTTGGGGGTTG 55

Db 17 GATCCTTGGGGGTTG 1

RESULT 8

AX217386/c

LOCUS AX217386 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2828 from Patent WO0159103.
 ACCSSION AX217386
 VERSION AX217386.1 GI:15527447
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2828 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 20.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 17;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 38
 DB 16 GCCCAAGAACAGAGA 2

RESULT 9
 LOCUS AX217387 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2829 from Patent WO0159103.
 ACCSSION AX217387
 VERSION AX217387.1 GI:15527448
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2829 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 20.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 17;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 38
 DB 15 GCCCAAGAACAGAGA 1

RESULT 10
 LOCUS AX217388 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 2830 from Patent WO0159103.
 ACCSSION AX217388
 VERSION AX217388.1 GI:15527449
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct

REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 2830 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGA 36
 DB 13 GCCCAAGAACAGA 1

RESULT 11
 LOCUS AX217756 17 bp RNA linear PAT 07-SEP-2001
 DEFINITION Sequence 3198 from Patent WO0159103.
 ACCSSION AX217756
 VERSION AX217756.1 GI:15527817
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Blatt, L., McSwiggen, J. and Chowrira, B. M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
 JOURNAL Patent: WO 0159103-A 3198 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)
 FEATURES
 source
 1..17
 /organism="synthetic construct"
 /mol_type="unassigned RNA"
 /db_xref="taxon:32630"
 /note="Nucleic Acid"

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGA 36
 DB 14 GCCCAAGAACAGA 2

RESULT 12
 LOCUS AX733882 17 bp DNA linear PAT 08-MAY-2003
 DEFINITION Sequence 5516 from Patent WO03025175.
 ACCSSION AX733882
 VERSION AX733882.1 GI:30513225
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 REFERENCE 1
 AUTHORS Telerman, A., Amson, R. and Tuijinder, M.
 TITLE Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines

JOURNAL Patent: WO 03025175-A 5516 27-MAR-2003;
 FEATURES Molecular Engines Laboratories (FR)
 source Location/Qualifiers
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 TCGAATTGACAT 22
 |||||
 Db 5 TCGAATTGACAT 17

RESULT 13
 AX757493 17 bp DNA linear PAT 25-JUN-2003
 LOCUS Sequence 814 from Patent WO03040369.
 DEFINITION AX757493
 ACCESSION AX757493.1 GI:32252109
 VERSION
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

REFERENCE 1
 Teلمان, A., Amson, R. and Tuijnder, M.
 Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines
 Patent: WO 03040369-A 814 15-MAY-2003;
 Molecular Engines Laboratories (FR)
 Location/Qualifiers
 1. .17
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

FEATURES
 source

Query Match 20.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 10 TCGAATTGACAT 22
 |||||
 Db 5 TCGAATTGACAT 17

RESULT 14
 AR053059 17 bp DNA linear PAT 29-SEP-1999
 LOCUS AR053059
 DEFINITION Sequence 29 from patent US 5834181.
 ACCESSION AR053059
 VERSION AR053059.1 GI:5977921
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.
 1 (bases 1 to 17)
 Shuber, A.P.
 High throughput screening method for sequences or genetic alterations in nucleic acids
 Patent: US 5834181-A 29 10-NOV-1998;
 Location/Qualifiers
 1. .17
 /organism="unknown"
 /mol_type="unassigned DNA"

FEATURES
 source

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 26 CCAAGAACAGAAAGAA 41
 |||||
 Db 2 CTAAGAACAGAAATGAA 17

RESULT 15
 AR065020 17 bp DNA linear PAT 29-SEP-1999
 LOCUS AR065020
 DEFINITION Sequence 29 from patent US 5849483.
 ACCESSION AR065020
 VERSION AR065020.1 GI:5995236
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 Unclassified.
 1 (bases 1 to 17)
 Shuber, A.P.
 High throughput screening method for sequences or genetic alterations in nucleic acids
 Patent: US 5849483-A 29 15-DEC-1998;
 Location/Qualifiers
 1. .17
 /organism="unknown"
 /mol_type="unassigned DNA"

FEATURES
 source

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 26 CCAAGAACAGAAAGAA 41
 |||||
 Db 2 CTAAGAACAGAAATGAA 17

RESULT 16
 BD254337 17 bp DNA linear PAT 17-JUL-2003
 LOCUS BD254337/c
 DEFINITION Regulation of repressor genes using nucleic acid molecules.
 ACCESSION BD254337
 VERSION BD254337.1 GI:33064107
 KEYWORDS JP 2002541795-A/2130.
 SOURCE unidentified
 ORGANISM unidentified
 Unclassified.
 1 (bases 1 to 17)
 Blatt, L., Zwick, M., Pavco, P. and Meswigen, J.
 Regulation of repressor genes using nucleic acid molecules
 Patent: JP 2002541795-A 2130 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC

REFERENCE 1
 (bases 1 to 17)
 Blatt, L., Zwick, M., Pavco, P. and Meswigen, J.
 Regulation of repressor genes using nucleic acid molecules
 Patent: JP 2002541795-A 2130 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC

COMMENT
 OS Eukaryote
 FN JP 2002541795-A/2130
 PD 10-DEC-2002
 PP 11-APR-2000 JP 2000611654
 PR 12-APR-1999 US 60/129390
 PI LAWRENCE BLATT, MICHAEL ZWICK PAMELA PAVCO JAMES MESWIGEN PC
 C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91),
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
 PC A61K37/02, C12R1:91)
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 Key Location/Qualifiers
 FT source 1. .17
 /organism="Eukaryote".
 Location/Qualifiers
 1. .17
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

FEATURES
 source

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTGGGGTTGGAGGTTT 62
 17 CTGGGGTTGGAGGCTT 2

Db

RESULT 17
 BD258370 17 bp DNA linear PAT 17-JUL-2003
 LOCUS Regulation of repressor genes using nucleic acid molecules.
 DEFINITION BD258370
 ACCESSION BD258370.1 GI:33068140
 VERSION JP 2002541795-A/6163.
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Blatt, L., Zwick, M., Pavco, P. and Mcswigen, J.
 TITLE Regulation of repressor genes using nucleic acid molecules
 JOURNAL Patent: JP 2002541795-A 6163 10-DEC-2002;
 RIBOZYME PHARMACEUTICALS INC
 COMMENT OS Eukaryote
 PN JP 2002541795-A/6163
 PD 10-DEC-2002
 PF 11-APR-2000 JP 2000611654
 PR 12-APR-1999 US 60/129390
 PI LAWRENCE BLATT, MICHAEL ZWICK, PAMELA PAVCO, JAMES MCSWIGEN
 PC C12N15/09, A61K38/00, A61K48/00, A61P43/00, A61P43/00, C12N5/10, PC
 C12P21/02,
 PC C12P21/02, C12P21/02//A61K31/711, (C12N5/10, C12R1:91), (C12P21/02, PC
 C12R1:91),
 PC (C12P21/02, C12R1:91), (C12P21/02, C12R1:91), C12N15/00, C12N5/00,
 PC A61K37/02,
 PC (C12N5/00, C12R1:91)
 CC Regulation of repressor genes using nucleic acid molecules FH
 Key Location/Qualifiers
 FT source 1..17
 Location/Qualifiers
 1..17 /organism='Eukaryote'.
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 10 TGGAAATTGGACATAGC 25
 17 TGGAGTTGGACACAGC 2

Db

RESULT 18
 I32565 17 bp DNA linear PAT 06-FEB-1997
 LOCUS Sequence 29 from patent US 5589330.
 DEFINITION I32565
 ACCESSION I32565.1 GI:1823356
 VERSION
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 17)
 AUTHORS Shuber, A.P.
 TITLE High-throughput screening method for sequence or genetic
 alterations in nucleic acids using elution and sequencing of
 complementary oligonucleotides

JOURNAL Patent: US 5589330-A 29 31-DEC-1996;
 FEATURES Location/Qualifiers
 source 1..17
 /organism='unknown'
 /mol_type='unassigned DNA'

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGACGAGAAAGAA 41
 2 CTAAGAACAGAAATGAA 17

Db

RESULT 19
 AX218301 17 bp RNA linear PAT 07-SEP-2001
 LOCUS Sequence 3743 from Patent WO0159103.
 DEFINITION AX218301
 ACCESSION AX218301
 VERSION AX218301.1 GI:15528362
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1
 AUTHORS Blatt, L., Mcswigen, J. and Chowitra, B.M.
 TITLE Method and reagent for the modulation and diagnosis of cd20 and
 nogo gene expression
 JOURNAL Patent: WO 0159103-A 3743 16-AUG-2001;
 RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ;
 Mcswigen, James (US) ; Chowitra, Bharat M. (US)
 Location/Qualifiers
 1..17
 /organism='synthetic construct'
 /mol_type='unassigned RNA'
 /db_xref='taxon:32630'
 /note='Nucleic Acid'

Query Match 19.7%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 22;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 26 CCAAGACGAGAAAGAA 41
 2 CCAAGACGAGAAAGAA 17

Db

RESULT 20
 BD233057 15 bp DNA linear PAT 17-JUL-2003
 LOCUS Method of detecting mutation selected by drug in HIV protease gene.
 DEFINITION BD233057
 ACCESSION BD233057
 VERSION BD233057.1 GI:33042827
 KEYWORDS JP 2002518065-A/153.
 SOURCE Aids-associated retrovirus
 ORGANISM Aids-associated retrovirus
 Viruses; Retroid viruses; Retroviridae.
 REFERENCE 1 (bases 1 to 15)
 AUTHORS Stuyver, L.
 TITLE Method of detecting mutation selected by drug in HIV protease gene
 JOURNAL Patent: JP 2002518065-A 153 25-JUN-2002;
 INNOGENETICS NV
 COMMENT OS Aids-associated retrovirus
 PN JP 2002518065-A/153
 PD 25-JUN-2002
 PF 22-JUN-1999 JP 2000556068
 PR 24-JUN-1998 EP 96870143.9
 PI LIEVEN STUYVER
 PC C12N15/09, C12Q1/68, C12Q1/70, C12N15/00
 CC Method of detecting mutation selected by drug in HIV protease
 gene
 FH Key Location/Qualifiers

FT source 1.15
/organism='Aids-associated retrovirus'
FEATURES
source
1.15
/organism='Aids-associated retrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:11966'

Query Match 19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 22;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGAGGTTT 62
|||
1 CGAGTTGAGGTTT 14

Db 1 CGAGTTGAGGTTT 14

RESULT 21
BD233078 15 bp DNA linear PAT 17-JUN-2003
LOCUS Method of detecting mutation selected by drug in HIV protease gene.
DEFINITION BD233078
ACCESSION BD233078.1 GI:33042848
VERSION JP 2002518065-A/174.
KEYWORDS Aids-associated retrovirus
SOURCE Aids-associated retrovirus
ORGANISM Aids-associated retrovirus
REFERENCE 1 (bases 1 to 15)
AUTHORS Stuyver,L.
TITLE Method of detecting mutation selected by drug in HIV protease gene
JOURNAL Patent: JP 2002518065-A 174 25-JUN-2002;
INNOGENETICS NV
FEATURES
source
1.15
/organism='Aids-associated retrovirus'
/mol_type='genomic DNA'
/db_xref='taxon:11966'

Query Match 19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 22;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGAGGTTT 62
|||
1 CGAGTTGAGGTTT 14

Db 1 CGAGTTGAGGTTT 14

RESULT 22
AX007611 15 bp DNA linear PAT 06-SEP-2000
LOCUS Sequence 153 from Patent WO9967428.
DEFINITION AX007611
ACCESSION AX007611.1 GI:9995308
VERSION
KEYWORDS Aids-associated retrovirus
SOURCE Aids-associated retrovirus
ORGANISM Aids-associated retrovirus
REFERENCE 1
AUTHORS Stuyver,L.
TITLE Method for detection of drug-selected mutations in the hiv protease gene

JOURNAL Patent: WO 9967428-A 153 29-DEC-1999;
INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
FEATURES
source
1.15
/organism='Aids-associated retrovirus'
/mol_type='unassigned DNA'
/db_xref='taxon:11966'

Query Match 19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 22;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGAGGTTT 62
|||
1 CGAGTTGAGGTTT 14

Db 1 CGAGTTGAGGTTT 14

RESULT 23
AX007632 15 bp DNA linear PAT 06-SEP-2000
LOCUS Sequence 174 from Patent WO9967428.
DEFINITION AX007632
ACCESSION AX007632.1 GI:9995329
VERSION
KEYWORDS Aids-associated retrovirus
SOURCE Aids-associated retrovirus
ORGANISM Aids-associated retrovirus
REFERENCE 1
AUTHORS Stuyver,L.
TITLE Method for detection of drug-selected mutations in the hiv protease gene
JOURNAL Patent: WO 9967428-A 174 29-DEC-1999;
INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
FEATURES
source
1.15
/organism='Aids-associated retrovirus'
/mol_type='unassigned DNA'
/db_xref='taxon:11966'

Query Match 19.1%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 22;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGAGGTTT 62
|||
1 CGAGTTGAGGTTT 14

Db 1 CGAGTTGAGGTTT 14

RESULT 24
AX104604 13 bp DNA linear PAT 30-APR-2001
LOCUS Sequence 796 from Patent W00122972.
DEFINITION AX104604
ACCESSION AX104604.1 GI:13920801
VERSION
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Krieg,A.M., Schetter,C. and Vollmer,J.C.
TITLE Immunostimulatory nucleic acids
JOURNAL Patent: WO 0122972-A 796 05-APR-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US); Coley Pharmaceutical GmbH (DE)
FEATURES
source
1.13
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 29;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTGGAGGTT 61
Db 1 GGGGTGGAGGTT 13

RESULT 25
LOCUS AX355422 13 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 450 from Patent WO0197843.
ACCESSION AX355422
VERSION AX355422.1 GI:18620090
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Weiner, G. and Hartmann, G.
TITLE Methods for enhancing antibody-induced cell lysis and treating cancer
JOURNAL Patent: WO 0197843-A 450 27-DEC-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US)
FEATURES
source Location/Qualifiers
1..13
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide-phosphorothioate backbone"

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 29;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTGGAGGTT 61
Db 1 GGGGTGGAGGTT 13

RESULT 26
LOCUS AX547657 13 bp DNA linear PAT 01-MAR-2003
DEFINITION Sequence 796 from Patent WO02053141.
ACCESSION AX547657
VERSION AX547657.1 GI:25812801
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Bratzler, R.L.
TITLE Inhibition of angiogenesis by nucleic acids
JOURNAL Patent: WO 02053141-A 796 11-JUL-2002;
Coley Pharmaceutical Group, Inc. (US)
FEATURES
source Location/Qualifiers
1..13
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic Sequence"

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 29;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTGGAGGTT 61
Db 1 GGGGTGGAGGTT 13

RESULT 27
LOCUS BD233079 14 bp DNA linear PAT 17-JUL-2003

DEFINITION Method of detecting mutation selected by drug in HIV protease gene.
LOCUS BD233079 1 GI:33042849
VERSION BD233079.1 GI:33042849
KEYWORDS JP 2002518065-A/175.
SOURCE Aids-associated retrovirus
ORGANISM Aids-associated retrovirus
REFERENCE 1
AUTHORS Stuyver, L.
TITLE Method of detecting mutation selected by drug in HIV protease gene
JOURNAL Patent: JP 2002518065-A 175 25-JUN-2002;
INNOGENETICS NV
COMMENT OS Aids-associated retrovirus
PN JP 2002518065-A/175
PD 25-JUN-2002
PF 22-JUN-1999 JP 2000556068
PR 24-JUN-1998 EP 98870143.9
PI LIEVEN STUYVER
PC C12N15/09, C12Q1/68, C12Q1/70, C12N15/00
CC Method of detecting mutation selected by drug in HIV protease
CC Method of detecting mutation selected by drug in HIV protease
FH Key gene
FT source Location/Qualifiers
1..14
/organism="Aids-associated retrovirus"
/mol_type="genomic DNA"
/db_xref="taxon:11966"

Query Match 17.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 31;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 50 GGGTGGAGGTT 62
Db 1 GAGTTGGAGGTT 13

RESULT 28
LOCUS AX007633 14 bp DNA linear PAT 06-SEP-2000
DEFINITION Sequence 175 from Patent WO9967428.
ACCESSION AX007633
VERSION AX007633.1 GI:9995330
KEYWORDS
SOURCE Aids-associated retrovirus
ORGANISM Aids-associated retrovirus
REFERENCE 1
AUTHORS Stuyver, L.
TITLE Method for detection of drug-selected mutations in the hiv protease gene
JOURNAL Patent: WO 9967428-A 175 29-DEC-1999;
INNOGENETICS NV (BE); STUYVER LIEVEN (BE)
FEATURES
source Location/Qualifiers
1..14
/organism="Aids-associated retrovirus"
/mol_type="unassigned DNA"
/db_xref="taxon:11966"

Query Match 17.5%; Score 11.4; DB 1; Length 14;
Best Local Similarity 92.3%; Pred. No. 31;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 50 GGGTGGAGGTT 62
Db 1 GAGTTGGAGGTT 13

RESULT 29
LOCUS I45950 15 bp DNA linear PAT 07-OCT-1997


```

DEFINITION Sequence 22 from patent US 5639603.
ACCESSION 145950
VERSION 145950.1 GI:2469915
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Dower, W.J., Barrett, R.W., Gallop, M.A. and Needeles, M.C.
TITLE Synthesizing and screening molecular diversity
JOURNAL Patent: US 5639603-A 22 17-JUN-1997;
FEATURES
source 1. .15
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 33;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TCGAATGGAATTG 17
| | | | | | | | | |
2 TCGAATGGAAGTG 14

Db

RESULT 30
AR278927 15 bp DNA linear PAT 10-APR-2003
LOCUS AR278927
DEFINITION Sequence 5 from patent US 6514693.
ACCESSION AR278927
VERSION AR278927.1 GI:29713570
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Lansdorf, P.
TITLE Method for detecting multiple copies of a repeat sequence in a
JOURNAL nucleic acid molecule
FEATURES Patent: US 6514693-A 5 04-FEB-2003;
source 1. .15
Location/Qualifiers
/mol_type="unknown"
/mol_type="genomic DNA"

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 33;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TCGAATGGAATTG 17
| | | | | | | | | |
13 TCGAATGGAATGG 1

Db

RESULT 31
AR278931 15 bp DNA linear PAT 10-APR-2003
LOCUS AR278931
DEFINITION Sequence 9 from patent US 6514693.
ACCESSION AR278931
VERSION AR278931.1 GI:29713574
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 15)
AUTHORS Lansdorf, P.
TITLE Method for detecting multiple copies of a repeat sequence in a
JOURNAL nucleic acid molecule
FEATURES Patent: US 6514693-A 9 04-FEB-2003;
source 1. .15
Location/Qualifiers
/mol_type="unknown"
/mol_type="genomic DNA"

```

```

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 33;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TCGAATGGAATTG 17
| | | | | | | | | |
3 TCGAATGGAATCG 15

Db

RESULT 32
AX587070 15 bp DNA linear PAT 10-JAN-2003
LOCUS AX587070
DEFINITION Sequence 92 from Patent WO02072883.
ACCESSION AX587070
VERSION AX587070.1 GI:27655945
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Roetger, A.
TITLE Nucleotide carrier for diagnosing and treating oral diseases
JOURNAL Patent: WO 02072883-A 92 19-SEP-2002;
FEATURES Roetger, Antje (DB)
source 1. .15
Location/Qualifiers
/mol_type="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
/note="Bacteria"

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 33;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 3 TCTGGAATGGAAT 15
| | | | | | | | | |
2 TCTGGAATGGAAT 14

Db

RESULT 33
BD086489 13 bp DNA linear PAT 27-AUG-2002
LOCUS BD086489
DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
ACCESSION BD086489
VERSION BD086489.1 GI:22632099
KEYWORDS JP 2001523451-A/20.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 13)
AUTHORS Anuschiwan, P., Uhlmann, B. and Weiser, C.
TITLE Tenascin antisense oligonucleotide for treating leukemia
JOURNAL Patent: JP 2001523451-A 20 27-NOV-2001;
COMMENT AVANTIS PHARMA DEUTSCHLAND GMBH
OS Unidentified
FN JP 2001523451-A/20
PD 27-NOV-2001
PF 29-OCT-1998 JP 2000521185
PR 15-NOV-1997 DE 197 50 702.6
PI PEYMAN ANUSCHIRWAN EUGEN UHLMANN CAROLINE WEISER PC
CI2N15/09,A61K31/711,A61K48/00,A61P17/00,C12Q1/68,C12N15/00 CC
Strandedness: Single;
CC Topology: Linear;
CC Tenascin antisense oligonucleotide for treating leukemia PH
Key Location/Qualifiers
FT exon 1. .13
Location/Qualifiers
1. .13
/mol_type="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

```

Query Match 16.9%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 34;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
 |||||
 3 ACAGAAAGAAC 13

RESULT 34

LOCUS BD086508 13 bp DNA linear PAT 27-AUG-2002
 DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
 ACCESSION BD086508
 VERSION BD086508.1 GI:22632118
 KEYWORDS JP 2001523451-A/39.
 SOURCE unclassified
 ORGANISM unclassified.

REFERENCE 1 (bases 1 to 13)
 AUTHORS Anuschirwan, P., Uhlmann, E. and Weiser, C.
 TITLE Tenascin antisense oligonucleotide for treating leukemia
 JOURNAL Patent: JP 2001523451-A 39 27-NOV-2001;
 COMMENT AVENTIS PHARMA DEUTSCHLAND GMBH
 OS unclassified
 PN JP 2001523451-A/39
 PD 27-NOV-2001
 PF 29-OCT-1998 JP 2000521185
 PR 15-NOV-1997 DE 197 50 702.6
 PI PEYMAN ANUSCHIRWAN, EUGEN UHLMANN, CAROLINE WEISER PC
 C12N15/09, A61K31/711, A61K48/00, A61P17/00, C12Q1/68, C12N15/00 CC
 Strandness: Single;
 CC Topology: Linear;
 CC Tenascin antisense oligonucleotide for treating leukemia FH
 Key Location/Qualifiers
 FT exon 1..13.
 Location/Qualifiers
 1..13
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

FEATURES

source

Query Match 16.9%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 34;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
 |||||
 3 ACAGAAAGAAC 13

RESULT 35

LOCUS BD086527 13 bp DNA linear PAT 27-AUG-2002
 DEFINITION Tenascin antisense oligonucleotide for treating leukemia.
 ACCESSION BD086527
 VERSION BD086527.1 GI:22632137
 KEYWORDS JP 2001523451-A/58.
 SOURCE unclassified
 ORGANISM unclassified.

REFERENCE 1 (bases 1 to 13)
 AUTHORS Anuschirwan, P., Uhlmann, E. and Weiser, C.
 TITLE Tenascin antisense oligonucleotide for treating leukemia
 JOURNAL Patent: JP 2001523451-A 58 27-NOV-2001;
 COMMENT AVENTIS PHARMA DEUTSCHLAND GMBH
 OS unclassified
 PN JP 2001523451-A/58
 PD 27-NOV-2001
 PF 29-OCT-1998 JP 2000521185
 PR 15-NOV-1997 DE 197 50 702.6
 PI PEYMAN ANUSCHIRWAN, EUGEN UHLMANN, CAROLINE WEISER PC

C12N15/09, A61K31/711, A61K48/00, A61P17/00, C12Q1/68, C12N15/00 CC
 Strandness: Single;
 CC Topology: Linear;
 CC Tenascin antisense oligonucleotide for treating leukemia FH
 Key Location/Qualifiers
 FT exon 1..13.
 Location/Qualifiers
 1..13
 /organism="unclassified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 16.9%; Score 11; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 34;
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 32 ACAGAAAGAAC 42
 |||||
 3 ACAGAAAGAAC 13

RESULT 36
 LOCUS AR178312 14 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 29 from patent US 6319672.
 ACCESSION AR178312
 VERSION AR178312.1 GI:20219450
 KEYWORDS .
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)
 AUTHORS Crouzet, J., Scherman, D., Wils, P., Blanche, F. and Cameron, B.
 TITLE Purification of a triple helix formation with an immobilized oligonucleotide
 JOURNAL Patent: US 6319672-A 29 20-NOV-2001;
 Location/Qualifiers
 1..14
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 40;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACGAGAGAA 41
 |||||
 1 AAGAAAAAAAAAGAA 14

RESULT 37
 LOCUS AR178313 14 bp DNA linear PAT 20-APR-2002
 DEFINITION Sequence 30 from patent US 6319672.
 ACCESSION AR178313
 VERSION AR178313.1 GI:20219451
 KEYWORDS .
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 14)
 AUTHORS Crouzet, J., Scherman, D., Wils, P., Blanche, F. and Cameron, B.
 TITLE Purification of a triple helix formation with an immobilized oligonucleotide
 JOURNAL Patent: US 6319672-A 30 20-NOV-2001;
 Location/Qualifiers
 1..14
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 40;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
 |||||
 Db 14 AAGAAAAAAGAA 1

RESULT 38
 LOCUS 128572 14 bp DNA linear PAT 06-FEB-1997
 DEFINITION Sequence 25 from patent US 5571937.
 ACCESSION 128572
 VERSION 128572.1 GI:1819348
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 14)
 AUTHORS Watanabe,K.A., Ren,W.-Y. and Weil,R.
 TITLE Complementary DNA and toxins
 JOURNAL Patent: US 5571937-A 25 05-NOV-1996;
 FEATURES Location/Qualifiers
 source 1..14
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 40;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
 |||||
 Db 1 AAGAAAAAAGATGAA 14

RESULT 39
 LOCUS 158734 14 bp DNA linear PAT 07-OCT-1997
 DEFINITION Sequence 25 from patent US 5652350.
 ACCESSION 158734
 VERSION 158734.1 GI:2477972
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 14)
 AUTHORS Watanabe,K.A., Ren,W.-Y. and Weil,R.
 TITLE Complementary DNA and toxins
 JOURNAL Patent: US 5652350-A 25 29-JUL-1997;
 FEATURES Location/Qualifiers
 source 1..14
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 40;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
 |||||
 Db 1 AAGAAAAAAGATGAA 14

RESULT 40
 LOCUS AX016242 14 bp DNA linear PAT 07-SEP-2000
 DEFINITION Sequence 9 from Patent WO949067.
 ACCESSION AX016242
 VERSION AX016242.1 GI:10041819
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1 artificial sequences.

AUTHORS Wils,P., Ciolina,C. and Scherman,D.
 TITLE Nucleic acid transfer vectors, compositions containing same and
 JOURNAL uses
 Patent: WO 9949067-A 9 30-SEP-1999;
 WILS PIERRE (FR); CIOLINA CAROLE (FR); SCHERMAN DANIEL (FR); RHONE
 POULENC RORER SA (FR)
 FEATURES Location/Qualifiers
 source 1..14
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="misc_binding"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 40;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41
 |||||
 Db 1 AAGAAAAAAGAA 14

RESULT 41
 LOCUS AX287231 14 bp DNA linear PAT 21-NOV-2001
 DEFINITION Sequence 31 from Patent WO0168122.
 ACCESSION AX287231
 VERSION AX287231.1 GI:17049164
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 REFERENCE 1
 AUTHORS Schlingensiepen,K.H., Schlingensiepen,R., Apfel,R., Brysch,W.,
 Jachimczak,P. and Bogdahn,U.
 TITLE A method for reversing the immunosuppressive effects of the
 JOURNAL melanoma inhibitory activity mla
 Patent: WO 0168122-A 31 20-SEP-2001;
 Biognostik Gesellschaft fuer Biomekulare Diagnostik mbH (DE)
 FEATURES Location/Qualifiers
 source 1..14
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 16.6%; Score 10.8; DB 1; Length 14;
 Best Local Similarity 85.7%; Pred. No. 40;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 17 GGAATAGCCCAAG 30
 |||||
 Db 1 GGAATAGCCCAAG 14

RESULT 42
 LOCUS AX323394 14 bp DNA linear PAT 07-JAN-2002
 DEFINITION Sequence 29 from Patent WO0192511.
 ACCESSION AX323394
 VERSION AX323394.1 GI:18094156
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 REFERENCE 1 artificial sequences.
 AUTHORS Crouzet,J., Scherman,D., Wils,P., Blanche,F. and Cameron,B.
 TITLE Purification of a triple helix formation with an immobilized
 JOURNAL oligonucleotide
 Patent: WO 0192511-A 29 06-DEC-2001;
 Aventis Pharma (FR)
 FEATURES Location/Qualifiers
 source 1..14

```

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/feature="synthetic oligonucleotide"

Query Match
Best Local Similarity 16.6%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db
1 AAGAACGAGAAAGAA 41
1 AAGAAAAAAAAAAGAA 14

RESULT 43
AX323395/c
LOCUS AX323395 14 bp DNA linear PAT 07-JAN-2002
DEFINITION Sequence 30 from Patent WO0192511.
ACCESSION AX323395
VERSION AX323395.1 GI:18094157
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1 Crouzet,J., Sherman,D., Wils,P., Blanche,F. and Cameron,B.
AUTHORS Purification of a triple helix formation with an immobilized
TITLE oligonucleotide
JOURNAL Patent: WO 0192511-A 30 06-DEC-2001;
Aventis Pharma (FR)
FEATURES
source location/Qualifiers
1..14
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/feature="synthetic oligonucleotide"

Query Match
Best Local Similarity 16.6%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db
28 AAGAACGAGAAAGAA 41
14 AAGAAAAAAAAAAGAA 1

RESULT 44
BD135020
LOCUS BD135020 14 bp DNA linear PAT 18-SEP-2002
DEFINITION vector having nucleic acid transferred thereinto, compositions
ACCESSION BD135020
VERSION BD135020.1 GI:23229655
KEYWORDS JP 2002507429-A/9.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 14)
AUTHORS Storrina,C., Sherman,D. and Wills,P.
TITLE Vector having nucleic acid transferred thereinto, compositions
JOURNAL Patent: JP 2002507429-A 9 12-MAR-2002;
AVENTIS PHARMA SA
COMMENT
OS Unidentified
PN JP 2002507429-A/9
PD 12-MAR-2002
PF 19-MAR-1998 JP 2000538027
PR 24-MAR-1998 FR 98/03573,18-MAY-1998 US 60/085 848 PI
CAROL STORRINA, DANIEL SHERMAN, PIERRE WILLS
PC C12N15/09,A61K39/39,A61K48/00,C12N1/15,C12N1/19,C12N5/10, PC
C12N15/00,
CC C12N5/00
Strandedness: Single;

```

```

CC Topology: linear;
CC Vector having nucleic acid transferred thereinto, compositions
CC containing
CC the vector and utilization thereof
FH Key Location/Qualifiers
FT source 1..14
FT /organism='unidentified'.
FEATURES
source location/Qualifiers
1..14
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 16.6%; Score 10.8; DB 1; Length 14;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db
28 AAGAACGAGAAAGAA 41
1 AAGAAAAAAAAAAGAA 14

RESULT 45
A14857/c
LOCUS A14857 12 bp DNA linear PAT 16-MAY-1994
DEFINITION Nucleotide sequence 1 from patent number EP0334694.
ACCESSION A14857
VERSION A14857.1 GI:512100
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 12)
AUTHORS Cravador,A., De Vos-Pierreux,M.J. and Bollen,A.
TITLE Nucleic acid probes with non-radioactive labels, and preparation
JOURNAL processes
PATENT: EP 0334694-A 1 27-SEP-1989;
IRB-CELLTARG S.A.; LA REGION WALLONNE
FEATURES
source location/Qualifiers
1..12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db
17 GGACATGAGCCCA 28
12 GGACGAGGCCCA 1

RESULT 46
AR036346
LOCUS AR036346 12 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 9 from patent US 5872105.
ACCESSION AR036346
VERSION AR036346.1 GI:5953014
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 12)
AUTHORS KOOL E.T.
TITLE Single-stranded circular oligonucleotides useful for drug delivery
JOURNAL Patent: US 5872105-A 9 16-FEB-1999;
FEATURES
source location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

```

```
Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
|||||
1 AAGAAAAAGAAAG 12

Db

RESULT 47
AR036347/c          12 bp      DNA      linear      PAT 29-SEP-1999
LOCUS               AR036347
DEFINITION          Sequence 10 from patent US 5872105.
ACCESSION            AR036347
VERSION              AR036347.1 GI:5953015
KEYWORDS
SOURCE               Unknown.
ORGANISM             Unclassified.
REFERENCE            1 (bases 1 to 12)
AUTHORS              Kool,E.T.
TITLE                Single-stranded circular oligonucleotides useful for drug delivery
JOURNAL              Patent: US 5872105-A 10 16-FEB-1999;
FEATURES             Location/Qualifiers
                     1..12
                     /organism="unknown"
                     /mol_type="unassigned DNA"

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
|||||
12 AAGAAAAAGAAAG 1

Db

RESULT 48
AR036365            12 bp      DNA      linear      PAT 29-SEP-1999
LOCUS               AR036365
DEFINITION          Sequence 28 from patent US 5872105.
ACCESSION            AR036365
VERSION              AR036365.1 GI:5953033
KEYWORDS
SOURCE               Unknown.
ORGANISM             Unclassified.
REFERENCE            1 (bases 1 to 12)
AUTHORS              Kool,E.T.
TITLE                Single-stranded circular oligonucleotides useful for drug delivery
JOURNAL              Patent: US 5872105-A 28 16-FEB-1999;
FEATURES             Location/Qualifiers
                     1..12
                     /organism="unknown"
                     /mol_type="unassigned DNA"

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
|||||
1 GAACAGAAAGAA 12

Db

RESULT 49
AR036366            12 bp      DNA      linear      PAT 29-SEP-1999
LOCUS               AR036366
DEFINITION          Sequence 29 from patent US 5872105.
ACCESSION            AR036366
VERSION              AR036366.1 GI:5953034
KEYWORDS
SOURCE               Unknown.
```

```
ORGANISM             Unknown.
REFERENCE            1 (bases 1 to 12)
AUTHORS              Kool,E.T.
TITLE                Single-stranded circular oligonucleotides useful for drug delivery
JOURNAL              Patent: US 5872105-A 29 16-FEB-1999;
FEATURES             Location/Qualifiers
                     1..12
                     /organism="unknown"
                     /mol_type="unassigned DNA"

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
|||||
1 GAACAGAAAGAA 12

Db

RESULT 50
AR036368/c          12 bp      DNA      linear      PAT 29-SEP-1999
LOCUS               AR036368
DEFINITION          Sequence 31 from patent US 5872105.
ACCESSION            AR036368
VERSION              AR036368.1 GI:5953036
KEYWORDS
SOURCE               Unknown.
ORGANISM             Unclassified.
REFERENCE            1 (bases 1 to 12)
AUTHORS              Kool,E.T.
TITLE                Single-stranded circular oligonucleotides useful for drug delivery
JOURNAL              Patent: US 5872105-A 31 16-FEB-1999;
FEATURES             Location/Qualifiers
                     1..12
                     /organism="unknown"
                     /mol_type="unassigned DNA"

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAA 41
|||||
12 GAACAGAAAGAA 1

Db

RESULT 51
I12563              12 bp      DNA      linear      PAT 26-JUL-1995
LOCUS               I12563
DEFINITION          Sequence 9 from patent US 5426180.
ACCESSION            I12563
VERSION              I12563.1 GI:309947
KEYWORDS
SOURCE               Unknown.
ORGANISM             Unclassified.
REFERENCE            1 (bases 1 to 12)
AUTHORS              Kool,E.T.
TITLE                Methods of making single-stranded circular oligonucleotides
JOURNAL              Patent: US 5426180-A 9 20-JUN-1995;
FEATURES             Location/Qualifiers
                     1..12
                     /organism="unknown"
                     /mol_type="unassigned DNA"

Query Match          16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
|||||
```

Db 1 AAGAAAGAAAG 12

RESULT 52

LOCUS 112564

DEFINITION Sequence 10 from patent US 5426180.

ACCESSION 112564

VERSION 112564.1 GI:909948

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 12)

AUTHORS Kool,E.T.

TITLE Methods of making single-stranded circular oligonucleotides

JOURNAL Patent: US 5426180-A 10 20-JUN-1995;

FEATURES

source

1. .12

/organism="unknown"

/mol_type="unassigned DNA"

Query Match

Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAG 39

Db 12 AAGAAAGAAAG 1

RESULT 53

LOCUS 112565

DEFINITION Sequence 11 from patent US 5426180.

ACCESSION 112565

VERSION 112565.1 GI:909949

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 12)

AUTHORS Kool,E.T.

TITLE Methods of making single-stranded circular oligonucleotides

JOURNAL Patent: US 5426180-A 11 20-JUN-1995;

FEATURES

source

1. .12

/organism="unknown"

/mol_type="unassigned DNA"

Query Match

Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAG 39

Db 12 AAGAAAGAAAG 1

RESULT 54

LOCUS 120199

DEFINITION Sequence 14 from patent US 5514546.

ACCESSION 120199

VERSION 120199.1 GI:1600554

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 12)

AUTHORS Kool,E.T.

TITLE Stem-loop oligonucleotides containing parallel and antiparallel binding domains

JOURNAL Patent: US 5514546-A 12 bp DNA linear PAT 07-OCT-1996

FEATURES

source

1. .12

/organism="unknown"

/mol_type="unassigned DNA"

Query Match

Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAG 39

Db 1 AAGAAATAGAAAG 12

JOURNAL Patent: US 5514546-A 14 07-MAY-1996;

FEATURES

source

1. .12

/organism="unknown"

/mol_type="unassigned DNA"

Query Match

Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAG 39

Db 1 AAGAAATAGAAAG 12

RESULT 55

LOCUS 120200

DEFINITION Sequence 15 from patent US 5514546.

ACCESSION 120200

VERSION 120200.1 GI:1600555

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 12)

AUTHORS Kool,E.T.

TITLE Stem-loop oligonucleotides containing parallel and antiparallel binding domains

JOURNAL Patent: US 5514546-A 15 07-MAY-1996;

FEATURES

source

1. .12

/organism="unknown"

/mol_type="unassigned DNA"

Query Match

Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAG 39

Db 1 AAGAAATAGAAAG 12

RESULT 56

LOCUS 120202

DEFINITION Sequence 17 from patent US 5514546.

ACCESSION 120202

VERSION 120202.1 GI:1600557

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 12)

AUTHORS Kool,E.T.

TITLE Stem-loop oligonucleotides containing parallel and antiparallel binding domains

JOURNAL Patent: US 5514546-A 17 07-MAY-1996;

FEATURES

source

1. .12

/organism="unknown"

/mol_type="unassigned DNA"

Query Match

Best Local Similarity 16.0%; Score 10.4; DB 1; Length 12;

Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAG 39

Db 12 AAGAAATAGAAAG 1

RESULT 57
LOCUS I72094 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 9 from patent US 5683874.
ACCESSION I72094
VERSION I72094.1 GI:3008233
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 9 04-NOV-1997;
FEATURES
source
1. .12
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 28 AAGACAGAAAG 39
Db 1 AAGAAAGAAAG 12
RESULT 58
LOCUS I72095 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 10 from patent US 5683874.
ACCESSION I72095
VERSION I72095.1 GI:3008234
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 10 04-NOV-1997;
FEATURES
source
1. .12
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 28 AAGACAGAAAG 39
Db 1 AAGAAAGAAAG 12
RESULT 59
LOCUS I72113 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 28 from patent US 5683874.
ACCESSION I72113
VERSION I72113.1 GI:3008252
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 28 04-NOV-1997;
FEATURES
source
1. .12
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 28 AAGACAGAAAG 39
Db 12 AAGAAAGAAAG 1

FEATURES
source
1. .12
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 30 GAACAGAAAGAA 41
Db 1 GAAGAGAAAGAA 12
RESULT 60
LOCUS I72114 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 29 from patent US 5683874.
ACCESSION I72114
VERSION I72114.1 GI:3008253
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 29 04-NOV-1997;
FEATURES
source
1. .12
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 30 GAACAGAAAGAA 41
Db 12 GAAGAGAAAGAA 12
RESULT 61
LOCUS I72116 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 31 from patent US 5683874.
ACCESSION I72116
VERSION I72116.1 GI:3008255
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 31 04-NOV-1997;
FEATURES
source
1. .12
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 30 GAACAGAAAGAA 41
Db 1 GAAGAGAAAGAA 12
RESULT 62
LOCUS I72116 12 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 31 from patent US 5683874.
ACCESSION I72116
VERSION I72116.1 GI:3008255
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Koal,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL Patent: US 5683874-A 31 04-NOV-1997;
FEATURES
source
1. .12
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 30 GAACAGAAAGAA 41
Db 12 GAAGAGAAAGAA 12

BD080369/c
LOCUS BD080369 12 bp DNA linear PAT 27-AUG-2002
DEFINITION Methods of synthesizing oligonucleotides with random codons.
ACCESSION BD080369
VERSION BD080369.1 GI:22625972
KEYWORDS JP 2001299342-A/35.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 12)
AUTHORS Huse, M.D.
TITLE Methods of synthesizing oligonucleotides with random codons
JOURNAL Patent: JP 2001299342-A 35 30-OCT-2001;
IXSYS INC
COMMENT OS Artificial Sequence
PN JP 2001299342-A/35
PD 30-OCT-2001
PF 15-MAR-2001 JP 2001075101
PR 24-AUG-1990 US 573648
PI WILLIAM D HUSE
PC C12N15/00, C07H21/04, C12Q1/68, C12N15/00
CC synthetic construct
FH Key
FT source 1..12 Location/Qualifiers
FEATURES
source 1..12 Location/Qualifiers
1..12 /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 16.0%; Score 10.4; DB 1; Length 12;
Best Local Similarity 91.7%; Pred. No. 40;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGAATGGAATT 16
Db 12 TGGATGGAATT 1
RESULT 63
LOCUS 121837 13 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 14 from patent US 5525468.
ACCESSION 121837
VERSION 121837.1 GI:1602191
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 13)
AUTHORS McSwigen, J.A.
TITLE Assay for ribozyme target site
JOURNAL Patent: US 5525468-A 14 11-JUN-1996;
FEATURES
source 1..13 Location/Qualifiers
1..13 /organism="unknown"
/mol_type="unassigned DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 43;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 10 TGAATGGAACA 21
Db 13 TGAATGGAACA 2
RESULT 64
LOCUS AR275240 13 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 45 from patent US 6506893.
ACCESSION AR275240

VERSION AR275240.1 GI:29708241
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 13)
AUTHORS El Solh, N. and Allignet, J.
TITLE Polynucleotides and their use for detecting resistance to streptogramin A or to streptogramin B and related compounds
JOURNAL Patent: US 6506893-A 45 14-JAN-2003;
FEATURES
source 1..13 Location/Qualifiers
1..13 /organism="unknown"
/mol_type="genomic DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 43;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 7 GAATGGAATTGG 18
Db 13 GAATGGAATTGG 2
RESULT 65
LOCUS AR339891 13 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 36 from patent US 6570001.
ACCESSION AR339891
VERSION AR339891.1 GI:33731110
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 13)
AUTHORS Solh, N.E. and Allignet, J.
TITLE Polynucleotides and their use for detecting resistance to streptogramin A or to streptogramin B and related compounds
JOURNAL Patent: US 6570001-A 36 27-MAY-2003;
FEATURES
source 1..13 Location/Qualifiers
1..13 /organism="unknown"
/mol_type="genomic DNA"
Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 43;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 7 GAATGGAATTGG 18
Db 13 GAATGGAATTGG 2
RESULT 66
LOCUS AX711144 13 bp DNA linear PAT 11-APR-2003
DEFINITION Sequence 444 from Patent EP1288296.
ACCESSION AX711144
VERSION AX711144.1 GI:29787525
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Draper, K.G., McSwigen, J.A., Holecsek, J.J., Dudycz, L.W., Macejak, D.G. and Mamone, J.A.
TITLE Method and reagent for inhibiting HBV viral replication
JOURNAL Patent: EP 1288296-A 444 05-MAR-2003;
FEATURES
source 1..13 Location/Qualifiers
1..13 /organism="synthetic construct"
/mol_type="unassigned DNA"

/db_xref="taxon:32630"
/note="Nucleic Acid"

Query Match 16.4%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 43;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 10 TGGATTGACA 21
| | | | |
DB 13 TGGATTGACA 2

RESULT 67
BD238904/c
LOCUS BD238904 10 bp DNA linear PAT 17-JUL-2003
DEFINITION Preparation and use of superior vaccines.
ACCESSION BD238904 GI:33048674
VERSION JP 2002534056-A/322.
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE 1 (bases 1 to 10)
JOURNAL Roberts, B.L. and Shankara, S.
Preparation and use of superior vaccines
Patent: JP 2002534056-A 322 15-OCT-2002;
GENZYME CORP

COMMENT
OS Homo sapiens (human)
PN JP 2002534056-A/322
PD 15-OCT-2002

PR 18-JUN-1998 JP 2000554749
PR 19-JUN-1998 US 60/090039, 19-JUN-1998 US 60/090040 PR
19-JUN-1998 US 60/090041, 19-JUN-1998 US 60/089853 PR
19-JUN-1998 US 60/089997, 19-JUN-1998 US 60/090079 PR
19-JUN-1998 US 60/090035, 19-JUN-1998 US 60/089993 PR
19-JUN-1998 US 60/089992, 19-JUN-1998 US 60/090072 PR
19-JUN-1998 US 60/089878, 19-JUN-1998 US 60/089991 PR
19-JUN-1998 US 60/090000, 19-JUN-1998 US 60/090048 PR
19-JUN-1998 US 60/089999, 19-JUN-1998 US 60/090043 PR
19-JUN-1998 US 60/090042, 19-JUN-1998 US 60/090036 PR
19-JUN-1998 US 60/090044, 19-JUN-1998 US 60/089844 PR
19-JUN-1998 US 60/090080, 19-JUN-1998 US 60/089833 PR
19-JUN-1998 US 60/089994, 19-JUN-1998 US 60/090077 PR
19-JUN-1998 US 60/090078, 19-JUN-1998 US 60/090047 PR
19-JUN-1998 US 60/090076, 19-JUN-1998 US 60/090045 PR
08-DEC-1998 US 60/111715
PI BRUCE L ROBERTS, SRINIVAS SHANKARA
PC C12N15/09, C12N15/09, A61K39/00, A61P35/00, A61P37/04, C12N1/15, PC
C12N1/19
PC C12N1/21, C12N5/10, G01N33/15, G01N33/50, G01N33/53, G01N33/566, PC
G01N33/00
CC C12N15/00, C12N5/00, C12N15/00
PC Preparation and use of superior vaccines
FH Key Location/Qualifiers
FT source 1.10
FT Location/Qualifiers
1.10
/organism='Homo sapiens (human)'.
/mol_type='genomic DNA'
/db_xref="taxon:9606"

FEATURES
source 1.10
Location/Qualifiers
1.10
/organism='Homo sapiens (human)'.
/mol_type='genomic DNA'
/db_xref="taxon:9606"

Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 TTGCTGGGGT 53
| | | | |
DB 10 TTGCTGGGGT 1

RESULT 68

AX153058/c
LOCUS AX153058 10 bp DNA linear PAT 22-JUN-2001
DEFINITION Sequence 973 from Patent WO0138577.
ACCESSION AX153058
VERSION AX153058.1 GI:14534709
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Mammalia; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE Human transcripts
JOURNAL Patent: WO 0138577-A 973 31-MAY-2001;
The Johns Hopkins University (US)
Location/Qualifiers
1.10
/organism='Homo sapiens (human)'.
/mol_type='unassigned DNA'
/db_xref="taxon:9606"

FEATURES
source 1.10
Location/Qualifiers
1.10
/organism='Homo sapiens (human)'.
/mol_type='unassigned DNA'
/db_xref="taxon:9606"

Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
| | | | |
DB 10 GAGGTTTCAC 1

RESULT 69
BD065196/c
LOCUS BD065196 10 bp DNA linear PAT 27-AUG-2002
DEFINITION Characterization of the yeast transcriptome.
ACCESSION BD065196
VERSION BD065196.1 GI:22610799
KEYWORDS JP 2001509017-A/132.
SOURCE Saccharomyces cerevisiae (baker's yeast)
ORGANISM Saccharomyces cerevisiae

REFERENCE
AUTHORS Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
TITLE Saccharomycetales; Saccharomycetaceae; Saccharomyces.
JOURNAL 1 (bases 1 to 10)
Velculescu, V.E., Vogelstein, B. and Kinzler, K.W.
Characterization of the yeast transcriptome
Patent: JP 2001509017-A 132 10-JUL-2001;
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
OS Saccharomyces cerevisiae (Yeast)
PN JP 2001509017-A/132
PD 10-JUL-2001

PR 22-JAN-1998 JP 1998532117
PR 23-JAN-1997 US 60/035917
PI VICTOR E VELCULESCU, BERT VOGELSTEIN, KENNETH W KINZLER PC
C12N15/10, C12N15/31, C07K14/395, C12Q1/68, C12Q1/02 CC
Characterization of the yeast transcriptome
FH Key Location/Qualifiers
FT source 1.10
FT Location/Qualifiers
1.10
/organism='Saccharomyces cerevisiae (Yeast)'.
/mol_type='genomic DNA'
/db_xref="taxon:4932"

FEATURES
source 1.10
Location/Qualifiers
1.10
/organism='Saccharomyces cerevisiae (Yeast)'.
/mol_type='genomic DNA'
/db_xref="taxon:4932"

Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 ATRGCCCAAG 30
| | | | |
DB 10 ATRGCCCAAG 1

RESULT 70

```

BD166544
LOCUS      BD166544                10 bp      DNA      linear      PAT 17-JAN-2003
DEFINITION Human liver disease-expressing genes.
ACCESSION  BD166544
VERSION    BD166544.1 GI:27872356
KEYWORDS   JP 2002209591-A/89.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 10)
AUTHORS   Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
TITLE     Human liver disease-expressing genes
JOURNAL   Patent: JP 2002209591-A 89 30-JUL-2002;
          JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT    OS Homo sapiens (human)
          PN JP 2002209591-A/89
          PD 30-JUL-2002
          PE 19-JAN-2001 JP 2001012328
          PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
          YAMASHITA
PC C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC C12P21/08,
PC C12N15/00
CC Human liver disease-expressing genes
FH Key Location/Qualifiers
FT source 1..10
          Location/Qualifiers
          /organism='Homo sapiens (human)'.
          /mol_type='genomic DNA'
          /db_xref='taxon:32644'

FEATURES
source

Query Match
Best Local Similarity 15.4%; Score 10; DB 1; Length 10;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 CTGGATGGA 13
Db 1 CTGGATGGA 10

RESULT 71
LOCUS      BD166682                10 bp      DNA      linear      PAT 17-JAN-2003
DEFINITION Human liver disease-expressing genes.
ACCESSION  BD166682
VERSION    BD166682.1 GI:27872494
KEYWORDS   JP 2002209591-A/227.
SOURCE     unidentified
ORGANISM   unclassified.
REFERENCE  1 (bases 1 to 10)
AUTHORS   Matsushima,K., Hashimoto,S., Kaneko,S. and Yamashita,T.
TITLE     Human liver disease-expressing genes
JOURNAL   Patent: JP 2002209591-A 227 30-JUL-2002;
          JAPAN SCIENCE AND TECHNOLOGY CORP
COMMENT    OS Homo sapiens (human)
          PN JP 2002209591-A/227
          PD 30-JUL-2002
          PE 19-JAN-2001 JP 2001012328
          PI KOJI MATSUSHIMA,SHINICHI HASHIMOTO,SHUICHI KANEKO,TARO PI
          YAMASHITA
PC C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC C12P21/08,
PC C12N15/00
CC Human liver disease-expressing genes
FH Key Location/Qualifiers
FT source 1..10
          Location/Qualifiers
          /organism='Homo sapiens (human)'.
          /mol_type='genomic DNA'
          /db_xref='taxon:32644'

FEATURES
source

Query Match
Best Local Similarity 15.4%; Score 10; DB 1; Length 10;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 CTGGATGGA 13
Db 1 CTGGATGGA 10

RESULT 72
LOCUS      AX471270/c              11 bp      DNA      linear      PAT 09-AUG-2002
DEFINITION Sequence 847 from Patent WO2053773.
ACCESSION  AX471270
VERSION    AX471270.1 GI:22206395
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Hofmann,K., Conradt,M. and Petersohn,D.
TITLE     Method for determining skin stress or skin ageing in vitro
JOURNAL   Patent: WO 02053773-A 847 11-JUL-2002;
          HENKEL KGAA (DE)
PC C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC C12P21/08,
PC C12N15/00
CC Human liver disease-expressing genes
FH Key Location/Qualifiers
FT source 1..10
          Location/Qualifiers
          /organism='Homo sapiens'
          /mol_type='unassigned DNA'
          /db_xref='taxon:9606'

FEATURES
source

Query Match
Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 AATTGACAT 22
Db 10 AATTGACAT 1

RESULT 73
LOCUS      AX472179/c              11 bp      DNA      linear      PAT 09-AUG-2002
DEFINITION Sequence 170 from Patent WO2053775.
ACCESSION  AX472179
VERSION    AX472179.1 GI:22207216
KEYWORDS
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1
AUTHORS   Huster,E., Haberl,M. and Wojnowski,L.
TITLE     Identification of the genetic determinants of the polymorphic
          CYP3A5 expression
JOURNAL   Patent: WO 02053775-A 170 11-JUL-2002;
          EPIDAUROS BIORECHNOLOGIE AG (DE)
PC C12N15/09,C07K14/47,C07K16/18,G01N33/15,G01N33/50//C12P21/02,
PC C12P21/08,
PC C12N15/00
CC Human liver disease-expressing genes
FH Key Location/Qualifiers
FT source 1..11
          Location/Qualifiers
          /organism='Homo sapiens'
          /mol_type='unassigned DNA'
          /db_xref='taxon:9606'

FEATURES
source

Query Match
Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 AATGGAATTG 17
Db 10 AATGGAATTG 1

FEATURES
source

```

```
RESULT 74
AX624183/c
LOCUS AX624183 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1224 from Patent WO02053774.
ACCESSION AX624183
VERSION AX624183.1 GI:28452124
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 1224 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1.11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
Db 10 GAGGTTTCAC 1

RESULT 75
AX624981/c
LOCUS AX624981 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2022 from Patent WO02053774.
ACCESSION AX624981
VERSION AX624981.1 GI:28452922
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2022 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1.11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
Db 10 GAGGTTTCAC 1

RESULT 76
AX625481/c
LOCUS AX625481 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2522 from Patent WO02053774.
ACCESSION AX625481
VERSION AX625481.1 GI:28453422
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2522 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1.11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 56 GAGGTTTCAC 65
Db 10 GAGGTTTCAC 1
```

```
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 2522 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1.11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 AATTGACAT 22
Db 10 AATTGACAT 1

RESULT 77
AX626412
LOCUS AX626412 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 3453 from Patent WO02053774.
ACCESSION AX626412
VERSION AX626412.1 GI:28454450
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3453 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1.11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 40 AACCTGCTG 49
Db 2 AACCTGCTG 11

RESULT 78
AX626765/c
LOCUS AX626765 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 3806 from Patent WO02053774.
ACCESSION AX626765
VERSION AX626765.1 GI:28454803
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 Petersohn,D., Conradt,M. and Hofmann,K.
AUTHORS Method for determining homeostasis of the skin
TITLE Patent: WO 02053774-A 3806 11-JUL-2002;
JOURNAL Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
source
1.11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 43;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 40 AACCTGCTG 49
Db 2 AACCTGCTG 11
```

/db_xref="taxon:9606"

Query Match

Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 44 TTGCTGGGGT 53
DB 10 TTGCTGGGGT 1

RESULT 79

LOCUS AX631604/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 8646 from Patent WO02053774.
ACCESSION AX631604
VERSION AX631604.1 GI:28459680
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE

AUTHORS 1 Petersohn, D., Conradt, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 8646 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
LOCATION/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match

Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 56 GAGGTTTCAC 65
DB 10 GAGGTTTCAC 1

RESULT 80

LOCUS AX632402/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 9444 from Patent WO02053774.
ACCESSION AX632402
VERSION AX632402.1 GI:28468017
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE

AUTHORS 1 Petersohn, D., Conradt, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 9444 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES
LOCATION/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match

Best Local Similarity 15.4%; Score 10; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 56 GAGGTTTCAC 65
DB 10 GAGGTTTCAC 1

RESULT 81

LOCUS 105995 12 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 12 from Patent EP 0275856.
ACCESSION 105995
VERSION 105995.1 GI:590815
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE

AUTHORS 1 (bases 1 to 12)
Bollen, A.J., Gheysen, D., Jacobs, P., Pierard, L. and Collen, D.J.
TITLE New plasmidogen activators
JOURNAL Patent: EP 0275856-A1 12 27-JUL-1988;
LOCATION/Qualifiers
1. .12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 42 CCTTGCTGGG 51
DB 2 CCTTGCTGGG 11

RESULT 82

LOCUS 108795 12 bp DNA linear PAT 02-DEC-1994
DEFINITION Sequence 16 from Patent WO 8804690.
ACCESSION 108795
VERSION 108795.1 GI:588500
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE

AUTHORS 1 (bases 1 to 12)
Bollen, A.J., Gheysen, D., Jacobs, P., Pierard, L. and Collen, D.J.
JOURNAL Patent: WO 8804690-A 16 30-JUN-1988;
LOCATION/Qualifiers
1. .12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 42 CCTTGCTGGG 51
DB 2 CCTTGCTGGG 11

RESULT 83

LOCUS AR349259/c 12 bp DNA linear PAT 17-AUG-2003
DEFINITION Sequence 6 from patent US 6583986.
ACCESSION AR349259
VERSION AR349259.1 GI:33749984
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE

AUTHORS 1 (bases 1 to 12)
Storti, W.J., Sibley, K., Ovadia, S., Kimball, S. and Falvo, B.
TITLE Method and apparatus for managing thermal energy emissions
JOURNAL Patent: US 6583986-A 6 24-JUN-2003;
LOCATION/Qualifiers
1. .12
/organism="unknown"
/mol_type="genomic DNA"

Query Match 15.4%; Score 10; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 47;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 AGCCCAAGAA 32
 |||||
 DB 11 AGCCCAAGAA 2

RESULT 84
 AR349261/c AR349261 12 bp DNA linear PAT 17-AUG-2003
 LOCUS Sequence 8 from patent US 6583986.
 DEFINITION AR349261
 ACCESSION AR349261
 VERSION AR349261.1 GI:33749986
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 12)
 AUTHORS Scotti,W.J., Sibley,K., Ovadia,S., Kimball,S. and Falvo,B.
 TITLE Method and apparatus for managing thermal energy emissions
 JOURNAL Patent: US 6583986-A 8 24-JUN-2003;
 FEATURES Location/Qualifiers
 source 1..12
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 15.4%; Score 10; DB 1; Length 12;
 Best Local Similarity 100.0%; Pred. No. 47;
 Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 23 AGCCCAAGAA 32
 |||||
 DB 11 AGCCCAAGAA 2

RESULT 85
 A01985/c A01985 13 bp DNA linear PAT 23-MAR-1993
 LOCUS Artificial sequence for promoter fragment for
 DEFINITION glyceralddehyde-3-phosphate dehydrogenase operon.
 ACCESSION A01985
 VERSION A01985.1 GI:344517
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1 (bases 1 to 13)
 AUTHORS
 JOURNAL Patent: WO 8404538-A 13 22-NOV-1984;
 FEATURES Location/Qualifiers
 source 1..13
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 55;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAAC 42
 |||||
 DB 13 GAACAGAAAGAAC 1

RESULT 86
 A06431/c A06431 13 bp DNA linear PAT 21-MAY-1993
 LOCUS Artificial sequence for promoter fragment for
 DEFINITION glyceralddehyde-3-phosphate dehydrogenase operon, duplicate.
 ACCESSION A06431

VERSION A06431.1 GI:411257
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 artificial sequences.
 REFERENCE 1 (bases 1 to 13)
 AUTHORS Edens,L., Russell,S.W., Visser,C. and Verrips,C.T.
 TITLE Improvements in the expression of newly introduced genes in yeast cells
 JOURNAL Patent: EP 0129268-A 14 27-DEC-1984;
 UNILEVER NV, UNILEVER PLC
 FEATURES Location/Qualifiers
 source 1..13
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 55;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 30 GAACAGAAAGAAC 42
 |||||
 DB 13 GAACAGAAAGAAC 1

RESULT 87
 BD062265/c BD062265 13 bp DNA linear PAT 27-AUG-2002
 LOCUS Nucleic acid for detecting Mycobacterium bacteria.
 DEFINITION BD062265
 ACCESSION BD062265.1 GI:22607870
 VERSION JP 2001299354-A/37.
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1 (bases 1 to 13)
 AUTHORS Fukushima,M., Kakimura,K., Kawaguchi,R. and Kasai,H.
 TITLE Nucleic acid for detecting Mycobacterium bacteria
 JOURNAL Patent: JP 2001299354-A 37 30-OCT-2001;
 COMMENT SRL INC,MARINE BIOTECHNOLOGY INST CO LTD,NIPPON GENE CO LTD
 OR Artificial Sequence
 SN JP 2001299354-A/37
 PN 30-OCT-2001
 PD 21-APR-2000 JP 2000121604
 PF MASAO FUKUSHIMA,KENICHI KAKIMURA,RYUJI KAWAGUCHI,HIROAKI KASAI
 PI C12N15/09,C12Q1/68,G01N33/569/(C12Q1/68,C12R1:325),(C12Q1/68,
 PC C12R1:32),
 PC C12N15/00
 CC Nucleic Acid for detecting Mycobacterium tuberculosis FH Key
 FEATURES Location/Qualifiers
 source 1..13
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 15.1%; Score 9.8; DB 1; Length 13;
 Best Local Similarity 84.6%; Pred. No. 55;
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 44 TTGCTGGGGTTGG 56
 |||||
 DB 13 TTGCTGGGGTTGG 1

RESULT 88
 I16094 I16094 11 bp DNA linear PAT 03-APR-1996
 LOCUS Sequence 3 from patent US 5474897.
 DEFINITION I16094
 ACCESSION I16094.1 GI:1251002
 VERSION
 KEYWORDS

```
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 11)
AUTHORS Weiss,A. and Fraser,J.
TITLE Screening assay for the identification of novel immunosuppressives
JOURNAL Patent: US 5474897-A 3 12-DRC-1995;
FEATURES
    source
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 14.5%; Score 9.4; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 54 TGGAGGTTTCA 64
Db 1 TGGAGGTTCCA 11

RESULT 89
AX393078/c 11 bp DNA linear PAT 23-MAR-2002
LOCUS Sequence 8 from Patent WO0210217.
DEFINITION AX393078
ACCESSION AX393078.1 GI:19701128
VERSION
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS St Croix,B., Kinzler,K.W. and Vogelstein,B.
TITLE Endothelial cell expression patterns
JOURNAL Patent: WO 0210217-A 8 07-FEB-2002;
The Johns Hopkins University (US)
FEATURES
    source
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 14.5%; Score 9.4; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 27 CAAGACAGAA 37
Db 11 CAAGACAGAA 1

RESULT 90
AX470597/c 11 bp DNA linear PAT 09-AUG-2002
LOCUS Sequence 174 from Patent WO02053773.
DEFINITION AX470597
ACCESSION AX470597.1 GI:22205722
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 174 11-JUL-2002;
HENKEL KGAA (DE)
FEATURES
    source
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 14.5%; Score 9.4; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGAACTT 44
Db 1 AGAAGAACTT 11

RESULT 91
AX470878/c 11 bp DNA linear PAT 09-AUG-2002
LOCUS Sequence 455 from Patent WO02053773.
DEFINITION AX470878
ACCESSION AX470878.1 GI:22206003
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 455 11-JUL-2002;
HENKEL KGAA (DE)
FEATURES
    source
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 14.5%; Score 9.4; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 GGACATAGCCC 27
Db 11 GGACATAGCCC 1

RESULT 92
AX471365 11 bp DNA linear PAT 09-AUG-2002
LOCUS Sequence 942 from Patent WO02053773.
DEFINITION AX471365
ACCESSION AX471365.1 GI:22206490
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS Hofmann,K., Conradt,M. and Petersohn,D.
TITLE Method for determining skin stress or skin ageing in vitro
JOURNAL Patent: WO 02053773-A 942 11-JUL-2002;
HENKEL KGAA (DE)
FEATURES
    source
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match
Best Local Similarity 14.5%; Score 9.4; DB 1; Length 11;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGAACTT 44
Db 1 AGAAGAACTT 11
```

RESULT 93
AX623489/c
LOCUS AX623489 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 530 from Patent WO02053774.
ACCESSION AX623489
VERSION AX623489.1 GI:28451430
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Petersohn,D., Conradt,M. and Hofmann,K.
JOURNAL Method for determining homeostasis of the skin
Patent: WO 02053774-A 530 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

QY
Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 15 TTGGACTATGAC 25
11 TTGGACTATGAC 1

RESULT 94
AX624179/c
LOCUS AX624179 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1220 from Patent WO02053774.
ACCESSION AX624179
VERSION AX624179.1 GI:28452120
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Petersohn,D., Conradt,M. and Hofmann,K.
JOURNAL Method for determining homeostasis of the skin
Patent: WO 02053774-A 1220 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

QY
Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 17 GGACATAGCCC 27
11 GGACATAGCCC 1

RESULT 95
AX624329/c
LOCUS AX624329 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1370 from Patent WO02053774.
ACCESSION AX624329
VERSION AX624329.1 GI:28452270
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Petersohn,D., Conradt,M. and Hofmann,K.
JOURNAL Method for determining homeostasis of the skin
Patent: WO 02053774-A 1370 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

QY
Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 11 GGCGGTTTCAC 65
11 GGCGGTTTCAC 1

RESULT 96
AX624484
LOCUS AX624484 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 1525 from Patent WO02053774.
ACCESSION AX624484
VERSION AX624484.1 GI:28452425
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Petersohn,D., Conradt,M. and Hofmann,K.
JOURNAL Method for determining homeostasis of the skin
Patent: WO 02053774-A 1525 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

QY
Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Db 34 AGAAGACTCT 44
1 AGAAGACTCT 11

RESULT 97
AX625720
LOCUS AX625720 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2761 from Patent WO02053774.
ACCESSION AX625720
VERSION AX625720.1 GI:28453661
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS 1
TITLE Petersohn,D., Conradt,M. and Hofmann,K.
JOURNAL Method for determining homeostasis of the skin
Patent: WO 02053774-A 2761 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
LOCATION/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

```

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGGAGG 59
Db 1 GGGGCTGGAGG 11

RESULT 98
LOCUS AX625789/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 2830 from Patent WO02053774.
ACCESSION AX625789
VERSION AX625789.1 GI:28453730
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A/2830 11-JUL-2002;
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 29 AGACAGAGAG 39
Db 11 ATACAGAGAG 1

RESULT 99
LOCUS AX626474/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 3515 from Patent WO02053774.
ACCESSION AX626474
VERSION AX626474.1 GI:28454512
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A/3515 11-JUL-2002;
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 27 CAAGAACGAGAA 37
Db 11 CAAGACGAGAA 1

RESULT 100
LOCUS AX627570/c

```

```

LOCUS AX627570 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 4611 from Patent WO02053774.
ACCESSION AX627570
VERSION AX627570.1 GI:28455608
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A/4611 11-JUL-2002;
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 50 GGGTTGGAGCT 60
Db 11 GGGTGGAGCT 1

RESULT 101
LOCUS AX628639/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 5680 from Patent WO02053774.
ACCESSION AX628639
VERSION AX628639.1 GI:28456677
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A/5680 11-JUL-2002;
FEATURES
source Location/Qualifiers
1..11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 49 GGGGTTGGAGG 59
Db 11 GGGGCTGGAGG 1

RESULT 102
LOCUS AX628640/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 5681 from Patent WO02053774.
ACCESSION AX628640
VERSION AX628640.1 GI:28456678
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
AUTHORS Petersohn,D., Conradt,M. and Hofmann,K.

```


TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 5681 11-JUL-2002; (DE)
FEATURES Henkel Kommanditgesellschaft auf Aktien (DE)
source Location/Qualifiers

1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 29 AGAAGAGAAAG 39
Db 11 AGAAGAGACAG 1

RESULT 103
LOCUS AX628771/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 5812 from Patent WO02053774.
ACCESSION AX628771
VERSION AX628771.1 GI:28456809
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 5812 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers

1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 26 CCAAGACACA 36
Db 11 CCAATACACA 1

RESULT 104
LOCUS AX629905 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 6946 from Patent WO02053774.
ACCESSION AX629905
VERSION AX629905.1 GI:28457943
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 6946 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers

1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 46 GCTGGGGTTGG 56
Db 1 GCTGGGGTTGG 11

RESULT 105
LOCUS AX630278/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 7319 from Patent WO02053774.
ACCESSION AX630278
VERSION AX630278.1 GI:28458316
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 7319 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers

1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 31 AACAGAAAGA 41
Db 11 AACAGAGAGA 1

RESULT 106
LOCUS AX630910/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 7951 from Patent WO02053774.
ACCESSION AX630910
VERSION AX630910.1 GI:28458950
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Petersohn, D., Conradt, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 7951 11-JUL-2002;
Henkel Kommanditgesellschaft auf Aktien (DE)
FEATURES Location/Qualifiers

1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 15 TTGGACATAGC 25
Db 11 TTGGATATAGC 1

RESULT 107
LOCUS AX631600/c 11 bp DNA linear PAT 21-FEB-2003
DEFINITION Sequence 8642 from Patent WO02053774.

ACCESSION AX631600.1 GI:28459676
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS Petersohn, D., Conrad, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 8642 11-JUL-2002;
FEATURES Henkel Kommanditgesellschaft auf Aktien (DE)
Location/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 GGACATAGCCC 27
11 GGACATAGCCC 1

Db 11 GGACATAGCCC 1

RESULT 108
AX631750 11 bp DNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 8792 from Patent WO02053774.
ACCESSION AX631750
VERSION AX631750.1 GI:28459857
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS Petersohn, D., Conrad, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 8792 11-JUL-2002;
FEATURES Henkel Kommanditgesellschaft auf Aktien (DE)
Location/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 55 GGAGCTTTCAC 65
11 GGAGCTTTCAC 1

Db 11 GGAGCTTTCAC 1

RESULT 109
AX631905 11 bp DNA linear PAT 21-FEB-2003
LOCUS
DEFINITION Sequence 8947 from Patent WO02053774.
ACCESSION AX631905
VERSION AX631905.1 GI:28460043
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
AUTHORS Petersohn, D., Conrad, M. and Hofmann, K.
TITLE Method for determining homeostasis of the skin
JOURNAL Patent: WO 02053774-A 8947 11-JUL-2002;

FEATURES Henkel Kommanditgesellschaft auf Aktien (DE)
Location/Qualifiers
1. .11
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 55;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGACCT 44
1 AGAAGACCT 11

Db 1 AGAAGACCT 11

RESULT 110
A03728 12 bp DNA linear PAT 30-AUG-1993
LOCUS
DEFINITION synthetic linker.
ACCESSION A03728
VERSION A03728.1 GI:410914
KEYWORDS
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 12)
AUTHORS Grundmann, U., Amann, E. and Zetelmeisel, G.
TITLE Production of factor XIIIa by gene technology
JOURNAL Patent: EP 0236978-A 2 16-SEP-1987;
FEATURES BEHRINGERwerke Aktiengesellschaft
Location/Qualifiers
1. .12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 9 ATGGAATTGGA 19
2 ATGGAATTGGA 12

Db 2 ATGGAATTGGA 12

RESULT 111
A03729 12 bp DNA linear PAT 30-AUG-1993
LOCUS
DEFINITION synthetic linker.
ACCESSION A03729
VERSION A03729.1 GI:410915
KEYWORDS
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 12)
AUTHORS Grundmann, U., Amann, E. and Zetelmeisel, G.
TITLE Production of factor XIIIa by gene technology
JOURNAL Patent: EP 0236978-A 3 16-SEP-1987;
FEATURES BEHRINGERwerke Aktiengesellschaft
Location/Qualifiers
1. .12
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 9 ATGGAATTGGA 19
11 ATGGAATTGGA 19

Db 11 ATGGAATTGCA 1

RESULT 112

LOCUS A03738

DEFINITION Nucleotide sequence 12 from patent number EP0236978.

ACCESSION A03738

VERSION A03738.1 GI:410920

KEYWORDS

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 12)

AUTHORS Grundmann, U., Amann, E. and Zettlmeis, G.

TITLE Production of factor XlIIa by gene technology

JOURNAL Patent: EP 0236978-A 12 16-SEP-1987;

BEHRINGERWERKE Aktiengesellschaft

LOCATION/Qualifiers

FEATURES

source 1. .12

/organism="unidentified"

/mol_type="unassigned DNA"

/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;

Best Local Similarity 90.9%; Pred. No. 59;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 9 ATGGAATTGCA 19

Db 2 ATGGAATTGCA 12

RESULT 113

LOCUS A03921

DEFINITION Nucleotide sequence 3 from patent number EP0238329.

ACCESSION A03921

VERSION A03921.1 GI:410932

KEYWORDS

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 12)

AUTHORS Jeffreys, A. J.

TITLE Improvements in genetic probes

JOURNAL Patent: EP 0238329-A 3 23-SEP-1987;

IMPERIAL CHEMICAL INDUSTRIES PLC

LOCATION/Qualifiers

FEATURES

source 1. .12

/organism="unidentified"

/mol_type="unassigned DNA"

/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;

Best Local Similarity 90.9%; Pred. No. 59;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGAGG 59

Db 2 GGGGCTGGAGG 12

RESULT 114

LOCUS A31783

DEFINITION synthetic linker DNA from patent EP0494702.

ACCESSION A31783

VERSION A31783.1 GI:1247277

KEYWORDS

SOURCE synthetic construct

ORGANISM synthetic construct

artificial sequences.

REFERENCE 1 (bases 1 to 12)

AUTHORS Grundmann, U., Amann, E. and Zettlmeis, G.

TITLE Production of factor XlIIa by gene technology

JOURNAL Patent: EP 0494702-A 1 15-JUL-1992;

BEHRINGERWERKE Aktiengesellschaft

LOCATION/Qualifiers

FEATURES

source 1. .12

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

Query Match 14.5%; Score 9.4; DB 1; Length 12;

Best Local Similarity 90.9%; Pred. No. 59;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 9 ATGGAATTGCA 19

Db 2 ATGGAATTGCA 12

RESULT 115

LOCUS A47652/c

DEFINITION Sequence 12 from Patent EP0692535.

ACCESSION A47652

VERSION A47652.1 GI:2301593

KEYWORDS

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 12)

AUTHORS Colore, S. and Pirozky, E.

TITLE Oligonucleotides to inhibit the role of isoprenyl protein transferases

JOURNAL Patent: EP 0692535-A 12 17-JAN-1996;

SOD CONSEILS RECH APPLIC (FR)

COMMENT Other publication CN 1124142 960612

Other publication CZ 9501688 960515

Other publication BR 9503015 960604

Other publication NZ 272398 960426

Other publication HU 72133 960328

Other publication JP 8051985 960227

Other publication FR 2721930 960105

Other publication FR 2721827 960105

Other publication FI 953170 951230

Other publication SE 9502259 951230

Other publication PL 309384 960108

Other publication NO 952601 960102

Other publication AU 2329995 960111

Other publication CA 2152233 951230

Other publication GB 2290791 960110.

FEATURES

source 1. .12

/organism="unidentified"

/mol_type="unassigned DNA"

/db_xref="taxon:32644"

Query Match 14.5%; Score 9.4; DB 1; Length 12;

Best Local Similarity 90.9%; Pred. No. 59;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 23 AGCCCAAGAAC 33

Db 11 AGCCCAAAAC 1

RESULT 116

LOCUS AR027870/c

DEFINITION Sequence 12 from patent US 5856461.

ACCESSION AR027870

VERSION AR027870.1 GI:5938690

KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Colote,S. and Pirotsky,E.
Oligonucleotides to inhibit the expression of Isoprenyl protein transferases
JOURNAL Patent: US 5856461-A 12 05-JAN-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 23 AGCCCAAGAC 33
Db 11 AGCCCAAAAC 1

RESULT 117
AR036375 12 bp DNA linear PAT 29-SEP-1999
LOCUS AR036375
DEFINITION Sequence 38 from patent US 5872105.
ACCESSION AR036375
VERSION AR036375.1 GI:5953043
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Kool,E.T.
TITLE Single-stranded circular oligonucleotides useful for drug delivery
JOURNAL Patent: US 5872105-A 38 16-FEB-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
Db 1 AAGAAAGAAAG 12

RESULT 118
AR036376 12 bp DNA linear PAT 29-SEP-1999
LOCUS AR036376
DEFINITION Sequence 39 from patent US 5872105.
ACCESSION AR036376
VERSION AR036376.1 GI:5953044
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Kool,E.T.
JOURNAL Single-stranded circular oligonucleotides useful for drug delivery
FEATURES Patent: US 5872105-A 39 16-FEB-1999;
Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
Db 1 AAGAAAGAAAG 12

RESULT 119
AR074233 12 bp DNA linear PAT 28-AUG-2000
LOCUS AR074233
DEFINITION Sequence 41 from patent US 5952490.
ACCESSION AR074233
VERSION AR074233.1 GI:10000988
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 12)
AUTHORS Hanecak,R.C., Anderson,K.P., Bennett,C.Frank., Chiang,M.-Y.,
Brown-Driver,V.L., Ecker,D.J., Vickers,T.A., Wyatt,J.R. and
Imbach,J.Louis.

TITLE Oligonucleotides having a conserved G4 core sequence
JOURNAL Patent: US 5952490-A 41 14-SEP-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 120
AR074249 12 bp DNA linear PAT 28-AUG-2000
LOCUS AR074249
DEFINITION Sequence 57 from patent US 5952490.
ACCESSION AR074249
VERSION AR074249.1 GI:10001004
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Hanecak,R.C., Anderson,K.P., Bennett,C.Frank., Chiang,M.-Y.,
Brown-Driver,V.L., Ecker,D.J., Vickers,T.A., Wyatt,J.R. and
Imbach,J.Louis.
TITLE Oligonucleotides having a conserved G4 core sequence
JOURNAL Patent: US 5952490-A 57 14-SEP-1999;
FEATURES Location/Qualifiers
source 1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 121
AR074305 12 bp DNA linear PAT 28-AUG-2000
LOCUS AR074305
DEFINITION Sequence 113 from patent US 5952490.
ACCESSION AR074305
VERSION AR074305.1 GI:10001060
KEYWORDS
SOURCE Unknown.

```

ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 12)
AUTHORS       Hanecak,R.C., Anderson,K.P., Bennett,C.Frank., Chiang,M.-Y.,
               Brown-Driver,V.L., Ecker,D.J., Vickers,T.A., Wyatt,V.R. and
               Imbach,J.Louis.
TITLE         Oligonucleotides having a conserved G4 core sequence
JOURNAL       Patent: US 5952490-A 113 14-SEP-1999;
FEATURES      Location/Qualifiers
               source
               1..12
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY              48 TGGGGTTGGAG 58
                |||||
Db              2 TGGGGTTGGG 12

RESULT 122
LOCUS      ARI72240
DEFINITION Sequence 64 from patent US 6303295.
ACCESSION  ARI72240
VERSION     ARI72240.1 GI:17911731
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 12)
AUTHORS     Taylor,B.Will., Nadiampalli,R.Gopal. and Ramanathan,C.Sekar.
TITLE       Selenoproteins, coding sequences and methods
JOURNAL     Patent: US 6303295-A 64 16-OCT-2001;
FEATURES    Location/Qualifiers
            source
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY              3 TCTGAATGGA 13
                |||||
Db              12 TCTGAATGGA 2

RESULT 123
LOCUS      I20197
DEFINITION Sequence 12 from patent US 5514546.
ACCESSION  I20197
VERSION     I20197.1 GI:1600552
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 12)
AUTHORS     Koal,E.T.
TITLE       Stem-loop oligonucleotides containing parallel and antiparallel
               binding domains
JOURNAL     Patent: US 5514546-A 12 07-MAY-1996;
FEATURES    Location/Qualifiers
            source
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY              28 AAGACGAAAG 39
                |||||
Db              1 AAGAAAGAAAG 12

RESULT 124
LOCUS      I20198
DEFINITION Sequence 13 from patent US 5514546.
ACCESSION  I20198
VERSION     I20198.1 GI:1600553
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 12)
AUTHORS     Koal,E.T.
TITLE       Stem-loop oligonucleotides containing parallel and antiparallel
               binding domains
JOURNAL     Patent: US 5514546-A 13 07-MAY-1996;
FEATURES    Location/Qualifiers
            source
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY              28 AAGACGAAAG 39
                |||||
Db              1 AAGAAAGAAAG 12

RESULT 125
LOCUS      I20474
DEFINITION Sequence 53 from patent US 5514577.
ACCESSION  I20474
VERSION     I20474.1 GI:1600829
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 12)
AUTHORS     Draper,R.G., Crooke,S.T., Mirabelli,C.K., Ecker,D.J., Hanecak,R.C.,
               Anderson,K.P., Brown-Driver,V.L. and Wyatt,V.R.
TITLE       Oligonucleotide therapies for modulating the effects of herpes
               viruses
JOURNAL     Patent: US 5514577-A 53 07-MAY-1996;
FEATURES    Location/Qualifiers
            source
            1..12
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY              48 TGGGGTTGGAG 58
                |||||
Db              2 TGGGGTTGGG 12

RESULT 126
LOCUS      I72123
DEFINITION Sequence 38 from patent US 5683874.
ACCESSION  I72123
VERSION     I72123.1 GI:3008262
KEYWORDS
SOURCE      Unknown.

```

```
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS 1 (bases 1 to 12)
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL triplex with a target sequence
FEATURES Patent: US 5683874-A 38 04-NOV-1997;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
Db 1 AAGANAGAAAG 12

RESULT 127
172124 12 bp DNA linear PAT 03-APR-1998
LOCUS Sequence 39 from patent US 5683874.
DEFINITION 172124
ACCESSION 172124.1 GI:3008263
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS Kool,E.T.
TITLE Single-stranded circular oligonucleotides capable of forming a
JOURNAL triplex with a target sequence
FEATURES Patent: US 5683874-A 39 04-NOV-1997;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 83.3%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACAGAAAG 39
Db 1 AAGAAAAAAG 12

RESULT 128
AR307251 12 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 5 from patent US 6551774.
DEFINITION AR307251
ACCESSION AR307251
VERSION AR307251.1 GI:31697778
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS West,M.D., Harley,C.B., Weinrich,S.L., Strahl,C.M., McEachern,M.J.,
TITLE Shay,J., Wright,W.E., Blackburn,E.H., Kim,N.W. and Vaziri,H.
JOURNAL Diagnostic methods for conditions associated with elevated cellular
FEATURES Patent: US 6551774-A 5 22-APR-2003;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="genomic DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 129
AR307276 12 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 33 from patent US 6551774.
DEFINITION AR307276
ACCESSION AR307276
VERSION AR307276.1 GI:31697803
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS West,M.D., Harley,C.B., Weinrich,S.L., Strahl,C.M., McEachern,M.J.,
TITLE Shay,J., Wright,W.E., Blackburn,E.H., Kim,N.W. and Vaziri,H.
JOURNAL Diagnostic methods for conditions associated with elevated cellular
FEATURES Patent: US 6551774-A 33 22-APR-2003;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="genomic DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 130
AR307278 12 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 35 from patent US 6551774.
DEFINITION AR307278
ACCESSION AR307278
VERSION AR307278.1 GI:31697805
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 12)
AUTHORS West,M.D., Harley,C.B., Weinrich,S.L., Strahl,C.M., McEachern,M.J.,
TITLE Shay,J., Wright,W.E., Blackburn,E.H., Kim,N.W. and Vaziri,H.
JOURNAL Diagnostic methods for conditions associated with elevated cellular
FEATURES Patent: US 6551774-A 35 22-APR-2003;
source Location/Qualifiers
1..12
/organism="unknown"
/mol_type="genomic DNA"

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 59;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 131
AX032595 12 bp DNA linear PAT 20-SEP-2000
LOCUS Sequence 41 from Patent EP1016715.
DEFINITION AX032595
ACCESSION AX032595.1 GI:10279533
VERSION
```


THIS PAGE BLANK (USPTO)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 12, 2004, 15:30:40 ; Search time 1 Seconds
(without alignments)
0.117 Million cell updates/sec

Title: US-10-033-742-3

Perfect score: 65
Sequence: 1 tttctcgatgcgattgcac.....gtctggggttcgaggttcac 65

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 0.5

Searched: 61 seqs, 898 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 61 summaries

Database : pub:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	25	38.5	25	1	US-10-717-597-3888
2	25	38.5	25	1	US-10-717-597-3889
3	20	30.8	20	1	US-10-033-742-20
4	20	30.8	20	1	US-10-033-742-21
5	20	30.8	20	1	US-10-033-742-22
6	20	30.8	20	1	US-10-033-742-23
7	19.8	30.5	23	1	US-10-345-859-12
8	15.8	24.3	21	1	US-10-004-551-107
9	13.8	21.2	17	1	US-09-848-754-2614
10	13.4	20.6	16	1	US-10-377-216-367
11	13.4	20.6	16	1	US-10-126-022-367
12	13.4	20.6	16	1	US-09-780-164-127
13	13.4	20.6	17	1	US-09-780-164-128
14	13	20.0	17	1	US-09-780-164-129
15	13	20.0	17	1	US-09-780-164-129
16	12.8	19.7	16	1	US-09-969-373-2913
17	12.8	19.7	17	1	US-09-866-108-2464
18	12.8	19.7	17	1	US-09-866-108-2465
19	12.8	19.7	17	1	US-09-780-164-1042
20	12.8	19.7	17	1	US-10-156-306-3729
21	12.8	19.7	17	1	US-10-723-361-2464
22	12.8	19.7	17	1	US-10-723-361-2465
23	11.4	17.5	13	1	US-09-888-326-450
24	11.4	17.5	13	1	US-09-776-479-796
25	11.4	17.5	13	1	US-09-776-479-796
26	11.4	17.5	13	1	US-10-314-578-796
27	11.4	17.5	13	1	US-10-112-653-769
28	11.4	17.5	13	1	US-10-017-995-796
29	11.4	17.5	15	1	US-10-132-002-5
30	11.4	17.5	15	1	US-10-132-002-9
31	10.8	16.6	14	1	US-09-981-803-32
32	10.8	16.6	14	1	US-09-981-803-48
33	10.8	16.6	14	1	US-10-275-071-29

Published - Applications - NA

C 34	10.8	16.6	14	1	US-10-275-071-30	Sequence 30, Appl
C 35	10.8	16.6	14	1	US-10-684-830-35	Sequence 35, Appl
C 36	10.8	16.6	14	1	US-10-684-830-36	Sequence 36, Appl
C 37	10.8	16.6	14	1	US-10-684-830-38	Sequence 38, Appl
C 38	10.4	16.0	13	1	US-10-253-904-45	Sequence 45, Appl
C 39	10.4	16.0	13	1	US-10-392-970-36	Sequence 36, Appl
C 40	10	15.4	10	1	US-10-033-145-322	Sequence 322, App
C 41	10	15.4	10	1	US-10-330-627-973	Sequence 973, App
C 42	10	15.4	11	1	US-10-450-797-847	Sequence 847, App
C 43	10	15.4	12	1	US-10-091-281-67	Sequence 67, Appl
C 44	9.8	15.1	13	1	US-09-789-836-31	Sequence 31, Appl
C 45	9.8	15.1	13	1	US-09-789-831-29	Sequence 29, Appl
C 46	9.4	14.5	11	1	US-09-918-715-8	Sequence 8, Appl1
C 47	9.4	14.5	11	1	US-10-450-797-174	Sequence 174, App
C 48	9.4	14.5	11	1	US-10-450-797-455	Sequence 455, App
C 49	9.4	14.5	11	1	US-10-450-797-942	Sequence 942, App
C 50	9.4	14.5	12	1	US-09-263-959-425	Sequence 425, App
C 51	9.4	14.5	12	1	US-09-263-959-587	Sequence 587, App
C 52	9.4	14.5	12	1	US-09-263-959-660	Sequence 660, App
C 53	9.4	14.5	12	1	US-10-140-896-4	Sequence 4, Appl1
C 54	9.4	14.5	12	1	US-10-232-927A-5	Sequence 3, Appl1
C 55	9.4	14.5	12	1	US-10-232-927A-33	Sequence 33, Appl
C 56	9.4	14.5	12	1	US-10-232-927A-35	Sequence 35, Appl
C 57	9.4	14.5	12	1	US-10-422-262-18	Sequence 18, Appl
C 58	9.4	14.5	12	1	US-10-422-262-19	Sequence 19, Appl
C 59	9.4	14.5	12	1	US-10-422-262-20	Sequence 20, Appl
C 60	9.4	14.5	12	1	US-10-422-262-21	Sequence 21, Appl
C 61	9.4	14.5	12	1	US-10-422-262-22	Sequence 22, Appl

ALIGNMENTS

```
RESULT 1
US-10-717-597-3888
; Sequence 3888, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dornier, Andrew J.
; APPLICANT: Trepcichio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AML101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3888
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-3888

Query Match      38.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 0.62;
Matches 25; Conservative 0; Mismatches 0; Incels 0; Gaps 0;

QY      11 GGAATTGACATAGCCCAAGAACAG 35
Db      1 GGAATTGACATAGCCCAAGAACAG 25

RESULT 2
US-10-717-597-3889
; Sequence 3889, Application US/10717597
```

```
/ Publication No. US20040110221A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Burezynski, Michael E.
/ APPLICANT: Twine, Natalie C.
/ APPLICANT: Dornier, Andrew J.
/ APPLICANT: Trepicchio, William L.
/ APPLICANT: Slonim, Donna K.
/ APPLICANT: Stover, Jennifer A.
/ TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
/ FILE REFERENCE: AM1010801
/ CURRENT APPLICATION NUMBER: US/10/717,597
/ CURRENT FILING DATE: 2003-11-21
/ PRIOR APPLICATION NUMBER: US 60/459,782
/ PRIOR FILING DATE: 2003-04-03
/ PRIOR APPLICATION NUMBER: US 60/427,982
/ PRIOR FILING DATE: 2002-11-21
/ NUMBER OF SEQ ID NOS: 4904
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 3889
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-717-597-3889
```

```
Query Match
Best Local Similarity 38.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 16 TGGACATAGCCCAAGACGAAAGA 40
DB 1 TGGACATAGCCCAAGACGAAAGA 25
```

```
RESULT 3
US-10-033-742-20/c
/ Sequence 20, Application US/10033742
/ Publication No. US20030144225A1
/ GENERAL INFORMATION:
/ APPLICANT: James Karras
/ APPLICANT: Thomas Condon
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA E
/ FILE REFERENCE: ISPH-0623
/ CURRENT APPLICATION NUMBER: US/10/033,742
/ CURRENT FILING DATE: 2001-12-28
/ NUMBER OF SEQ ID NOS: 32
/ SEQ ID NO 20
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-033-742-20
```

```
Query Match
Best Local Similarity 30.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 TTCTCGAATGGATTGAC 20
DB 20 TTCTCGAATGGATTGAC 1
```

```
RESULT 4
US-10-033-742-21/c
/ Sequence 21, Application US/10033742
/ Publication No. US20030144225A1
/ GENERAL INFORMATION:
/ APPLICANT: James Karras
/ APPLICANT: Thomas Condon
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA E
/ FILE REFERENCE: ISPH-0623
/ CURRENT APPLICATION NUMBER: US/10/033,742
```

```
/ CURRENT FILING DATE: 2001-12-28
/ NUMBER OF SEQ ID NOS: 32
/ SEQ ID NO 21
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-033-742-21
```

```
Query Match
Best Local Similarity 30.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 11 GGAATGACATAGCCCAAG 30
DB 20 GGAATGACATAGCCCAAG 1
```

```
RESULT 5
US-10-033-742-22/c
/ Sequence 22, Application US/10033742
/ Publication No. US20030144225A1
/ GENERAL INFORMATION:
/ APPLICANT: James Karras
/ APPLICANT: Thomas Condon
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA
/ FILE REFERENCE: ISPH-0623
/ CURRENT APPLICATION NUMBER: US/10/033,742
/ CURRENT FILING DATE: 2001-12-28
/ NUMBER OF SEQ ID NOS: 32
/ SEQ ID NO 22
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-033-742-22
```

```
Query Match
Best Local Similarity 30.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 27 CAAGACAGAAAGACCTTG 46
DB 20 CAAGACAGAAAGACCTTG 1
```

```
RESULT 6
US-10-033-742-23/c
/ Sequence 23, Application US/10033742
/ Publication No. US20030144225A1
/ GENERAL INFORMATION:
/ APPLICANT: James Karras
/ APPLICANT: Thomas Condon
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA F
/ FILE REFERENCE: ISPH-0623
/ CURRENT APPLICATION NUMBER: US/10/033,742
/ CURRENT FILING DATE: 2001-12-28
/ NUMBER OF SEQ ID NOS: 32
/ SEQ ID NO 23
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-033-742-23
```

```
Query Match
Best Local Similarity 30.8%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 46 GCTGGGGTTGGAGGTTTCAC 65
```

Db 20 GCTGGGCTTGAGCTTTCAC 1

```
RESULT 7
US-10-345-859-12/c
; Sequence 12, Application US/10345859
; Publication No. US20030175895A1
; GENERAL INFORMATION:
; APPLICANT: Lesslauer, Werner
;         Utans-Schneitz, Ulrike
; TITLE OF INVENTION: NEW CHEMOKINE
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: N.J.
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/345,859
; FILING DATE: 16-Jan-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,353
; FILING DATE: <Unknown>
; APPLICATION NUMBER: EP 97107135.2
; FILING DATE: 30-APR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Kreisler, Lewis J
; REGISTRATION NUMBER: 38522
; REFERENCE/DOCKET NUMBER: 13235
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (973) 235-4387
; TELEFAX: (973) 235-2363
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-345-859-12

Query Match          30.5%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 3;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 CTGGATGGAATTGCATRACC 26
Db 23 CTGGATGGAATTGGACACAGCC 1

RESULT 8
US-10-004-551-107/c
; Sequence 107, Application US/10004551
; Publication No. US20030004310A1
; GENERAL INFORMATION:
; APPLICANT: SHIMKETS, RICHARD A
; APPLICANT: FERNANDES, RIMA
; TITLE OF INVENTION: POLYNUCLEOTIDES AND POLYPEPTIDES ENCODED THEREBY
; FILE REFERENCE: 15966-559
; CURRENT APPLICATION NUMBER: US/10/004,551
; CURRENT FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: 09/635,949
```

```
; PRIOR FILING DATE: 2000-08-10
; NUMBER OF SEQ ID NOS: 110
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 107
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR PRIMER
US-10-004-551-107
```

```
Query Match          24.3%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 9.6;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 42 CCTTGCTGGGCTTGAGCT 60
Db 21 CCTTCTGGGCTGTAGCT 3

```
RESULT 9
US-09-848-754A-2614
; Sequence 2614, Application US/09848754A
; Publication No. US20030073207A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
; FILE REFERENCE: MBH800-958-I (400/018)
; CURRENT APPLICATION NUMBER: US/09/848,754A
; CURRENT FILING DATE: 2001-05-03
; NUMBER OF SEQ ID NOS: 9645
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2614
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-848-754A-2614
```

```
Query Match          21.2%; Score 13.8; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 14;
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

QY 34 AGAAGAACCTTGCTGC 50
Db 1 AGAAGAACCTTGCTGC 17

```
RESULT 10
US-10-277-216-367
; Sequence 367, Application US/10277216
; Publication No. US20040002470A1
; GENERAL INFORMATION:
; APPLICANT: KEITH, TIM
; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
; TITLE OF INVENTION: OBESITY, AND INFLAMMATORY BOWEL DISEASE
; FILE REFERENCE: 2976-4051
; CURRENT APPLICATION NUMBER: US/10/277,216
; CURRENT FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 10/126,022
; PRIOR FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: 09/834,597
; PRIOR FILING DATE: 2001-04-13
; PRIOR APPLICATION NUMBER: 09/548,797
; NUMBER OF SEQ ID NOS: 420
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 367
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
```

US-10-277-216-367

Query Match

Best Local Similarity 20.6%; Score 13.4; DB 1; Length 16;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 46 GCTGGGTTGGAGGT 60
 DB 2 GCTGGGTTGGAGGT 16

RESULT 11

US-10-126-022-367
 ; Sequence 367, Application US/10126022
 ; Publication No. US20040023215A1
 ; GENERAL INFORMATION:
 ; APPLICANT: KEITH, TIM
 ; TITLE OF INVENTION: NOVEL HUMAN GENE RELATING TO RESPIRATORY DISEASES,
 ; FILE REFERENCE: 2976-4039US2
 ; CURRENT APPLICATION NUMBER: US/10/126,022
 ; CURRENT FILING DATE: 2002-04-19
 ; PRIOR APPLICATION NUMBER: 09/834,597
 ; PRIOR FILING DATE: 2001-04-13
 ; PRIOR APPLICATION NUMBER: 09/548,797
 ; NUMBER OF SEQ ID NOS: 420
 ; SOFTWARE: PatentIn Ver. 2.1
 ; SEQ ID NO 367
 ; LENGTH: 16
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Primer
 US-10-126-022-367

Query Match

Best Local Similarity 20.6%; Score 13.4; DB 1; Length 16;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 46 GCTGGGTTGGAGGT 60
 DB 2 GCTGGGTTGGAGGT 16

RESULT 12

US-09-780-164-127/C
 ; Sequence 127, Application US/09780164
 ; Publication No. US20030092646A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Blact, Larry
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
 ; FILE REFERENCE: 400/010
 ; CURRENT APPLICATION NUMBER: US/09/780,164
 ; CURRENT FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/185,516
 ; PRIOR FILING DATE: 2000-02-28
 ; NUMBER OF SEQ ID NOS: 2603
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 127
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-780-164-127

Query Match

Best Local Similarity 20.6%; Score 13.4; DB 1; Length 17;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 38
 |||||

DB 16 GCCCAAGAACAGAA 2

RESULT 13

US-09-780-164-128/C
 ; Sequence 128, Application US/09780164
 ; Publication No. US20030092646A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Blact, Larry
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
 ; FILE REFERENCE: 400/010
 ; CURRENT APPLICATION NUMBER: US/09/780,164
 ; CURRENT FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/185,516
 ; PRIOR FILING DATE: 2000-02-28
 ; NUMBER OF SEQ ID NOS: 2603
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 128
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-780-164-128

Query Match

Best Local Similarity 20.6%; Score 13.4; DB 1; Length 17;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 38
 DB 15 GCCCAAGAACAGAA 1

RESULT 14

US-09-780-164-129/C
 ; Sequence 129, Application US/09780164
 ; Publication No. US20030092646A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Blact, Larry
 ; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
 ; FILE REFERENCE: 400/010
 ; CURRENT APPLICATION NUMBER: US/09/780,164
 ; CURRENT FILING DATE: 2001-02-09
 ; PRIOR APPLICATION NUMBER: 60/185,516
 ; PRIOR FILING DATE: 2000-02-28
 ; NUMBER OF SEQ ID NOS: 2603
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 129
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-780-164-129

Query Match

Best Local Similarity 20.0%; Score 13; DB 1; Length 17;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCCCAAGAACAGAA 36
 DB 13 GCCCAAGAACAGAA 1

RESULT 15

US-09-780-164-497/C
 ; Sequence 497, Application US/09780164
 ; Publication No. US20030092646A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Blact, Larry
 ; APPLICANT: McSwigen, Jim

```
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; CURRENT FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 497
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-497

Query Match          20.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 GCGGCAAGACAGA 36
Db 14 GCGGCAAGACAGA 2

RESULT 16
US-09-969-373-2913/c
; Sequence 2913, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Efferetz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 2913
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-2913

Query Match          19.7%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 17;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 44 TTGCTGGGGTTGGAGC 59
Db 16 TTGCTGGTGTGTGGTG 1

RESULT 17
US-09-866-108-2464
; Sequence 2464, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2464

Query Match          19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 CTGATGGAATTGGA 19
Db 2 CTGATGGAATTGGA 17

RESULT 18
US-09-866-108-2465
; Sequence 2465, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2465
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2465
```

```
Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      4 CTGGAATGGAATTGGA 19
         |||||
Db       1 CTGGAATGGAATTGGA 16
```

```
RESULT 19
US-09-780-164-1042
; Sequence 1042, Application US/09780164
; Publication No. US20030092646H1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; TITLE OF INVENTION: Method and Reagent for the Inhibition of CD20
; FILE REFERENCE: 400/010
; CURRENT APPLICATION NUMBER: US/09/780,164
; PRIOR FILING DATE: 2001-02-09
; PRIOR APPLICATION NUMBER: 60/185,516
; PRIOR FILING DATE: 2000-02-28
; NUMBER OF SEQ ID NOS: 2603
; SOFTWARE: PatentIn Version 3.0
; SEQ ID NO 1042
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-780-164-1042
```

```
Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      26 CCAAGAACGAAAGAA 41
         |||||
Db       2 CCAAGAACGAAAGAA 17
```

```
RESULT 20
US-10-156-306-3729
; Sequence 3729, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
```

```
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat
; FILE REFERENCE: MEH801-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; PRIOR FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn Version 3.0
; SEQ ID NO 3729
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-3729
```

```
Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 18;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      5 TGGAAATGGAATTGAC 20
         :|||:
Db       2 UGGAAGAGAAUGGAC 17
```

```
RESULT 21
US-10-723-361-2464
; Sequence 2464, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wenheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2464
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2464
```

```
Query Match      19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      4 CTGGAATGGAATTGGA 19
```

Db 2 CTGATTGACTTGA 17

```

RESULT 22
US-10-723-361-2465
; Sequence 2465, Application US/10723361
; Publication No. US2004013758A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; SEQ ID NO 2465
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2465

Query Match 19.7%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 4 CTGAATGGAATGGA 19
Db 1 CTGATTGACTTGA 16

RESULT 23
US-09-888-326-450
; Sequence 450, Application US/09888326
; Publication No. US20030026801A1
; GENERAL INFORMATION:
; APPLICANT: Weiner, George
; APPLICANT: Hartmann, Gunther
; TITLE OF INVENTION: Methods for Enhancing Antibody-Induced
; FILE REFERENCE: C1039/7052 (AWS)
; CURRENT APPLICATION NUMBER: US/09/888,326
; PRIOR FILING DATE: 2001-06-22
; PRIOR APPLICATION NUMBER: US 60/213,346
; PRIOR FILING DATE: 2000-06-22
; NUMBER OF SEQ ID NOS: 848

```

```

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 450
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (0)...(0)
; OTHER INFORMATION: phosphorothioate backbone
US-09-888-326-450

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGTT 61
Db 1 GGGGTTGGAGTT 13

RESULT 24
US-09-776-479-796
; Sequence 796, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouton, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 796
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-796

Query Match 17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 49 GGGGTTGGAGTT 61
Db 1 GGGGTTGGAGTT 13

RESULT 25
US-09-776-479-796
; Sequence 796, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouton, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; PRIOR FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 796

```

```
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-796

Query Match          17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTT 61
        |||||
Db       1 GGGGTTGGAGGTT 13

RESULT 26
US-10-314-578-796
; Sequence 796, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jörg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 796
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-796

Query Match          17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTT 61
        |||||
Db       1 GGGGTTGGAGGTT 13

RESULT 27
US-10-112-653-769
; Sequence 769, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Berg, Daniel J.
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
; TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
; FILE REFERENCE: C01039/70060 (AMS)
; CURRENT APPLICATION NUMBER: US/10/112,653
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/279,642
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 769
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-769

Query Match          17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTT 61
        |||||
Db       1 GGGGTTGGAGGTT 13

RESULT 28
US-10-017-995-796
; Sequence 796, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 796
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-796

Query Match          17.5%; Score 11.4; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 20;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      49 GGGGTTGGAGGTT 61
        |||||
Db       1 GGGGTTGGAGGTT 13

RESULT 29
US-10-132-002-5/C
; Sequence 5, Application US/10132002
; Publication No. US2003002204A1
; GENERAL INFORMATION:
; APPLICANT: Lansdorp, Peter
; TITLE OF INVENTION: Method for Detecting Multiple Copies of
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HOWSON & HOWSON
; STREET: 321 NO. US2003002204A1ristown Road
; CITY: Spring House
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19477
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/132,002
; FILING DATE: 25-Apr-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/730,635
; FILING DATE: 11-Oct-1996
; ATTORNEY/AGENT INFORMATION:
```


NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-132-002-5

Query Match 17.5%; Score 11.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 24;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 5 TGGATGGAATG 17
DB 13 TGGATGGAATG 1

RESULT 30
US-10-132-002-9
Sequence 9, Application US/10132002
Publication No. US2003022204A1
GENERAL INFORMATION:
APPLICANT: Landsorp, Peter
TITLE OF INVENTION: Method for Detecting Multiple Copies of
a Repeat Sequence in a Nucleic Acid Molecule
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: HOWSON & HOWSON
STREET: 321 No. US2003022204A1ristown Road
CITY: Spring House
STATE: PA
COUNTRY: U.S.A.
ZIP: 19477
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/132,002
FILING DATE: 25-Apr-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/730,635
FILING DATE: 11-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Bak, Mary E.
REGISTRATION NUMBER: 31,215
REFERENCE/DOCKET NUMBER: B&P7USA
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 540-9200
TELEFAX: (215) 540-5818
TELEX: N/A
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-132-002-9
Query Match 17.5%; Score 11.4; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 24;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 5 TGGATGGAATG 17
DB 3 TGGATGGAATG 15

RESULT 31
US-09-981-803-32
Sequence 32, Application US/09981803
Publication No. US20030032092A1
GENERAL INFORMATION:
APPLICANT: Joel CROUZET
APPLICANT: Daniel SCHERMAN
APPLICANT: Beatrice CAMERON
APPLICANT: Pierre WILS
APPLICANT: Anne-Marie DARQUET
TITLE OF INVENTION: DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY
FILE REFERENCE: MINICIRCLE
CURRENT APPLICATION NUMBER: US/09/981,803
CURRENT FILING DATE: 2001-10-19
NUMBER OF SEQ ID NOS: 50
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 32
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Description of the artificial sequence:
US-09-981-803-32

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACGAAAGAA 41
DB 1 AAGAAAAAAGAA 14

RESULT 32
US-09-981-803-48/C
Sequence 48, Application US/09981803
Publication No. US20030032092A1
GENERAL INFORMATION:
APPLICANT: Joel CROUZET
APPLICANT: Daniel SCHERMAN
APPLICANT: Beatrice CAMERON
APPLICANT: Pierre WILS
APPLICANT: Anne-Marie DARQUET
TITLE OF INVENTION: DNA MOLECULES, PREPARATION AND USE IN GENE THERAPY
FILE REFERENCE: MINICIRCLE
CURRENT APPLICATION NUMBER: US/09/981,803
CURRENT FILING DATE: 2001-10-19
NUMBER OF SEQ ID NOS: 50
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 48
LENGTH: 14
TYPE: DNA
ORGANISM: Artificial sequence
FEATURE:
OTHER INFORMATION: Description of the artificial sequence:
US-09-981-803-48

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 28 AAGAACGAAAGAA 41

Db 14 AAGAAAAAAGAA 1

RESULT 33

US-10-275-071-29
; Sequence 29, Application US/10275071
; Publication No. US20030186268A1
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; FILE REFERENCE: 08888.0138-02
; CURRENT APPLICATION NUMBER: US/10/275,071
; PRIOR FILING DATE: 2003-04-07
; PRIOR APPLICATION NUMBER: 09/580,923
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 08/860,038
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-10-275-071-29

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41

Db 1 AAGAAAAAAGAA 14

RESULT 34

US-10-275-071-30/c
; Sequence 30, Application US/10275071
; Publication No. US20030186268A1
; GENERAL INFORMATION:
; APPLICANT: Crouzet, Joel
; APPLICANT: Scherman, Daniel
; APPLICANT: Wils, Pierre
; APPLICANT: Cameron, Beatrice
; APPLICANT: Blanche, Francis
; TITLE OF INVENTION: PURIFICATION OF A TRIPLE HELIX FORMATION WITH AN
; FILE REFERENCE: 08888.0138-02
; CURRENT APPLICATION NUMBER: US/10/275,071
; PRIOR FILING DATE: 2003-04-07
; PRIOR APPLICATION NUMBER: 09/580,923
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: 08/860,038
; PRIOR FILING DATE: 1997-06-09
; PRIOR APPLICATION NUMBER: PCT/FR95/01468
; PRIOR FILING DATE: 1995-11-08
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 30
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:

; OTHER INFORMATION: oligonucleotide
US-10-275-071-30

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41

Db 14 AAGAAAAAAGAA 1

RESULT 35

US-10-684-830-35
; Sequence 35, Application US/10684830
; Publication No. US20040142452A1
; GENERAL INFORMATION:
; APPLICANT: Gencell S.A.; Aventis Pharmaceuticals, Inc.
; APPLICANT: Soubrier, Fabienne
; TITLE OF INVENTION: Circular DNA Molecule with Conditional Origin of Replication, Me
; FILE REFERENCE: 8888.0132-02
; CURRENT APPLICATION NUMBER: US/10/684,830
; PRIOR FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: US 10/268,948
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: US 09/043,193
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: PCT/FR96/01414
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 35
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Escherichia coli
US-10-684-830-35

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGAACAGAAAGAA 41

Db 1 AAGAAAAAAGAA 14

RESULT 36

US-10-684-830-36/c
; Sequence 36, Application US/10684830
; Publication No. US20040142452A1
; GENERAL INFORMATION:
; APPLICANT: Gencell S.A.; Aventis Pharmaceuticals, Inc.
; APPLICANT: Soubrier, Fabienne
; TITLE OF INVENTION: Circular DNA Molecule with Conditional Origin of Replication, Me
; FILE REFERENCE: 8888.0132-02
; CURRENT APPLICATION NUMBER: US/10/684,830
; PRIOR FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: US 10/268,948
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: US 09/043,193
; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: PCT/FR96/01414
; PRIOR FILING DATE: 1996-09-13
; NUMBER OF SEQ ID NOS: 39
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 36
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Escherichia coli
US-10-684-830-36

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACGAGAGAA 41
|||||
14 AAGAAAAAAAAA 1

RESULT 37
US-10-684-830-38/c

; Sequence 38, Application US/10684830
; Publication No. US20040142452A1
; GENERAL INFORMATION:

; APPLICANT: Genecell S.A.; Aventis Pharmaceuticals, Inc.

; APPLICANT: Soubrier, Fabienne

; TITLE OF INVENTION: Circular DNA Molecule with Conditional Origin of Replication, Met

; FILE REFERENCE: 888.0132-02
; CURRENT APPLICATION NUMBER: US/10/684,830

; PRIOR FILING DATE: 2003-10-15
; PRIOR APPLICATION NUMBER: US 10/268,948

; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: US 09/043,193

; PRIOR FILING DATE: 1998-03-13
; PRIOR APPLICATION NUMBER: PCT/FR96/01414

; PRIOR FILING DATE: 1996-09-13
; NUMBER OF SEQ ID NOS: 39

; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 38

; LENGTH: 14
; TYPE: DNA

; ORGANISM: Escherichia coli
US-10-684-830-38

Query Match 16.6%; Score 10.8; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 27;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 28 AAGACGAGAGAA 41
|||||
14 AAGAAAAAAAAA 1

RESULT 38
US-10-253-904-45/c

; Sequence 45, Application US/10253904
; Publication No. US20030158135A1
; GENERAL INFORMATION:

; APPLICANT: EL SOLH, NEVINE

; TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE

; TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED

; FILE REFERENCE: 03715-0059
; CURRENT APPLICATION NUMBER: US/10/253,904

; CURRENT FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 51

; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 45

; LENGTH: 13
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-253-904-45

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 27;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GAATGAGATTGG 18
|||||
|||||

Db 13 GAATGAGATTGG 2

RESULT 39
US-10-392-970-36/c

; Sequence 36, Application US/10392970
; Publication No. US20030176679A1
; GENERAL INFORMATION:

; APPLICANT: El Solh, Nevine

; TITLE OF INVENTION: POLYNUCLEOTIDES AND THEIR USE FOR DETECTING RESISTANCE

; TITLE OF INVENTION: TO STREPTOGRAMIN A OR TO STREPTOGRAMIN B AND RELATED

; FILE REFERENCE: 03495.0173-00000
; CURRENT APPLICATION NUMBER: US/10/392,970

; CURRENT FILING DATE: 2003-03-21
; PRIOR APPLICATION NUMBER: US/09/099,932

; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 60/050,380

; PRIOR FILING DATE: EARLIER FILING DATE: 1997-06-20
; NUMBER OF SEQ ID NOS: 50

; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36

; LENGTH: 13
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: primer
US-10-392-970-36

Query Match 16.0%; Score 10.4; DB 1; Length 13;
Best Local Similarity 91.7%; Pred. No. 27;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GAATGAGATTGG 18
|||||
13 GAATGAGATTGG 2

RESULT 40
US-10-033-145-322/c

; Sequence 322, Application US/10033145
; Publication No. US2002015151A1
; GENERAL INFORMATION:

; APPLICANT: GENZYME CORPORATION

; APPLICANT: ROBERTS, BRUCE

; TITLE OF INVENTION: SHANKARA, SRINIVAS

; FILE REFERENCE: GA0201C
; CURRENT APPLICATION NUMBER: US/10/033,145

; CURRENT FILING DATE: 2001-11-05
; PRIOR APPLICATION NUMBER: PCT/US99/13800

; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 2137

; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 322

; LENGTH: 10
; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-033-145-322

Query Match 15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 44 TTGCTGGGGT 53
|||||
10 TTGCTGGGGT 1

RESULT 41
US-10-330-627-973/c
; Sequence 973, Application US/10330627

```
; Publication No. US20030175771A1
; GENERAL INFORMATION:
; APPLICANT: Velculescu, Victor E.
; APPLICANT: Kinzler, Kenneth W
; APPLICANT: Vogelstein, Bert
; TITLE OF INVENTION: Human Transcripts
; FILE REFERENCE: 00107.00319
; CURRENT APPLICATION NUMBER: US/10/330,627
; CURRENT FILING DATE: 2002-12-30
; PRIOR APPLICATION NUMBER: US 09/448,480
; PRIOR FILING DATE: 1999-11-24
; NUMBER OF SEQ ID NOS: 1564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 973
; LENGTH: 10
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-330-627-973
```

```
Query Match      15.4%; Score 10; DB 1; Length 10;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      56 GAGGTTTCAC 65
Db      10 GAGGTTTCAC 1
```

```
RESULT 42
US-10-450-797-847/c
; Sequence 847, Application US/10450797
; Publication No. US20040142335A1
; GENERAL INFORMATION:
; APPLICANT: Petersohn, Dirk
; APPLICANT: Conradt, Marcus
; APPLICANT: Hofmann, Kay
; TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
; FILE REFERENCE: HEK-0041
; CURRENT APPLICATION NUMBER: US/10/450,797
; CURRENT FILING DATE: 2003-12-04
; PRIOR APPLICATION NUMBER: PCT/EP01/15178
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: DE 101 00 121.5
; PRIOR FILING DATE: 2001-01-03
; NUMBER OF SEQ ID NOS: 1435
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 847
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-450-797-847
```

```
Query Match      15.4%; Score 10; DB 1; Length 11;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      13 AATTGGACAT 22
Db      10 AATTGGACAT 1
```

```
RESULT 43
US-10-091-281-67/c
; Sequence 67, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06
```

```
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 67
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative PCAT/CAAT.01 motif
US-10-091-281-67
```

```
Query Match      15.4%; Score 10; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      14 ATTGACATA 23
Db      10 ATTGACATA 1
```

```
RESULT 44
US-09-789-836-31
; Sequence 31, Application US/09789836
; Patent No. US20020082204A1
; GENERAL INFORMATION:
; APPLICANT: BRIGHAM, KENNETH L.
; APPLICANT: STECENKO, ARLINE A.
; APPLICANT: SEALY, LINDA
; TITLE OF INVENTION: TREATMENT OF INFLAMMATION WITH P20
; FILE REFERENCE: N-6977
; CURRENT APPLICATION NUMBER: US/09/789,836
; CURRENT FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/183,584
; PRIOR FILING DATE: 2000-02-18
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 31
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
US-09-789-836-31
```

```
Query Match      15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 33;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      9 ATGGAATTGGACA 21
Db      1 ATGGAAGTGGCCA 13
```

```
RESULT 45
US-09-789-831-29
; Sequence 29, Application US/09789831
; Publication No. US2003016586A1
; GENERAL INFORMATION:
; APPLICANT: SEALY, LINDA
; TITLE OF INVENTION: C/EBP-BETA ISOFORMS AND METHODS OF USE IN CELL REGULATION
; FILE REFERENCE: N-6978
; CURRENT APPLICATION NUMBER: US/09/789,831
; CURRENT FILING DATE: 2001-02-20
; PRIOR APPLICATION NUMBER: 60/183,532
; PRIOR FILING DATE: 2000-02-18
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 13
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: oligonucleotide
US-09-789-831-29

Query Match 15.1%; Score 9.8; DB 1; Length 13;
Best Local Similarity 84.6%; Pred. No. 33;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 9 ATGGAATTGACA 21
|||||
Db 1 ATGGAAGTGCCA 13

RESULT 46
US-09-918-715-8/C
Sequence 8, Application US/09918715
Publication No. US20030017157A1
GENERAL INFORMATION:
APPLICANT: Brad St. Croix
APPLICANT: Bert Vogelstein
APPLICANT: Kenneth Kinzler
TITLE OF INVENTION: ENDOTHELIAL CELL EXPRESSION PATTERNS
FILE REFERENCE: 1107.00134
CURRENT APPLICATION NUMBER: US/09/918,715
PRIOR FILING DATE: 2001-08-01
PRIOR APPLICATION NUMBER: 60/222,599
PRIOR FILING DATE: 2000-08-02
PRIOR APPLICATION NUMBER: 60/224,360
PRIOR FILING DATE: 2000-08-11
PRIOR APPLICATION NUMBER: 60/282,850
PRIOR FILING DATE: 2000-04-11
NUMBER OF SEQ ID NOS: 358
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 8
LENGTH: 11
TYPE: DNA
ORGANISM: Homo sapiens
US-09-918-715-8

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 30;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 27 CAAGACACAGA 37
|||||
Db 11 CAAGACACAGA 1

RESULT 47
US-10-450-797-174/C
Sequence 174, Application US/10450797
Publication No. US20040142335A1
GENERAL INFORMATION:
APPLICANT: Petersohn, Dirk
APPLICANT: Conradt, Marcus
APPLICANT: Hofmann, Kay
TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
FILE REFERENCE: HENK-0041
CURRENT APPLICATION NUMBER: US/10/450,797
CURRENT FILING DATE: 2003-12-04
PRIOR APPLICATION NUMBER: PCT/EP01/15178
PRIOR FILING DATE: 2001-12-20
PRIOR APPLICATION NUMBER: DE 101 00 121.5
PRIOR FILING DATE: 2001-01-03
NUMBER OF SEQ ID NOS: 1435
SOFTWARE: PatentIn version 3.2
SEQ ID NO 174
LENGTH: 11
TYPE: DNA
ORGANISM: Homo sapiens
US-10-450-797-174

Query Match 14.5%; Score 9.4; DB 1; Length 11;

Best Local Similarity 90.9%; Pred. No. 30;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 27 CAAGACACAGA 37
|||||
Db 11 CAAGACACAGA 1

RESULT 48
US-10-450-797-455/C
Sequence 455, Application US/10450797
Publication No. US20040142335A1
GENERAL INFORMATION:
APPLICANT: Petersohn, Dirk
APPLICANT: Conradt, Marcus
APPLICANT: Hofmann, Kay
TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
FILE REFERENCE: HENK-0041
CURRENT APPLICATION NUMBER: US/10/450,797
CURRENT FILING DATE: 2003-12-04
PRIOR APPLICATION NUMBER: PCT/EP01/15178
PRIOR FILING DATE: 2001-12-20
PRIOR APPLICATION NUMBER: DE 101 00 121.5
PRIOR FILING DATE: 2001-01-03
NUMBER OF SEQ ID NOS: 1435
SOFTWARE: PatentIn version 3.2
SEQ ID NO 455
LENGTH: 11
TYPE: DNA
ORGANISM: Homo sapiens
US-10-450-797-455

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 30;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 17 GGACATAGCCC 27
|||||
Db 11 GGACATAGCCC 1

RESULT 49
US-10-450-797-942
Sequence 942, Application US/10450797
Publication No. US20040142335A1
GENERAL INFORMATION:
APPLICANT: Petersohn, Dirk
APPLICANT: Conradt, Marcus
APPLICANT: Hofmann, Kay
TITLE OF INVENTION: METHOD FOR DETERMINING SKIN STRESS OR SKIN AGEING IN VITRO
FILE REFERENCE: HENK-0041
CURRENT APPLICATION NUMBER: US/10/450,797
CURRENT FILING DATE: 2003-12-04
PRIOR APPLICATION NUMBER: PCT/EP01/15178
PRIOR FILING DATE: 2001-12-20
PRIOR APPLICATION NUMBER: DE 101 00 121.5
PRIOR FILING DATE: 2001-01-03
NUMBER OF SEQ ID NOS: 1435
SOFTWARE: PatentIn version 3.2
SEQ ID NO 942
LENGTH: 11
TYPE: DNA
ORGANISM: Homo sapiens
US-10-450-797-942

Query Match 14.5%; Score 9.4; DB 1; Length 11;
Best Local Similarity 90.9%; Pred. No. 30;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 34 AGAAGAACTT 44
|||||
Db 1 AGAAGAACTT 11

Query Match 14.5%; Score 9.4; DB 1; Length 11;

```
RESULT 50
US-09-263-959-425
; Sequence 425, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 425:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-425
Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 28 AAGAACAGAA 38
DB 2 AAGAAAAGAA 12

RESULT 51
US-09-263-959-587/C
; Sequence 587, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 660:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-660
Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 587:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-587
Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 28 AAGAACAGAA 38
DB 11 AAGAAAAGAA 1

RESULT 52
US-09-263-959-660
; Sequence 660, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 660:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-09-263-959-660
Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

QY 28 AAGACAGAAA 38
|||||
Db 2 AAGAAAAGAAA 12

RESULT 53
US-10-140-896-4
; Sequence 4, Application US/10140896
; Publication No. US20030167518A1
; GENERAL INFORMATION:
; APPLICANT: Yeh, Kai-Wun
; APPLICANT: Wang, Shu-Jen
; TITLE OF INVENTION: SPORAMIN PROMOTER AND USES THEREOF
; FILE REFERENCE: 12139-002001
; CURRENT APPLICATION NUMBER: US/10/140,896
; PRIOR FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: 60/289,630
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Ipomoea batatas
US-10-140-896-4

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 35 GAAGAACCCTT 45
|||||
Db 2 GAAGACACCTT 12

RESULT 54
US-10-232-927A-5
; Sequence 5, Application US/10232927A
; Publication No. US20030190638A1
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; Calvin B. Harley
; Scott L. Weinrich
; Catherine M. Strahl
; Michael J. Mceachern
; Jerry Shay
; Woodring E. Wright
; Elizabeth H. Blackburn
; Nam Woo Kim
; Homayoun Vaziri
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
; CONDITIONS RELATED TO
; TELOMERE LENGTH AND/OR
; TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/232,927A
; FILING DATE: 29-Aug-2002
; CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,535
; FILING DATE: 20-Aug-1999
; APPLICATION NUMBER: 08/819,867
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Chambers, Daniel M.
; REGISTRATION NUMBER: 34,561
; REFERENCE/DOCKET NUMBER: 224/232
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-232-927A-5

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGCTTGGAG 58
|||||
Db 2 TGGGCTTGGAG 12

RESULT 55
US-10-232-927A-33
; Sequence 33, Application US/10232927A
; Publication No. US20030190638A1
; GENERAL INFORMATION:
; APPLICANT: Michael D. West
; Calvin B. Harley
; Scott L. Weinrich
; Catherine M. Strahl
; Michael J. Mceachern
; Jerry Shay
; Woodring E. Wright
; Elizabeth H. Blackburn
; Nam Woo Kim
; Homayoun Vaziri
; TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
; CONDITIONS RELATED TO
; TELOMERE LENGTH AND/OR
; TELOMERASE ACTIVITY
; NUMBER OF SEQUENCES: 80
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/232,927A
; FILING DATE: 29-Aug-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,535
; FILING DATE: 20-Aug-1999
; APPLICATION NUMBER: 08/819,867

FILED DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561
REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-232-927A-33

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 56
US-10-232-927A-35
Sequence 35, Application US/10232927A
Publication No. US20030190638A1
GENERAL INFORMATION:
APPLICANT: Michael D. West
Calvin B. Hatley
Scott L. Weinrich
Catherine M. Scrahl
Michael J. Mceachern
Jerry Shay
Woodring E. Wright
Elizabeth H. Blackburn
Nam Woo Kim
Homayoun Vaziri
TITLE OF INVENTION: THERAPY AND DIAGNOSIS OF
CONDITIONS RELATED TO
TELOMERE LENGTH AND/OR
TELOMERASE ACTIVITY
NUMBER OF SEQUENCES: 80
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
Street: 633 West Fifth Street
Suite 4700
City: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Fastseq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/232,927A
FILING DATE: 29-Aug-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/378,535
FILING DATE: 20-Aug-1999
APPLICATION NUMBER: 08/819,867
FILING DATE: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Chambers, Daniel M.
REGISTRATION NUMBER: 34,561

REFERENCE/DOCKET NUMBER: 224/232
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 35:
SEQUENCE CHARACTERISTICS:
LENGTH: 12 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 35:
US-10-232-927A-35

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 48 TGGGGTTGGAG 58
Db 2 TGGGGTTGGAG 12

RESULT 57
US-10-422-262-18/c
Sequence 18, Application US/10422262
Publication No. US20030219848A1
GENERAL INFORMATION:
APPLICANT: NAOVI, TABASSUM
APPLICANT: ROUHANI, RIAZ
APPLICANT: SINGH, RAJENDRA
TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
FILE REFERENCE: 3817.11-1
CURRENT APPLICATION NUMBER: US/10/422,262
PRIOR APPLICATION NUMBER: 2003-04-24
PRIOR FILING DATE: 2002-05-02
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 18
LENGTH: 12
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-422-262-18

Query Match 14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 30 GAACAGAAAGA 40
Db 12 GAACAGAAAGA 2

RESULT 58
US-10-422-262-19/c
Sequence 19, Application US/10422262
Publication No. US20030219848A1
GENERAL INFORMATION:
APPLICANT: NAOVI, TABASSUM
APPLICANT: ROUHANI, RIAZ
APPLICANT: SINGH, RAJENDRA
TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
FILE REFERENCE: 3817.11-1
CURRENT APPLICATION NUMBER: US/10/422,262
PRIOR APPLICATION NUMBER: 2003-04-24
PRIOR FILING DATE: 2002-05-02
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.1


```

; SEQ ID NO 19
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide from PNA sequence
US-10-422-262-19

```

```

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      30 GAACAGAAAGA 40
        |||||||
Db       12 GAGCAGAAAGA 2

```

```

RESULT 59
US-10-422-262-20/C
; Sequence 20, Application US/10422262
; Publication No. US20030219848A1
; GENERAL INFORMATION:
; APPLICANT: NAQVI, TABASSUM
; APPLICANT: ROUHANI, RIAZ
; APPLICANT: SINGH, RAJENDRA
; TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
; FILE REFERENCE: 3817.11-1
; CURRENT APPLICATION NUMBER: US/10/422,262
; CURRENT FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: 60/376,935
; PRIOR FILING DATE: 2002-05-02
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide from PNA sequence
US-10-422-262-20

```

```

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      30 GAACAGAAAGA 40
        |||||||
Db       12 GAGCAGAAAGA 2

```

```

RESULT 60
US-10-422-262-21/C
; Sequence 21, Application US/10422262
; Publication No. US20030219848A1
; GENERAL INFORMATION:
; APPLICANT: NAQVI, TABASSUM
; APPLICANT: ROUHANI, RIAZ
; APPLICANT: SINGH, RAJENDRA
; TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
; FILE REFERENCE: 3817.11-1
; CURRENT APPLICATION NUMBER: US/10/422,262
; CURRENT FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: 60/376,935
; PRIOR FILING DATE: 2002-05-02
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

```

```

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide from PNA sequence
US-10-422-262-21

```

```

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      30 GAACAGAAAGA 40
        |||||||
Db       12 GAGCAGAAAGA 2

```

```

RESULT 61
US-10-422-262-22/C
; Sequence 22, Application US/10422262
; Publication No. US20030219848A1
; GENERAL INFORMATION:
; APPLICANT: NAQVI, TABASSUM
; APPLICANT: ROUHANI, RIAZ
; APPLICANT: SINGH, RAJENDRA
; TITLE OF INVENTION: SHORT ENZYME DONOR FRAGMENT
; FILE REFERENCE: 3817.11-1
; CURRENT APPLICATION NUMBER: US/10/422,262
; CURRENT FILING DATE: 2003-04-24
; PRIOR APPLICATION NUMBER: 60/376,935
; PRIOR FILING DATE: 2002-05-02
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide from PNA sequence
US-10-422-262-22

```

```

Query Match      14.5%; Score 9.4; DB 1; Length 12;
Best Local Similarity 90.9%; Pred. No. 33;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY      30 GAACAGAAAGA 40
        |||||||
Db       12 GAGCAGAAAGA 2

```

```

Search completed: August 12, 2004, 15:30:41
Job time : 1 secs

```

THIS PAGE BLANK (USPTO)